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Abstract 
Duchenne muscular dystrophy (DMD) is the most common inherited muscle disease in 
men and currently there is no effective treatment for this debilitating and lethal disorder. 
Although the absence of dystrophin is identified as the main cause of DMD, multiple 
secondary changes have been found to result from the dystrophin deficiency both in 
muscle and in non-muscle tissues. Among these abnormalities, our laboratory and others 
have demonstrated a dramatic increase in the expression of the P2RX7 receptor in cells 
and tissues from DMD patients and the mdx mouse model of DMD.  
The aim of this study was to determine the effects of P2RX7 ablation on biological 
functions in mdx muscle in situ and to identify suitable diagnostic and prognostic 
biomarkers for use in studies on the pharmacological inhibition of P2RX7. RNA 
transcription was profiled in muscle from wild-type and mdx mice, and also from double 
knock-out mdx/P2rx7
-/- 
mice which lack both functional Dmd and P2rx7 genes, and the 
effects of P2RX7 antagonists were assessed on pathological markers at the acute disease 
stage of disease in mdx mice, which resembles the human pathology. 
RNA sequencing was performed using the Illumina HiSeq 2000 platform to characterise 
the differential gene expression in tibialis anterior (TA) muscles from four week old 
wild type, mdx and mdx/P2rx7
-/- 
mice. The biological functions and molecules that are 
most affected in mdx and corrected in mdx/P2rx7
-/-
 tissues are those of the immune 
response, including the innate immune response, cytokine regulatory genes and the NF-
кB pathway followed by fibrosis, telomerase regulatory genes, atherosclerosis signalling 
and the LXR/RXR activation pathway. Moreover, activation of the cell cycle, 
mitochondrial dysfunction, apoptosis and the adherens junction genes were found to be 
altered in mdx compared to wild type but not normalised in mdx/P2rx7
-/-
 muscles. This 
analysis also demonstrated that the mdx mutation disrupts the non-sense-mediated RNA 
decay and splicing mechanisms, which leads to an increase in out-of-frame transcripts 
that may have unexpected cellular impact. One of these altered transcripts, Bmp7, was 
significantly down-regulated in the mdx myoblasts, myofibres and in TA muscles and 
restored to the normal level in mdx/P2rx7
-/-
 muscle. Different analyses were used to map 
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this alteration to the 5'exons of Bmp7 but the identification of this abnormal transcript 
was not successful. 
Four P2RX7 antagonists (oxidised ATP, A438079, AFC-5128 and azidothymidine 
(AZT)) were administered to male mdx mice and their effects on the pathology were 
analysed using different methods and biomarkers. All of the antagonists inhibited 
P2RX7 receptor-mediated responses in mdx mice without any detectable side effects. 
A438079 and AZT were found as the most effective in attenuating the wide range of the 
pathological features.  
The reduction in dystrophic features as results of ablation and antagonism the P2RX7 
confirms the involvement of this purinoreceptor in the DMD pathology and making it an 
attractive target for a pharmacological treatment of this lethal disease. Additionally, as 
AZT is already in clinical use for other diseases, also in children, this drug could be 
relatively easily re-purposed and trialled for the treatment of DMD. 
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General  Introduction 
 
 Duchenne muscular dystrophy  1.1
Duchenne muscular dystrophy (DMD) is a severe X-linked recessive muscle disease 
affecting 1: 5000 males (Emery, 1991; Emery, 2001). The disease was first described by 
Edward Meryon (Meryon, 1852). Later in the middle of the 19
th
 century, a French 
neurologist Guillaume Benjamin Amand Duchenne described patients with muscular 
dystrophy and mental retardation (Duchenne, 1867). DMD patients are born without 
obvious abnormalities except for the high serum levels of the creatine kinase. The first 
clinical symptoms are observed between the ages of 3 and 5, when the weakness in the 
proximal muscles of the arms and legs starts (Dubowitz, 1978; Jennekens  et al., 1991). 
The symptoms include delay in walking, difficulties in climbing the stairs and getting up 
from the floor (Gower’s sign) (Gowers, 1879). Later, the pseudohypertrophy of the 
calves appears when the muscle is damaged and replaced by connective tissue and fat. 
Subsequently, the weakness in the lower limb muscle develops to the point where a 12-
year old child needs a wheelchair (Emery, 1993). The progression in fibrosis and the 
loss of muscle strength reduce the life expectancy of individuals with untreated DMD, 
who die in their early 20s due to respiratory or heart failure (Emery, 1993; Eagle et al., 
2002). The primary cause of death in DMD is respiratory insufficiency, which results 
from a defect in the respiratory muscle contraction followed by thoracic malformations. 
The risk of death in a DMD patient with respiratory dysfunction is associated with vital 
capacity that declines at about 8-12% in a year. Cardiac dysfunction is the first 
manifestation of DMD after the age of 10 and the second cause of death in DMD. 
Cardiomyopathy is present in one-third of the children at the age of 14 and in all patients 
after the age of 18. The heart disease starts with a weakness of cardiac muscle leading to 
a defect in cardiac output, dilated cardiomyopathy, atrial and ventricular arrhythmias. 
When patients receive respiratory and cardiac therapy with an aggressive care, the 
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lifespan can be extended to 30 years and there are exceptional cases of patient living to 
40s (Hermans et al., 2010; Blake, et al., 2002; Allen et al., 2016). 
Moreover, about 30% of children with DMD have a non-progressive learning disability 
but the average Intelligence quotient (IQ) for all the DMD patients is about 1 standard 
deviation lower than in the unaffected population, with average IQ of 85 (Karagan et al, 
1979; Emery et al, 1993; Deng et al, 2009; Taylor et al., 2010). The bone density is also 
reduced with remarkable elevation of osteoclast and bone resorption parameters and the 
pro-inflammatory IL6 elevation has been detected as the main contributor (Rufo et al., 
2011). 
Duchenne MD is caused by mutations in the DMD gene that codes for the cytoskeleton 
protein (dystrophin) (Hoffman et al., 1987). Dystrophin is located in the skeletal, cardiac 
muscles and in the brain, and it is considered necessary for maintaining the structural 
integrity of muscles (Barnea  et al., 1990; Chelly  et al., 1990). The diagnosis of the 
disease involves several steps; first, measurement of creatine kinase level (enzyme 
released from damaged muscle) in blood. Second, genetic screening test for the mutated 
DMD gene in DNA isolated from white blood cells and histological analysis of muscle 
biopsy using anti-dystrophin antibody that indicates DMD protein deficiency in the 
muscle fibre membrane (sarcolemma)(Laing et al., 2011; Kobayashi et al., 2012; 
Peverelli et al., 2015; Allen et al., 2016). 
 DMD gene 1.2
Located on the short arm of chromosome X, in the p21 locus (Body and Bukle, 1986), 
DMD gene is the largest known gene, with approximately 2.4 mega bases, which 
represents about 0.1% of the entire human genome. The gene consists of 79 exons (1% 
of the gene) transcribed into a 14 kb full length dystrophin mRNA (Roberts 1993; 
Lander 2001). The remaining 99% of the dystrophin gene is composed of non-coding 
intronic regions (Lander 2001). The main transcript translates to a cytoskeletal protein 
named dystrophin, which has a molecular weight of 427kDa and consists of 3685 amino 
acid residues (Koenig et al., 1987). 
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Dystrophin gene encodes three full length isoforms: Dp427c (cortex, brain), Dp427m 
(muscle) and Dp427p (Purkinje, cerebellum). These isoforms contain the same number 
of exons, however they are regulated by independent, tissue-specific promoters and 
therefore each has a unique first exon. The muscle isoform is highly expressed in 
skeletal muscles, cardiomyocytes and some glial cells in the brain (Koenig et al., 1987; 
Rapaport et al., 1992). The Dp427c isoform is found in brain cortex and pyramidal 
hippocampal neurons whereas the Dp427p isoform is expressed in Purkinje cells and 
also in the developing skeletal and cardiac muscles (Nudel et al., 1989; Gorecki et al., 
1992; Muntoni et al., 1995; Abdulrazzak et al., 2001).  
The dystrophin gene also transcribes into four shorter isoforms controlled through four 
intragenic promoters. These isoforms have unique 5' exons but share the same COOH-
termini. The promoters for these isoforms are located on intron 29, 44, 55, and 62 
respectively and control expression of transcripts that produce the protein products 
whose names were given according to their molecular weight: 260 kDa (Dp260) and the 
predominant expression site e.g. in retina (R) (D'Souza et al., 1995), 140 kDa (Dp140) 
in brain and kidneys (B3) (Lidov et al., 1995), 116 kDa (Dp116) in Schwann cell (S) 
(Byers et al., 1993), the general isoform (G) 71 kDa (Dp71) expressed in various non-
muscle tissues (Bar et al., 1990) (Figure 1.1) and recently, a new dystrophin isoform 412 
kDa (Dp412) has been detected in human embryonic stem cells (Massouridès et al., 
2015) . 
The greater numbers of short isoforms translated from the 3' mRNAs are well conserved 
in different human, mouse and chicken tissues. The function of these isoforms could be 
tissue-specific, but generally they are believed to provide the connection between 
dystrophin isoform and dystrophin associated proteins (Bies et al., 1992). Some of these 
isoforms are expressed in many tissues while some are unique for peripheral nerves or 
brain regions. Additionally, some observations indicate the presence of some of these 
isoforms at the embryonic developmental stages only, while others are present in the 
adult tissues. 
 In addition, dystrophin transcripts are alternatively spliced. The alternative splice 
variants are clustered in two major regions of the dystrophin transcript. The first region 
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where alternative splicing occurs is in exons 71-74 and results in in-frame deletions of 
one or all exons. The resulting proteins have slightly modified functions than the 
original one; for example, splicing of exon 74 romoves the dystrophin-syntrophin 
binding site (Ceccarini et al., 1997). The second region in which alternative splicing can 
occur is exon 78, creating a frame shift in the dystrophin transcript, which encodes 
proteins with a different C-terminus. The difference in the C-terminus results in 
changing the hydrophobicity of protein and affects the protein folding (Feener et al., 
1989; Roberts and Bobrow, 1998). 
 
 
Figure 1.1: 
Schematic illustrating the DMD gene locus in the chromosome X, p21 region, the genomic 
arrangement of exons within the DMD gene and the dystrophin isoforms (except the 
Dp412) translated from different transcripts controlled by specific promoters (depicted by 
arrows) and resulting in proteins that display differences in their NH2-termini (from 
Muntoni et al., 2003). 
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The large size and complex structure of the dystrophin gene makes it vulnerable to 
mutations and therefore this gene has a high mutation frequency of 1 x 10
–4
 genes per 
generation. Two-thirds of the DMD cases are caused by deletion or duplication in one or 
more exons. 65% of these mutations are deletions (Monaco et al., 1985), which usually 
occur in two high incident regions, the major hotspot region flanking exons 45-53 
(Beggs et al., 1990), and the minor mutated region locates in the 5' end between exon 2 
and 20 (Koenig et al., 1989). Point mutation is another type of mutation, which displays 
a severe phenotype and accounts for one-third of DMD patients (Lenk et al., 1993). 
Occasionally, a large deletion in DMD causes a phenotype similar to the one resulting 
from a single point mutation. It has been shown that there is no clear relation between 
the variation in the size and position of DMD mutation and the severity of the clinical 
presentation. The frame shift hypothesis of Monaco et al. in 1988 can explain this 
scenario. When the mutation alters the reading frame of the DMD gene, such as non-
sense or frame shift mutation, the result is a truncated dystrophin protein causing a 
severe DMD phenotype. In contrast, the in-frame mutation gives rise to a small and 
partially functional protein leading to the development of a milder phenotype associated 
with the allelic form of Becker muscular dystrophy (BMD). This difference is exploited 
in therapeutic approaches discussed below. 
 Pathophysiology of DMD 1.3
The absence of the dystrophin protein renders the muscle more vulnerable to damage 
and is considered a primary cause of this severe muscle disease. The mechanism leading 
from the loss of dystrophin to the degeneration is still debated. However, the current 
dogma stress fragile membranes that eventually lead to many secondary processes such 
as disruption of cell signalling, activation of calcium-dependent proteases, inflammation, 
abnormal regeneration processes and cell death. 
1.3.1 Fragile membrane structure 
The 427 kDa dystrophin protein (Figure 1.2) is localised to the cytoplasmic side of the 
muscle membrane (Hoffman and Kunkel, 1989). This isoform has two actin binding 
sites, one in the N-terminus and the other in the central rod domain. In addition, 24 
spectrin-like regions are encompassed by the rod domain, which constitutes the biggest 
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part of dystrophin. These domains supply dystrophin with flexibility and are considered 
as a scaffold for binding signalling proteins, such as the neural nitric oxide synthase 
(nNOS), actin, polarity regulating kinase Par-1b and anionic lipids (Brenman  et al., 
1996; Legardinier et al., 2009; Le Rumeur et al., 2010;Yamashita et al., 2010). The 
subregion (ww domain) separates the central rod domain from the cysteine-rich domain 
and contains the binding site for β-dystroglycan (Rosa et al., 1996). The third dystrophin 
region is the cystein-rich domain, which contains a binding site for calmodulin and two 
EF-hand motifs for binding intracellular Ca
2+ 
(Koenig et al., 1988; Korsgren et al., 
2010). Finally, two coiled C-terminal regions attach dystrophin to dystrobrevin and 
syntrophins (Rybakova et al., 1996; Sadoulet-Puccio et al., 1997). In a normal muscle, 
dystrophin, β-dystroglycan, sarcoglycan (α, β, γ, δ), sarcospan, syntrophin (α1, β1) and 
α-dystrobrevin are the main components of the dystrophin-associated protein complex 
(DAPC) (Yoshida et al., 1994; Blake et al., 2002; Ehmsen et al., 2002). Together, these 
components provide a strong link between the cytoskeleton from one side and the 
extracellular matrix from another, playing an important role in protecting the muscle 
membrane during physiological contractions (Campbell and Kahl, 1989; Petrof et al., 
1993a) (Figure 1.3).  
 
 
 Figure 1.2: 
The dystrophin protein structure. The dystrophin protein contains numerous binding sites 
for interacting proteins: the ABD is the N-terminal actin binding site The 24 spectrin-like 
domains contain an additional actin-binding site and the binding sites for anionic lipids, 
Par-1b, nNOS, cholesterol and synemin. These regions are followed by the dystroglycan 
binding domain (DBD), syntrophin binding domain (SBS) and finally the dystrobrevin 
binding site in coiled-coiled region (CC); (Figure from Allen et al., 2016).  
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Figure 1.3:  
Schematic showing  the full length dystrophin anchoring the dystrophin associated protein 
complex (DAPC). The DAPC is sub-classified into the dystroglycan subcomplex, the 
sarcoglycan-sarcospan subcomplex, and the sarcoplasm subcomplex. The sarcoplasm 
complex contains syntrophin (α1, β1) and α-dystrobrevin. The sarcoglycan-sarcospan 
subcomplex contains sarcoglycan (α, β,γ,δ) and sarcospan (SSPN)  while β-dystroglycan 
and laminin are shown as part of  the dystroglycan subcomplex. Also, there are several 
proteins that interact with the DAPC such as syncoilin, dysferlin, calpain, caveolin-3, 
filamin-c, Grb-2, and nNOS. ABD, N-terminal actin binding site, DBD, dystroglycan 
binding domain, SBS, syntrophin binding domain  and CC, dystrobrevin binding site in 
coiled-coiled region (Figure from Allen, et al., 2016). 
 
Dystrophin is believed to serve as a shock absorber during muscle contraction, in which 
the force transmits from the contractile filament through dystrophin towards the 
extracellular matrix (Petrof et al 1993a). In DMD, absence of dystrophin leads to the 
disruption of the entire dystrophin associated protein complex and thereby 
destabilisation of the connection between the actin cytoskeleton and laminin in the 
extracellular matrix (bound by dystroglycan), resulting in sarcolemma fragility. Fragile 
membrane affects cellular responses, such as reducing the ability of the muscle fibre to 
resist the eccentric contractions, leading to a significant stress on the sarcolemma, which 
in turn escalates the leakage of sarcoplasmic enzyme such as creatine kinase (CK) to the 
serum and can be used as biomarker for muscle damage (Baird et al., 2012; Jeanson-Leh 
et al., 2014; Kobayashi et al., 2012). In turn, it allows influx of non-muscle proteins 
such as albumin and alters the Ca
2+
 haemostasis (Zatz et al., 1991; Clarke et al., 1993; 
Straub et al., 2000; Blake 2002). The influx of the extracellular Ca
2+
 activates the 
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proteolytic enzymes and triggers the muscle degradation (Alderton and Steinhardt 2000; 
Spencer 1995).  
Investigators suggested the possibility that DAPC has cellular signalling functions 
because some of its components bind with cellular signalling proteins. Dystrophin-
dystrobrevin-syntrophin interaction supports a number of important signalling pathways 
at the sarcolemma. The PDZ domain of syntrophin, for example, is involved in 
assembling various proteins in muscle and brain. In the muscle, the following proteins 
and enzymes are bound with syntrophin: nNOS (Adams et al., 2001), europhin receptor-
associated protein (ARMS) (Luo et al., 2005), sodium channels (Nav 1.4 and Nav 1.5) 
(Gee et al., 1998), potassium channels (Kir 2.1 and Kir 4.1) (Connors et al., 2004; 
Leonoudakis et al., 2004), transient receptor potential cation channels (TRPC1 and 
TRPC4) (Sabourin et al., 2009), Aquaporin-4 (Neely et al., 2001), Diacylglycerol kinase 
zeta (Abramovici et al., 2003), microtubule-associated serine/threonine kinase 
(MAST205) (Lumeng et al., 1999) and Myocilin (Joe  et al., 2012). Because the T-
tubules penetrate into muscle cells and surround the myofibrils, the absence of 
dystrophin disrupts the T-tubules system from the sarcolemma during the contraction. 
These tubules play an essential role in muscle contraction, particularly in conducting the 
action potential from the sarcolemma into the sarcoplasm (Allen et al, 2016). 
Additionally, dystrophin connects with caveola in the sarcolemma indirectly. The 
caveolae is a vesicular structure of plasma membrane, which makes membrane 
stretchable by providing spare membrane organised as folds. Absence of dystrophin 
removes this folding and gives rise to abnormal osmotic and muscle fibre stiffness 
(Menke and Jockusch, 1991; Hutter, 1992).  
The stability of the membrane seems to be important for the blood brain barrier (BBB) 
function and losing its integrity may be a factor that contributes to cognitive impairment 
in DMD patients (Vajda et al., 2002; Nico, 2003; Nico, 2004; Nico et al., 2005). 
Moreover, Lien et al. (2012) found that the α-dystrobrevin, a member of glial DAPC, is 
essential for BBB formation and functions by anchoring aquaporin-4 and Kir4.1 that 
maintain water homeostasis at the astrocyte-endothelial interphase.  
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Mutations in one or more proteins that compose the DAPC also result in muscle 
disorders or another form of muscle dystrophy (Campbell, 1995). For example, 
mutations in Sarcoglycan-encoding genes are observed in Limb girdle muscular 
dystrophies (LGMD2C,D,E and F) (Roberds, 1994; Piccolo, 1995). Any alteration in 
syntrophin genes produces lethal myopathy (Compton et al., 2008).  Dystrophin and 
integrin knockout mouse shows severe phenotype of the disease. Restoration of the 
integrin expression, on the other hand, ameliorates the contraction-mediated muscle 
injury and increases the regeneration cycle (Rooney et al., 2006). In addition, 
glycosylation defect of α-dystrogycan due to mutation in glycosyltransferases-encoded 
gene has been identified as a main contributor in both muscle-eye-brain disease (MEB) 
and Fukuyama congenital muscular dystrophy (FCMD) (Muntoni et al., 2002). 
1.3.2 Inflammation 
Inflammation plays a central role in the progression of the DMD (Porter et al., 2002). 
Evidence has shown that dystrophic muscle is initially invaded by macrophages, 
neutrophils, eosinophils and CD8+ and CD4+ T cells. Depletion of one of these cell 
types reduces the severity of muscular dystrophy. These inflammatory cells cause 
muscle damage and lesion that exacerbates the muscle fibre damage leading to necrosis 
(Spencer et al., 1997; Cai et al., 2000; Nguyen and Tidball, 2003; Wehling-Henricks et 
al., 2008 Villalta et al., 2009). In humans, the peak of immune cell infiltration occurs 
between the ages of 2-8 years and later muscle is replaced by the connective tissue and 
fat (Engel and Arahata, 1986; Morgan and Partridge, 2003). The infiltration of immune 
cells in the mdx mouse model of DMD (see later) is evident between ages of 2-4 weeks 
and then this infiltration declines by the age of three months (Spencer et al., 1997). 
 It has been proven that the muscle injury in DMD triggers the immune response in a 
different way than the inflammatory response to an acute muscle injury, because the 
cellular immune response involved is like in chronic injury. In the mdx model, the innate 
immune response shows similarity to that accompanying the acute muscle injury at the 
early stage of the disease, in which neutrophils and macrophages type 1 (M1) are the 
most predominant infiltrating cells. These cells influence further muscle damage by 
enhancing the cell lysis through inducible nitric oxide synthase (iNOS) mechanism, 
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which generates the nitric oxide (NO) (Wehling et al., 2001; Hodgetts et al., 2006; 
Villalta et al. 2009). Later on, another macrophage population (type M2) is found in 
mdx muscles. Unlike M1, M2 stimulate the satellite cell proliferation and thereby 
activate the regeneration process. Two types of the macrophage 2 subpopulation (M2a, 
M2c) are increased over the course of the disease progression. Both types can attenuate 
the immune response by supressing the cytolytic effect of M1. M2 release arginase, 
which hydrolyses the arginine to ornithin and urea and both molecules are associated 
with muscle repair. The arginine is a common substrate shared between arginase and 
iNOS, but in the acute stage of the disease the iNOS oxidates the arginine to citrulline 
and NO, and the latter is responsible for muscle damage. Thereby, the cytotoxic function 
of iNOS is attenuated upon releasing the arginase that reduces its availability for 
conversion into NO (Nguyen and Tidball, 2003; Villalta et al., 2009; Tidball and 
Wehling-Henricks, 2014). 
Cytokines and chemokines have been shown to be involved in the DMD disease. It is 
believed that both cytokines and chemokines are elevated before the onset of muscle 
damage and are associated with triggering the infiltration of immune cells such as 
macrophages and neutrophils (Porter et al., 2002; Warren et al., 2002; Gordon 
and Taylor, 2005; Pescatori et al., 2007). These cells also release the pro-inflammatory 
cytokines that recruit additional immune cells leading to the inflammation (Cruz-
Guzmán et al., 2015; De Paepe and De Bleecker, 2013). Furthermore, the damaged 
muscle fibres release danger associated molecular patterns (DAMPS), which also initiate 
the immune response (Tang et al., 2012). Cytotoxines regulate the predominance of 
macrophages in the degeneration and regeneration processes in the dystrophic muscle.  
TNF-α  and IFNγ stimulate M1 to produce iNOS, while IL4, IL10 and IL13 activate the 
M2 and supress the M1 (Villalta et al., 2009; Deng et al., 2012; van de Vyver and 
Myburgh, 2012). The expression of Tnf continues after the acute stage of disease, during 
the time of regeneration, suggesting the role of Tnf in modulating the satellite cell 
proliferation and differentiation (Zádor et al., 2001). The expression of Tgfβ gene 
reduces the immune cell response but increases the muscle fibrosis. The function of 
chemokines is to regulate the trafficking of immune cell to the site of infection or 
damage and to initiate the inflammatory response. However, several chemokines such as 
11 
 
CCL2, CCL3 and CCL4 also stimulate the proliferation of muscle satellite cells (De 
Paepe and De Bleecker, 2013). 
The numbers of CD4+ and CD8+ T- cells were found to be elevated in the DMD and 
mdx mouse in the acute stage of the disease. The location of these cells at the surface of 
the muscle fibre indicates their involvement in the pathological process. It is well known 
that cytotoxic T-lymphocytes (CTLs) kill the targets by cell interaction (Berke, 1995) 
involving three cytotoxic mechanisms: perforin-mediated killing, Fas–mediated killing 
and cytokine–mediated killing (Nagata, 1994; Spencer et al., 1997; Spencer et al., 
2001). Spencer et al., 1997 demonstrated that perforin-released by cytotoxic T-
lymphocytes is the main contributor to the dystrophic apoptosis and necrosis and 
deletion of perforin significantly reduced the apoptosis in mdx mice. 
Clusters of eosinophils are observed near the surface of the necrotic fibre in both  DMD 
and mdx mice (Cai et al., 2000; Wehling-Henricks et al., 2008). The increase of 
eosinophils has been detected in dystrophic muscle at 4 weeks of age and this invasion is 
dependent on the lymphocyte activity (Cai et al., 2000). However, Heredia et al. 
demonstrated the early invasion of IL4-induced eosinophils into the acutely injured 
muscle before the monocyte invasion, and targeting the IL4 receptor caused regeneration 
deficiency and fibrosis, indicating an additional role of these cells in regeneration 
(Horsley  et al., 2003; Heredia et al., 2013). However, in dystrophic muscle, these cells 
produce muscle injury, apoptosis, fibroblast proliferation and fibrosis (Wehling-
Henricks et al., 2008; Vidal et al., 2012). The cytotoxicity of eosinophils is related to the 
degranulation of their protein content [major basic protein (MBP), cationic protein 
(ECP), eosinophil peroxidase (EPO), and eosinophil derived neurotoxin (EDN)]. These 
cytotoxic proteins protrude the surface of the target cell causing cell swelling, influx of 
Ca
2+ 
and efflux of the cytosolic proteins (Cai et al., 2000). 
Mast cells are also observed near the necrotic muscle fibre and their role in fibrosis has 
been documented. Stimulation of mast cells causes the release of their granule contents 
that are biogenic amines, proteoglycans, cytokines and proteases like chymase, tryptase 
and carboxypeptidase (Gorospe et al., 1994a). The daily cromolyn treatment in mdx 
mice reduced the necrosis that was stimulated by mast cell degranulation, indicating the 
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important role of mast cells in DMD pathology (Radley and Grounds, 2006). However, 
Granchelli et al. (1995) found that double deletion of dystrophin and mast cells result in 
severe necrosis continuee to 8 weeks of age with significant reduction of the 
regeneration events. 
1.3.3 Abnormal cell signalling 
In dystrophin-deficient skeletal muscle, the disruption of the sarcolemma affects the 
anchoring of cell signalling molecules and evokes their abnormality. Among many 
disrupted pathways, the nitric oxide and calcium signalling appear to be most important. 
Three nitric oxide synthase (NOS) isoforms are expressed in the skeletal muscle (nNOS, 
iNOS and eNOS), and the nNOS has been indicated as the most predominant isoform 
there. The nNOS connects with syntrophin of the DAPC in normal muscle while it is 
displaced into the cytoplasm in dystrophic one (Brenman et al., 1996; Stamler and 
Meissner, 2001). It generates the NO and citrulline as a result of catalysing the L-
arginine (Bredt and Snyder, 1994). Nitric acid (free radical) is associated with a wide 
variety of biological processes carried out in the skeletal muscle, including the 
maintenance of the glucose uptake, regulation of the contractile and mitochondria 
functions, proliferation of satellite cell and cell growth, modulation of the vascular 
dilation, and preventing the vessel injury (Merry and McConell, 2009; Tousoulis et al., 
2012; Tidball and Wehling-Henricks, 2014; Allen et al., 2016). Therefore, the reduction 
in bioavailability of NO in dystrophic muscle due to the mislocalisation of nNOS is 
associated with free-radical-mediated damage, especially NO acting as an antioxidant by 
normalising other free radicals. In contrast, the concentration of NO donated by iNOS 
present in immune cells is elevated in dystrophic muscle. The interaction between the 
nitric acid and the reactive oxygen species (ROS) causes oxidative stress leading to cell 
damage, atrophy and regeneration impairment (McConell et al., 2012). 
Hypernitrosylation of Ryanodine Receptor (RyRs) reduces the calstabin-1 protein and 
the calcium RyR1 channel stabiliser protein. This stimulates the calcium RyR1 channel 
to open widely and promotes Ca
2+
 leaking from the sarcoplasmic reticulum.The NO 
resulting from the up-regulation of iNOS in mdx muscle contributes to this nitrosylation 
(Bellinger et al., 2008; Bellinger et al., 2009). 
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The role of calcium signalling in regulating muscle functions such as the contraction and 
activation of the proteolytic enzymes is well known (Blake et al., 2002).  Bodensteiner 
and Engel, (1978) demonstrated that the concentration of Ca
2+
 is greatly elevated (about 
≈100 fold) in cytosol of DMD patients and this free intracellular Ca2+ could be a 
significant contributor to the pathology of the disease. In addition to the human muscle, 
it has been shown that the Ca
2+
 influx is markedly increased in dystrophic mouse muscle 
(Turner et al., 1991), cat, dog (Chen et al., 2000) and pig (Klymiuk et al., 2013). Also, 
the elevation of Ca
2+ 
levels was observed in mdx myofibres and myotubes in culture 
(Turner et al., 1988; Bakker et al., 1993; Young et al., 2006). The Ca
2+
 level seems to be 
increased three-fold near the sarcolemmal region and 50% at the sarcoplasmic reticulum 
(SR) compared with the wild type values (Mallouk et al., 2000).  
Different hypotheses considered the mechanism of Ca
2+ 
accumulation inside the 
dystrophic muscle. The first hypothesis suggested that Ca
2+ 
enters during the 
microrupture induced by mechanical event such as contraction to re-seal these tears in 
Ca
2+
-dependent process. Furthermore, it predicts that the absence of dystrophin leads to 
introduce more tears in sarcolemma, which lead to infiltrate the higher concentration of 
Ca
2+ 
level, this hypothesis however is no longer acceptable (Cornelio and Dones 1984; 
Nagy and Samaha, 1986; McNeil and Khakee, 1992; Petrof et al., 1993a; Reddy et al., 
2001). The second hypothesis suggests the main entry route of Ca
2+ 
through
 
mechanosensitive channels (MSC), as their overactivation has been detected in DMD 
and mdx myotubes (Vandebrouck et al., 2001; Franco-Obregon and Lansman, 2002). 
Yeung et al. (2005) demonstrated the reduction of Ca
2+ 
level induced by stretched 
contractions in mdx fibre after treatement with MSC-inhibitors (Gd3, streptomycin, and 
GsMTx-4), supporting the role of MSC in the increased Ca
2+
 and muscle damage. 
However, the MSC abnormality in mdx has been found corrected after the expression of 
utrophin, while the Ca
2+ 
entry was still elevated (Squire et al., 2002).
 
 The third 
hypothesis suggests abnormal Ca
2+ 
cycle due to the dysfunction of SR and mitochondria, 
which causes elevated resting Ca
2+
 (cytosolic) and depleted SR Ca
2+
. At the same time it 
has been indicated  that there is a dysfunction of SR Ca
2+
 pumps responsible for 
returning the Ca
2+ 
to SR under normal conditions (Kargacin and Kargacin 1996; Ducret 
et al., 2006; Bellinger et al., 2008; Bellinger et al 2009). The up-regulation of store-
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operated calcium entry (SOCE) mechanism has been reported in mdx (Onopiuk et al., 
2015). The ATP and inositol-dependent depletion of the stored Ca
2+ 
ions stimulates 
SOCE channels located in the plasma membrane (Putney, 1986; Putney, 2010) leading 
to the influx of Ca
2+ 
from the extracellular milieu via SOC, L-type, transient receptor 
potential (TRP) and stretch-activated channels (Vandebrouck et al., 2002; Friedrich et 
al., 2004). Stromal interaction molecule 1 (STIM1) and calcium release-activated 
calcium channel protein 1 (Orai1) are indicated as the most predominant regulator 
proteins for SOCE (Mercer et al., 2006; Dziadek and Johnstone, 2007). Another 
hypothesis suggests that TRPC1-syntrophin binding makes a macromolecular complex 
with dystrophin and the absence of dystophin leads TRPC1 to form a complex with 
caveolin3 (Cav-3) and src-kinase. The later complex is associated with the entry of high 
levels of Ca
2+
.
 
This Ca
2+ 
is
 
restored when mini-dystrophin and syntrophin are 
reintroduced to the myotube (Yuan et al., 2003; Vandebrouck et al 2007; Gervasio et al., 
2008). Recently, a new Ca
2+
-influx hypothesis pointed to the purinergic receptor 
(P2RX7) contributing to the increased influx of Ca
2+ 
into dystrophic muscles. These 
studies showed that not only the P2RX7 expression is up-regulated in mdx muscle, but 
also that the cystolic Ca
2+ 
overload is due to the stimulation of this receptor by its native 
agonist ATP, whereas P2X7 antagonists blocked this effect (Yeung et al., 2006). 
Increasing the intracellular Ca
2+ 
concentration modifies the calcium leak channel 
function leading to further Ca
2+
 influx. 
The intracellular influx of Ca
2+
 ion is considered the causative factor of activating the 
proteases, such as calpains in dystrophy (Turner et al., 1988; Alderton and Steinhardt, 
2000). The high cytosolic Ca
2+ 
level is able to elevate the calpain activity by about 50 to 
100% (Gailly et al., 2007). Calpain translocates the phospholipase from cytoplasm to the 
cellular membrane, where phospholipids are hydrolysed and then the integrity of plasma 
membrane reduced (Fink and Cookson, 2005). 
In normal muscles after local injury, dystrophin is dissociated from the sarcolemma and 
calpain degrades dystrophin, starting from the COOH terminus, which is likely to be 
more sensitive to hydrolysis than the N-terminus (Lovering and Deyne, 2004). Using 
mdx as a model, calpain activation has been detected in the degeneration and 
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regeneration stages of the disease, while its level was the same as in control animals in 
pre-necrotic muscles (Spencer and Tidball, 1996). Besides the role of calpain in 
degradation and regeneration, it also interferes with the expression of several cellular 
components, including transcription factor (c-Fos and c-Jun), cytosolic enzymes and 
molecules involved in apoptosis (Carafoli and Molinari, 1998; Pariat et al., 2000). The 
calpain activity can be significantly decreased by the pharmacological inhibitor, 
calpeptin, which also reduces Ca
2+
 influx as well as degeneration events (Alderton and 
Steinhardt, 2000). Furthermore, Badalamente and Stracher (2000) found that calpain 
activity was reduced with improvements in the disease histological features, such as 
fibrosis, when the calpain inhibitor (leupeptin) was injected in mdx mice. This finding 
link increased Ca
2+
 ion levels in the cytosol with activation of this proteolytic enzyme 
(Leijendekker et al., 1996; Alderton and Steinhardt, 2000). 
1.3.4 Abnormal regeneration process 
The damaged muscle membrane and muscle fibre stimulates the regeneration process. 
However, in DMD,  the capacity of membrane repair systems together with muscle stem 
cell (satellite cell) are unable to keep up with the ongoing damage (Chargé and 
Rudnicki, 2004; Ciciliot and Schiaffino, 2010). The membrane repair system is 
stimulated as a first response to muscle damage and is activated by Ca
2+ 
influx from torn 
membranes. Subsequently, Ca
2+ 
activates the dysferlin (membrane resealing protein) that 
participates in vesicle-mediated patching. The vesicles aggregate and merge to reseal the 
membrane lesion. Bansal et al., 2003 found that the ability of repairing the membrane in 
dysferlin-deficient muscle is disrupted and resulting the degeneration of the muscle. The 
severe muscle damage triggers immune cells to invade muscle and release cytokines 
(Tatsumi et al., 1998). The immune response along with muscle mitogens (e.g. 
hepatocyte growth factor, HGF) activates the quiescent satellite cells, which start 
proliferating. The asymmetric division of satellite cells produces muscle precursor cells 
(myoblasts) and these are driven by chemotaxis to the injury site, where they fuse and 
differentiate to myotubes. Thus, the damaged muscle fibres are replaced by newly 
generated myofibres (Ciciliot and Schiaffino, 2010; Tidball and  Villalta, 2010). 
However, studies have shown increased satellite cell numbers in DMD patients 
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compared with controls and that the ability of these cells for regeneration is exhausted 
(Webster and Blau, 1990; Watkins et al., 1988; Renault et al., 2000). The failure of 
regeneration in DMD may be due to incapability of satellite cells to proliferate because 
they are under the senescent conditions (Blau et al., 1983). Furthermore, shortening of 
telomeres in DMD muscles undergoing great numbers of regeneration cycles were 
linked to the reduced proliferation ability of satellite cells according to the replicative 
aging mechanism (Decary et al., 2000). The differentiation of myoblasts into the 
myotubes is also attenuated due to the unfavourable degeneration environment that 
exists in muscles. For example, the high level of TGFβ and insulin binding protein (IGF) 
and low level of NO accompanying infiltrating immune cells as well as replacement of 
muscle with adipose and connective tissues (Melone et al., 1999; Melone et al., 2000; 
Tatsumi et al., 2002; Merly et al., 1999) affect dystrophic muscle regeneration. 
1.3.5 Cell death 
The reasons behind dystrophin-deficient muscle death have been investigated and the 
results indicate that apoptosis is a primary contributor, which is observed already at the 
age of two weeks, even before the onset of necrosis (Tidball et al., 1996). Abdel-Salam 
et al., in 2009 suggested that the extrinsic (Fas and FasL) and intrinsic (Bax/Bcl-2) 
apoptosis markers are indicators of degeneration in the DMD disease. Matsuda et al. 
(1995) indicated that elevated Ca
2+ 
in dystrophic
 
muscle cells stimulates the proteases 
and endonucleases and both enzymes are associated with the activation of apoptosis. 
Additionally, the CTL cells are activated by inflammatory cytokines, released cytosolic 
proteins and elevated heat shock protein levels. When CTL become activated, they can 
induce apoptosis via perforin and perforin-independent mechanisms. Perforin is secreted 
from CTLs, as soon as they interact with the surface of target cells, which are then killed 
by apoptosis (Nagata, 1994; Spencer et al., 1997; Spencer et al., 2001). Moreover, the 
increase in extracellular ATP levels has been linked to the induction of apoptosis. A 
high level of ATP can activate the Bax, Bim, Puma and cytochrome c, which are pro-
apoptotic factors mediating the activation of the apoptotic protease caspase (Tews, 2003; 
Altamirano et al., 2013). The apoptosis in dystrophic muscles is followed by necrosis 
(Tidball et al., 1996).  
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Unlike apoptosis, necrosis damages cells and their components are released and this 
potentiates harmful effects by damaging other cells (Kalai et al., 2002). In addition, it 
has been reported that necrosis cells are recognised and phagocytosed by macrophages, 
but in a less efficient mechanism than the clearance of the apoptotic cells (Brouckaert et 
al., 2004). Using Three-dimensional optical coherence tomography (3D-OCT), the 
necrotic lesions were observed in individual fibres of 12-week mdx mice (Klyen et al., 
2011). Infiltration of immune cells combined with multiple unsuccessful regeneration 
cycles and intracellular Ca
2+
 overload are the major causes of myofibre necrosis 
(Spencer and Tidball, 2001; Tidball   and Wehling-Henricks, 2005; Burr and Molkentin, 
2015). Additionally, necrosis can be induced by overexpression of leukocyte mediated 
killing mechanisms including IFN-γ and TNF (Shelton et al., 1999). 
Increased intracellular Ca
2+
 also mediates the oncosis cell death mechanism, 
characterised by swelling of all cell components and increased cell membrane 
permeability. The oncosis also induces proteolysis of the plasma membrane by 
activating the calpain enzyme (Fink and Cookson, 2005). 
Damaged muscle initiates the regeneration process to replace the damaged fibre with a 
new one (Tidball and Villalta, 2010). In DMD, the newly generated fibre also 
degenerates resulting in unsuccessful regeneration ending with excessive accumulation 
of extracellular matrix (ECM) in the muscle tissue (Kääriäinen et al., 2000; Porter et al., 
2002). This fibrosis process impairs the muscle function and leads to premature death 
via respiratory and cardiac failure. The chronic inflammatory response plays a key role 
in fibrosis. M2 macrophages are found abundant during the late stage of tissue repair 
and fibrosis. Although M2 have beneficial effects in regenerating the damaged muscle, 
their prolonged activation promotes fibrosis and this is related to the release of the pro-
fibrotic factors such as TGFβ, fibronectin, proline and CCL17. CCL17 interacts with 
CCR4 and enhances fibrosis. Surprisingly, the metabolism of L-arginine by M2 
increases the fibrosis in heart and leg muscle of mdx mice (Yogo et al., 2009; Tidball 
and Villalta, 2010). Therefore, Wehling-Henrichs et al. (2010) demonstrated that long 
term arginine supplementation in DMD patient has a prospective risk of worsening the 
pathology of the disease by promoting fibrosis. In addition to macrophages, CD4+Th2 
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cells also regulate fibrosis by producing the pro-fibrotic cytokines IL4, IL5, IL6 and 
IL13. The perturbation of satellite cells or fibroblast regeneration also causes fibrosis 
(Serrano and Muñoz-Cánoves, 2010; Mann et al., 2011). 
Very recently, a novel mechanism of autophagic cell death has been identified in 
dystrophic myoblasts by Young et al., 2015. The prolonged activation of P2RX7 with a 
high level of ATP leads to the large pore formation and interaction with heat shock 
protein 90 (HSP90) triggers autophagic flux and muscle cells death. Inside a normal 
muscle, there is a high concentration of intracellular ATP, which is involved in 
physiological processes such as contraction, and only a small amount is released from 
the muscle as an autocrine and a paracrine signal (Becq et al., 2010). However, large 
quantities of ATP are released as one of the ‘Damage–Associated Molecular Patterns’ 
(DAMPs) as a result of muscle damage and activate the immune response by activating 
the P2RX7 receptor (Di Virgilio, 2007; Tang et al., 2012). Any excess of extracellular 
ATP (eATP) in normal muscle is eliminated by ectonucleotidase (ATPase) enzymes 
including α-sarcoglycan. This member of dystrophin associated proteins hydrolyses 
about 25% of eATP (see below). Therefore, loss of dystrophin and thus dystrophin 
associated proteins affects the regulation of eATP release and degradation (Sandonà et 
al., 2004; Young et al., 2013).  
 P2RX7 receptor  1.4
P2RX7 receptor is a trimeric ATP-gated nonselective cation channel that belongs to the 
P2X superfamily, which includes seven distinct members P2RX1-7 (Coddou et al., 
2011). P2RX7 shows 45% structure similarity with other P2X receptors, which are 
characterised by intracellular amino and carboxyl termini separated by the large 
extracellular ATP binding loop and two transmembrane domains. Another property it 
shares with other members of this family is opening a non-selective ion channel 
allowing passage of Ca
2+
, Na
+
, and K
+
 in response the short stimulation by extracellular 
ATP. However, P2RX7 has a unique property by which it is distinguished from other 
P2X members, which is an unusual additional opening state characterised by a larger 
pore formation in response to prolonged stimulation with its ligand, which permits 
permeation of molecules of up to 900Da, such as ethidium bromide (EtBr) dye 
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(Surprenant et al., 1996; Rassendren et al., 1997; Chessell et al., 1998; Gever et al., 
2006). Moreover, P2RX7 has a long C-terminal tail that comprises of 244 amino acids 
interacting with lipid and cysteine-rich domains (Figure 1. 4). This unique region has a 
role in the large pore formation and the trafficking response. 
P2RX7 receptor is widely distributed on a variety of cell types, mainly on the surface of 
immune cells (macrophages, dendritic cells, lymphocytes, eosinophils and mast cells) 
but also in glia (microglia, astrocytes, oligodendrocytes and Schwann cells), some 
epithelial cells, fibroblasts, osteoblasts and some neurons (in the spinal cord, cerebellum, 
hypothalamus, and substantia nigra) (Collo et al., 1997; Surprenant et al., 1996; 
Gro¨schel-Stewart et al., 1999; Franke et al., 2001; Gartland et al., 2001; Papp et al., 
2004; Sperlagh et al., 2006; Cotrina and Nedergaard, 2009; Di Virgilio et al., 2009; 
Lenertz et al., 2011).  
Activation of P2RX7 seems to regulate a diverse range of downstream signalling 
cascades such as the activation and secretion of pro-inflammatory cytokines (mature 
IL1β and IL18), proteases (metalloproteases, caspases and cathepsins) (Ferrari et al., 
1999; Jiang et al., 2005; Gu and Wiley, 2006; Lopez-Castejon et al., 2010), prostanoids 
(Prostaglandin E2 (PGE2), thromboxane B2, and leukotriene B4) (Barberà-Cremades et 
al., 2012), glutamate and aspartate (Duan et al., 2003), killing the invading pathogen, 
generating the reactive oxygen species (ROS) leading to activation of NLRP3 
inflammasome (Wang et al., 2013; Franceschini et al., 2015), stimulating transcription 
factors (Ferrari et al. 1997a), regulating the phagocytosis (Wiley and Gu, 2012) and 
proving the fast-growing cells such as cancer with needed energy resulting from aerobic 
glycolysis (Di Virgilio et al., 2009; Amoroso et al., 2012). Moreover, in skeletal 
muscles, researchers have shown the role of P2RX7 in the activation of myoblast 
proliferation (Lu and Smith, 1991), differentiation into myotubes (Martinello et al., 
2011; Ryten et al., 2002) and in the DMD pathology and cell death (Young et al., 2015). 
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Figure 1.4: 
The zebrafish model of P2RX7 showing the unique structure of this receptor amongst other 
P2X members. It has a long C terminal tail that consists of 244 aa. The extracellular loop 
contains 10 cysteine residues that allow the formation of the disulphide bonds. The 
extracellular loop has also three ATP binding sites, marked yellow (Khakh and North, 
2006). 
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Crucially, the high levels of P2RX7 receptor expression have been demonstrated in a 
number of diverse pathologies such as Huntington’s disease (Díaz-Hernández et al., 
2009), Alzheimer’s disease (Diaz-Hernandez et al., 2012), neuropathic and 
inflammatory pain (Chessell et al., 2005), rheumatoid arthritis (Portales-Cervantes et al., 
2010), graft-versus-host disease (Wilhelm et al., 2010), cancer (Adinolfi et al., 2012) 
and limb-girdle muscular dystrophy type 2B (Rawat et al., 2010). Over-expression of 
P2RX7 receptor was indicated in both DMD as a result of organ transplant rejection 
(Ferrari et al., 1994; Gazzerro et al., 2015) and mdx mice (Young et al., 2012). Very 
recently, it has been found that the enhancement contributes to the muscle damage 
directly by autophagic cell death and indirectly by contributing to the immune response 
(Young et al., 2015; Sinadinos et al., 2015). 
The skeletal muscle normally contains high concentration of intracellular ATP (5 to 10 
mM), where it breaks down into ADP and inorganic phosphate, releasing energy 
required for the muscle contraction cycle (Davies et al., 1990; Kushmerick et al., 1992; 
Gordon et al., 2000; Hetherington et al., 2001; Barclay, 2003). A small quantity of ATP 
is released from a healthy cell in response to physiological activities (Becq, 2010). In 
contrast, during muscle injury and excessive exercise, the large amount of this cytosolic 
ATP is released into the extracellular space. Located in the outer surface of the 
membrane, the eco-ATPase enzymes serve as a protective mechanism against 
overabundance of this released and now extracellular ATP (Yegutkin et al., 2008). Betto 
et al. (1999) have demonstrated that one of the DAPC members (α-sarcoglycan) is a 
Ca
2+
 and Mg
2+
 dependent ecto-ATPase and that it hydrolyses about 25% of the 
extracellular ATP in muscles. In the DMD, as a result of dystrophin absence and 
disruption of the DAPC, the ATP is released from fragile myofibres and becomes one of 
DAMPs (Di Virgilio, 2007). When the concentration of ATP in extracellular space 
exceeds 100μM, the ecto-ATPases are less able to cope and degrade the ATP overload 
(Bodin and Burnstock, 1996). In DMD muscle, this decreased ecto-ATPase activity 
together with the absence of -sarcoglycan raises the eATP levels dramatically. The 
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high level of eATP is considered the appropriate environment for the activation of the 
P2RX7 receptor, which is significantly less sensitive to eATP than any other P2X 
receptors. Consequently, it has been found that the activation of P2RX7 in dystrophic 
muscle by high levels of ATP can lead to the Ca
2+
 ions influx, increased extracellular 
signal-regulated kinase (ERK) phosphorylation, and increased sensitivity to 
nicotinamide adenine dinucleotide (NAD) that also induces Ca
2+
 influx (Ryten et al., 
2004;Yeung et al., 2006; Young et al., 2012). Furthermore, the large pore formation in 
response to prolonged exposure to high eATP allows non-selective permeability of high 
molecular weight molecules and ions, triggers autophagic cell death and further release 
of intracellular components (DAMPs), and thus stimulates the inflammatory cell 
infiltration and ameliorates the regeneration, which are factors responsible for the DMD 
damage (Ferrari et al., 1996; Surprenant et al., 1996; Browne et al., 2013; Gever et al., 
2006; Young et al., 2015). The P2RX7 receptor is therefore considered a danger 
receptor and ATP is a danger signal (Ferrari et al., 1996; Gallucci and Matzinger, 2001). 
The danger signal, in general, is classified as a small-size molecule (<650Da) found in a 
normal tissue, but released at high concentrations from damaged cells only. It has the 
ability to travel quickly in extracellular fluids to induce the innate and adaptive immune 
system responses (Di Virgilio, 2005). 
The role of P2RX7 receptor in stimulating the immune response is studied widely, and 
the chronic inflammation is a hallmark of the DMD disease. As mentioned, P2RX7 
receptor is expressed on immune cells and on dystrophic muscle, therefore it may 
contribute directly to the inflammatory phenotype in DMD (Ferrari et al., 1996; Ferrari 
et al., 1997c; Gu et al., 2000; Di Virgilio et al., 2001; Gudipaty et al., 2001; Lenertz et 
al., 2009; Wewers & Sarkar, 2009). Since P2RX7 receptor is expressed on 
macrophages, its activation is involved in releasing the pro-inflammatory cytokines such 
as IL1β, IL1α, IL18 and TNFα (Ferrari et al., 1996; Beigi et al., 2003). The mechanism 
in which the P2RX7 receptor leads to the production of these cytokines is as follows: 
binding of eATP with P2RX7 receptor triggers the efflux of the intracellular K
+
 ion, the 
activation of the Ca
2+
-independent phospholipase, and the activation of caspase-1. Then, 
caspase-1-proIL1β- inflammasome is assembled, where the caspase-1 cleaves pro-IL1β 
to mature IL1β in the cytosol, lysosomes, or both. The Ca2+ ion influx through the 
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P2RX7 channel provides a mechanism for the secretion of mature IL1β (Ferrari et al., 
1996). Labasi et al., 2002 found that releasing IL1β can stimulate expression of other 
inflammatory markers. They demonstrated the up-regulation of Il6, Tnf and 
cyclooxygenase-2 (Cox-2) after ATP administration to wild type animals, while in 
P2RX7
-/-
 deficient mouse, the cytokines signalling was markedly reduced as well as the 
severity and incidence of disease were lower (Uaesoontrachoon et al., 2008). It is well 
known that both IL1β and TNF-α are important inflammatory mediators in stimulating 
the immune response in the DMD (Lundberg et al., 1995; Grounds & Torrisi, 2004; 
Hodgetts et al., 2006; Pierno et al., 2007). Therefore, targeting P2RX7 receptor with 
specific drugs could bring a therapeutic benefit in this lethal disease. 
P2RX7 receptor antagonists with different chemical structure, specificity, selectivity and 
potency are available commercially. Reactive Blue 2, suramin, pyridoxal phosphate-6-
azophenyl-2-4-disulfonic acid (PPADS), periodate-oxidized ATP (oATP) are non-
selective P2RX7 inhibitors, which are capable of antagonising other members of the 
P2X family (Kerr and Krantis, 1979; Dunn and Blakeley, 1988; Lambrecht  et al., 1992; 
Murgia et al., 1993; Gever et al., 2006). For example, oATP has pharmacological 
activity against P2X1 and P2X2 (Evans et al., 1995). Additionally, to block P2RX7 
effectively, several hours of incubation and concentrations between 100-300µM are 
required (Murgia et al., 1993). However, in experimental studies, it is used widely 
because it binds with P2RX7 receptor irreversibly, and it can ameliorate the immune 
response by inhibiting the NF-κB  (mechanism independent of P2 receptor activation) 
(Murgia et al., 1993; Beigi et al., 2003; Ferrari et al., 2006). Brilliant Blue G (BBG) 
(Soltoff et al., 1989 ), and 1-[N,O-bis (5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-
phenylpiperazine (KN-62) (Gargett and Wiley, 1997) are also the first generation 
antagonists being considerably more selective than the first group at low concentrations, 
however their selectivity appears to be species-dependent (North, 2002). For instance, 
Brilliant Blue G (BBG) blocks the rat receptor with more potency than the human 
receptor. 
The new generation of antagonist was developed in the beginning of 2000s. It contains 
cyclic imides and adamantane amides such as AZ11645373 (3-(1-(3’-nitrobiphenyl- 4-
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yloxy)-4-(pyridine-4-yl) butan-2-yl) thiazolidine2, 4-dione (Stokes et al. 2006). In spite 
of the high potency of this antagonist in blocking P2RX7 receptor, the species affinity 
presents a limitation for using AZ11645373 in preclinical trials. The antagonists 
mentioned above are not suitable for medical use because they are either rapidly-
degraded nucleotides or polyanionic molecules (dyes) (Gover et al., 2006). The 
connection between P2RX7 receptor and various pathological conditions lead to the 
design of drug-like antagonists that specifically block the P2RX7 receptor in vivo and 
with therapeutic efficacy. It has to be remembered that the outcome of using the 
antagonist in vivo may be drastically different from the in vitro treatment. Furthermore, 
the differences of the antagonist activity in various species need to be considered when 
used in vivo, and therefore some of the pre-clinically efficacious antagonist cannot be 
used as a therapeutic drug in humans while some of the drugs tested in clinical trials 
cannot be tested in certain animal models of other diseases. Importantly, the numerous 
and different P2RX7 variants also should be taken into account when choosing the 
appropriate antagonist (Bartlett et al., 2014).  
The Abbott Laboratories developed two groups of tetrazoles and cyanoguanidines 
(Nelson et al., 2006; Honore et al., 2006). Both are reversible, competitive and highly 
specific for the P2RX7 receptor and show the same activity in different species. The 
novel example of tetrazoles is 3-[[5- (2, 3-dichlorophenyl)-1H-tetrazol-1-yl] methyl] 
pyridine (A438079) and the novel antagonist from cyanoguanidine series is A-740003 
((N-(1-{[(cyanoimino) (5-quinolinylamino) methyl] amino}-2,2-dimethylpropyl)-2-(3,4-
dimethoxyphenyl) acetamide). These pharmacophores inhibit the release of Il1β, pore 
formation and reduce the intracellular Ca
2+
 accumulation. The additional feature that 
made A-740003 more attractive than A438079 is the more potency and bioavailability in 
preclinical treatments. This compound was used to reduce the disease phenotypes of 
neuropathic pain, chronic constriction injury and neuropathy in animal models (Honore 
et al., 2006).   
The abnormality of P2RX7 receptor has been demonstrated in DMD. The expression 
level of this receptor was found to be up-regulated in both muscle (Young et al., 2006; 
Rawat et al., 2010; Young et al., 2012) and non-muscle cells (Ferrari et al., 1994). 
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Therefore, targeting P2RX7 receptor may be a significant new development in treating 
the disease. Very recently, our group found that genetic ablation of P2RX7 in mdx 
attenuates muscle and non-muscle disease phenotype, including increasing muscle 
strength, reducing creatine kinase levels in the serum, reducing the inflammation and 
fibrosis as well as improving the bone and cognitive phenotypes (Sinadinos et al., 2015). 
 Animal models of DMD 1.5
Investigations using animal models in the study of human diseases provide insights into 
the complex mechanism of the pathophysiological process on the one hand and allow 
studying the effect of putative treatments on the other. In the case of a genetic disease, 
the genetic defect and the pathological characteristics of an animal model should be 
representative of the human defect. Using appropriate models emphasises the value of 
collected data and accelerates the preclinical stage of a new therapeutic drug into clinical 
trial (Willmann et al., 2009). 
About 60 animal models are either naturally occurring or have been laboratory-
generated to understand the pathology of DMD and identify effective therapeutic drugs 
for the treatment of this disease (Allamand and Campbell, 2000; McGreevy et al., 2015). 
The most common mammalian models are: dogs (golden retriever dystrophy) (Kornegay 
et al., 2012), cats (hypertrophic feline muscular dystrophy (HFMD) (Winand et al., 
1994) and recently pig and rat (Klymiuk et al., 2013; Nakamura et al., 2014). Dog and 
pig models show many similarities with the human disease in terms of the severity of the 
disease. However, any work with these models is very expensive and there are 
difficulties in maintaining their colonies due to a high mortality rate among the pups and 
piglets. For these reasons these models are used for advanced stages of therapeutic 
testing (Banks and Chamberlain, 2008; Ng et al., 2012).  
The mdx mice are widely used as an animal model for DMD because of their less-
sentient nature, small size, the ease to breed, widespread availability and relatively low-
price (Willmann et al., 2009). Beyond these advantages, there are a large number of 
studies providing outstanding information about the disease progression and the mdx 
characteristics. The mdx mouse was firstly identified in 1984 in a c57BL/10sScSn 
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colony by the high creatine kinase levels in the serum and features of muscle dystrophy 
(Bulfield 1984). It carries a spontaneous point mutation in exon 23 introducing a 
premature stop codon leading to no dystrophin protein translation (Sicinski et al., 1989; 
Durbeej and Campbell, 2002). This means that the mdx mice and DMD patients share 
the same key hallmarks of the disease, particularly the underlying genetic abnormality. 
However, mdx mice display a milder disease phenotype than humans with nearly normal 
life span with only ~20% reduction (Chamberlain et al., 2007). Furthermore, mdx mice 
are born with nearly normal muscles and experience a sudden wave of muscle damage 
starting at 3-4 weeks and lasting until around 12 weeks of age, followed by a 
regeneration response evidenced by centrally nucleated fibres, increasing numbers of the 
heavy chain myosin (MyHC)-expressing fibres and heterogeneity of fibre size. 
Thereafter, degeneration-regeneration cycles in limb muscles remain balanced (Coulton 
et al., 1988; Petrof et al., 1993b; Kobayashi et al., 2012). However, diaphragms appear 
to be significantly more affected than limb muscles, with the histological pathological 
features remaining throughout (Stedman et al., 1991). However, the progression of 
respiratory muscle disease does not lead to premature death. Although the mdx mice 
display a milder phenotype, the acute stage of disease supplies an affordable model to 
study the disease progression that can be identified easily by standard readouts and 
parameters. Accordingly, mdx are considered as a model of choice for pre-clinical 
studies and for testing new therapeutic modalities (Willmann et al., 2009; McGreevy et 
al., 2015).   
There are many possibilities that could explain why the mdx mice show this milder 
phenotype, some of which are relevant for the work presented here. Perhaps the first 
established explanation is that the homologous protein utrophin replaces the absent 
dystrophin as utrophin levels are increased in mdx mice (Matsumura et al., 1992) and 
further over-expression of utrophin in mdx mice ameliorates the phenotype, while mdx 
lacking both the utrophin and dystrophin suffer from a more severe phenotype (Grady et 
al., 1997; Deconinck et al., 1997). The second possible reason for the milder phenotype 
is the substantial regeneration, based on the satellite cells capacity to repeatedly divide 
and repair the mdx muscle damage. It has been hypothesised that the satellite cells with 
long length telomere has highly regenerative capacity (Sacco et al., 2010). Importantly, 
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study by Kipling and Cooke in 1990 indicated that mdx mice have telomere length of 
about > 40 kilobases, whereas human cells have shorter telomeres of ~5–15 kb. The 
third reason might be the small body size of mdx mice that reduces the force on the 
muscle fibre and therefore the damage is less severe (Bodor and McDonald, 2013; 
Partridge, 2013). 
In order to identify biomarkers that were altered in mdx as the result of ablation of the 
P2RX7 receptor, mdx and Pfizer -mdx/P2rx7
-/-
 were compared. The Pfizer-mdx/P2rx7
-/-
 
was developed by crossing Pfizer-P2rx7 gene knockout (Solle et al. 2001) with the mdx 
mouse (Sinadinos et al., 2015, Young et al., 2015). These mice lack both the dystrophin 
and the functional P2RX7 receptor.  
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  Hypothesis and statement of aims 1.6
P2RX7 purinoceptor activation is an important pathological event in Duchenne muscular 
dystrophy (DMD). Pharmacological interference with P2RX7 functions will modulate 
the dystrophic phenotype and alter the disease progression. 
Aims: 
The main aims of this work were to: 
 Study the effects of pharmacological inhibition of P2RX7 in dystrophic (mdx) mice at 
the acute disease stage and to compare these to the effects of genetic purinoceptor 
ablation.   
 Characterise the local and systemic changes in the immune status (infiltrating immune 
cells and prevailing immune mediators) associated with the ablation of P2RX7 
purinoceptor in mdx mice. 
 Understand functions of P2RX7 in dystrophic muscles using primary muscle cells 
from mice lacking dystrophin, P2RX7 or both dystrophin and P2RX7 purinoceptors. 
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2  
                                        Materials and methods  
 
  Chemicals and reagents 2.1
  Table 2.1: List of chemicals and reagents 
Products name Manufacturer 
A  
A-438079 hydrochloride hydrate Sigma-Aldrich Ltd. 
Acetic acid, glacial Fisher Scientific Ltd. 
Acrylamide/bis-acrylamide Bio-Rad Laboratories Ltd. 
Adenosine 5′-triphosphate, periodate oxidized sodium salt Sigma-Aldrich Ltd. 
AFC-5128 Affectis pharmaceutical company 
Agarose Promega Ltd. 
Agarose  loading buffer Life Technologies Ltd. 
Ammonium persulphate (APS) Sigma-Aldrich Ltd. 
B  
β-mercaptoethanol Sigma-Aldrich Ltd. 
Bicinchoninic acid (BCA) Sigma-Aldrich Ltd. 
Bovine serum albumin (BSA) Sigma-Aldrich Ltd. 
C  
Calcium chloride Sigma-Aldrich Ltd. 
Carboxymethylcellulose (CMC) Sigma-Aldrich Ltd. 
Chick embryo extract  Sera Labs Ltd 
Chemiluminescent substrate, Luminata Crescendo  Merk Millipore Ltd. 
Chemiluminescent substrate, Luminata Forte Merk Millipore Ltd. 
Chloroform Fisher Scientific Ltd. 
Collagenase, type 1 Sigma-Aldrich Ltd. 
Complete Lysis-M protein extraction reagent Roche Applied Science Ltd. 
30 
 
Complete Mini Protease Inhibitor Cocktail Tablets Roche Applied Science Ltd. 
Coomassie brilliant blue Sigma-Aldrich Ltd. 
Copper II sulphate (4%w/v) Sigma-Aldrich Ltd. 
D  
DDH2O, RNase free water Invitrogen Ltd 
Dibutyl Polystyrene Xylenes synthetic mounting media 
DPX 
Fisher Scientific Ltd. 
Direct-zol
TM
 RNA mini prep Zymo Research 
DNA ladder 1 kb New Ehgland Biolabs Ltd. 
DNA ladder 100 bp New Ehgland Biolabs Ltd. 
DNA polymerase buffer Life Technologies Ltd. 
DNA polymerase, Taq Life Technologies Ltd. 
DNeasy
TM
 blood and tissue DNA extract kit Qiagen 
E  
Eosin Y solution, alcoholic Vector Labs Ltd. 
Ethanol Fisher Scientific Ltd. 
Ethidium bromide solution Sigma-Aldrich Ltd. 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich Ltd. 
F  
Fluor SaveTM fluorescence mounting media Merk Millipore Ltd. 
G  
geNorm Kit Primer Design Ltd 
Glacial acetic acid Sigma-Aldrich Ltd. 
Glycerol Sigma-Aldrich Ltd. 
Glycine Sigma-Aldrich Ltd. 
Go Taq 2x green master mix Promega Ltd 
H  
Haematoxylin and eosin kit Vector Labs Ltd. 
Hank’s buffered saline solution (HBSS) Thermo Scientific Ltd. 
Hoechst 33342 fluorescent nuclear counterstain Life Technologies Ltd. 
Honey TESCO 
Horse serum (HS) Thermo Scientific Ltd. 
Hydrochloric acid Thermo Scientific Ltd. 
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Hydrogen peroxide Life Technologies Ltd. 
I  
iProof™ High-Fidelity DNA Polymerase  Bio-Rad Laboratories Ltd 
Isopropanol Sigma-Aldrich Ltd. 
Laemmli sample buffer Bio-Rad Laboratories Ltd 
LB broth Sigma-Aldrich Ltd. 
M  
Magnesium chloride Life Technologies Ltd. 
Methanol Fisher Scientific Ltd. 
2-methylbutane Fisher Scientific Ltd. 
Milk, dried skimmed TESCO 
miRNasy mini kit Qiagen 
miRNeasy Serum/Plasma Kit Qiagen 
MspI restriction enzyme New Ehgland Biolabs Ltd. 
N  
N,N,N,N,-Tetramethylethylenediamine (TEMD) Sigma-Aldrich Ltd. 
NMDI-14 Chembridge 
Normal donkey serum Vector Laboratories Ltd 
Normal goat serum Vector Laboratories Ltd 
O  
OCT cryo-resin Themo Scientific Ltd 
P  
Paraformaldehyde Sigma-Aldrich Ltd. 
Phosphate buffered saline tablets Sigma-Aldrich Ltd. 
PhosSTOPphosphatase Inhibitor Cocktail Tablet Roche Applied Science Ltd. 
Poly-L-lysine Sigma-Aldrich Ltd. 
Polyvinylidene fluoride (PDVF) membrane GE Healthcare 
Precision FAST qPCR master mix Primer design Ltd 
Primer only geNorm 12 gene kit for use with SYBR Green Primer design Ltd 
PROTEAN TGX
TM
 pre-cast polyacrylamide gel  
Protein Ladder Bio-Rad Laboratories Ltd 
Proteinase K Qiagen 
R  
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5' RACE System for Rapid Amplification of cDNA Ends Invitrogen Ltd 
RNasy mini kit Qiagen 
RNeasy Plus Universal mini kit (50) Qiagen 
S  
Sodium chloride Sigma-Aldrich Ltd. 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich Ltd. 
Sodium hydroxide  
SuperScript® VILO II cDNA Synthesis Kit Invitrogen Ltd  
 SYBR®Safe DNA gel stain Invitrogen Ltd. 
T  
TaqMan® Universal Master Mix II, with UNG  Applied Biosystems 
TM
 
Tris-base Sigma-Aldrich Ltd. 
Tris-hydroxide Sigma-Aldrich Ltd. 
TRIzol Life Technologies Ltd 
Tween 20 Sigma-Aldrich Ltd. 
X  
Xylene Sigma-Aldrich Ltd. 
Z  
Zidovudine European Pharmacopoeia (EP) Reference 
Standard 
Sigma-Aldrich Ltd. 
 
Table 2.2: List of buffers used in the study. 
Buffers Components 
TAE 
Tris-base(40mM), Glacial acetic acid (19mM), EDTA 
(0.5mM) in 1L of DDH2O, pH=8 
PBST 
Five tablet of phosphate buffer saline dissolved in 1L of 
DDH2O, 0.05% Tween 20  
TBST 
Tris-HCl (15.2mM), Tris-base (4.62mM), NaCl (150.7 mM), 
(0.05 % Tween 20) in 1L of DDH2O, pH= 7.6 
Western blot-Running buffer 
Tris-base (27.2 mM), Glycine (0.192M), SDS (3.468 mM), in 
1L of DDH2O 
Western blot-Transfer Buffer Tris-base (27.2mM), Glycine (0.192M), Methanol (20%) in 1L 
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of DDH2O 
BCA Copper II sulphate ( 2% ) in Bicinchoninic acid  
Acid alcohol HCl  (0.02M ) in 70% ethanol 
PFA Paraformaldehyde (4%) in 1X TBST 
Poly-L-Lysine  Poly-L-lysine (5mg/ml ) in DDH2O 
Western blot blocking buffer Milk, skimmed (5% ) in TBST 
Stacking buffer Tris-HCl (0.5M), in DDH20  pH=6.8 
Resolving buffer Tris-HCl ( 1.5M) in DDH2O  pH=8.8 
5% Stacking gel 
H2O (2.1 ml),  acrylamide (30%),  stacking buffer (0.3 ml) , 
SDS(10%),  APS(10%), TEMD (0.003 ml) 
10% Resolving gel 
H2O (4 ml), acrylamide (30%),  resolving buffer (2.5 ml), 
SDS(10%),  APS(10%), TEMD (0.004 ml) 
15% Resolving gel 
H2O (2.3 ml),  acylamide (30%), resolving buffer (2.5 ml),  
SDS (10%),  APS (10%), TEMD (0.004 ml) 
Western blot stripping buffer 
SDS (2%), β-Mercaptoethanol (2 mM), Tris-HCl (50mM) in 
DDH2O pH=6.7 
AE buffer 10 mM Tris·Cl, 0.5 mM EDTA, pH= 9.0 
 
Table 2.3: List and detailed description of primary antibodies used in Western blotting. 
Antibodies Host Species 
Molecular 
weight of 
target protein 
Dilution Manufacturer 
ACTIN Rabbit Many 42 kDa 1/1000 WB Sigma-Aldrich 
GAPDH Goat Many 37 kDa 1/500 WB Santa Cruz 
CD11B Rabbit Mouse 160 kDa 
1/1000 WB 
1/500 IF 
Abcam 
CD68 Rat Mouse 87-115 kDa 1/500 IF AbD Serotec 
CD206 Rat Mouse 175 kDa 1/500 IF AbD Serotec 
Collagen-IV Goat Human, mouse Not tested 1/500 IF Abcam 
Dystrophin Rabbit Mouse 427 kDa 
1/500 WB 
1/500 IF 
Sigma-Aldrich 
F4/80 Rat Mouse 130 kDa 1/500 IF Abcam 
LY6G Rat Mouse 21-25kDa 1/250 IF eBioscience 
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P2RX4 Rabbit Mouse 60 kDa 
1/500 WB 
1/1000 IF 
Alomone 
P2RX7 Rabbit Rat, mouse 75 kDa 
1:1000 WB 
1:500 IF 
Synaptic 
Systems 
LC3BII Rabbit 
Human, rat, 
mouse 
16-18 kDa 1/1000 WB Sigma-Aldrich 
NF-κB Rabbit Many 65 kDa  
Cell Signalling 
Technology 
BMP7 Rabbit Many 49 kDa 
1/500 WB 
1/500 IF 
Sigma 
Abcam 
SMAD 1/5/8 Rabbit Many 60 kDa 1/1000 WB 
Cell Signalling 
Technology 
SMAD 3 Rabbit Many 60 kDa 1/1000 WB 
Cell Signalling 
Technology 
 
Table 2.4: Secondary antibodies used in Western blotting and immunostaining  
Name Host species Dilution Manufacturer 
Alexa Fluor 488 Goat Rabbit 1/1000 IF Life technologies 
Alexa Fluor 488 chicken Rabbit 1/1000 IF Life technologies 
Alexa Fluor 488 Chicken Mouse 1/1000 IF Life technologies 
Alexa Fluor 555 Donkey  Rabbit 1/1000 IF Life technologies 
Alexa Fluor 594 Chicken Goat 1/1000 IF Life technologies 
Alexa Fluor 594 Donkey Rabbit 1/1000 IF Life technologies 
Alexa Fluor 594 Donkey Rat 1/1000 IF Life technologies 
Alexa Fluor 647 Chicken  Rat 1/1000 IF Life technologies 
HRP Goat Rabbit 1/5000 WB Sigma 
HRP Goat Rat 1/5000 WB Life technologies 
HRP Rabbit Goat 1/5000 WB Life technologies 
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Primer 
type 
Symbol Name of the target gene 
Accession no. in 
NCBI 
Anchor 
nt 
Context 
sequence 
length 
(bp) 
T
a
rg
et
  
g
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e 
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B
R
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en
 (
p
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m
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 D
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ig
n
) 
P2rx4 
Purinergic receptor P2X, ligand-
gated ion channel4 
NM-011026 795 95 
P2rx7 
Purunergic receptor P2X, ligand-
gated ion channel 
NM-01127 4612 113 
Ly6g 
Lymphocyte antigen 6 complex, 
locus G 
NM-000713 301 111 
Il1b Interleukin 1 beta NM-008361 801 127 
Tnf Tumer necrosis factor NM-013693 1594 96 
Dmd Dystrophin, muscular dystrophy NM-007868 12692 102 
Dag1 Dystroglycan 1 NM-020017 2749 105 
Sgca Sarcoglycan NM-009161 1008 105 
Tgfb 1 Transforming growth ,beta 1 NM-011577 232 113 
Rorc 
RAR-related orphan receptor 
gamma 
NM-011281 401 96 
Pakaa1 
AMP-activated, alpha 1 catalytic 
subunit 
NM-001013367 3650 97 
Foxp3 Forhead box p3 NM-054039 3194 127 
Cx3cl1 
Chemokine(C-X3-C motif) ligand 
1 
NM-009142 3015 128 
Mapk14 
Mitogen-activated protein kinase 
14, transcript variant3 
NM-001168513 2117 75 
Myog Myogenin NM-031189 923 145 
Ifng Interferon gamma NM-008337 806 128 
Cd4 Cd4 antigen NM-013488 1819 123 
Il10 Interleukin 10 NM-010548 242 102 
Il6 Interleukin6 NM-031168 1030 106 
Cd8a 
CD8antigen, alpha chain,transcript 
variant 1 
NM-001081110 2490 75 
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Table 2.6: List of primers used in the-TaqMan qPCR experiments. 
Irs1 Insulin receptor substrate NM-010570 928 85 
Myod1 Myogenic differentiation 1 NM-010866 1836 119 
Primer 
type 
Symbol Name of the target gene 
Accession no. in 
NCBI 
Anchor 
nt 
Context 
sequence 
length 
(bp) 
T
a
q
M
a
n
 g
en
e 
ex
p
re
ss
io
n
 a
ss
a
y
 
Il10 interleukin 10 (Il10) Nm-010548.2 232 79 
Il17a interleukin 17A  NM-010552.3 86 80 
Il6 Interleukin 6 NM-031168.1 237 78 
Il12a Ilterleukin 12 a NM-001159424.1 307 68 
Rela 
V-rel reticuloendotheliosis viral 
oncogene homolog An avian 
NM-009045.4 1224 67 
Cd4 CD4 antigen NM-013488.2 785 78 
Cd8a CD8a antigen NM-001081110.2 675 68 
Tnf Tumor necrosis factor NM-001278601.1 352 81 
Ifng Interferon gamma NM-008337.3 469 100 
Mrc1 mannose receptor, C type 1 NM-008625.2 158 76 
Cd163 Cd163 antigen NM-001170395.1 1509 83 
Bmp7 Bone morphogenic protein7 NM-007557.3 1009 72 
Igf1 insulin-like growth factor 1 NM-001111274.1 433 77 
Ccl2 chemokine (C-C motif) ligand 2 NM-011333.3 165 74 
Il4 Interluekin4 NM-021283.2 241 79 
Pml promyelocytic leukemia (Pml) NM_008884.5 244 68 
Srsf9 serine/arginine-rich splicing 
factor 9 
NM-025573.3 
327 81 
Upf3a 
UPF3 regulator of nonsense 
transcripts homolog A 
NM-023011.3 261 94 
Upf3b 
UPF3 regulator of nonsense 
transcripts homolog B 
NM-026573.2 1360 66 
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Table 2.7: List of primers and reaction conditions used in PCR, RT-PCR and semi-
quantitative PCR (sq-PCR) Experiments. 
Primer name Primer  sequences Tm 
P2RX7 wt Fv  5'-TGGACTTCTCCGACCTGTCT-3' 60°C 
P2RX7 wt Rv  5'-TGGCATAGCACCTGTAAGCA-3' 60°C  
P2RX7 Neomycin Fv 5'-CTTGGGTGGAGAGGCTATTC-3' 60°C  
P2RX7 Neomycin Rv 5'-AGGTGAGATGACAGGAGATC-3' 60°C  
Dystrophin wt Rv 
(P260E)(DNA and cDNA) 
5'-GTCACTCAGATAGTTGAAGCCATTTAG-3' 56˚C 
Dystrophin mdx Fv (p9427) 5'-AACTCATCAAATATGCGTGTTAGTG-3' 56˚C 
Dystrophin mdx Rv (259E) (DNA 
and cDNA) 
5'-GTCACTCAGATAGTTGAAGCCATTTAA-3' 56˚C 
Dystrophin wt and mdx Fv 
(Bam)(cDNA)  
5'-TCAGGACATGGGTCCAGCAGTCAG -3' 
57˚C 
 
Dystrophin Fv (m-nd) 5'-CATTCACAAAATGGGTAAATGCACA-3' 60°C 
Dystrophin Rv (5b) 5'-TGCTGTGAAGGAAATGGGCTCCGT-3' 60°C 
Dystrophin Fv (5A) 5'-GCTGCTTATGTCACCACCTCTGAC-3' 60°C 
Dystrophin Rv (5C) 5'-CAGTGTTGAAAGAAGATCTTGTTT-3' 60°C 
Dystrophin Fv (mr-1) 5'-GAAGTGTTACTTTTTTTAAAGC-3' 58°C  
Hnrnpa1 
Heterogeneous nuclear 
ribonucleoprotein A1 
NR-104427.1 1170 99 
Mfn2 mitofusin 2  NM-001285921.1 778 61 
miR-206 microRNA 206 NR-029593.1 31 70 
Tgfb1 transforming growth factor, beta 1 NM-011577.1 1728 59 
Gapdh 
glyceraldehyde-3-phosphate 
dehydrogenase 
NM-008084.2 75 107 
Foxo3 forkhead box O3 NM-001106395.1 2385 95 
Foxp3 forkhead box P3 NM-001199347.1 986 47 
Dmd dystrophin, muscular dystrophy NM-007868.5 9787 143 
Dmd dystrophin, muscular dystrophy NM-007868.5 774 81 
Dmd dystrophin, muscular dystrophy NM-007868.5 1860 77 
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Dystrophin Rv (exo5) 5'-GCCAGTGGAGGATTATATTCCAAAT-3' 58°C  
Dystrophin Fv (m-type) 5'-GCTTTGGTGGGAAGAAGTAGAGGAC-3'  58°C  
Dystrophin 5D 5'-GCTGCTTATGTTGCCACCTCTGAT -3' 60°C 
mdx
βGeo
GL-105 Fv (wt) 5'-GTTGAAAAGGTGAGGGCAAA-3' 58°C 
mdx
βGeo
GL-105 Rv (wt and mdx
βGeo
) 5'-GCACGAGCATATGGTTGACA-3' 56°C 
mdx
βGeo
 Rosa Beta-geo Fv (mdx
βGeo
) 5'-GATATCCTGTTTGGCCCA-3' 54°C 
Dystrobrevin alpha Fv (DB-8f) 5'-CCAACCACTCACCAAATCCA-3' 58°C 
Dystrobrevin alpha Rv (DB-23r) 5'-TGGATTTGGTGAGTGTTGG-3' 58°C 
Gapdh Fv 5'-GACCACAGTCCATGCCATCACT-3' 58°C  
Gapdh Rv 5'-CTACAGCAACAGGGTGGTGGA-3' 58°C  
Bmp7 exo1  ATG   5'-GATGCACGTGCGCTCGCTGC-3' 67˚C 
Bmp7 Long Fv   5'-CATGGTCATGAGCTTCGTCAACCTAGTGG-3' 66˚C 
Bmp7 Long Rv 5'-GGACCACCATGTTTCTGTACTTCTTCAGG-3' 65˚C 
Bmp7 short Fv   5'-AGGACTACATCCGGGAGCGATTTGACAAC-3' 68˚C 
Bmp7 short Rv (exon 5) 5'-GAAGCTGACGTACAGCTCATGTTTCTTGC-3' 66˚C 
Bmp7 Gsp2 (exon 4-5) 5'-TCACTGCTGCTGTTTTCTGCC-3' 66 ˚C 
Bmp7 Gsp3 (exon 4) 5'-TTCTTTGGCGTCTTGGAGCG-3' 66 ˚C 
Bmp7 Gsp1 yellow (exon 4) 5'-TCCATGCCGTCCAATCAGGC-3' 67 ˚C        
Bmp7 Gsp2- orange (exon 4) 5'-TTAGTCCGGACGGTTGAACCCC-3' 66 ˚C    
Bmp7 Gsp3- red (exon 3) 5'-CACTTCGGGTCCAACACGGC-3' 66 ˚C    
Bmp7 Gsp1- green (exon 4) 5'-TCCATGCCGTCCAATCAGGC-3' 67 ˚C 
Bmp7 gsp2-blue (exon 3-4) 5'-AGACGGGTAGGTCCCAGAGG-3' 68˚C    
Bmp7 gsp3-pink (exon 3) 5'-TCGACATTCGGGTCCAACACG-3' 67 ˚C 
Ccnb1 Fv 5'-ATGATGGGGCTGACCCAAAC-3' 59°C 
Ccnb1 Rv 5'-TCCAGTCACTTCACGACCCT-3' 60°C 
Ccnb2 Fv 5'-AACCCACAGCCTCTGTGAAA-3' 59°C 
Ccnb2 Rv 5'-CTTGCAGAGCAGAGCATCAGA-3' 60°C 
Ccnd3 Fv 5'-GGCCCTCTGTGCTACAGATTA-3' 58°C 
Ccnd3 Rv 5'-GTGGCGATCATGGATGGAGG-3' 60°C 
E2f2 Fv 5'-AAATTGTGCGATGTGCACCC-3' 59°C 
E2f2 Rv 5'-CTTGGGGGTTTTGGGGCTT-3' 60°C 
Aurka Fv 5'-CATGACGCCACCCGAGTTTA-3' 60°C 
Aurka Rv 5'-GAGCGTTTGCCAACTCAGTG-3' 59°C 
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Cdk4 Fv 5'-CGGCCTGTGTCTATGGTCTG-3' 59°C 
Cdk4 Rv 5'-GAAGCAGGGGATCTTACGCT-3' 59°C 
Cdk6 Fv 5'-CGCAGAAAGCCTCTTTTTCGT-3' 59°C 
Cdk6 Rv 5'-GTCCCTAGGCCAGTCTTCCT-3' 59°C 
 
 
Table 2.8: The list of genes used in the candidate reference genes assay. 
Primer 
type         
Symbol Name of the target gene 
Accession no. in    
NCBI 
Anchor     
nt 
Context 
sequence 
length (bp) 
R
ef
er
en
ce
s 
g
en
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 Actb actin, beta, cytoplasmic NM_007393.3 597 94 
Gapdh 
glyceraldehyde-3-phosphate 
dehydrogenase 
NM_008084.2 793 180 
Ubc ubiquitin C NM_019639.4 2225 178 
B2m beta-2 microglobulin NM_009735.3 202 159 
Ywhaz phospholipase A2 YWHAZ NM_011740.3 1045 195 
Rpl13a ribosomal protein L13a NM_009438.5 691 180 
Canx calnexin NM_007597.3 2827 127 
Cyc1 cytochrome c-1 NM_025567.2 514 203 
Sdha 
succinate dehydrogenase 
complex, subunit A 
NM_023281.1 2018 181 
Eif4a2 
eukaryotic translation initiation 
factor 4A2 
NM_013506.2 876 215 
Atp5b ATP synthase subunit NM_016774.3 1115 142 
18S 18S  rRNA gene NR_003278.3 134 99 
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 Animal  2.2
All the experimental animals used in the current study were provided by the Bioresource 
Unit of Portsmouth University. All the animal procedures were performed in accordance 
with the local guidelines and as approved by the specific UK Home Office project 
licence. These procedures included animal handling, breeding, collecting the ear 
punches for genotyping, treating the animals with pharmacological inhibitors either by 
intraperitoneal injection or by feeding with a drug and also killing using CO2 
asphyxiation followed by cervical dislocation. 
The mice were maintained in pathogen-free conditions. They were housed at a 12-hour 
light/12-hour dark cycle, 19-23°C temperature, and 45-65% humidity. They were fed a 
pathogen-free pellet diet (economy rodent breeder diet services, Witham, UK) and were 
given water ad libitum. 
The details of the animals that were used in this study are summarised in Table 2.9. 
Importantly, Pfizer-mdx/P2rx7
-/- 
were generated by our group by breeding the Pfizer-
P2rx7
-/-
 male with mdx female mouse. The first generation (F1) resulting from this 
breeding has males being dystrophic and heterozygous for P2X7 knockout (P2rx7
+/-
). 
These males were back-crossed with parental females to generate males and females that 
were 100% dystrophic and 50% of them P2rx7
-/+
 and 50% P2rx7
+/+
. Finally, the P2rx7
-/+ 
mdx males were mated with P2rx7
-/+ 
mdx females to generate double mutant mice 100 
% dystrophic and 25% of them being P2rx7
-/-
. Genotyping was performed to identify the 
genotype of animals at each step of the breeding process (Appendix 10.1).   
Table 2.9: List of animal models and their description. 
 
Genotype   Sex  Phenotype Description 
1 C57/BL10  Male  
Wild type (healthy 
control) 
This mouse was derived from 
C57BL/10SsSnJ 
2 mdx  Male  Dystrophic
-/-
 
Found naturally with spontaneous 
mutation in exon 23 (Bulfield et al., 
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The genotypes of these animals were established by PCR, using specific primer sets 
(Table 2.7) and the results are discussed in Chapter 3. Further genotyping experiments 
were performed on animals treated with pharmacological antagonists. Different samples 
were collected from animals: the leg muscles gastrocnemius (GC), and tiabialis anterior 
(TA), diaphragms, hearts, brains, blood, ear punches or tail snips. Half of tissue samples 
were frozen directly in liquid nitrogen and kept at -80° C until they were used for RNA 
and protein extraction (for example the TA and GC muscles). The other half of GC, 
heart, diaphragm and brain were mounted on cork supports with OCT-embedding 
medium and frozen in 2-methylbutane cooled in liquid nitrogen and then stored at -80˚C 
to be used for cryosectioning and immunostaining. Blood was withdrawn by heart 
puncture right after death and incubated for ten minutes in a water bath at 37˚C, then 
centrifuged twice at 2,500 g for 10 minutes.  The serum was transferred to a fresh tube 
and stored at -80 ˚C to be used in the creatine kinase assay.  
For genotyping, ear clips were removed from living animals under local anaesthesia 
while small fragments of tail were cut off from recently killed animals and both sample 
types kept at -80˚C or immediately used for genomic DNA (gDNA) extraction. 
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 Cell culture - isolation of primary myoblasts 2.3
Leg muscles (TA) from four week-old C57/BL10, mdx and mdx/P2rx7
-/-
 were dissected 
from tendon to tendon carefully to avoid muscle damage, according to the protocol 
described in Rosenblatt et al. (1995). Muscles were cleaned to remove the bacterial 
contamination from the surface by washing them with 5 ml 1X Hank’s buffered saline 
solution (HBSS). These muscle samples were transferred to 15 ml centrifuge tubes 
containing 0.1% type 1 collagenase in PBS and then incubated in a shaking water bath 
for 45 minutes. The muscles were transferred to six well plates and suspended with the 
DMEM medium supplemented with 10% horse serum HS, 0.5% chick embryo extract 
(CEE) and 2 mM L-glutamine. Then muscles were passed several times through 
different diameter pipettes (25, 10 and 1 ml) to disperse them into single fibres. The 
single muscle fibre was isolated from the debris under the inverted bright field 
microscope (Leica). This step was repeated three times to ensure isolation of fibres 
without contaminating cells or un-dissociated fibres. In the last step, 20µl DMEM 
medium containing a single myofibre were transferred into 24-well plates coated with 
100µl (1mg/ml) Matrigel. These fibres were first settled for a few minutes to adhere and 
then incubated with 1ml of DMEM for three to five days. 
Myoblasts and myotubes were provided by Dr. Christopher Young. In addition, 
myoblast and myotube that were incubated with Dimethyl sulfoxide (DMSO) and 50uM 
of NMDI-14 dissolved in DMSO for 6h, 16h, 24h and 48h and according to the protocol 
of Martin et al. (2014) were also provided by Dr. Young.  
 Molecular Biology analyses 2.4
2.4.1 DNA extraction 
Genomic DNA was extracted from mouse tail or ear clips following the manufacturer’s 
protocol of DNeasy
TM
 blood and tissue DNA extraction kit (Qiagen). First, to complete 
hydrolysis of the cell membrane and to digest DNase and RNase enzymes, < 0.5 cm of 
samples was incubated overnight with 180 µl of ATL (lysis buffer) and 20 µl of 
proteinase K at 56˚C in a shaker incubator. Samples were mixed by vortexing before 
200 µl of AL (binding buffer) was added, another mixing step followed before adding 
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200µl of absolute ethanol. Samples were loaded onto DNeasy Mini spin column and 
centrifugation at 6000g for one minute left DNA samples bound to silica membranes.  
Next, to remove the remaining cells debris and enzyme inhibitors, two washing steps 
were performed. First, AW1 washing buffer (500µl) was added to a column. AW1 
contains guanidinium chloride and is used to denature the proteins that were washed 
away from filter by centrifugation. Second, washing buffer AW2 containing 70% 
ethanol was added (500 µl) to remove the salt. Each of these washing steps was 
followed by centrifugation at 6000 g for one minute, and 20000 g for three minutes, 
respectively. Finally, the DNA samples were eluted by pipetting 75µl of AE buffer 
(Table 2.2) into the middle of membranes and incubation at room temperature for 5 
minutes before centrifugation at 6000g for 1 minute.  
2.4.2 RNA extraction from muscles, myoblasts, myotubes and myofibres 
Five RNA extraction kits were assessed to establish the most suitable and convenient 
method to isolate high quality and purity RNA from muscles. These kits included: 
RNasy mini kit, miRNasy mini kit, RNeasy Plus Universal mini kit (all Qiagen) as well 
as Direct-zol
TM
 RNA mini prep (Zymo Research) and Trizol reagent protocol (Life 
Technology). Except for the RNeasy Plus Universal mini kit, the resulting RNA samples 
were treated with DNase according to manufacturer’s protocol of the Precision TM 
DNase kit (Primer Design) to inhibit the nuclease activity. Finally, the RNeasy Plus 
Universal mini kit was chosen as the best extraction kit for isolating RNA from tissues, 
especially that it contains gDNA eliminator, which was used during the protocol and 
allowed to wash away all remnants of the enzyme. Frozen tissues (~35 mg) were 
crushed with mortar and pestle under liquid nitrogen. Tissue powder or cell samples 
were homogenised with 900 µl QIAzol by passing through 25G needle attached to a 1 
ml syringe. The homogenated samples were left at room temperature for five minutes 
before 100µl of gDNA Eliminator Solution was added. The 200 µl of chloroform was 
added followed by vigorous shaking of samples for 15 seconds and then incubation at 
room temperature for two to three minutes. Samples were centrifuged at 12000 g for 15 
minutes at 4°C. The aqueous phase containing RNA was transferred into a fresh 2 mL 
RNase–free tube containing equivalent volume of 70% ethanol and samples mixed by 
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pipetting. Ethanol allows RNA to bind efficiently to the silica membrane. The mixture 
of samples and ethanol was transferred into a spin column where the RNA bound to the 
membrane. A short 15 seconds centrifugation at 8000 g at room temperature was 
performed, and the flow-through was discarded while the columns were reinserted into 
the same collecting tube. This step was repeated twice until all the samples passed 
through the spin column. Biomolecules like carbohydrates, proteins and fatty acids were 
washed away from RNA samples by adding 700 µl of RWT buffered (7-13% guanidine 
hydrochloride solution) and centrifugation at 8000 g for 15 seconds. RPE buffer was 
added twice (in two separate steps) each one followed by two minutes centrifugation at 
8000 for 15 seconds, respectively and the flow-through was discarded. These washing 
steps were used to eliminate the contaminants that could be carriedover during the 
purification steps. To remove the ethanol, the spin column was centrifuged at full speed 
for one minute in a fresh collection tube. The final steps included eluting RNA samples 
into new 1.5 ml collection tubes by adding 35µl of RNase-free water directly to the 
centre of membrane, incubating for five minutes at room temperature and centrifugation 
at 8000 g for one minute. To retrieve the maximum amount of RNA, the elution step 
was repeated by re-adding the eluted RNA sample to the same membrane. The eluted 
RNA samples were immediately stored at -80°C until used in the gene expression study 
or sent to Source BioScience Company for RNA-Seq. The same protocol was used to 
extract RNA from myoblast and myotube samples. 
2.4.3 RNA extraction from serum 
Total RNAs were extracted from serum samples according to the manufacturer’s 
procedure from the miRNeasy Serum/Plasma kit (Qiagen). Frozen serum samples (100 
µl) were thawed for 30 minutes at 37°C. To denature protein complexes, RNases, and to 
remove most of the residual DNA and proteins, samples were mixed with five volumes 
of QIAzol Lysis Reagent (500 µl) that contains phenol and guanidine thiocyanate. 
Samples were kept at room temperature for five minutes before 3.5 μl miRNeasy 
Serum/Plasma Spike-In Control (1.6 x 108 copies/μl working solution) was added and 
mixed thoroughly. 100 µl of chloroform was then added and samples mixed by 
vortexing for 15 seconds then incubated at room temperature for two to three minutes.  
Samples were centrifuged at 12,000 g at 4°C for 15 minutes to separate phases. The 
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upper aqueous phase (containing RNA) was collected and transferred to a new 
Eppendorf tube containing 450 µl of absolute ethanol. The sample was transferred to the 
RNeasy MinElute spin column assembled on the 2 ml collection tube and passed twice 
through the membrane by centrifugation at 8000 g for 15 seconds at room temperature. 
The membranes containing bound RNA were washed with 700 μl buffer RWT and 
centrifuged for 15 seconds at 8000 g. This was followed by addition of 500 μl buffer 
RPE and centrifugation for 15 seconds at 8000 g and this step was repeated twice to 
remove any residual contaminants. Next,  500 μl of 80% ethanol was added to the 
RNeasy MinElute spin column and centrifuged for two minutes at 8000 g. To eliminate 
residual ethanol carry-over, the column was centrifuged at full speed for five minutes to 
dry the membrane. Finally, the RNA samples were eluted by adding 10 µl of RNase-free 
water directly to the centre of the column and kept at room temperature for five minutes 
before centrifugation for one minute at 13000 g, this step was repeated by re-adding the 
eluted sample to the same membrane to increase the RNA yield. 
2.4.4 Nucleic acid quantification and quality control 
The first method used to assess the RNA quality was the visualisation of RNA samples 
following agarose gel electrophoresis. The RNA samples were mixed with (6x) loading 
buffer (4:1), loaded into 1% of EtBr-stained-agarose gel, then placed in gel tanks and 
resolved by electrophoresis in the TAE buffer. The gel was run for 40 minutes with 
constant voltage 5V/cm. RNA samples were separated according to their molecular 
weight, and the gel was visualised using Gel Doc EZ system (BioRad). 
NanoDrop 1000 spectrophotometer was used to determine the concentration and purity 
of RNA and DNA samples. 1µl of samples were used to determine the concentration of 
nucleic acid by measuring the A206 absorbance of samples. The purity of samples from 
protein contamination was established by assessing the ratio of A260/A280. The ratio of   
A260/A280 = 1.8 was generally accepted as denoting pure DNA samples and the 
absorbance ratio = 2 was considered as pure RNA samples. Also, the measurement of 
A260/A230 was used to establish the existence of other contaminations such as guanidine 
thiocyanate, carbohydrates and phenol. When the ratios were significantly lower than 
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the expected 2.0-2.2, the presence of one or more of these contaminants could be 
expected. RNase-free water was used to calibrate the NanoDrop.  
 In addition, 1µl of the RNA sample (25-500ng/µl) was assessed for integrity by using 
Bioanalyzer 2100 (Agilent Technologies, Germany) in accordance with the kit guide of 
the Agilent RNA 6000 Nano. The Bioanalyzer and RNA 6000 Nano kit together became 
a standard method to assess the quality and purity of RNA samples. The microfabricated 
chip contains interconnected channels allowing the separation of the nucleic acids 
electrophoretically according to their molecular weight. First, the reagents were 
equilibrated to room temperature for 30 minutes. The gel was prepared by adding 550µl 
of RNA gel matrix into the spin filter and centrifugation at 1500 g for 10 minutes. 1µl of 
vortexed RNA dye was added to the 65µl aliquot of gel and, after mixing the tube by 
vortexing, centrifuged at 13000g for 10 minutes. In the meantime, the 2µl of samples 
and ladder were denatured for two minutes at 70°C, then were placed on ice directly to 
avoid reannealing of nucleic acids. The RNA Nano 6000 Labchip was placed in the 
priming station and 9 µl of gel-dye-mixture was added into position . The plunger was 
set at 1ml location to load the syringe with air, then the priming station was closed, and 
the air was injected into the chip and secured with aclip for 30 seconds. Another 9 µl of 
gel-dye-mixture was added into two wells marked with . Next, 5 µl of the RNA 
marker, 1 µl of ladder, and 1 µl of RNA samples were loaded to their appropriate 
positions on the chip. Finally, the chip was vortexed at 2400 rpm for one minute using 
(Vortex Mixer) before inserting it in Agilent 2100 Bioanalyzer. The electropherogram 
and gel-like images were generated by Bioanalyzer and provided detailed information 
about the purity and integrity of RNA samples. The RNA integrity number (RIN) was 
used to estimate the intactness of RNA samples. This number ranges from 1 to 10, 
where the degraded RNA has RIN of 1 and the intact RNA sample has RIN that equals 
10. Only the RNA samples with RIN > 7 were used in subsequent analyses. 
2.4.5 cDNA synthesis 
The first complementary strand was reverse transcribed from total RNA following the 
instructions of SuperScript VILO
TM
 cDNA synthesis kit (Invitrogen). The first strand 
was prepared from 1 µg of RNA using random primers in a final volume of 20µl. The 
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RNA samples were incubated for 10 minutes at 25° C in 4 µl of 5X VILO™ Reaction 
Mix (containing random primers, MgCl2, and dNTPs) and 2 µl  of 10X SuperScript® 
Enzyme Mix in final reaction volume of 20µl. The RNA samples were reverse 
transcribed at 42°C for 60 minutes. Finally, the enzymatic reaction was terminated at 
85°C for five minutes. The same protocol has been followed to prepare the no RT 
control (-RTC
 
samples) without addition of the reverse transcriptase enzyme. These -
RTC controls were used to check for genomic DNA contamination. cDNA samples were 
either directly used or stored at -20°C. 
2.4.6 PCR, RT-PCR  
Genomic DNA samples (1-5µl) and cDNA samples (1-3µl) were added into PCR tube 
containing Go Taq 2x Green master mix (Promega) and (20pmol/µl) of specific reverse 
and forward primers in a final reaction volume of 25µl. Go Taq master mix consists of 
G2 Reaction Buffer pH8.5, 15 mM MgCl2, 200µM dNTP, 1.25 units of Taq polymerase 
enzyme and blue and yellow loading dye. This master mix was used in all of PCR 
amplifications except in Bmp7 analysis, in which another commercial mater-mix 
iProof
TM
 high-Fidelity DNA polymerase (Bio-Rad) was also used for amplification. In 
this reaction, 5X iProof HF buffer, dNTP, forward and reverse primers, iProof DNA 
polymerase, cDNA template, were made up to 50µl with RNase-free water. 
Samples were amplified according to the following amplification condition using 
thermal cycler (either Primus 25 advanced® or 96 Plus® PEQLAB Biotechnologies 
GmbH, Erlangen, Germany): Denaturation at 94°C for three minutes, followed by 35–40 
cycles of 94°C for 30–40 seconds; appropriate annealing temperature for 30-40 seconds 
and elongation at 72° C for one minute per 1 kb of the product size, then final extension 
step at 72° C for 10 minutes. 
The specificity of PCR product depends on the good design of primers. Primers used in 
the current study were either designed by mafacturer or in our laboratory and their 
sequence and melting temperature were given in Table 2.7.  Standard RT-PCR primers 
were designed to be 20-30bp long, 40-60 % GC content, 55-60°C annealing 
temperature, 3 GC clamp in the last five nucleotides at the 3' end. The NCBI tool was 
used to design primers (https://blast.ncbi.nlm.nih.gov/Blast.cgi).  
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The genotype of experimental animals was confirmed by PCR using DNA (template) 
samples extracted from tail or ear punches. In RT-PCR, cDNA (template) samples (5 
ng/µl) were taken to re-confirm the genotype of animals or to study the specific gene 
expression. RNA samples were also tested for gDNA contamination by amplification 
with primers to Gapdh.  
10 µl of PCR/RT-PCR products were resolved in 2% agarose gels and visualised by 
either EtBr or SYBR Safe staining. The size of amplicons was compared with either 1kb 
or 100 bp ladders.  
2.4.7 Semi-quantitative PCR (sqPCR) 
Semi-quantitative PCR is a PCR reaction, in which the cDNA samples were used as 
templates and the expression of a target gene was quantified relatively to a control gene. 
In order to compare the expression level of the dystrophin transcript between C57/BL10 
and mdx, equal amounts of cDNA samples were amplified under an increasing number 
of PCR cycles. 2.4 µl of cDNA was amplified with Go Taq 2xGreen master mix 
(Promega) and the dystrophin-specific primer pair (mnd-5B) or Gapdh primers (See 
Table 2.7 for more details) in final reaction volume 60 µl. The PCR reaction was 
conducted in 96 Plus® PEQLAB Biotechnologies GmbH, Erlangen, Germany. The 
thermal condition was as follows: initial denaturation 94°C for three minutes, 20-35 
cycles of denaturation at 94°C for 30 seconds, annealing at 58°C or 60°C for one 
minute, extension at 72°C for one minute per 1 kb of the product size and the final 
extension at 72°C for 10 minutes.  
 Consequently, at the cycle 26, 28, 30, 32 and 35 for dystrophin and cycle 20, 23, 26, 29, 
and 32 for Gapdh, 10 µl aliquot of PCR product was removed and resolved by agarose 
gel electrophoresis. The intensity of bands in gels was quantified using image lab
TM
 
software (BioRad). This allowed the expression of dystrophin to be compared with 
Gapdh as an internal control. 
2.4.8 Agarose gel electrophoresis 
2g of agarose powder were dissolved in 100 ml of TAE buffer by heating it in the 
microwave. This mixture was allowed to cool to 50-60º C before (0.05 µg/ml) EtBr or 
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(5µl/10.000x) SYBR Safe was added. The gel was poured into the prepared gel casting 
tray and left in room temperature for 30 minutes to solidify. Next, the gel was placed in 
a gel electrophoresis apparatus and covered with TAE buffer. 
Samples were mixed with loading buffer 4:1 and loaded into the gel wells. The 1kb or 
100bp DNA ladders were used as a size reference. These samples were resolved 
electrophoretically at 5V/cm in 1x TAE buffer for 40-50 minutes. Images of bands 
resolved in gels were captured by Gel Doc EZ system (BioRad). 
2.4.9 Real time PCR 
Two different detection methods were used for studying the expression level of genes of 
interest quantitatively.  
2.4.9.1 SYBR Green detection method: 
This method was used to detect the stability of reference genes used for normalisation of 
qPCR results as well as to study the expression of target genes.  
To minimise the technical variations, one or multiple stable references gene should be 
used for qPCR data normalisation (Vandesompele et al., 2002). Therefore, twelve genes 
from different pathways and functions (geNorm of 12 gene kit from Primer Design) 
(Table 2.8) were used to identify the most stable references genes for qPCR analysis in 
dystrophic muscles. 25ng/µl of cDNA samples were mixed with 10µl of Primer Design 
Precision Plus master mix and 1 µl of primer mix in PCR tubes. The mixture was mixed 
by vortexing, spun and then 15µl of this mix were pipette into Bright White 96 wells 
plate (Primer Design). This experiment was performed once per cDNA batch and the 
stability of genes was calculated by using the geNorm tool in qBase
+
 software version 
2.6 (Biogazelle, France). geNorm depends on expression stability value (M) to rank the 
genes; a gene with the lowest M value is considered as the most stable in its expression. 
Also, the optimal numbers of references genes required for normalisation was detected 
by geNorm. The calculation of optimal numbers depends on the pairwise variation 
Vn/Vn+1 value, the value bellow the cutoff of 0.15 indicates that extra reference gene is 
not needed. 
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To detect the gene expression, the reaction was carried out by adding 25 ng/µl cDNA 
samples into 10µl Precision 2 x real-time PCR Master Mix with SYBR Green (Primer 
Design, Southampton, UK) and 1µl specific primer (Table 2.5) in the final reaction 
volume of 20 µl. The primers with SYBR Green detection method were purchased from 
Primer Design or from Eurofins Genomics. The analysis of gene expression was 
calculated using 2
-ΔΔCT
method either manually or by qBase
+
 software version 2.6 
(Biogazelle, France). 
Basically, five biological replicates of cDNA samples were used in duplicate. All 
samples were placed on the same plate to avoid inter-run calibration. The plate was 
covered with adhesive cover and centrifuged at 2000 rpm at 4°C for one minute. The 
amplification conditions were set according to the manufacturer: enzyme activation at 
95°C for two minutes followed by 40 cycles (10 seconds at 95°C for denaturation step 
followed by one minute at 60°C). The final stage was the melt curve, which consists of 
three steps: 95°C for 15 seconds then decreased to 60°C for one minute and again 95°C 
for 15 seconds. At the end of the reaction, the melt curve was analysed to confirm the 
specificity of amplification. No template control was used for each gene to confirm the 
absence of primer dimer or contamination with PCR products in reagents. 
Moreover, for further validation of qPCR results, 20 µl cDNA was shipped on dry ice to 
Plate-Forme d’Imagerie PRIMACEN, IRIB, University of Rouen, France to test mouse 
inflammatory pathway panel array-qPCR-SYBR Green detection method (Table 2.10), 
as a part of INTERREG-funded collaboration between our laboratories. 
Table 2.10: List of primers for target genes in the inflammatory panel.  
Gpx1 Ptprc Rplp0 Bcl10 Igf1 Il6ra Il1a Tgfb1 Pla2g5 Cx3cr1 Irf1 Gapdh 
Gpx4 Tollip Hspd1 Trem2 C1ra Il10ra Il1b Tgfb2 Ptges Cxcr4 Irf3 Actb 
Ucp2 Twist1 Tlr9 Mmp2 Bdnf Il10rb C2 Tnf Acvr1 Ccr2 Irf9 Pgk1 
Sod1 Socs1 Tlr4 Mmp9 Csf1 Ifngr1 Il6 ccl2 Adora1 Ccr5 Hif1a B2m 
Prdx5 Socs3 P2rx7 Timp1 Serping1 Ifngr2 Il10 Ccl5 Fas Cxcr3 Fos Nono 
Nos2 Stat1 P2rx4 Apoe Vegfa Tgfbr1 Ifng Cxcl12 Casp3 Cebpa Jun Ppia 
Ncf1 Sat3 P2ry12 Myd88 Vegfb Tnfrsf1a Il18 Cx3cl1 Casp9 Cebpb Nfkb1 Tfrc 
Bax Bcl2 P2ry6 Mrc1 Bmp7 Tnfrsf1b Hspb1 Hspa1b Rbpj Hmox1 Rela Hsp90ab1 
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2.4.9.2 TaqMan qPCR analysis 
This experiment was carried out according to the guidelines provided by Applied 
Biosystems. Specific cDNAs (40 ng/µl) were added to PCR tubes containing  a mixture 
of 10µl of 1x TaqMan Universal Master Mix II with UNG (Applied Biosystems) and 
1µl of the 20x specific TaqMan hybridisation probe in the final reaction volume of 20 
µl. All primers were purchased from Life Technologies, and the majority of these 
primers span exon/exon boundaries (Table 2.6). This mixture was vortexed and spun 
then dispensed into MicroAmp® Fast Optical 96-wells reaction plate (Applied 
Biosystems). Three to five biological replicates for each genotype were analysed in 
duplicate and all samples were analysed in the same plate to avoid the inter-run 
calibration. Two types of controls were included, first one was the no template control, 
which was performed for each single experiment to validate the reaction was free from 
contamination with PCR products or formation of the primer dimer. In this case RNase- 
free water was added instead of cDNA. Second control was the no RT control (-RTC), 
which was used only once for each newly prepared cDNA sample to validate samples 
being free from gDNA contamination. The plate was covered with an adhesive cover 
and centrifuged at 2000 rpm at 4°C for one minute.  
The real time PCR reactions were performed using Applied Biosytems ® ViiA
TM
7 real 
time PCR system. The thermal conditions were set as follows: UNG incubation 50°C for 
two minutes, polymerase activation 90°C for 10 minutes, followed by 40 cycles of 
denaturation at 95°C for 15 seconds and annealing at 60°C for one minute. To accurately 
compare the expression of the genes of interest before and after treating animals with 
pharmacological inhibitor, the threshold was set up at 2 for all target and control genes 
used in this study. The analysis of relative expression levels of genes was conducted 
manually using the 2
-ΔΔCT 
method. 
2.4.10 Restriction enzyme analysis 
The nucleotide sequence of the region between exons 1 and 5 of Bmp7 was uploaded 
into NEBcutter V2.0 (available in the New England Biolab website) to identify a 
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specific restriction enzyme cutting this sequence. Msp1 was chosen as a single cutter 
that digested the selected region into two fragments with lengths of 871 bp and 204bp. 
The Bmp7 amplicon of the region spanning exons 1-5 was digested by Msp1 in the 
following way: 9 µl of PCR product was incubated with 1 µl of Msp1 at 37°C for one 
hour. Subsequently, the enzyme was inactivated at 70°C for 10 minutes and then the 
reaction was resolved in a 2% agarose gel.  
2.4.11 Sequencing 
The Bmp7 PCR product amplified using iProof was purified by NucleoSpin® and PCR 
Clean-up kit (Macherey-Nagel) to eliminate the small PCR fragments. The PCR mixture 
was first adjusted to 100 µl with RNase-free water, two volumes of binding buffer 
(NTL) were added to one volume of PCR and 700 µl of a sample were loaded into 
NucleoSpin® Gel and PCR Clean-up column inserted into a 2 ml collection tube. The 
sample was spun at 11,000 g for 30 seconds, the flow-through was removed and the 
column was reinserted in the same collection tube. The PCR amplicon trapped on silica 
membrane was washed with 700 µl of NT3 buffer, which passes through the membrane 
by centrifugation at 11,000g for 30 seconds. This washing step was repeated to prevent 
the salt carryover and also to improve the purification of the PCR amplicon. Further 
centrifugation for one minute was used to remove the residual ethanol present in the 
NT3 buffer. The purified PCR amplicon was eluted from the membrane and collected 
into a new 1.5 µl collection tube by adding 20 µl of NE buffer, incubation at 70°C for 
five minutes, followed by centrifugation at 11,000 g for one minute. To increase the 
yield, the elution step was repeated using the first flow-through. 15 µl of the purified 
PCR product was mixed with 2 µl of the forward (Bmp7 exo1 ATG) or reverse primers 
(Bmp7 short Rv exon 5) (10pmol/µl) in a 1.5 ml safe locked tubes and shipped off to 
Eurofins for sequencing. 
2.4.12 RNA sequencing 
Total RNA samples were extracted by using RNeasy Plus Universal mini kit (Qiagen) 
from C57/BL10, mdx and mdx/P2rx7
-/-
. The quality of these samples was checked by 
NanoDrop ND-1000 and subsequently by using the Bioanalyzer. 20µl (250-900ng/µl) of 
pure RNA samples were sent to Source BioScience for Next Generation Sequencing 
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using Illumina HiSeq 2000 platform (HiSeq). 1µg of total RNA was used to prepare the 
Illumina library according to the manufacturer’s protocol of Illumina TruSeq Stranded 
Total RNA Sample Preparation kit with Ribo-Zero Human/Mouse/Rat (October 2013 
Rev E.). Using this kit, both cytoplasmic and mitochondrial RNAs were removed from 
the total RNA. The remaining RNA was purified, fragmented and reverse transcribed 
with random hexamer primer into first strand cDNA. Subsequently, RNA template was 
removed through replacing the dTTP with dUTP to generate ds cDNA with blunt ends. 
To prevent the cDNA fragments from binding with each other, single nucleotide adenine 
(A) was added to 3' end of these fragments in Adenylate step. Furthermore, the cDNA 
samples were ligated with adapters and indexes hybridised onto Illumina flow cell. The 
fragments that contain adaptor at both ends were selected after 15 PCR cycles using 
PCR Primer Cocktail (complementary to the adaptors). The size and purity of DNA 
samples were checked by Bioanalyzer using Agilent DNA 1000 chip. The resulting 
libraries were pooled into four pools, diluted to 10 nM and again validated by 
Bioanalyzer using Agilent DNA 1000 chip. Finally 8pM of each pool of samples was 
loaded onto one lane of Illumina HiSeq2000 flow cell and was sequenced using 100bp 
PE runs. Millions of sequenced reads were aligned to mm10 genome assembly, UCSC 
Genome Browser. The bioinformatics pipeline used for data analysis is summarised in 
Figure 2.1. 
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Figure 2.1: 
The bioinformatics pipeline for Next Generation Sequencing. The first step was the output 
from the Illumina HiSeq 2000 platform, which is presented as FastQ file. Fast QC program 
assessed the quality of data, such as the length of reads, nucleotide content and GC content. 
This generated two files; R1 representing the read with the forward primer and R2 
representing the reads with the reverse primer. TopHat was used to align the reads to mm10 
genome assembly, UCSC Genome Browser. Sam tool was used to manipulate and convert 
the Sam and Bam files (text file containing information required for downstream analysis 
such as mapping position and location of mismatch) to make them easily accessible for 
downstream analyses. Cufflinks was performed to assemble transcripts to identify the 
differences in genes expression and for isoforms by Cuffdif. 
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2.4.13 Rapid amplification of cDNA ends (RACE) PCR 
RNA samples were extracted from control (IMO) and dystrophic myoblast (SC5) using 
RNeasy Plus Universal mini kit (Qiagen). 5µg of these samples were reverse transcribed 
into cDNA according to manufacturer’s protocol of 5' rapid amplification of cDNA ends 
(RACE) kit (Invitrogen). This step was performed in 0.5ml PCR tube by mixing the 
RNA sample with GSP1 (Table 2.7) in the final volume of 15.5µl. The RNA was 
denatured at 70°C for 10 minutes, chilled on ice for one minute and spun to collect the 
mixture. The mixture was added to a tube containing 2.5 µl of 10x PCR buffer, 2.5 µl of 
25mM MgCl2 , 1 µl of 10mM dNTP and 2.5 µl of 0.1M DTT  in the final volume of 24 
µl. After a gentle mixing and brief centrifugation, samples were incubated at 42°C for 
one minute. 1 µl of SuperScript II RT was added to the reaction tubes and incubated at 
42°C for one hour. The enzyme was inactivated by incubating the reaction tubes at 70°C 
for 15 minutes. To denature the RNA template, the samples were incubated for 30 
minutes at 37°C with 1µl of RNase mix. These cDNA samples were either stored in -
20°C or used for the next step. 
120 µl of binding solution was mixed with prepared cDNA and the mixture transferred 
into the S.N.A.P. column, centrifuged at 13,000g for 20 seconds to pass the binding 
solution through the membrane. Three washing steps were applied by adding 0.4 ml cold 
washing buffer, and centrifugation at 13,000g for 20 seconds. 70% of cold ethanol was 
added twice, each time followed by centrifugation at 13,000g for 20 seconds. Another 
one minute centrifugation was used to remove the residual ethanol. The purified cDNA 
was eluted by soaking the membrane for five minutes with 35 µl of RNase-free water 
preheated to 65°C, followed by centrifugation at 13,000g for 20 seconds. To check the 
quality of the synthesised cDNA, 1µl was used to RT-PCR amplify exon 1-2 region of 
Bmp7.  
The TDT tailings of cDNA samples were carried out by mixing gently the following 
components: 16.5 µl cDNA, 5 µl of 5x tailing buffer and 2.5 of 2mM dCTP in the final 
reaction volume of 24 µl. The reactions were incubated at 94°C for two minutes, chilled 
on ice for one minute, centrifuged before incubation with 1 µl of TdT for 10 minutes at 
37°C. The reaction was terminated at 65°C for 10 minutes. To check the efficiency of 
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the tailing step, the dC-tailed cDNA was PCR amplified using the forward primer 
complementary to the dC-tail Abridged Anchor Primer(AAP) and the reverse primer 
located in exon 1. 
5µl dC-tailed cDNAs were mixed with 5µl of 10X PCR buffer, 3 µl of 25 mM MgCl2, 
1µl of 10 mM dNTP mix, 2µl of 10 µM GSP2 primers, 2µl of Abridged Anchor Primer 
(designed to be complementary to the dC region), 31.5 µl RNase-free water and 1µl of 
Taq DNA polymerase (5 units/μl). After brief mixing of the components, the PCR 
reaction was conducted in 96 Plus® PEQLAB Biotechnologies GmbH, Erlangen, 
Germany. The thermal condition was set as follows: initial denaturation 94°C for two 
minutes followed by 35 cycles of: denaturation at 94°C for 30 seconds, annealing at 
55°C or 65°C for one minute, extension at 72°C for one minute per 1 kb of product size 
and final extension at 72°C for seven minutes. The product of this PCR round was used 
as a template in the second round of PCR (nest amplification). Using 0.2 µl PCR tubes, 
5 µl of the product of previous PCR was mixed with 33.5 µl RNase-free water, 5 µl 10X 
PCR buffer, 3 µl 25 mM MgCl2, 1 µl nested GSP (prepared as 10 µM solution), 1 µl 
AUAP (10 µM) (designed to be complementary to the Abridged Anchor Primer) and 0.5 
µl of Taq DNA polymerase (5 units). The components of reaction were mixed 
immediately before the reaction tubes were inserted in the PCR machine under the 
thermal conditions described above. The resulting products were resolved in 2% agarose 
gel. Three sets of primers (GSP1, GSP2 and GSP3) were used and their structure, 
location and melting temperatures were listed in Table 2.7. The same experiment was 
carried out using control RNA as well as the gene-specific primers (GSP1 5'-TTG TAA 
TTC ATT AAG CAT TCT GCC-3', GSP2 5'-GAC ATG GAA GCC ATC ACA GAC-
3', GSP3 5'-CGA CCG TTC AGC TGG ATA TTA C-3'). 
 Western blotting  2.5
2.5.1 Protein extraction 
GC muscles were crushed using mortar and pestle under liquid nitrogen to generate the 
fine powder. 100 mg of crashed muscles were lysed on ice by adding 500µl of complete 
lysis M reagent. To prevent proteolysis of proteins, 1 Roche Mini Protease Inhibitor 
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Cocktail tablet and 1 Roche PhosSTOP phosphatase inhibitor cocktail tablet were added 
to 10 ml of complete lysis M reagent. Samples were homogenised by passing through 
25G needles for 30 seconds. The homogenated samples were then centrifuged at 4°C at 
12.000 rpm for 20 minutes. The supernatant was stored at -80°C or used immediately for 
an experiment. 
2.5.2 Protein concentration measurement 
The concentration of protein was established by using the bicinchonic acid (BCA) assay. 
1-10µl of the standard protein (bovine serum albumin, BSA) was added, in duplicate, 
into 96 wells plate (Nunc-96), the measurement of this protein was used to calculate the 
standard curve. 1µl of test protein samples were added to separate wells in triplicate. 
The standard and test proteins were made up to 10µl by adding the appropriate amount 
of RNase-free water. 190µl of BCA working reagent (Table 2.2) that consists of 50 parts 
BCA and one part of 4% CuSO4.H2O were added to both standard and test proteins. The 
plate was incubated at 55°C for 15 minutes and the absorbance was then measured at 
550 nm using a microplate reader (POLARstar OPTIMA, BMG LABTECH, GmbH, 
Germany). The concentration of protein was calculated based on the value of y=mx+c 
that was obtained from the standard curve of standard protein. 
2.5.3 SDS-PAGE 
20-40µg of protein samples were mixed with Laemmli buffer (62.5 mM Tris-HCl, 2% 
SDS, 25% glycerol and 0.01% bromophenol blue) in the final reaction volume of 20-
30µl. β-mercaptoethanol (2.5%) was added to the mixture before it being heated at 95°C 
for five minutes.  The denatured protein samples were placed immediately on ice.   
20µl of protein samples were loaded into SDS-PAGE gel, which was either anykD
TM
 
Mini-PROTEAN®TGX
TM
 precast polyacrylamide gel (BioRad) or a lab-made gel. The 
lab prepared gel contained two parts with different concentrations: the 4% stacking gel 
was overlaid on resolving gel with concentrations ranging between 6 and 12% (Table 
2.2). The resolving gel was made by mixing 30% acrylamide/bis, 0.01ml of 10% SDS, 
25% of 1.5M Tris-HCl (pH8.8) and polymerising factors (10% w/v APS and 0.002% v/v 
TEMED). This gel was poured into assembled gel cassette with casting frame placed on 
the casting stand and then it was covered with water and incubated at room temperature 
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for 30 minutes for polymerasation. Next, the stacking gel made of  13% of 30% 
acrylamide/bis, 0.01ml of 10% SDS, 0.5 M Tris-HCl (pH6.8) and polymerising factors 
(10% w/v APS and 0.002% v/v TEMED) was added to the top of the resolving gel (after 
removing water). Gently, 1.5 mm comb was inserted and the gel was set for further 30 
minutes to solidify. Consequently, the gel cassette was placed in the electrophoresis 
apparatus filled with the running buffer (Table 2.2), 20-30µl of denatured protein 
samples were loaded alongside the protein ladder (Kaleidoscope™ Standards-BioRad). 
The apparatus was connected to the power supply and set up at 80 V for stacking gel and 
120 V for resolving gel until the bromophenol dye reached to the bottom of the gel.  
2.5.4 Electro-transfer 
Polyvinylidene fluoride (PDVF) membrane was cut to the same size as the resolved 
protein gel from the previous step. This membrane was treated with methanol and 1x 
transfer buffer (Table 2.2), for one minute each. Both gel and membrane were 
sandwiched between wet filter paper and sponges inside the gel holding cassette. The 
sandwich was located in the transfer apparatus (Bio-Rad) filled with the cold transfer 
buffer with the ice pack. Proteins were transferred from the gel to the membrane at 4°C 
and 40V, overnight. 
2.5.5 Blocking and immunodetection 
The blot with transferred protein was washed with 1x TBST or 1x PBST (Table 2.2) 
before it was blocked with 5% of non-fat skimmed milk in PBS/TBS for one hour. To 
investigate more than one protein in the same blot, the blot was cut into strips based on 
the molecular weight of the target protein. Later, those strips were incubated with a 
specific primary antibody (Table 2.3) prepared in 5% skimmed milk in TBST at 4°C 
overnight on a shaker, followed by three washes in 1x TBST for five minutes each. The 
blot strips were then incubated with a secondary antibody (Table 2.4) also prepared in 
5% skimmed milk in TBST at room temperature for one hour. Again, the blots were 
washed three times with 1x TBST for 10 minutes each. Finally, the blots were incubated 
with chemiluminescent substrates (Millipore) and the protein bands were visualised 
using ChemiDoc™ XRS+ System (Bio Rad). The membranes were either stored at room 
temperature or stripped. In order to remove the previous primary and secondary 
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antibodies from membranes, two stripping methods were used, based on their harshness. 
First, the harsh stripping method involved incubating the membranes in a stripping 
buffer (Table 2.2) for two hours at 50°C in a shaking incubator, followed by three 
washing steps with 1x TBST for five minutes each. Then the blot was re-activated with 
methanol and again washed three times and incubated with a primary antibody. Second, 
the milder method to quench the horseradish peroxidase enzyme bound to a secondary 
antibody was used and involved incubating the membrane with 30% H2O2 for 20 
minutes at 37°C. The membranes were washed three times, reactivated with methanol, 
and incubated with a primary antibody (raised in species different from those used in the 
previous experiment).  
The relative level of protein was calculated by comparing the relative density of the 
target protein band with the control protein using the image J software. The analysis of 
the results was based on a protocol described in the following link: 
http://lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-with-image-j/ 
 Histology 2.6
2.6.1 Muscle samples collection 
Tibialis anterior(TA), gastrocnemius (GC), diaphragm, heart and brain were collected 
from C57/BL10, mdx, mdx/P2rx7
-/-
 and also mdx mice treated with pharmacological 
inhibitors to be used in histological and immunostaining studies. To avoid the 
morphological distortions resulting from tissue drying or slow freezing artefacts and 
autolysis the tissues were frozen immediately after collection. 
Tissues were removed carefully and placed on ice-cold aluminium foil. Tissues were 
mounted on 20 mm diameter cork disks with OCT-embedding matrix, frozen in 2-
methylbutane chilled in liquid nitrogen and then stored at -80˚C. 
2.6.2 Cryosectioning 
Frozen muscles were left in the cryostat chamber for 30 minutes to equilibrate to -20°C. 
The cork disk was then fixed on the chuck by using the OCT-embedding matrix. 
Sections were cut from the middle third of muscle samples at the thickness of 10µm. 
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Next, the sections were adhered on poly-L-lysine (Table 2.2) coated glass slide. To 
maximise the adherence of the tissue to the slide, the sections were air dried for several 
hours at room temperature. Finally, these sections were used for immunodetection or 
stored at -80°C.    
2.6.3 Haematoxylin and eosin staining 
The haematoxylin and eosin can be used in diagnosing the normal and abnormal tissue 
morphology. The sections were stained with H and E to evaluate tissue preservation and 
orientation after cryosectioning. The glass-attached sections were kept at room 
temperature for 30 minutes to dry. The sections were then stained with haematoxylin for 
10 minutes and rinsed with tap water for 5 minutes. Later, slides were differentiated with 
acid alcohol for 5 seconds and washed with tap water for 5 minutes. The sections were 
counterstained with eosin Y solution for 5 minutes and rinsed briefly with tap water. 
Consequently, slides were placed in a glass Coplin jar containing alcoholic series to 
dehydrate (70 %, 95% alcohol and 100% x2) for 3 minutes each. Finally, the sections 
were cleared in xylene (2x) for 3 minutes before being mounted in DPX under the 
coverslip. The sections were visualised under the bright-field microscope or using the 
Fully Automated Upright Microscope System (Leica DM6000 B). 
2.6.4 Immunofluorescence staining 
Frozen sections were kept at room temperature for 30 minutes to dry. Hydrophobic wax 
pen was used to separate the sections on the slide into targets and negative control 
groups. Samples were fixed in 4% paraformaldehyde solution (Table 2.2) in PBS for 15 
minutes at 4°C. Three five minutes washing steps with TBST (Table 2.2) were applied. 
Sections were then blocked for 30 minutes in 10% serum in TBST (serum was extracted 
from the same animal that the secondary antibody was raised in). The slides were 
covered with primary antibody solution prepared in 10% serum in TBST overnight at 
4°C on a shaker. Other three washing steps with TBST were performed for five minutes 
each. The slides were incubated with the secondary antibody solution diluted in 2% 
serum in TBST that contains the nuclear counterstaining agent (Hoechst). Last three 
washing steps were carried out for 10 minutes and then the slides were mounted in Merk 
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Millipore Fluorsave
TM
 fluorescent mounting medium. The immunofluorescence was 
visualised using confocal microscope (LSM710 Zeiss). 
2.6.5 Morphometric analysis 
A whole section of three biological replicates was scanned by confocal microscope and 
then analysed by using Fiji package in imageJ software (Schindelin et al., 2012; 
Rasband, 1997-2012). Three macros were created by Dr Anthony Sinadinos (Appendix 
10.2, 10.3 and 10.4): the first one was used to calculate the minimum Feretʼs diameter 
and centrally nucleated fibres, then the Variance of coefficient was calculated in this 
study according to the formula of the Briguet et al., 2004 study: 
‘Variance of coefficient Z = 1000 x standard deviation of muscle fibre minimum 
diameters/mean muscle fibre minimum diameter’. 
Second was used to analyse the IgG positive area and the third was used to count the 
individual cells representing infiltrated immune cells. These macros were generated to 
compare the morphometric variation between samples semi-automatically, in order to 
reduce bias due to the user input. 
 Analyses of the sarcolemmal integrity 2.7
2.7.1 Measurements of sarcolemma permeability to IgG 
In mdx, loss of sarcolemmal integrity can be measured by assessing permeability of 
different molecules, particularly the blood born immunoglobulins. In order to detect 
these serum proteins in damaged muscle, the immunostanining protocol (exclusion the 
primary antibody incubation step) was used in GC muscle sections with secondary anti-
mouse IgG antibody as suggested by Straub et al., 1997.  The percentage of fibres with 
intracellular staining to total fibre numbers was calculated using the macros mentioned 
earlier and the Fiji package. 
2.7.2 Measurements of the serum creatine kinase (CK) levels 
Serum samples were used to measure the creatine kinase activity according to the kit 
manufacturer’s protocol (Sigma). Two enzymatic reactions lead to the release of 
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NADPH as a final product and this corresponds to the CK activity in samples. In the 
first reaction, the phosphocreatine and ADP are converted into creatine and ATP. The 
released ATP is utilised by hexokinase enzyme to phosphorylate the glucose to glucose-
6-phosphate. The latter is oxidised by NADP in the presence of glucose-6-phosphate 
dehydrogenase to produce NADPH and 6-phosho-D-gluconate. This kit has a linear 
range of 30–1,800 units/L CK activity. 
The components of the kit were equilibrated to room temperature for 30 minutes before 
being used. 110µl of water was added in one well of 96 wells optical plate (Nunc-96) as 
a blank. The 10 µl of calibrator was mixed with 100µl of water and added to a separate 
well. Then 10 µl of three replicates of each sample with 100 µl of the reconstituted 
reagent were pipetted into the wells. The plate was incubated at 37°C for 20 minutes and 
the initial absorbance was measured at 340 nm in microplate spectrometer (POLARstar 
OPTIMA, BMG LABTECH, GmbH, Germany). Additional incubation for further 20 
minutes at 37°C was performed and another measurement at 340 nm was taken. Values 
were calculated according to the following formula: 
CK Activity (units/L) = (A340) final – (A340) initial x 150/ (A340) calibrator – (A340) 
blank. 
 Pharmacological inhibiton studies 2.8
The mdx mice were treated with different pharmacological antagonists to block the 
P2RX7 receptor activity. Firstly, two week-old mdx mice were injected with 8.4 mg/kg 
of oxidized ATP (oATP) intra-peritoneally (i.p.) every two days for four weeks, until 
they were analysed at six weeks of age. The age-matched mdx mice were injected with 
sterile PBS as a negative control and were analysed in parallel with the oATP group. 
Secondly, two week-old mdx mice were injected i.p. with 150 μmol/kg body weights of 
A438079 (Tocris) every day over two weeks and analysed at four weeks. The age-
matched control mice were injected with the same volume of sterile PBS and 25% of 
DMSO. Thirdly, four week-old mdx mice were injected i.p. with 50mg/kg body weight 
of Zidovudine (AZT) twice a day over two and four week seperatly and analysed at six 
and eight weeks, respectively. The age-matched control mice were injected with the 
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same volume of sterile PBS.  Finally, four week-old mdx mdx mice were fed with 
2.5µl/g of 200mg/kg AFC-5128 prepared in (1:1) honey and Carboxymethylcellulose 
(CMC) mixture twice a day over four weeks and analysed at eight weeks. The age-
matched control mice were fed with the same volume of (1:1) honey and CMC mixture.  
In all cases, animals were killed and the TA, GC, heart, diaphragm, brain, blood were 
collected within one hour and 30 minutes from the last treatment and were used in 
different analyses. For instance, TA was used to study gene expression using qPCR, GC 
muscles were used to analyse protein levels and tissue-localisation by western blotting 
and immunofluorescence, respectively. Blood was used for serum CK analysis. In all 
cases tail samples were taken for gDNA extraction (as described above) and this was 
used to confirm the genotype of treated animals. Diaphragm, heart and brain were fixed 
on cork disks and used for immunofluorescent studies. 
For the Affectis group analysis, frozen serum samples were sent to the Affectis 
Company to measure the drug concentration. 
  Statistical analysis 2.9
All statistical analysis was performed in Minitab
TM
17 software. One way ANOVA with 
post-hoc Tukey or Fisher test was employed with one variable and three or more data 
groups (genotypes). Student t-test was used for comparisons between two unrelated 
groups. In any test performed, the P<0.05 was considered as statistically significant. The 
vertical bars in graphics represent SEM, N=3-5 in qPCR, N=3 in Western blot, NGS and 
immunofluorescent analyses whereas N=6-8 in CK activity assays. 
The analysis of the NGS data was carried out by Source BioScience and by Dr. Mikhail 
Shugay as a part of our collaboration. The R studio software was used to analyse the 
NGS data and generate some of the figures related to this experiment. 
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3  
Characterisation of the dystrophic and dystrophic/P2RX7 double 
mutant mice 
 
 Introduction 3.1
Canine Duchenne muscular dystrophy (cDMD) is important DMD animal model. 
Despite the characterisation of numerous cDMD breeds, golden retrievers (GRMDs) 
are the most widely used (Sharp et al., 1992; McGreevy et al., 2015). They present a 
more severe dystrophic phenotype than mdx mice. This model shares the same 
clinical aspect as that present in DMD patients (Valentine et al., 1988; Smith et al., 
2011). However, variation in the severity of the disease has been reported: for 
example, some dogs die directly after birth while others present remarkably mild 
phenotypes (Ambrósio et al., 2008). The symptoms of disease start around two to 
three months of age and include muscle weakness and gait abnormalities. At the age 
of six months, atrophy, muscle wasting, low rate of muscle regeneration and fibrosis, 
joint contracture and the symptoms of cardiac deficiency occur (Valentine et al., 
1988). At 12 months, GRMDs show pharyngeal and oesophageal dysfunctions and 
respiratory functions are also reduced. Animals die early at three years of age 
(Kornegay et al., 2003; McGreevy et al., 2015). Unlike DMD, 20–30 % of neonatal 
GRMDs die due to diaphragm dysfunction and the other specific GRMD feature is 
growth retardation (Nakamura et al., 2013; West et al., 2013). The changing of one 
single base in the 3' end of the dystrophin gene leads to altering the splice site of 
intron 6 and skipping the exon 7. This causes alteration of the reading frame of exon 
8 and creation of a premature stop codon (Sharp et al., 1992). The high mortality rate 
in the first two weeks of life makes the use of this model in preclinical studies 
limited (Banks and Chamberlain, 2008). 
Dystrophic pigs are one of the important lab-generated DMD models (Klymiuk et 
al., 2013). They have been generated by targeting the kidney primary cells with an 
artificial recombinant DMD construct in which the exon 52 was replaced by a 
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neomycin resistance cassette. Exon 52 is one of the hot -spot regions for mutations in 
the DMD gene (Koenig et al., 1989). Because this animal resembles human size and 
dystrophin is completely absent, the pig model mirrors the situation in DMD 
patients. The symptoms of disease start from two days, however they share the same 
dystrophic phenotypes as DMD patients at three months of age, with inflammation, 
degeneration, regeneration and fibrosis being notable processes at this age. The 
symptoms of disease also include the elevation of serum creatine kinase levels and 
muscle weakness. This model differs from DMD in its short lifespan of three months 
as a result of respiratory defects. Additionally, the muscle sections of these animals 
show 10% of central nuclei compared with 60% in mdx, indicating a severe muscle 
phenotype and low rate of regeneration (Spurney et al., 2009).  
Unlike mdx mice, young dogs and pigs lack the sarcolemma utrophin and the 
expression of utrophin is increased clearly in adult animals (Lanfossi et al., 1999). It 
is believed that the absence of utrophin in young animals is associated with the 
lethality among their population (Lanfossi et al., 1999). 
We and others have detected the elevation of P2RX7 receptor expression in mdx 
coinciding with the release of ATP from damaged muscle in DMD (Ferrari et al., 
1994; Yeung et al., 2006; Rawat et al., 2010; Young et al., 2012; Valladares et al., 
2013; Young et al., 2015; Sinadinos et al., 2015). In addition to its role in 
inflammation, P2RX7 up-regulation in dystrophic muscles made this receptor a 
particularly good target in DMD (Yeung et al., 2006; Rawat et al., 2010; Young et 
al., 2012; North and Jarvis, 2013). Given the widespread use of mdx mice in 
preclinical studies and the availability of mouse gene knockouts, mdx/P2rx7
-/-
 
double mutant mouse models were established by our group to investigate whether 
ablation of the P2RX7 receptor reduces the dystrophic pathology and also to 
determine the suitability of this receptor as a therapeutic target. Two lines of 
mdx/P2rx7
-/-
 were developed, both being generated by breeding mdx with either 
Glaxo-P2rx7 or Pfizer-P2rx7 (Sinadinos et al., 2015). The Pfizer-mdx/P2rx7
-/-
 lack 
both dystrophin and P2RX7 receptor functions, while the Glaxo-mdx/P2rx7
-/-
 lack 
dystrophin and the P2RX7a isoform (the full length 595 amino acid proteins). The 
Glaxo-P2rx7 KO was genetically engineered by inserting the LacZ transgene and 
neomycin cassette into exon 1 to disrupt the open reading frame of the P2rx7 gene 
(Chessell et al., 2005).  The Pfizer-P2rx7 KO line was established by Solle et al. 
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(2001) by inserting a neomycin cassette into exon 13 of the P2rx7 gene, resulting in 
an out of frame disruption, replacing the region that encodes the C terminus. 
However, there are molecular and functional differences between these two KO 
mice. For example, macrophages isolated from the Pfizer KO display reduced 
production of IL6, while the macrophages isolated from the Glaxo KO release high 
levels of this cytokine (Chessell et al., 2005).  
It transpired that there are several P2rx7 splice variants, some of which escape 
deletion in these KO.  The naturally occurring C terminal P2RX7 variants have been 
identified in mice, such as 13B and 13C. These two are encoded by alternative exon 
13 sequences (Masin et al., 2012). In addition, a novel splice variant, P2X7K, which 
is encoded by an alternative exon 1, was also identified in P2RX7 knockout mice 
(Nicke et al., 2009). The function of this variant correlates with large pore 
formation-mediated apoptosis (Nicke et al., 2009).  It has been found that while the k 
variant remaining in the Glaxo KO is functional, the 3' end transcript variants in the 
Pfizer KO are not functional or even have a dominant-negative effect (Nicke et al., 
2009; Masin et al., 2012). The analysis of both KO mice suggests that the P2RX7 
receptor has an important role in many physiological and pathological conditions, for 
instance, bone formation, inflammation and cytokine release and neuropathic pain 
(Solle et al., 2001; Labasi et al., 2002; Ke et al., 2003; Chessell et al., 2005; Hughes 
et al., 2007; Portales-Cervantes et al., 2010).  
We have previously identified that mutation in the dystrophin gene increases the 
sensitivity of dystrophic cells to eATP. It has been shown that exposure of 
dystrophic cells to a high concentration of eATP leads to accumulation of the 
synergistic level of Ca
2+
. The accumulation of intracellular Ca
2+
 is increased with 
cell exposure to P2RX7 agonists and is inhibited by its antagonists, confirming the 
involvement of P2RX7 in the pathogenic entry of Ca
2+ 
(Yeung et al., 2006). 
Reduction of the number of degeneration–regeneration cycles in mdx muscle upon 
blockade of P2RX7 confirmed the role of this receptor in DMD disease (Young et 
al., 2012). Recently, demonstration of the role of P2RX7 large pore formation in 
stimulating autophagic cell death in dystrophic myoblasts has also been identified by 
our group. Furthermore, Sinadinos et al. in 2015 studied the role of the P2RX7 
receptor in DMD pathology in more details. This study showed that genetic ablation 
and pharmacological inhibition of P2RX7 reduces a wide range of muscle and non-
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muscle dystrophic phenotypes in this DMD model. Overall, improvement in muscle 
structure and strength and a reduction of a number of important parameters:  fibrosis, 
creatine kinase levels, muscle permeability to immunoglobulin G and inflammation 
were detected in this study. 
Another model used in this study was mdx
βgeo 
mouse, which has a promoterless 
ROSA
βgeo
 vector inserted in the Dmd gene exon 63 (Wertz and Füchtbauer, 1998). 
This model was used to follow the changes in expression of Dmd under the non-
sense mediated decay mechanism.  
 Aim and objectives 3.2
Characterise the impact of the P2RX7 purinoceptor ablation in the mouse 
model of Duchenne muscular dustrophy by comparing mdx and mdx/P2rx7
-/-
 
mice. 
 Confirm genotypes of animals used in this study.  
 Establish the performance parameters of various qPCR methods. Validate the 
quality and the purity of RNA and cDNA samples, and the most stable and 
optimal numbers of reference genes. 
 Compare the expression of transcripts (qPCR) and levels of proteins 
(Western blotting) for DMD and P2RX7 in C57/BL10, mdx and mdx/P2rx7
-/-
 
mice.  
 Use immunostaining to study the distribution and sub-cellular localisation of 
dystrophin and P2RX7 proteins in muscle sections of all three genotypes. 
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 Results 3.3
3.3.1 Genotypic and phenotypic characterisation of the mdx/P2rx7-/- mice 
The DNA samples extracted from tail or ear snips were used to confirm the genotype 
of the mdx, mdx/P2rx7
-/-
, C57/BL10 and ROSA
βgeo
 mice by PCR. Specific primers 
were designed to identify the wild-type and mutant Dmd and P2rx7 genes (Table 
2.7). Figure 3.1 shows the expression of the wild-type Dmd and P2rx7 in C57/BL10, 
the mutant Dmd and wild-type P2rx7 gene in mdx, whereas Pfizer-mdx/P2rx7
-/-
 has 
both mutant Dmd and P2rx7 genes. The same protocol was used to confirm the 
genotype of mdx mice used for pharmacological inhibitor studies. With primers in 
the region of the ROSA
βgeo
 construct, specific 179 bp bands were observed in 
mdx
βgeo
 indicating the correct genotype. 
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Figure 3.1: 
PCR products visualised in 2% agarose gels showing genotyping results for C57/BL10, 
mdx, mdx/P2rx7
-/-
 and mdxβgeo. (A) C57/BL10 had expression of 105 and 363 bp 
bands denoting the presence of wild-type Dmd and P2rx7 receptor, respectively. (B) 
mdx showed 105 bp bands for mutant Dmd and 363 bp bands for the wild-type P2rx7. 
(C) All mdx/P2rx7
-/-
 showed 105 bp bands for mutant dystrophin and 280 bp bands 
representative of neomycin resistance cassette inserted in exon 13 of the P2rx7 gene. 
(D) All mdxβgeo mouse samples showed amplification of 179 bp bands corresponding 
with promoterless ROSAβgeo construct insertion. Negative control (NC) represents 
water used instead of gDNA samples. 
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Further supporting the genotype results, the expression of Dmd and P2rx7 were 
analysed by qPCR in 4 week-old TA muscles. Both mdx and mdx/P2rx7
-/-
 show 
down-regulation of dystrophin expression compared with C57/BL10. In contrast, 
mRNA transcript level of P2rx7 was significantly increased in mdx compared to 
C57/BL10, and reduced in mdx/P2rx7
-/-
 (Figure 3.2). 
 
 
 
Figure 3.2: 
Real Time PCR analysis in 4 week-old TA muscles representing the expression levels 
of Dmd and P2rx7 genes. (Left) Significantly decreased levels of dystrophin expression 
in mdx and mdx/P2rx7
-/-
 compared to C57/BL10. (Right) Increased expression level of 
P2rx7 gene in mdx compared with C57/BL10 and mdx/P2rx7
-/-
. One way ANOVA, 
N=5, **P≤ 0.01. 
 
 
 
In addition to PCR, western blot was used to confirm the phenotype. Proteins were 
extracted from four week-old gastrocnemius (GC) muscles to assess the level of 427 
kDa dystrophin protein: clear bands were present in the C57/BL10 samples and 
absent in both mdx and mdx/P2rx7
-/-
. Furthermore, GC and heart muscles were used 
to detect the protein levels of P2RX7. The same expected size bands were seen for 
P2RX7 in GC and heart muscles but the protein levels varied: Figure 3.3 shows the 
protein level of P2RX7 in C57/Bl10 controls, higher levels in mdx and it being 
absent in mdx/P2rx7
-/-
. 
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Figure 3.3: 
Representative Western blots showing the level of dystrophin (Sigma) and P2RX7 
(Synaptic system) proteins in C57/BL10, mdx and mdx/P2rx7
-/-
. (A) The full length 
dystrophin protein  (427 kDa) was present in C57/BL10 and absent in both mdx and 
mdx/P2rx7
-/-
. (B) High levels of P2RX7 receptor in 4 week-old GC muscles from mdx 
compared to C57/BL10 and no detectable protein in mdx/P2rx7
-/-
, confirming 
genotyping data of the receptor ablation. (C) Immunoblot of P2RX7 protein in the 
heart: there are two bands visible. The top band is stronger in heart from mdx than 
C57/BL10 while it is not detectable in mdx/P2rx7
-/-
. The identity of the bottom band 
found in all heart samples is unknown but its presence in mdx/P2rx7
-/-
 indicates that it 
is non-specific. (D) Densitometric quantification of P2RX7 protein levels relative to 
control proteins (GAPDH or ACTIN) in the GC muscles (Left) and in heart muscle 
samples (Right) demonstrating the increased P2RX7 protein in mdx (one way ANOVA, 
N=3,  P<0.005, P=0.018 for muscle and heart respectively). 
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To detect the distribution and sub-cellular localisation of dystrophin and P2RX7 
proteins, immunostaining was performed in 4 week-old GC muscles. Dystrophin 
protein was present at the cytoplasmic side of the sarcolemma and had uniform 
pattern in C57/BL10 muscle fibres. However, dystrophin was absent in mdx and 
mdx/P2rx7
-/-
 with the exception of a few dystrophin positive (revertant) fibres 
present in some muscle sections from these animals. Results in Figure 3.4 show the 
high level of P2RX7 protein in mdx (in the areas of accumulation of inflammatory 
cells) compared with C57/BL10 and only a weak signal in areas of inflammation in 
mdx/P2rx7
-/-
. These results together confirmed the genotyping data for the animals 
used in this study. 
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Figure 3.4: 
Representative confocal microscope images of C57/BL10, mdx and mdx/P2rx7
-/-
 
muscle sections immunostained with anti-dystrophin (Sigma) and anti-P2RX7 
(Synaptic system) antibody. (Left) Dystrophin Dp427 isoform (red signal) was 
identified in the sarcolemma of GC muscle from C57/BL10 while the dystrophin is 
almost absent in mdx and mdx/P2rx7
-/-
 except the few-dystrophin positive revertant 
fibres being present. (Right) confocal images show the P2RX7 protein (green signal) 
localised and overexpressed in areas of immune cell infiltrations in mdx versus 
C57/BL10. In mdx/P2rx7
-/-
, the signal of P2RX7 is nearly absent. Cell nuclei were 
stained with Hoechst (blue). All images have the same scale bar (30µm). 
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3.3.2 Real time PCR analyses 
Several steps were performed to validate the real time PCR data. Firstly, five RNA 
extraction kits were tested to establish the most effective and convenient method for 
the isolation of high quality and purity RNA from muscles: RNasy mini kit (Qiagen), 
miRNasy mini kit (Qiagen), Direct-zol
TM
 RNA mini prep (Zymo Research), Trizol 
reagent protocol (Life Technology) and RNeasy Plus Universal mini kit (Qiagen). 
Based on results of these comparisons, RNeasy Plus Universal mini kit was chosen 
as the best one for isolating RNA from skeletal muscle samples. RNA samples were 
validated for their quality and quantity by assessment of their ribosomal ratios in the 
native agarose gel electrophoresis and using the Bioanalyzer. These methods 
confirmed the existence of intact RNA both according to the size distribution of 
rRNA fragments, for example the double amount of the 28S representative band 
compared to 18S (Figure 3.5.A). Furthermore, NanoDrop and Bioanalyzer 2100 
were used to measure the quality and quantity of RNA samples. The sample was 
considered of a good quality when the NanoDrop showed the 260/280 ratio equal or 
close to two, and if Bioanalyzer showed RNA integrity (RIN) value above 7 (Figure 
3.5 B).  
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Figure 3.5: 
The quality and purity of RNA samples extracted by RNeasy Plus Universal mini kit. 
(A-Left) The integrities of RNA samples visualised in 1% agarose gel, the three distinct 
bands indicated a good quality of RNA samples. The top band corresponds to 28S 
ribosomal RNA (rRNA), the bottom band represents 18S rRNA. Further indicator of 
good RNA quality is the band intensity ratio of 2:1 corresponding to 28S:18S. (Right) 
Bioanalyzer image, which shows both intact RNA identified by the double intensity of 
the top bands (28S) compared with lower bands (18S) and the RIN=10, (B-Top). 
NanoDrop result shows good RNA sample represented by a sharp peak, concentration 
and the ratio of 260/280 and 260/230, (Bottom).  
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Secondly, to check the purity of RNA samples from gDNA contamination, another 
test was performed, which used PCR amplification with the Gapdh primer set 
detecting both the transcript and the gene in any sample. The results of Gapdh 
amplification demonstrated the sensitivity of PCR method for detecting the gDNA 
contamination. Even though RNA samples were treated with DNase enzyme, the 
PCR still detected Gapdh, which indicated the gDNA contamination in those 
samples. The multiple DNase treatment with prolonged incubation cleaned the RNA 
from this contamination but, at the same time, reduced the quality of RNA (Figure 
3.6.A and B). Therefore, the RNeasy Plus Universal mini kit was used exclusively as 
it contains, as another advantage of this kit, gDNA eliminator solution. This solution 
was used during the extraction steps and that eliminated gDNA and also protected 
RNA samples from degradation while allowing removing the residual enzyme 
through a simple washing step. In addition to PCR-Gapdh method, the purity of 
samples from gDNA contamination was tested by using single exon primers in qPCR 
experiments. The Cq value of the no-reverse transcriptase control (–RTC) gave a late 
signal after about five additional cycles than the highest Cq value for the test sample. 
This late signal may relate to the primer-dimer formation or to a small amount of 
gDNA. As suggested by D’haene and Hellemans (2010) the small amount of 
contaminating gDNA can be ignored because it does not affect the measurement of 
the gene expression (Figure 3.6.C). Additionally, to avoid measuring the gDNA 
contamination, most of the primers used in this study spanned exon-exon junction. 
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Figure 3.6: 
Validation of the RNA samples being free from gDNA contamination. PCR products 
visualised in 2% agarose gels showing (A) the validation of RNA purity by testing the 
Gapdh gene expression in crude RNA samples extracted from muscles. (B) Failure of 
amplification after repeated and prolonged incubation with DNase indicates RNA being 
clean from gDNA contamination. Positive control represents the cDNA sample, while 
the negative control refers to RNase/DNase free water instead of the cDNA. (C) 
Amplification plots of qPCR revealing the distance between the –RT signal and the 
amplification signal of the test samples (PC). Further distance between them indicates 
that the samples are suitable for use in qPCR experiments. 
 
 
 
The quality of cDNA samples was also validated by using RT-PCR with α-
dystrobrevin primers. The expression of a large portion (over 1kb) of a rare transcript 
such as α-dystrobrevin demonstrated the good quality of first strands (Figure 3.7. A). 
Moreover, no template controls (NTCs) to demonstrate the purity of qPCR 
amplification from DNA or reagent contamination and primer-dimer formation were 
undertaken in each individual experiment and the result of the SYBR Green 
detection method showing signal five cycles later than expected while the negative 
control in TaqMan hybridisation probe was given no-detection signal, and both were 
ignored (Figure 3.7.B). Finally, in SYBR Green-based detection, given that this dye 
reacts with any double stranded nucleotides, the specificity of the reaction was 
measured based on the shape and melting temperature of the peak in melt curve 
graphs (Figure 3.7.C). In fact, not every SYBR Green primer set gave the specific 
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amplification (sharp single peak) (Figure 3.7.C). Therefore, the TaqMan 
hybridisation probes (Life Technologies) were used in all subsequent experiments as 
it showed high specificity in all qPCR reactions. The relative expression between the 
test and the reference gene was calculated by 2
-ΔΔCT
 method, and the results were 
analysed by using the one way ANOVA test or t-test. 
 
 
 
Figure 3.7: 
Validation of cDNA samples. (A) RT-PCR analysis showing the quality of the first 
strand. The presence of the large size product (1120bp) of the rare α- dystrobrevin 
transcript in muscles of the mdx, mdx/P2rx7
-/-
 and C57/BL10 demonstrated the good 
quality of cDNA. (B) Amplification plots with SYBR Green (left) and TaqMan 
hybridisation probe (right) show either a signal five cycles later than expected or no 
signal in the negative controls, respectively. (C-left) Single peak in the melt curve 
graph represents the specific qPCR amplification product. (C–right) multiple melt 
curves indicate nonspecific priming (in this case a problem with the primer design). 
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Twelve candidate reference genes from different pathways and functional classes 
(Actb, Gapdh, 18S, Ubc, Cyc1, Canx, Sdha, Ywhaz, B2m, Rpl13a, Elf4a2 and Atp5b) 
were chosen for normalisation experiments (See Table 2.5 for more details). 
Normalisation to the wide spectrum of reference genes is considered an important 
step to minimise the error introduced into the experiment from the technical input 
variation (Huggett et al., 2005). The geNorm tool in qBase
+
 software was used to 
evaluate the expression stability of the most reliable reference genes across all 
experimental samples. Figure 3.8.A shows that both the Gapdh and Cyc1 genes were 
identified as most stable reference genes in skeletal muscle samples. Additionally, 
the optimal number of reference genes required for an accurate normalisation was 
established by geNorm tool. Results revealed that the pairwise variation value of 
V2/3 was below the cut-off threshold 0.15, therefore the two most stable references 
genes were sufficient for good normalisation and adding another gene was not 
required (Figure 3.8 .B). 
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Figure 3.8: 
Graph showing stability of the reference genes calculated by geNorm tool in the qBase
+
 
software: (A) Shows ranking of reference genes according to their average expression 
stability-the lower value of expression denotes the more stable gene. (B) The optimal 
number of reference genes needed for accurate normalisation. Here the result indicates 
that minimum two references genes are required for optimal normalisation. 
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 Discussion 3.4
The PCR experiment confirmed the genotype of the animals used in this study. The 
mdx harbour point mutation in exon 23 resulting in a loss of the full length 
dystrophin (Bulfield et al., 1984). The genotype of mdx
βgeo
 was also confirmed by 
positive amplification of the ROSAβgeo vector inserted into exon 63, resulting in the 
loss of all dystrophin isoforms (Wertz and Füchtbauer, 1998). The Pfizer-
mdx/P2rx7
-/-
 was confirmed by showing positive results for mutated dystrophin gene 
and the neomycin inserted in exon 13 region of the P2rx7 gene. However, the 
dystrophin mRNA expression was still detected in both mdx and mdx/P2rx7
-/-
 
(Figure 3.2). The reason for this is perhaps related to the location of the DMD 
primers. The DMD primer pair used was complementary to exon 65-66, where the 
Dp71 variant is located (Austin et al., 1995). Therefore, qPCR amplification most 
likely represents the Dp71 dystrophin transcript. The low expression of P2rx7 was 
also detected in mdx/P2rx7
-/-
 when primers complementary to exon 13 were used. 
This result can be explained by few P2rx7 transcripts that escaped the RNA 
nonsense-mediated decay (NMD) mechanism. It has been demonstrated that the 
NMD mechanism cannot degrade transcripts harbouring premature termination 
codons (PTCs) located less than 50 bp upstream the last exon-exon junction, or in 
other words the transcript has a PTC that is not separated from the original stop 
codon by an intron (Baker and Parker, 2004; Huang and Wilkinson, 2012; Fang et 
al., 2013). The insertion of the neomycin cassette in exon 13 (the last exon) of the 
Pfizer-P2rx7 knockout changed the reading-frame, creating the PTC, so that the PTC 
moved closer to the original stop codon and was not separated by an intron. The 
other possibility for the detectable expression of P2rx7 in mdx/P2rx7
-/-
 may be the 
identification of splice variants escaping inactivation of the P2rx7 gene (Taylor et 
al., 2009). The importance of these variants in health and disease has been indicated. 
There are two main causes of P2rx7 variants: Single nucleotide polymorphisms 
(SNPs) and splice variant isoforms such as 13B and 13C (Adriouch et al., 2002; 
Yeung et al., 2006; Bartlett et al., 2014). These variants have been seen to escape 
from the inactivation of a neomycin insertion cassette in Pfizer-P2rx7 knockout and 
may therefore be recognised by primers that were used to target the exon 13. 
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The western blotting result matched the genotyping results, where the dystrophin 
protein was lost in mdx and mdx/P2rx7
-/-
, while the P2RX7 protein was lost in 
mdx/P2rx7
-/- 
only. It should taken into account that Westren blotting is a semi-
quantitative method, which can be successfuly used to detect the general level of 
protein (the purpose of this study). However,  this method provides the relative 
comparasion of target protein to the control protein levels. The non-quantitaive 
feature of this method can be explained by the technical variation in loading and 
transferring samples and also by detection the non-linear signal across samples 
concentration (Mahmood and Yang, 2012). 
The immunofluorescence of cryosectioned GC muscles displayed drastically 
diminished levels of dystrophin protein in both mdx and mdx/P2rx7
-/-
, except for a 
slight, isolated signal, which may indicate revertant fibres. Previously, it has been 
demonstrated that dystrophic muscles express truncated dystrophin isoforms during 
the regeneration process. This protein arises by a mechanism that restores the reading 
frame. The number of revertant fibres in the muscle indicates the frequency of 
regeneration-degeneration cycles (Yokota et al., 2006; Arechavala-Gomeza et al., 
2010).  
It has been reported that the best RNA yield can be obtained by dicing the tissue into 
small fragments in liquid nitrogen (Bustin and Nolan, 2004a). In this study, the 
muscle tissue was crushed into a fine powder in liquid nitrogen and then either kept 
at -80°C or directly homogenised using QIAzol solution. To normalise the RNA 
samples, the approximately equal weight of tissue was used for RNA extraction. 
RNeasy Plus Universal Mini Kit (Qiagen) has been found to be the best kit for the 
isolation of RNA from muscles. The integrity of RNA samples is a key factor for the 
efficient synthesis of cDNA and can influence the downstream analysis and therefore 
good RNA samples are needed, especially when the diagnosis and therapeutic 
application depend on this analysis (Raeymarkers, 1993; Imbeaud et al., 2005; 
Vermeulen et al., 2011). It has been seen that a good RNA sample should not contain 
gDNA contamination and PCR inhibitor (Hoorfar et al., 2004; Rådström et al., 2004; 
Espy et al., 2006). Genomic DNA carryover is the main problem affecting the 
quality of RNA samples (Pfaffl, 2004). Using the RNeasy Plus Universal Mini Kit 
reduced this problem because it contains the gDNA eliminator without influencing 
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the quality of RNA samples. Most commercial DNase kits have trace amounts of 
RNase and therefore affect the quality of extracted RNA (Pfaffl, 2004). The 
extraction of good RNA depends on accurate separation in the aqueous phase 
containing the RNA without removing the solution from the organic phase. In 
addition, the RNA yield was increased by the incubation of samples with free 
RNase-DNase water in the elution step twice, for 5 minutes each.  
Measuring the quality of RNA using minor amounts of samples is very important in 
pharmacological inhibitor studies when only a small amount of tissue is taken from 
treated animals. Both the NanoDrop and Bioanalyzer consume about 1 µl of RNA 
samples (Fleige and Pfaffl, 2006). High quality RNA samples for downstream 
applications need to have an A260/A280 ratio equal to or close to 2.0 because a ratio 
below 1.8 indicates protein contamination (Sambrook et al., 1989; Manchester, 
1996). Furthermore, the A260/A230 ratio also needs to be close to 2; values below 
this indicate the presence of phenol and phenol ring compounds such as chaotropic 
salts (guanidinium thiocyanate carryover) (Fleige and Pfaffl, 2006). The phenol 
carryover can inhibit the PCR and qPCR enzymatic reactions. The advantage of the 
NanoDrop over other conventional spectrophotometers is that it prevents variation 
and contamination due to the use of cuvettes (Fleige and Pfaffl, 2006).  
The major advantage of using a Bioanalyzer to assess the quality of RNA is the 
measurement of RIN (Mueller et al., 2004). Samples with RIN values over 7 were 
considered good quality RNA samples in this study. The high value RNA integrity 
value is an indicator of RNA intactness. It is already known that the integrity of 
RNA samples can be influenced by several external and internal factors. The external 
factor that may decay RNA is introduced through inadequate sample handling, 
prolonged storage, the delay in collecting samples after animal death and the 
presence of inhibitors (phenol, salt and other chemicals used during RNA extraction) 
(Holland et al., 2003; Schoor et al., 2003; Catts et al., 2005). The internal factors are 
associated with various types of stress (Barton et al., 1993), necrosis and apoptosis in 
samples and ubiquitous RNase that destroys the transcripts shortly after death (Phang 
et al., 1994). The further advantage of using a Bioanalyzer is that it provides the 
microfluidic capillary electrophoresis graph that estimates the RNA band size. The 
intact RNA samples are observed by a 28S:18S ratio equal to 2:1 (Sambrook and 
Russel, 2001; Mueller et al., 2004). The reason for the assessment of rRNA integrity 
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to check the mRNA quality is perhaps related to difficulties in visualising the 
mRNA; there is also an assumption that RNase decays rRNA and mRNA at the same 
rate. Miller et al. (2004) assumed that 18S integrity represents the mRNA integrity, 
while Santiago et al. (1986) and Fleige and Pfaffl (2006) found that the mRNA 
integrity correlates to 28S integrity. These methods are considered more sensitive in 
the assessment of RNA integrity than gel electrophoresis, which has low-throughput 
and requires a significant amount of sample (Bustin and Nolan, 2004b).  
Other techniques were performed to check the purity of RNA samples from gDNA 
contamination, in which the RNA samples were amplified with Gapdh in the PCR 
reaction. The results indicate the sensitivity of this method in the detection of gDNA 
contamination, even after incubating the samples with DNase. However, Sun et al. 
(2012) determined that the human genome contains 64 and 197 pseudogenes 
showing high homology with the Actin and Gapdh mRNA, respectively. The same 
author emphasised the responsibility of these pseudogenes for the amplification of 
PCR products in an mRNA–independent fashion (gDNA). The pseudogenes are 
intronless, located on different chromosomes and are silent; however, under specific 
circumstances, they start to be expressed. Also, because their transcription is 
controlled by different factors, they are considered different genes (Sun et al., 2012). 
Treating RNA samples with DNase to remove the residual gDNA as well as 
mitochondrial DNA is therefore necessary for successful PCR and qPCR tests. The 
multiple DNase treatments with prolonged incubation removed the contamination, 
but, at the same time, this reduced the quality of the RNA (Figure 3.6A and B). The 
gDNA is usually introduced during RNA purification because of the similarity in 
physiochemical features between RNA and DNA (Laurell et al., 2012). There is no 
record of using this method in the detection of gDNA contamination in RNA 
samples. Alternatively, the no-reverse-transcriptase control (–RTC) test was included 
to confirm the absence of residual DNA in RNA samples, as suggested in a previous 
study (Pfaffl, 2004). Furthermore, the sensitivity of the qPCR assay to gDNA was 
reduced by using primers across the exon-exon junction. Indeed, it is not possible to 
design primers spanning exon-intron junction all of the time, because the introns are 
sometimes short or the gene may contain only one exon (pseudogene) (Laurell et al., 
2012). It has been demonstrated that most of the prepared RNA is contaminated with 
gDNA, in spite of high-quality commercial RNA extraction kits (Mannhalter et al., 
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2000). D’haene and Hellemans (2010) reported that the small amount of 
contaminating gDNA can be ignored because it does not affect the measurement of 
gene expression. In particular, the Cq value of –RTC gives a late signal about five 
cycles after the highest Cq value for the test sample, which was the case for some 
samples in this study. Furthermore, it is clearly visible that the amplification of long 
products (over 400bp) in qPCR depends on the quality of the RNA samples (Fleige 
and Pfaffl, 2006). In this study, the length of the amplicons ranged from 59-143bp 
and the quality of the RNA samples was sufficient for amplifying products of this 
size.  
The cDNAs were synthesised using an enzyme that is thermostable up to 70°C 
(MMLV H–RT). The advantage of higher reaction temperatures is that it reduces the 
chance of hairpin loop formation, which causes the RT to break off and results in 
poor cDNA being amplified. In addition, the lower content of intrinsic RNAse H 
activity allows the cDNA length and yield to increase and provides higher resistance 
to the inhibitor with a faster reaction (Freeman et al., 1996; Wong et al., 1998). The 
RT step can be the source for variability in gene expression analysis; for that reason, 
the reaction condition was optimised, including the starting concentration of RNA 
and the choice of the first primer (Wong et al., 1998; Schwabe et al., 2000). There 
are two types of priming methods used to create cDNA: gene-specific and non-
specific primers (Fleige and Pfaffl, 2006). In this study, the non-specific priming 
method was used to generate the large pool of cDNA with nearly full length copies 
of mRNA. This method can maximise the number of genes tested by PCR or qPCR. 
The importance of synthesising cDNA from intact RNA rather than partially 
degraded RNA is shown by the fact that gene expression results may not represent 
the real biological conditions (Wang, 2005). Variation in cDNA quality near the 5' 
end compared with sequences close to the poly-A tail has been demonstrated (Swift 
et al., 2000; Sugita et al., 2001). Therefore, amplification of the α-dystrobrevin 
transcript to check the quality of cDNA was performed. α-dystrobrevin is a rare large 
(>1Kb) transcript in muscle tissue; amplification of such a transcript requires a good 
quality cDNA and, as shown in Figure 3.7.A the quality of cDNA samples used in 
this study was adequate.  
Normalisation to the reference gene is very important for reducing technical 
variation in qPCR experiments introduced from using unequal amounts and differing 
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qualities of starting material (Glasel, 1994; Mannhalter et al., 2000). However, an 
ideal reference gene should express identically in target samples in the same 
experiment and in different experimental conditions (Robledo et al., 2014). The 
selection of the reference gene in this study was based on analysis of the geNorm kit. 
Gapdh and Cyc1 were found to be the most stable reference genes in muscle 
samples. There is no universal reference gene known to date; therefore, it should be 
carefully chosen regardless of the type of samples, the treatment and the disease 
stage of samples (Vandesompele et al., 2002; Nicot et al., 2005) because many 
studies have demonstrated that the expression of reference genes can vary and affect 
the reliability of qPCR analysis (Thellin et al., 1999; Bustin, 2000; Suzuki et al., 
2000). It is not recommended to use reference genes with Cq <15 or >30, and those 
within this range need to be neglected (Wan et al., 2010). Besides choosing an 
accurate reference gene, normalisation to multiple reference genes is also important 
to reduce the estimation of systematic error (Vandesompele et al., 2002). However, 
several research studies have indicated the suitability of Gapdh, Actin, 18S rRNA 
and tubulins as reference genes, especially that they are available in all nucleated cell 
types and are essential for cell functions (Goidin et al., 2001; Tichopad et al., 2004; 
Huggett et al., 2005; Everaert et al., 2011; Stephens et al., 2011). 
Most of the SYBR Green-based detection showed non-specific amplification. It has 
been determined that qPCR using the SYBR Green detection method reveals the 
presence of non-specific products very easily due to the non-specific feature of this 
dye to detect any double stranded nucleotides (Morrison et al., 1998). In addition, the 
amplification efficiency of qPCR is reduced when the non-specific products are 
amplified instead of the experimental target (Das et al., 1999). The specificity of the 
reaction was measured in this study based on the shape and melt temperature of melt 
curve analysis graphs and according to previous studies (Ririe et al., 1997; Hidalgo-
Grass and Strahilevitz, 2010). Melt curve is the easiest method used for monitoring 
and verification of duplex hybridisation (Pryor and Wittwer, 2006). The pure and 
homogenous qPCR products displayed a single sharp peak melt curve with a melting 
temperature >80°C. In contrast, most of the reactions (using Primer Design assays) 
showed several melt curves. It is well known that wider melt curves with melting 
temperatures <80°C represent the formation of primer-dimers. The amplification of 
gDNA also produces abnormal melt curves with a side shoulder, while two sharp 
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peaks represent the existence of two specific products (splice variants). Therfore, the 
observation of product size in gel electrophoresis is required to clarify the target 
amplicon (Downey, 2015). Because of the identification of non-specific products in 
SYBR Green-based detection, the TaqMan hybridisation probes were used in all 
subsequent experiments. The amplification plot of all reactions was observed to 
check for the presence of inhibitors that may reduce the reaction efficiency. It has 
been reported that even intact RNA samples can contain inhibitors (Bustin and 
Nolan, 2004b; Wong and Medrano, 2005; Nolan et al., 2006). Therefore, to avoid 
this problem, samples with 10-fold dilution were used for testing target genes while 
20-fold dilutions were used to test the expression of reference genes.  
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4   
The impact of P2rx7 gene ablation on the mdx pathology, the Next 
Generation Sequencing findings 
 
 Introduction/ Next Generation Sequencing 4.1
Completion of the human genome sequencing project provided medical research 
with a wealth of knowledge about the whole genome that can be used to understand 
the genetic basis of inherited disease (Venter et al., 2001). Developing low cost 
sequencing techniques and instruments opened up a new avenue in research and 
clinical approaches. This helped researchers to predict changes in cellular pathways 
and ultimately target the altered pathways associated with diseases (Dewey et al., 
2012). Since the introduction of Next Generation Sequencing (NGS) in 2005, not 
only it has become the technology of choice to study gene expression, but has also 
started to replace the use of microarrays with a tremendous impact on the field of 
genetics. In this method, a small sample generates billions of short sequences, 
allowing the sequencing of the entire genome in a matter of days. Using this method 
does not require prior knowledge about targets, and at the same time the microarray 
has many limitations, such as the background and accuracy in measuring the gene 
expression for low abundance transcript and, more importantly, using probe sets to 
measure the gene expression of certain targets which do not allow discovery of novel 
transcripts (Gautier et al. 2004).  
The sequencing targets either the whole genome or whole exome, or involves 
transcriptome sequencing (RNA-Seq). The transcriptome sequencing allows 
sequencing of RNA from different physiological conditions with an applicant range 
from gene expression, identifying structural variants, detecting single inserted or 
deleted nucleotides, discovering rearrangements of non-coding RNA, determining 
the causative allele and identifying rare variants.  
Currently, three NGS platforms are commercially available: The Roche 454 platform 
(Margulies et al., 2005), the Illumina (Bennett et al., 2005) and the SOLiD platforms 
(Mardis, 2008). Although these platforms differ in the strategies for library 
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preparation and sequencing and the length of the resulting fragments, all platforms 
are based on the same principle of Sanger sequencing (Sanger et al., 1977). In 
Sanger sequencing, the DNA strand is synthesised by adding radio- or fluorescently-
labelled 2´-deoxynucleotide triphosphates (dNTPs) or 2´, 3’-dideoxynucleotides 
(ddNTPs) to terminate the DNA chain. The ddNTP acts as a terminator for the 
growing chain due to the presence of a 3'-H instead of 3-OH sugar. The absence of 
the 3-OH prevents the generation of a phosphodiester bond between two nucleotides; 
as a result, the products differ in length. Sequencing then can be detected using the 
gel electrophoresis.  
Nowadays, this technique is still used, and the advance modifications are added 
(Smith et al., 1986; Prober et al., 1987; Hodges et al., 2007). NGS displays further 
advances; for example, the Illumina platform (Figure 4.1) includes preparation of the 
genomic template by random fragmentation of DNA samples and then attaches these 
samples to the solid surface using an adapter. The second step is cluster formation, 
where more than 40 million separate template clusters are generated through bridge 
amplification (the free end of a DNA molecule bends over and hybridises with the 
adapter to form a template to generate a new strand). The third step, based on the 
reverse terminator method, involves the detection of the sequenced template by 
fluorescence emission from naturally incorporated dye-labelled-dNTPs in the new 
growing strand. Finally, these reads align to the reference sequence, followed by 
variant analysis and identification. Significant numbers of aligned reads of a 
particular transcript represent the abundance of this nucleic acid in the cell (Bennett 
et al., 2005; Bentley, 2006; Bentley et al., 2008). 
90 
 
 
Figure 4.1: 
The  Illumina sequencing procedure: (A) shows the preparation of a DNA or cDNA 
library by the fragmentation of  DNA and ligation of the fragments with adaptors to 
attach them to the flow cell. (B) shows the free end of the fragments bending to attach 
the primers that are complementary to the adaptor and PCR amplification is then 
carried out to amplify both the reverse and forward strand of fragments; these 
fragments are attached to the flow cell at both ends. (C) shows the formation of a 
cluster of fragments around the initial one by several PCR amplifications, followed by 
sequencing. Consequently, the unique primers are attached to the free end of fragments. 
Due to addition of the nucleotide-attached fluorescent reporter with an elongation 
terminator, only a single nucleotide is incorporated into the newly synthesised strand in 
each sequencing cycle. The laser of the machine excites the fluorophore each time the 
new nucleotides are added, producing a signal captured by the sensor and converted 
into a colour. Finally, the data are collected and analysed by a professional (From Lu et 
al., 2016). 
 
The developments in NGS technology open the door to use this technique in 
research, health care applications and the diagnosis of diseases (Bonnefond et al., 
2010; Bolze et al., 2010; Montenegro et al., 2011). The large size of the dystrophin 
gene and different locations of mutations that cause DMD make the molecular 
diagnosis of this disease very difficult. The basic genetic detection method was 
described by Chamberlain et al. in 1988 and was developed by others who used 
multiplex PCR to detect 98% of the two hotspot region mutations in DMD. 
 
A 
B 
C 
91 
 
However, this method failed to detect duplications or carrier females. In the past few 
years, NGS has become the major tool to diagnose the causative gene or pathway 
that contributes to disease. Lim et al. (2011) sequenced the whole region of 
dystrophin gene in DMD/BMD patients using NGS sequencing technology and 
identified deleted and duplicated exons. Wie et al. (2014) developed a novel 
computational framework to determine copy number variations (CNVs) and single-
nucleotide variations (SNVs) within the dystrophin gene of DMD/BMD patients and 
female carriers. This method provides high-accuracy for gene therapy, making it 
suitable for clinical practice. Okubo et al. (2016) described the first method to detect 
deletions, additions and small mutations in the dystrophin gene using Ion Torrent 
next-generation sequencing in a large number of patients. A novel mechanism 
contributing to DMD was discovered as a result of using RNA-Seq; it has been 
found that HDAC–myomiR–BAF60 variant network regulates the fibroadipogenic 
progenitors (FAPs) activity in controlling regeneration. During muscle injury, FAP 
induces muscle satellite cells for regeneration, while in DMD; the FAP cells are 
converted into the fibro-adipocytes that accumulate in muscle, resulting fat 
deposition (Joe et al., 2010; Uezumi et al., 2010; Saccone et al., 2014). Our RNA-
Seq results also found a new feature in mdx muscles (See the Results section of this 
chapter). 
Despite great efforts to advance NGS, this method is still in its infancy in terms of its 
practical application. In order for this method to become a routine technique in 
disease diagnosis and treatment strategies development, there are several technical 
requirements to consider, such as developing a comprehensive program to translate 
the NGS data outcome in a clinically meaningful way, quickly and easily (Anderson 
and Schrijver, 2010 Moreover, sufficient depth coverage must be considered, as the 
minimum coverage range of between 8 and 10 reads per base is required to 
determine high quality and reliable sequencing data, especially for regions with 
polymorphisms (Thomas et al., 2006). Accurate short read assembly is important, as 
shorter reads (100 bp) are preferable for chemical reactions. The assembly of these 
reads to the reference gene is complicated due to repetitive regions of the genome 
(Dewey et al., 2012).  
After sequencing, an extensive bioinformatics effort is required for the storage, 
analysis and interpretation of a huge amount of data (Horner et al., 2010; El-
92 
 
Metwally et al., 2013). Four complex work flows are needed to analyse the NGS 
data. The first task is converting the raw signal from the NGS instrument into reads 
of nucleotides in the base-calling process (Huse et al., 2007). The error rate of 
sequencing is reduced when using accurate base calling; otherwise, resequencing the 
same template multiple times is required (to increase depth) (Huang and Madan, 
1999; Ledergerber and Dessimoz, 2011). Several limitations have been detected with 
Illumina platform: inefficiency filter in isolation the similar fluorophores (Kircher et 
al., 2009), Elevating the leading and lagging signal (phasing noises) results from 
incomplete synthesis of the cDNA strand (Erlich et al., 2008) and the location of the 
signal; stronger intensity is detected close to the centre of image (Rougemont et al., 
2008).The NGS data are stored in FASTQ format or native raw data file formats. 
Using these file formats requires high speed computer system to enable the 
researcher to read and process the data easily; alternatively, these files can be 
converted to a more compact format, like Sequence Alignment Map (SAM) and 
Binary Alignment Map (BAM) (El-Metwally et al., 2013; Oliver et al., 2015).  
The second task involves aligning short reads to the reference genome. Several 
algorithms and software packages were developed to perform accurate and rapid 
alignment (Appendix 10.5). The short reads align to the reference genome in two 
steps, matching seeds to the reference genome and extending the seeds to assemble 
long contigs. The accurate alignment and assembly of short reads is the most 
important step in NGS and is essential for the biological application and downstream 
analysis (Li and Homer, 2010). The low sensitivity of matching seeds and the 
existing repeat elements in the genome are a common problem in this step (Ma et al., 
2002; Kalyanaraman et al, 2007; Li et al., 2008; Chistoserdova, 2010). Therefore, a 
huge effort to find optimal programs that overcome these problems has been 
required. The developed programs (Appendix 10.5) show differences in their 
efficiency, filling the gaps, deleting repeats from the genome and distinguishing 
between sequencing errors and SNPs (El-Metwally et al., 2013). Recently, a new 
assembler (anytag) with the ability to fill gaps between paired-end reads correctly is 
available to use. It can generate an almost error-free scaffold of about 190kb; as a 
result, this software has advantages over other de novo assemblers by about 5-fold 
(Ruan et al., 2013). Nevertheles, the approach is not using one assembler in the 
alignment of the short reads, but instead selecting a program that has sufficient 
93 
 
coverage and low error rate (Bradnam et al., 2013). Most assembler programs are 
based on the identification of common sequences between pairs of reads and the 
removal of the suffix of one read and prefix of another to prevent errors from 
overlapping (Pevzner et al., 2001; Zerbino and Birney, 2008; Birol et al., 2009; Li et 
al., 2010; Gnerre et al., 2011).  
The third task of bioinformatics is the annotation, in which the assembled reads are 
converted into predicted genes. The annotated genes contain defined exon 
boundaries, exonic coding DNA sequences (CDS), non-coding sequences, repeated 
elements, the name and reference number of genes, alternative and novel transcripts 
(Yandell and Ence, 2012). Masking the repeat elements (microsatellites, 
retrotransposons, and transposons) is an important step of the annotation, excluding 
this step leads to the generation of an incorrect genome with artefacts (Yandell and 
Ence, 2012). Several tools and programs dealing with annotations of the eukaryotic 
genome are listed in Appendix 10.5. Yandell and Ence, (2012) mentioned that the 
best combination to handle RNA-Seq data is to use TopHat and Cufflink together.  
The fourth task of bioinformatics is the visualisation of annotated data with genome 
browsers (Appendix 10.5) (Medina et al., 2013; Cunningham et al., 2015). The 
output data can be represented in pathways covering the molecular and functional 
aspects of genes using one of the gene ontology software packages. The KEGG 
program is an example of a free gene ontology software, while IPA is a paid for 
software (Ogata et al., 1999; Bionaz  et al., 2012; Viollet et al., 2015).  
Some NGS manufacturers supply their own software that deals with raw data and 
produces reads that are ready to assemble. Other manufacturers provide software 
including the first three bioinformatics tasks. For example, Illumina produces a 
computing program for the storage and analysis of NGS data (BaseSpace genomics 
cloud). This program enables the instrument to use different applications that are 
essential for the alignment and assembly of reads (Kulski, 2016). 
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 Aim and objectives 4.2
Identify new genes and pathways that are altered due to the Dmd gene 
mutation and characterise the alterations in the pathological phenotype 
resulting from the ablation of the P2RX7 receptor in mdx mice. 
 Prepare RNA samples for RNA sequencing using the Illumina HiSeq 2000 
platform to characterise the differential gene expression in tibialis anterior 
(TA) muscles from four week old wild type, mdx and mdx/P2rx7
-/- 
mice.  
 Analyse RNA-Seq datasets using different computational approaches such as 
IPA and GSEA and manual analysis of  additional pathways.  
 Validate RNA-Seq dataset with the qPCR-array and specific qPCR-
hybridisation probe detection analyses.  
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 Results 4.3
4.3.1 Validation of samples for the RNA-Seq experiment  
To identify the impact of P2rx7 gene ablation on pathogenic events in the mdx 
muscle, genes expressions were examined by RNA-Seq method. Four individual 
total RNA samples were extracted from 4 week-old TA muscles of C57/BL10, mdx 
and mdx/P2rx7
-/-
 and
 
each
 
of these 12 samples was treated as an individual biological 
replicate. To ensure successful sequencing, the purity and quality of the samples 
were measured using Bioanalyzer 2100 (Agilent). The RNA-Seq was performed by 
Source BioScience (a commercial service provider) using Illumina HiSeq 2000 
platform. During the library preparation in Source BioScience, another quality and 
quantity (QC) assessments were conducted for both RNA and cDNA samples 
(Figure 4.2.A and B). After the preparation of libraries, the samples were loaded on 
the four lanes of Illumina HiSeq2000. Figure 4.2 C shows good quality pooled 
library readouts validated by Bioanalyzer 2100 with an average size of 260bp. 
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Figure 4.2: 
Electropherogram obtained from Bioanalyzer 2100 (Agilent) showing three QC 
checkpoints for starting RNA and cDNA samples. (A) Two main peaks indicate the 
18S and 28S rRNA. The 28S peaks are twice the quantity of 18S, which indicates good 
quality RNA. (B) Successful ligation of the adaptor with DNA fragment samples (pre-
capture amplification) represented in a single peak with an average size range between 
225 and 275 bp. (C) An example of successful pooled libraries represented as a peak 
with an average size between 250 and 350 bp. 
  
 
 
 
 
 
  
  
                                                                                     - - 
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The sequencing produced millions of reads (Table 4.1) as raw data in FASTQ 
format, which were then mapped to mouse genome (mm10 genome assembly, UCSC 
Genome Browser). The TopHat and Cufflink software were used to calculate 
transcript expression and to compare the differential expression levels between 
samples (Trapnell et al., 2012). 
  
Table 4.1: The number of reads for each sample that were generated by RNA 
sequencing. 
Lane 
Sample 
ID 
(a) 
Sample Ref 
(b) 
Index 
(c) 
Yield 
(Mbases) 
(d) 
Reads 
(e) 
 
% of 
raw 
cluster
s per 
lane 
(f) 
% of >= 
Q30 
Bases 
(PF) 
(g) 
Mean 
Quality 
Score 
(PF) 
(h) 
4 B5 SOL6932 CGATGT 7,560 75,595,772 32.81 96.64 34.85 
4 B6 SOL6933 TGACCA 7,764 77,639,960 33.7 98.1 35.42 
4 B7 SOL6934 GCCAAT 7,349 73,486,546 31.9 97.84 35.32 
5 B9 SOL6936 CTTGTA 9,333 93,331,882 32.87 98.94 36.1 
5 M5 SOL6937 AGTCAA 10,972 109,716,454 38.65 98.39 35.92 
5 M6 SOL6938 AGTTCC 7,786 77,862,872 27.43 98.19 35.81 
6 M7 SOL6939 ACAGTG     8,498 84,980,738 30.62 98.62 35.53 
6 M8 SOL6940 CAGATC 9,307 93,074,896 33.54 98.63 35.77 
6 P5 SOL6941 ATGTCA 9,644 96,440,752 34.75 98.79 35.63 
7 P6 SOL6942 CCGTCC 7,596 75,963,516 31.82 98.7 35.53 
7 P7 SOL6943 GTCCGC 9,347 93,465,426 39.15 98.84 35.45 
7 P8 SOL6944 GTGAAA 6,689 66,894,988 28.02 98.19 35.56 
 
a. Sample ID:                                ID of the sample from customer. 
b. Sample Ref:                             Source BioScience Internal ID for the sample. 
c. Index:                                        Sample-specific Index sequence. 
d. Yield:                                         The sum of all bases in clusters that passed filtering for each sample. 
e. Reads :                                      Number of reads from the HiSeq flow cell 
f. % of raw clusters per lane:    Percentage of reads in the sample as a fraction of total reads in that                
lane. 
g. % of >=Q30 Bases:                 Yield of bases with Q30 or higher from clusters passing filter. 
h. Mean Quality Score:             The mean of quality scores of clusters passing filter. 
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Next, the relations between the C57/BL10, mdx and mdx/P2rx7
-/-
 were analysed 
using the pairwise correlations test, to establish whether the alterations in RNA-Seq 
results are related to biological or statistical variations. The result of this test 
indicates that nearly all samples have a strong positive correlation between each pair. 
Figure 4.3 representing the pairwise correlations of log2 FPKM values performed for 
all versus of genes except the gene with 0 FPKM of all muscle samples using 
TopHat cuffnorm was generated in collaboration with Dr Mikhail Shugay. 
To conclude, all these different validation methods ensured the quality and power of 
the RNA-Seq datasets and results. 
 
Figure 4.3: 
The pairwise correlation test. The intensity of colour (from yellow to red) determines 
the positive relationship in the heat map. White colour indicates degree of negative 
correlation, which means samples have more differences. All samples strongly 
correlated with each other except the B5 sample which tends to correlate weakly with 
mdx and mdx/P2rx7
-/-
. 
99 
 
4.3.2 General findings 
The gene expression output from Cuffdiff provides fold change and P values as well 
as information about the location and common name of genes. Following the 
statistical analysis, 23236 genes were identified by RNA-Seq as the total number of 
those differentially expressed. 2031 genes were statistically significantly up-
regulated in mdx/P2rx7
-/-
 compared to C57/Bl10. Similarly, there were 275 
significantly up-regulated genes in mdx/P2rx7
-/-
 when compared to mdx. According 
to the automated functional enrichment summary created using the GSEA software, 
most of the genes altered in mdx/P2rx7
-/- 
versus mdx were related to the fibrosis 
pathway, whereas inflammation and lysosome-related-genes were altered when 
compared to C57/BL10 (Figure 4.4). In mdx, there were 2159 genes up-regulated 
when compared to C57/BL10. Again, inflammation-related- and lysosomal genes 
were observed to be the main groups altered in mdx. In comparison to mdx/P2rx7
-/-
, 
503 genes in mdx exhibited change in their expression levels. The functional 
enrichment analysis revealed that most of these genes were related to inflammation 
and chemotaxic cytokines. Finally, 2258 and 2136 of genes in C57/BL10 dataset 
were up-regulated compared to mdx and mdx/P2rx7
-/-
, respectively. In a comparison 
between C57/BL10, mdx and mdx/P2rx7
-/-
, the most altered genes were associated 
with the cellular respiration and muscle contraction (Figure 4.4). 
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Figure 4.4: 
Graph representing the comparison of gene expressions and potential functional 
alterations between C57/BL10, mdx and mdx/P2rx7
-/-
. (A) The differentially expressed 
gene counts across genotypes compared to each other. (B) The alteration of genes in 
specific functional categories for each genotype compared to the state pointed by the 
nearby arrow. 
 
4.3.3 IPA analysis of genes expressions 
To develop a deeper understanding of the genes responsible and/or involved in the 
DMD pathology, the RNA-Seq expression datasets were analysed using the 
Ingenuity Pathway Analysis (IPA). The analysis focused on the differences between 
C57/BL10 and mdx on the one hand and mdx/P2x7
-/-
 and mdx on the other. The 
computational analysis of gene expressions identified the top five of canonical 
pathways, disease and bio-functions, molecular and cellular functions, top up and 
down-regulated molecules.  
In the first analysis, 4418 genes that show statistically significant differences in 
expression between mdx and C57/BL10 were uploaded into IPA and the results of 
this analysis are shown in the Appendix 10.6. Second analysis was based on the 
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same selection criteria but involved the comparison between mdx/P2rx7-/- and mdx. 
The 780 genes were uploaded into IPA and 52 canonical pathways were detected. 
The top five canonical pathways were: granulocyte adhesion and diapedesis (25/109 
molecule), hepatic fibrosis/hepatic stellate cell activation (28/146) (See below), 
which is representative of general fibrosis, agranulocyte adhesion and diapedesis 
(21/107), atherosclerosis signalling and LXR/RXR activation (17/81) (Table 4.2). 
 
 
Table 4.2: List of top Ingenuity Canonical Pathways and the most relevant pathways to 
DMD pathology shows the genes that were involved in these canonical pathways. 
These gene expressions were detected by IPA as being altered in mdx/P2rx7
-/- 
vs. mdx. 
The colour code represents the regulation of gene expression (red: up-regulated gene. 
Green: down-regulated gene). 
Ingenuity Canonical 
Pathways 
Molecules 
Granulocyte 
Adhesion and 
Diapedesis 
Ccl2, Il1rl1, Cxcl9,  Itgam,  Mmp9, Tnfrsf1a, Csf3r, Il1r2, Ccl3l3, Cxcl6, 
Il1rn, Il1r1, C5ar1, IL33, Ccl7, Il1b, Fpr2, Cxcl2, Tnfsf11b, Hspb1, Ccl2, 
Cxcr2, Selplg, Sdc4, Itga5. 
Hepatic Fibrosis / 
Hepatic Stellate Cell 
Activation 
Fgfr2, Il1rl1, Mmp9, Tnrsf1a, Ctgf, Il2r2, Acta2, Cyp2e1, Ccr5, Il1r1, 
Col28a1, Stat1, Smad3, Igfbp3, Il1b, Kdr, Cd14, Myl6b, Col22a1, Igf2, 
Tnfrsf11B, Ccl2, Csf1, Il4r, Myh8, Timp1, Serpine1, Col11a2. 
Agranulocyte 
Adhesion and 
Diapedesis 
Ccl2, Cxcl9, Ccl7, Il1b, Mmp9, Tnfrsf1A, Myl6b, Acta2, Ccl3l3, 
Cxcl2,Cxcl6, Il1rn, Il1r1, C5ar1,Ccl2, Cxcr2, Selplg, Myh8, Sdc4, Itga5, 
Il33. 
Atherosclerosis 
Signalling 
S100a8, Il1b, Mmp9, Apod, Tnfsf14, Cd36, Il1rn, Clu, Ccl2, Selpg, Csf1, 
Lpl, F3, Col11a2, Ccr3, Il33, Alox15. 
LXR/RXR 
Activation 
Il1rl1, S100a8, Il1b, Mmp9, Tnfrsf1a, Cd14, Apod, Il1r2, TnfrsfF11b, 
Cd36, Il1rn, Il1r1, Scd, Clu, Ccl2, Lpl, Il33. 
Dendritic Cell 
Maturation 
Pik3r3, Myd88, Il1b, Tnfrsf1a, Fcgr1a, Sat2, Tlr9, B2m, Fcer1g, Trem2, 
Tnfrsf11b, Hla-a, Fcgr2b, Il1rn, Stat1, Col11a2, Cd86, Il33. 
IL10 Signalling 
Jun, Il1rl1, Il1b, Ccr1, Socs3, Cd14, Il1r2, Ccr5, Fcgr2b, Il1rn, Il1r1, Il4r, 
Il33. 
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The RNA-Seq analysis using IPA showed the granulocyte (eosinophil and basophil) 
and agranulocyte (lymphocyte and monocyte) adhesion and diapedesis pathways 
from the top five ranked canonical pathways (Figures 4.5 and 4.6). These pathways 
represent the first line of host response against inflammation after muscle injury. The 
analysis showed that ablation of P2RX7 receptor down-regulated the expression of 
several genes that are included in these pathways, which is suggesting the reduction 
of inflammatory/immune responses. The Ccl2, Cxcl9, Ccl7, Il1b, Tnfrsf1A, C5ar1, 
Il1r1, Il1rn, Cxcr2, Selplg, Sdc4, Itga5 and Il33 were common tagets between these 
two pathways and were up-regulated in mdx compared with C57/BL10. Moreover, 
the expression levels of these genes in mdx/P2rx7
-/- 
were down-regulated compared 
with mdx. The Il1rl1, Ccl3l3, Cxcl6, Cxcl2 and Mmp9 were also common between 
them but they showed no statistically significant difference between mdx and 
C57/BL10 while these were down-regulated in mdx/P2rx7
-/-
 compared with mdx. 
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Figure 4.5: 
Granulocyte adhesion and diapedesis canonical pathway. 25 genes from RNA-Seq 
datasets were identified as altered in this pathway, which contains 109 genes. All of 
these genes were down-regulated in mdx/P2rx7
-/-
 compared to mdx. Colour intensity 
denotes the degree of regulation, red: up-regulation, green: down-regulation, white: no 
significant difference or a gene present in the pathway but not found in our datasets. 
For instance, Tnf transcript is up-regulated in mdx and significantly reduced in 
mdx/P2x7
-/-
. 
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Figure 4.6 
Agranulocyte adhesion and 
diapedesis pathway. 21 genes 
associated with this pathway 
were down-regulated in 
mdx/P2rx7-/- compared to mdx. 
They were highlighted based to 
their regulation, red: up-
regulation, green: down-
regulation, white: no significant 
difference or a gene present in 
the pathway, but not shown in 
our datasets. The genes that 
show differences in RNA-Seq 
datasets, but do not pass the 
threshold were added manually 
to the pathway. Particularly, 
Jam2 transcript presents in 
RNA-Seq datasets as down-
regulated in mdx and up-
regulated in mdx/P2rx7-/-. Jam2 
is expressed by daughter 
satellite cells after 3 days of 
muscle injury and it plays role 
in maintaining the quiescent 
satellite cell population (Troy, 
2012). 
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The atherosclerosis signalling pathway has appeared as a fourth top canonical 
pathways when the RNA-Seq data was analysed using IPA. Importantly, via both the 
induction and repression of target genes, this pathway regulates lipid metabolism and 
inflammation, processes important for the atherosclerosis but not unique to this 
pathological process (Calkin and Tontonoz, 2010). This pathway harbours 81 genes, 
17 of them were altered significantly in mdx/P2rx7
-/-
 compared with mdx. The Apod, 
Il1rn, Clu, Ccl2, Selplg, Csf1, Ccr3, Il33 and Alox15 were up-regulated in mdx 
compared with C57/BL10 and were down-regulated in mdx/P2rx7
-/-
 compared with 
mdx. Cd36, Lpl and Col11a2 were down-regulated in mdx compared to C57/BL10 
and up-regulated in mdx/P2rx7
-/-
 compared with mdx. The expression levels of 
S100a, Il1b, Mmp9, Tnfsf14 and F3 showed no statistically significant difference in 
mdx compared with C57/BL10 and significant down-regulation in mdx/P2rx7
-/-
. The 
alteration of these genes in mdx/P2rx7
-/-
compared with mdx may suggest the role of 
P2RX7 ablation in reducing the atherosclerosis signalling pathway in general as well 
as indicating commonalities in gene expression pathways altered in atherosclerosis 
and the dystrophic pathology in these animals. 
Again the analysis of RNA-Seq using IPA showed that the LXR/RXR activation 
pathway as one of top canonical pathways. This pathway contains 81 genes and in 
mdx/P2rx7
-/-
, there were 17 altered genes compared with mdx. The expression level 
of Il1rl1, Il1r1, Il1r2, Il1rn, Il33, S100a8, Tnfrsf1a, Tnfrsf11b, Cd14, Apod, Clu and 
Ccl2 were elevated in mdx compared with C57/BL10 and down-regulated in 
mdx/P2rx7
-/-
 compared with mdx. The expression level of Cd36, Scd and Lpl were 
significantly down-regulated in mdx and up-regulated in mdx/P2rx7
-/-
. Il1b and 
Mmp9 showed no statistically significant difference in mdx compared with 
C57/BL10 and significantly down-regulated in mdx/P2rx7
-/- 
compared with mdx. 
This result concludes that ablation of P2RX7 reduces the LXR/RXR pathway, but at 
same time increase the CD36, which may indicate the activation of PPARγ-LXR 
pathway in macrophages that is involved in the conversion of soluble cholesterol to 
the crystal form. 
Another two pathways (IL10 signalling and dendritic cell maturation) were selected 
for analysis, based on the close relevance of these canonical pathways in the 
pathology of DMD (Table 4.2). The role of Il10 in reducing the inflammation and 
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triggering the regeneration has been reported (Villalta et al., 2009; Deng et al., 
2012). The RNA-Seq analysis using IPA showed that the expression level of Ccr1, 
Socs3, Cd14, Il1r2, Ccr5, Fcgr2b, Il1rn, Il1r1, Il4r, Il33 and Il1rl1 were up-
regulated in mdx compared with C57/BL10 and were down-regulated in mdx/P2rx7
-
/-
 compared with mdx (Figure 4.7). In addition, it showed that the expression level of 
Jun was down-regulated in mdx compared with C57/BL10 and further down-
regulation in mdx/P2rx7
-/-
 was noticed when compared with mdx. Finally, the 
expression level of Il1b did not show a statistically significant difference in mdx 
compared with C57/BL10 but it was down-regulated significantly in mdx/P2rx7
-/-
 
compared with mdx.  
 
Figure 4.7: 
IL10 signalling pathway showing alterations in RNA-Seq datasets in mdx/P2rx7
-/-
 
compared to mdx. The colour code represents the following: red: up-regulation, green: 
down-regulation, white: no significantly difference or genes present in the pathway, but 
not shown in our datasets. The outline colour of each shape represents mdx, while the 
inside colour of the shapes represents mdx/P2rx7
-/-
. For example, Ccr1 is up-regulated 
in mdx and down-regulated in mdx/P2rx7
-/-
, while Arg2 was found not to be 
significantly different in both mdx and mdx/P2rx7
-/-
. 
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Dendritic cells are responsible for triggering the immune response after injury due to 
their modulation by the nucleotides (Di Virgilio, 2005). The analysis of RNA-Seq 
indicated that the Tnfrsf1a, Tnfrsf11b, Fcgr1a, Fcgr2b, Fcer1g, Stat1, Stat2, Tlr9, 
B2m, Trem2, Myd88, Il33, Il1rn and Cd86 were up-regulated in mdx compared with 
C57/BL10 and were down-regulated in mdx/P2rx7
-/-
 compared with mdx (Figure 
4.8). Furthermore, expressions of Pik3r3 and Col11a2 were down-regulated in mdx 
compared with C57/BL10 and were up-regulated in mdx/P2rx7
-/-
 compared with 
mdx. The expression levels of Il1b (see above) and Hla-a did not show statistically 
significant difference in mdx while they were down-regulated in mdx/P2rx7
-/-
 
compared with mdx. A deep investigation of the genes that regulate the Il10 
signalling and dendritic cell maturation may give a clear understanding of the 
background of the inflammatory events in DMD.
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Figure 4.8: 
Dendritic cell maturation pathway. 18 out of 111 genes involved in this pathway were down-regulated in their expression, except Pik3r3, 
Trem2 and Col11a2, which were up-regulated in mdx/P2rx7-/- versus mdx. The colour code represents the following: red: up-regulation, 
green: down-regulation, white: no significant differences or genes present in the pathway, but not shown in our datasets. The outline 
colour of each shape represents mdx while the inside colour of the shapes represents mdx/P2rx7-/-. 
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IPA analysis identified the top ten most significantly up- and down-regulated genes 
in mdx/P2rx7
-/-  
compare to mdx (Table 4.3). 
Table 4.3: List of top ten most significantly up- and down-regulated genes was 
identified in mdx/P2rx7
-/- 
vs. mdx. These genes were detected by IPA, the colour code 
represents the regulation of gene expression (red: up-regulated gene. Green: down-
regulated gene). 
 Entrez Gene Name  Synonym Cellular Function   Ref 
Chemokine (C-X-C Motif) Ligand 6 Cxcl6  attracts immune cells Mittal  et al., 2008 
Keratin 14, Type I Krt14  intermediate filament 
binding  
Windoffer et al., 2011   
ELOVL Fatty Acid Elongase 4 Elvol4  fatty acid elongase  Logan  et al., 2013 
Desmoplakin  Dsp  encodes desmoplakin  Vasioukhin  et al.,2001 
Desmocollin  Dsc3  
involved in formation of 
the intercellular 
junctions  
Petrof  et al., 2012  
keratin 17, type I Krt17  
stimulates T –
lymphocytes  
Jin and Wang, 2014 
Keratin 79, Type II Krt79  
encodes epithelial 
keratin  
Veniaminova et al., 2013  
S100 Calcium Binding Protein A9 S100a9  supports Treg function  Lin et al., 2015   
Schlafen Family Member 12-Like  Slfn12l  
controls proliferation 
and induces the  immune 
responses 
Mavrommatis et al., 
2013 
S100 Calcium Binding Protein A8 S100a8 
produces pro-
inflammatory cytokines 
(Il1b, Il6,Tnf) 
Sunahori  et al.,2006 
Pituitary Tumor-Transforming 1 Pttg1 pro-fibrotic factor  Buko et al., 2015  
Glycoprotein (Transmembrane) 
Nmb  
Gpnmb  attracts the immune cells Ripoll  et al., 2007 
Tescalcin  Tesc  
differentiation of 
granulocytes 
Levay and Slepak, 2010 
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Secreted Phosphoprotein 1  Spp1 
regulates production of 
Il12, Il10, Ifnγ 
Saika et al., 2007 
Collagen, Type XXVIII, Alpha 1 Col28a1 
formation of collagen 
filaments  
Veit et al., 2006  
ATPase, H+ Transporting, 
Lysosomal 38kDa, V0 Subunit D2 
Atp6v0d2  osteoblast cell fusion  Wu et al., 2009  
D Site Of Albumin Promoter 
(Albumin D-Box) Binding Protein 
Dbp  hepatic metabolism Hamamura  et al., 2016 
Myosin Binding Protein H-Like Mybphl  
stimulates hypertrophic 
cardiomyopathy  
Harris et al., 2011  
SEC14-Like 2 (S. Cerevisiae) Sec14l2  
regulates the cholesterol 
level 
Shibata  et al., 2001 
Zinc Finger Protein 676 Znf676  
regulates the expression 
of telomere 
Mangino et al., 2012  
  
4.3.4 Characterisation of the local and systemic changes in the immune 
response associated with ablation of P2RX7 receptor in mdx mice: RNA-
Seq data analysis 
The RNA-Seq produces a large amount of data that needs careful and meaningful 
biological interpretation. Thus, the output from the IPA did not cover all important 
information about the inflammatory pathways. In addition, the immune cells play a 
critical role in the initiation and progression of the DMD pathology, and for these 
considerations the gene expression results were additionally analysed by using Gene 
Set Enrichment Analysis (GSEA) software. The GSEA provides the results as heat 
maps. The analyses were based on the differences between mdx/P2rx7
-/-
 versus mdx.   
First, the heat map analysis identified several genes that were involved in the 
regulation of cytokine receptor activity (Figure 4.9). 12 of 32 transcripts were 
statistically significantly down-regulated in mdx/P2rx7
-/- 
compared to mdx. Some of 
these genes encode the chemokine receptors, such as Ccr1, Ccr3, Ccr5, Ccr7, Ccr8 
and Cxcr6. Chemokines are classified into four families CXC, CC, C and CX3C. 
Chemokine and chemokine receptors regulate immune cell trafficking and 
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localisation within tissue and with each other in inflammatory events (Sallusto et al., 
2000).  
 
Figure 4.9: 
GSEA heat map illustrating the genes involved in cytokine receptors activity. The 
expression levels of 13 genes in RNA-Seq datasets were down-regulated in mdx/P2rx7
-
/-
 (P) compared with mdx (M). Red and blue colours indicate the up and down-
regulated transcripts respectively. Colour intensity indicates the strength of regulation. 
N=4. 
 
 
Second, the expression levels of 105 genes that regulate the innate immune response 
were detected by GSEA. Figure 4.10 represents heat map that shows 9 out of 42 
genes were found to be statistically significantly down-regulated in their expression 
levels in mdx/P2rx7
-/-
 compared to mdx. The majority of these genes play crucial 
roles in stimulating the infiltration of macrophages and neutrophils to the muscle 
tissue after the injury (Tidball and Villalta, 2010). Further analysis between 
mdx/P2rx7
-/-
 compared with mdx using GSEA software were shown in (Appendix 
10.7-10.10). 
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Figure 4.10: 
Heat map illustrating the genes involved in the innate immune response. The 
expression levels of 42 genes in the RNA-Seq datasets were down-regulated in 
mdx/P2rx7
-/-
 (P) compared with mdx (M). Red and blue colours indicate the up and 
down-regulated transcript, respectively. Colour intensity indicates the strength of 
regulation. N=4. 
 
 
In order to represent the expression levels of inflammatory genes from the RNA-Seq 
datasets in a meaningful biological presentation, the inflammatory response and 
autoimmunity qPCR array (Qiagen) was used.  Figure 4.11 illustrates the expression 
of the genes related to this panel. Notably, the majority of genes were down-
regulated in mdx/P2rx7
-/- 
compared with mdx. Reduction of the inflammatory 
response in mdx/P2rx7
-/-
 indicates an important improvement in the pathological 
phenotype associated with DMD. 
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 Figure 4.11: 
Visualisation of the differences in gene expression associated with the inflammatory response and autoimmunity. The colour code represents 
the following: red: up-regulation, green: down-regulation, white: no statistically significant difference and grey: not shown in our datasets. 
The outline colour of each shape represents mdx while the inside of the shape represents mdx/P2rx7-/-. e.g. in the humoral immune response, 
Ccl2 was found up-regulated in mdx compared to wild-type and down-regulated in mdx/P2rx7-/- compared to mdx while Ccr2 was up-
regulated in mdx but not altered in mdx/P2rx7-/-.   
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4.3.4.1 Quantitative Real Time PCR (qPCR) validation of the RNA-Seq 
immune response genes results  
A further study was performed using qPCR inflammatory pathway gene panel to 
validate the alteration in gene expression detected in the RNA-Seq data (to exclude 
false positives) and to study several genes known to be linked to the DMD chronic 
inflammatory changes, which were not found in sequencing datasets. Five RNAs 
from 4 week-old TA muscles of C57/BL10, mdx and mdx/P2rx7
-/-
 were analysed for 
purity and quality as described before and converted to cDNA.  The 96 gene qPCR-
array with SYBR Green-detection method was obtained and used in collaboration 
with Dr. David Vaudry at the University of Rouen, France. 
Table 4.4 shows these real time PCR results: The expression levels of the majority of 
the inflammatory genes were statistically significantly up-regulated in mdx 
compared to C57/BL10. Interestingly, P2rx7, Cx3cr1, P2rx4, Rela, Rorc, Bmp7 and 
Foxp3 were normalised toward the wild-type phenotype in mdx/P2x7
-/-
 compared to 
mdx. The following genes were not differentially expressed based on this qPCR 
analysis: Bcl10, C1ra, C2, Casp3, Casp9, Cd163, Cebpa, Csf1, Cxcr3, Cxcr4, Fas, 
Fos,Foxo3, Gpx4, Hif1a, Hspa1b, Hspd1, Ifngr1, Igf1, Il6ra, Il10rb, Irf1, Irf3, Irf9, 
Jun, Mmp2, Nfkb1,Nos2, P2ry12, Prdx5, Ptges, Rbpj, Rplp0, Socs1, Socs3, Sod1, 
Stat1, Stat3, Tgfbr1, Tnfrsf1a, and Twist1. The remaining genes gave expression 
values below the detection threshold: Adora1, Bdnf, Ccl5, Il1a, Il6, Il17a, Il18, 
Pla2g5, Serping1 and Tnfrsf1b. 
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Table 4.4:  qPCR data comparing relative gene expression levels in TA muscle mRNAs from 
C57/BL10, mdx and mdx/P2X7
−/−
mice. Red and green denote up- and down-regulated genes, 
respectively. Grey indicates no statistically significant difference. The relative differences in 
gene expression were measured by 2
−ΔΔCT
 method, one way ANOVA test, P< 0.005, N=5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mdx vs. WT mdx/P2rx7
-/-
vs. WT mdx/P2rx7
-/- 
vs. mdx 
Apoe 3.298 3.309 1.004 
Bax 0.266 0.13 0.491 
Bcl2 0.651 0.986 1.515 
Bmp7 0.237 0.835 3.526 
Ccr2 7.237 7.015 0.969 
Ccr5 3.779 3.759 0.995 
Cd4 2.49493 2.45887 0.98554 
Cx3cr1 9.399 6.064 0.645 
Cxcl12 0.627 0.607 0.969 
Gpx1 1.761 1.837 1.043 
Hmox1 1.255 1.651 1.316 
Hspb1 0.783 0.888 1.133 
Ifngr2 0.768 0.907 1.18 
Il10ra 3.589 2.817 0.785 
Il1b 4.204691 3.48945 0.82989 
Mmp9 1.451 3.394 2.339 
Myog 4.26338 3.28296 0.770037 
Myod1 2.0237 2.48113 1.226 
Mrc1 1.585 1.843 1.162 
Myd88 1.273 2.603 2.045 
Ncf1 2.084 2.991 1.435 
P2rx4 4.205 2.825 0.672 
P2rx7 6.228 0.0662 0.0106 
P2ry6 2.855 3.37 1.18 
Ptprc 9.377 7.161 0.764 
Rela 0.648 0.999 1.542 
Rorc 0.57714 1.33514 2.31337 
Timp1 2.11 3.557 1.686 
Tlr4 0.405 0.187 0.461 
Tlr9 5.415 5.096 0.941 
Tollip 0.665 0.636 0.956 
Trem2 20.07 15.218 0.758 
Ucp2 1.94 1.992 1.026 
Vegfa 0.437 0.466 1.067 
Vegfb 0.577 0.655 1.134 
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Furthermore, several crucial genes were further re-analysed in qPCR using TaqMan 
probes. Following the statistical analysis of qPCR results, the expression levels of the 
altered transcripts in mdx/P2rx7
-/-
 were shown in Figure 4.12. Interestingly, this alteration 
in the gene expression in mdx/P2rx7
-/-
 indicates that blockage of the P2RX7 receptor 
ameliorates the mdx dystrophic inflammation. The remaining transcripts were selected 
according to the literature and the previous knowledge about their roles in inflammation. 
P2x4, Tnf and Ccl2 genes were significantly up-regulated in mdx and down-regulated in 
mdx/P2rx7
-/-
. The expressions of Foxp3, Il12a, Rela and Ifnγ were significantly elevated in 
mdx/P2rx7
-/-
 compared with both mdx and C57/BL10. Together these data suggest that 
ablation of P2RX7 reduced the macrophage load, migration of immune cells and also 
triggered immunosuppression. Bmp7 expression level, which is an anti-fibrotic factor (See 
Chapter 5), was reduced in mdx and restored to normal levels in mdx/P2rx7
-/-
. The 
expression of P2rx7 was up-regulated in mdx and not detectable in mdx/P2x7
-/-
, whereas 
Dmd gene showed a very low expression in both mdx and mdx/P2rx7
-/-
. The significance 
of the changes in expression of P2rx7, Dmd, P2rx4 and Bmp7 genes will be discussed 
below. The relative expression of the following genes: Il10, Il6, Mrc1, Cd4, and Tgfb1, 
was significantly increased in both mdx and mdx/P2rx7
-/-
 compared to the C57/BL10 but 
these transcripts do not show statistically significant differences between mdx and 
mdx/P2rx7
-/-
. 
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Figure 4.12: 
Results of qPCR gene expression analyses showing relative expression levels (2
-ΔΔCT
) 
in 4 week-old TA muscle-derived mRNAs. The result demonstrates differences in 
expression levels of Foxp3, Ccl2, Il12a, Tnf, Rela and Ifnγ in C57/BL10, mdx and 
mdx/P2x7
-/-
. One way ANOVA, N=5, *P ≤ 0.05, **P≤ 0.01 and ***P≤ 0.001. 
 
4.3.4.2 Ablation of P2RX7 receptors reduces muscle inflammation in 18 month 
old mdx mice 
The above qPCR results and RNA-Seq analyses performed in four week-old mdx 
mice suggested that ablation of the P2RX7 receptor produced a significant reduction 
of the muscle inflammatory phenotype. Next, it was determined whether the ablation 
of P2RX7 receptor would have a long-term effect, i.e. beyond the acute degeneration 
phase in this mdx mouse model. The gene expression analyses were performed by 
qPCR in TA muscles from 18 month old mice (Figure 4.13). Interestingly, there was 
a similar alteration in the expression levels of the key genes identified at the peak of 
the degeneration/regeneration process in four week-old muscles. Specifically, the 
macrophage marker P2rx4 (Yeung et al., 2004) and Tnf were significantly decreased 
in mdx/P2rx7
-/- 
compared to mdx. Moreover, the expression levels of Foxp3 and 
Il12a mRNAs were increased in mdx/P2rx7
-/- 
compared to mdx. These results 
together suggest that the ablation/inhibition of P2RX7 receptors ameliorates tissue 
inflammation by both reducing the macrophage infiltration and increasing the Treg 
levels (Schenk et al., 2011) long term.   
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Figure 4.13: 
Results of qPCR gene expression analyses (relative expression levels 2
-ΔΔCT
) of mRNAs 
derived from 18 month-old TA muscles. The result demonstrates differences in 
expression levels of Tnf, P2rx4, Foxp3, Ccl2 and Il12a in C57/BL10, mdx and 
mdx/P2rx7
-/-
. One way ANOVA, N=5, *P ≤ 0.05, **P≤ 0.01 and ***P≤ 0.001.   
 
4.3.4.3 Ablation of P2RX7 receptor reduces the macrophages infiltration into 
mdx muscles 
Inflammatory cells, especially macrophages, play an important role in the 
progression of DMD muscle disease. A previous study showed that cytotoxic 
macrophages (M1) are the predominant cell type in the early stage of this disease 
(Villalta et al., 2009). The cytotoxicity of M1 comes from the production of nitric 
oxide NO, which promotes muscle lysis. Moreover, these macrophages release pro-
inflammatory cytokines such as TNF-α, IL1β and IL6, which initiate the 
inflammatory response (Tidball and Villalta, 2010; Villalta et al., 2009). Hence, the 
mRNA expression levels of the P2rx4 (macrophage biomarker) (Yeung et al., 2004; 
Coutinho-Silva et al., 2005) were determined by qPCR in 4 week- and 18 month-old 
TA muscles, as described. In both ages, the expression levels of P2rx4 were found 
statistically significantly up-regulated in mdx compared to the wild-type and down-
regulated in mdx/P2rx7
-/-
 compared to mdx (Figure 4.12 and 4.13). This result 
demonstrated a clear reduction in macrophage load in response to P2rx7 ablation.  
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In the next step, the P2RX4 protein level was determined by immunoblotting in 4 
week-old GC muscles, and the pattern observed for mRNA was also found for 
protein. The mdx showed up-regulation of P2RX4 protein expression compared to 
C57/BL10, while the expression levels were normalised in mdx/P2rx7
-/-
 compared to 
mdx (Figure 4.14.B and C).  
 
 
Figure 4.14: 
Representative qPCR analysis and western blot data showing the P2rx4 mRNA and 
P2RX4 protein levels in C57/BL10, mdx and mdx/P2rx7
-/-
. (A) The relative expression 
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levels (2
-ΔΔCT 
) of P2rx4 in 4 week-old TA muscles revealed the significantly higher 
expression levels in mdx compared with both the C57/BL10 and mdx/P2rx7
-/-
. (B) 
Representative immunoblots showing the P2RX4 protein levels (Alomone) in 4 week-
old GC muscles. (C) Densitometric analysis of western blots revealed the high 
expression levels of P2RX4 protein in mdx compared with age-matched C57/BL0 and 
mdx/P2rx7
-/-
 samples. The statistical analysis was performed using one way ANOVA, 
N=3-5, *P ≤ 0.05, **P≤ 0.01 and ***P≤ 0.001.  
 
 
 
Further proof of the reduced macrophage accumulation as a result of ablation of the 
P2RX7 receptor was sought by using the immunofluorescence detection method and 
the confocal microscope. Staining with anti-P2RX4 antibody indicated the 
accumulation of P2RX4 receptor in the regions of immune cell infiltrations in GC 
muscles of mdx mouse. Unlike mdx, in the C57/BL10, P2RX4 was undetectable, 
while in mdx/P2rx7
-/-
 the receptor showed a significantly lower level compared to 
mdx (Figure 4.15). Another macrophage marker F4/80 was also studied. The 
immunofluorescence images showed infiltration of large numbers of F4/80 positive 
cells in mdx compared to C57/BL10, whereas in mdx/P2rx7
-/-
, fewer F4/80 positive 
cells were observed in regions of fibres degeneration (Figure 4.15). These results 
were analysed statistically but are not discussed here as this analysis was done by 
another researchers and published recently (Sinadinos et al., 2015). 
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Figure 4.15: 
Examples of fluorescent confocal microscopy images of four week-old GC muscles 
from C57/BL10, mdx and mdx/P2rx7
-/-
. (A) The location of P2RX4 receptor 
(Alomone) (green) (scale bar-100 µm) on macrophages within immune cell infiltration 
areas (identified by concentration of cell nuclei, stained blue). High numbers of P2RX4 
positive cells were presented in mdx compared with C57/BL10. In mdx/P2rx7
-/-
 the 
number of labelled cells was decreased compared with mdx. (B) Immunofluorescence 
images illustrating the high levels of pan-macrophage marker (Abcam) (F4/80)(scale 
bar-50 µm) in mdx compared to C57/BL10 samples and lower F4/80 infiltrate levels in 
mdx/P2rx7
-/-
. Cell nuclei were stained with Hoechst (blue). The statistical analysis of 
F4/80 has been performed by and published in Sinadinos et al., (2015).  
 
 
 
  
            
    
         
    
         - - 
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4.3.4.4 The P2RX7 receptor knockdown reduced the autophagy in mdx mouse 
The expression levels of the autophagy hallmark protein (LC3BII) (Zois et al., 2011) 
were investigated in 4 week-old GC muscles using immunoblot. Indeed, much higher 
levels of LC3BII protein expression were detected in mdx compared to wild-type 
samples. In turn, the immunoblot analysis showed the significantly lower levels of 
LC3BII protein in mdx/P2rx7
-/-
 compared to mdx (Figure 4.16). 
 
Figure 4.16:  
The LC3BII autophagy marker levels in 4 week-old GC muscles from the wild-type, 
mdx and mdx/P2rx7
-/-
. (A) Examples of representative immunoblots show the high 
expression levels of LC3BII protein (Sigma) in mdx compared to C57/BL10 and lower 
intensity bands found in mdx/P2rx7
-/-
 compared to mdx. (B) The densitometric analysis 
confirmed statistically significant differences in expression of LC3BII between mdx 
and wild-type as well as in the mdx/P2rx7
-/-
 samples. The statistical analysis was 
performed using one way ANOVA, N=3 and **P<0.01.  
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In an attempt to characterise the cellular location of autophagy, LC3BII was used in 
an immunofluorescence study in GC sections from four week-old of C57/BL10, mdx 
and mdx/P2rx7
-/-
 muscles. Figure 4.17 illustrates the localisation of the LC3BII 
positive cells, which are predominated in the region of immune cell infiltrations and 
between the muscle fibres (endomysium and perimysium). Furthermore, the LC3BII 
expression levels were markedly increased in mdx samples. In comparison, LC3BII 
expression was reduced in mdx/P2rx7
-/-
 compared to mdx, while the signal was 
barely detectable in C57/BL10. 
It appears from these results that targeting P2RX7 receptor ameliorates the 
inflammation by reducing the immune cell infiltrations and also reduces autophagic 
flux. It has been discovered that inhibition of the innate immune response could slow 
the progression of DMD disease (Giordano et al., 2015). Therefore, inhibiting the 
immune cell subsets could be a good target for treating the DMD disease. 
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Figure 4.17: 
Immunofluorescent localisation of LC3BII (Sigma) (green) in 4 week-old GC muscles 
from C57/BL10, mdx and mdx/P2rx7
-/-
. The autophagy marker was located in the 
region of degeneration as well as the areas of connective tissue that ensheath the muscle 
fibres (highlighted by arrows). LC3BII was found predominantly in mdx compared 
with both C57/BL10 and mdx/P2rx7
-/-
. Cell nuclei were stained with Hoechst (blue). 
 
 
 
 
 
 
 
 
    
    
                  -  - 
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4.3.5 Reduce activation of NF-кB signalling due to ablation of P2RX7 receptor 
To identify the key genes that are involved in NF-кB signalling pathway and to study 
the role of ablation of the P2RX7 receptor in altering these genes in dystrophic 
muscles, we used the list of genes from an RT2 profiler Qiagen PCR “NF-кB 
signalling pathway” array for cross-referencing against our RNA-Seq datasets. The 
genes that are involved in this array are regulated by NF-кB such as cytokines, 
chemokines, apoptosis, anti-apoptosis, inflammation, development and 
differentiation, type I interferon-responsive genes, immune response, stress response, 
transcription factor and the NF-кB pathway itself. Interestingly, most of these genes 
were up-regulated in mdx compared to C57/BL10, while they were down-regulated 
in mdx/P2rx7
-/-
 compared with mdx (Figure 4.18). The expression level of some of 
these genes was confirmed by the qPCR method (Table 4.4). Additionally, the 
corresponding protein levels were detected by Western blotting using protein 
samples from C57/BL10, mdx and mdx/P2rx7
-/-
.  In 4 week-old GC muscle, the NF-
кB protein level was statistically significantly up-regulated in mdx compared with 
C57/BL10, but importantly, the level was significantly down-regulated in 
mdx/P2rx7
-/-
 compared with mdx (Figure 4.19). These findings supported the RNA-
Seq data and together suggested the activation of the NF-кB pathway in mdx and 
most importantly that it was suppressed by the ablation of P2rx7 gene. This 
suggested a reduction in the formation of the inflammatory molecules (chemokines 
and cytokines) and in transcription of genes encoding for growth factors and 
apoptosis.
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Figure 4.18: 
Schematic diagram showing genes from RNA-Seq datasets represented in an NF-кB signalling pathway array. The colour codes represent the 
following: red: up-regulation, green: down-regulation, white: not statistically significantly different and grey: not shown in our dataset. The 
outline colour of each shape represents mdx while the inside of the shape represents mdx/P2rx7-/-. The results indicated alteration of multiple 
genes in mdx compared to C57/BL10 and normalisation of these genes in mdx/P2rx7-/- compared with mdx. 
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Figure 4.19: 
NF-кB protein levels (Cell Signalling Technology) in muscle from different genotypes. 
(A) Representative Western blotting images showing the level of protein to be up-
regulated in mdx muscles compared with C57/BL10 and down-regulated in mdx/P2rx7
-
/-
 compared with mdx. (B) The densitometric analysis confirmed the level of NF-кB in 
immunoblot images and showed the statistically significant difference at P<0.01 in 
muscles. 
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4.3.6 Mitochondrial dysfunctions stimulate the programmed cell death 
(apoptosis) 
To test the hypothesis that dystrophin deficiency can be coupled with mitochondrial 
dysfunction and also to prove whether ablation of the P2RX7 receptor reduced the 
impact of mitochondrial dysfunction, we gathered the relevant mitochondrial genes 
identified in RNA-Seq datasets and analysed them against the key mitochondrial 
genes listed in the specific qPCR array (Qiagen). The changes found are represented 
in a schematic format. Figure 4.20 illustrates the expression levels of genes involved 
in regulation and mediation of the mitochondrial molecular transport, maintaining 
the membrane polarisation and energy production (ATP). This array also contains 
genes encoding for apoptosis pathway proteins as well as nuclear translocated 
transcripts essential for mitochondrial replication. This analysis suggested that 
numerous genes were altered in mdx compared to C57/BL10, of which only two 
genes, Bcl2l1 and Slc25a25, were down-regulated in mdx/P2rx7
-/-
 compared to mdx. 
The alteration in mdx genes predicts (i) activation of the apoptosis pathway, (ii) 
reduced ability to transfer small molecules such as nucleotides, cofactors and ATP, 
(iii) reduced ability to remove damaged mitochondria as a result of suppressing 
genes-mediated fission and fusion mechanism, (iv) decreased expression levels of 
nuclear genes associated with replication and functions of mitochondria, and (v) 
reduced ATP synthesis resulting from inhibiting the ADP transition through the 
potential-changed membrane. Thus, this result supports the dysfunction of 
mitochondria in DMD disease and, at the same time, provides evidence that ablation 
of the P2RX7 receptor does not improve this mitochondrial deficiency. 
. 
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Figure 4.20: 
Schematic diagram showing gene expression levels from RNA-Seq datasets 
represented in mouse mitochondria qPCR array. The colour codes indicate the 
following: red: up-regulation, green: down-regulation, white: not statistically 
significantly different and grey: not shown in our datasets. The outline colour of each 
shape represents mdx while the inside of the shape represents mdx/P2rx7
-/-
. The results 
indicate alteration of multiple transcripts in mdx compared to C57/BL10. In contrast, 
comparison of mdx/P2rx7
-/-
 with mdx showed only two altered genes: Bcl2l1 and 
Slc25a25. 
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Further study was performed using one of the important mitochondrial transcripts, 
Mitofusin 2 (Mfn2), to check the effect of ablation of P2RX7 in reducing the 
mitochondrial dysfunction in mdx. Mfn2 is a mitochondrial outer membrane protein 
that is considered a major contributor in mitochondrial functions (Chen et al., 2003). 
In particular, mediated mitochondrial membrane fusion, is essential for its integrity 
and molecule transport. Given that RNA-Seq analysis indicated a significant 
alteration in Mfn2 transcript expression, the analysis in Figure 4.20 shows the 
significant down-regulation of this transcript in mdx compared with C57/BL10 and 
no significant difference between mdx and mdx/P2rx7
-/-
. This indicates the reduction 
in fusion capacity of mitochondrial membrane in both mdx and mdx/P2rx7
-/-
, which 
is in line with mitochondrial abnormalities described in DMD and mdx in previous 
studies (Percival et al., 2013; Kelly-Worden and Thomas, 2014; Rybalka et al., 
2014). The expression levels of Mfn2 were also examined by qPCR in TA muscles 
from C57/BL10, mdx and mdx/P2rx7
-/-
. Interestingly, the analysis of Mfn2 
expression did not show similarity with RNA-Seq analysis but indicated the opposite 
change in expression (up-regulation) in mdx compared with C57/BL10. However, 
there was again no significant difference between mdx/P2rx7
-/-
 and mdx samples 
(Figure 4.21). 
 
          
Figure 4.21: 
The relative expression levels of Mfn2 in TA muscles from C57/BL10, mdx and 
mdx/P2rx7
-/-
 showing the up-regulation of Mfn2 transcript in mdx compared with 
C57/BL10 and no significant difference between mdx and mdx/P2rx7
-/-
 (one way 
ANOVA, N=4, P=0.014). 
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Apoptosis is a programmed cell death process characterised by nuclear and 
cytoplasm condensation and fragmentation of the DNA without damaging the 
neighbouring cells (Elmore, 2007). Since the activation of apoptosis occurs in 
response to mitochondrial dysfunction and as it also plays a fundamental role in 
muscle degeneration (Abdel-Salam et al., 2009), the expression of genes involved in 
apoptosis was studied to understand their role in DMD disease before and after 
ablation of the P2RX7 receptor. The relevant genes in RNA-Seq datasets were 
compared against those listed in the apoptosis qPCR array. This array includes genes 
that play an essential role in the regulation and stimulation of the apoptosis, and are 
responsible for regulating the release of caspases and anti-apoptosis factors. In mdx, 
the expression levels of genes that positively regulate and induce apoptosis were 
increased compared to C57/BL10. Moreover, a few of the anti-apoptosis genes were 
identified as possessing significantly higher expression levels in mdx compared to 
wild-type (Figure 4.22). This showed that the absence of dystrophin eventually 
recruits the programmed cell death in mdx. There were no significant differences in 
the expression levels of most apoptotic genes in mdx/P2rx7
-/-
 compared to mdx, 
indicating that ablation of the P2RX7 receptor does not reduce the apoptotic death 
(Figure 4.22). 
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Caspase activation 
Other pro-
apoptotic genes 
Death domain receptor 
Figure 4.22: 
Schematics representing genes regulating the apoptotic pathway identified in RNA-Seq datasets. The absence of dystrophin leads to a decrease in muscle 
membrane stability. As a result of muscle membrane fragility, Ca
2+
 accumulates inside the muscle cells. Overloading muscle with Ca
2+
 ion prevents 
mitochondria acting as a Ca
2+
 buffer and therefore the Ca
2+
 uptake is increased by mitochondria. This causes mitochondrial swelling and cytochrome C 
release and is followed by apoptosis (Kelly-Worden and Thomas, 2014).This indicates that the apoptotic cell death is activated in mdx compared to wild-
type while the ablation of the P2RX7 receptor does not reduce this apoptotic effect. The colour codes represent the following: red: up-regulation, 
green: down-regulation, white: not statistically significantly different and grey: not shown in the dataset. The outline colour of each shape 
represents mdx while the inside of the shape represents mdx/P2rx7-/-. 
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4.3.7  The impact of  P2RX7 ablation on adherens junctions activity 
To investigate whether the genes of adherens junctions are involved in muscular 
dystrophy and to study the effect of ablation of the P2RX7 receptor on the 
expression of these genes, the same approach was used. Genes represented in the 
adherens junction array (Qiagen) and in our RNA-Seq data were identified and their 
expression levels in C57/BL10, mdx and mdx/P2rx7
-/-
 compared. Figure 4.23 shows 
these genes’ differential expression in RNA-Seq. The results revealed the alteration 
of multiple genes in mdx compared with C57/BL10 and four genes were altered in 
mdx/P2rx7
-/-
 compared with mdx (Pkp1, Dsp, Dsc3 and Mllt4). Furthermore, the 
epithelial adherens junction was identified as the sixth top predominant pathway in 
mdx compared with C57/BL10 by IPA analysis of RNA-Seq and the cellular 
location of these expressions is shown in Figure 4.24. The RNA-Seq results 
indicated that the adherens junction pathway could possibly be involved in Duchenne 
muscular dystrophy, and ablation of the P2RX7 receptor did not change the 
expression of genes involved in this pathway significantly.  
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Figure 4.23: 
Schematic illustrating the expression level of genes belonging to “adherens junction” 
Qiagen array in the RNA-Seq dataset. Results revealed the alteration of most of the 
genes in mdx compared with C57/BL10. Four genes, Pkp1, Dsp, Dsc3 and Mllt4, were 
altered in mdx/P2rx7
-/-
 compared with mdx. The colour code represents the following: 
red: up-regulation, green: down-regulation, white: no significant difference. The outline 
colour of each shape represents mdx while the inside colour of the shapes represents 
mdx/P2rx7
-/-
.  
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Figure 4.24: 
Epithelial adherens junction canonical pathway changes found in RNA-Seq using IPA 
software. A total of 54 genes were involved in this pathway, 22 of them were down-
regulated in their expression, while 32 genes were identified as being up-regulated in 
mdx versus C57/BL10. The colour code represents the following: red: up-regulation, 
green: down-regulation, white: no significant differences or genes present in the 
pathway but not shown in our datasets. 
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4.3.8 The telomerase and the cell cycle regulators alteration in mdx and 
mdx/P2x7
-/-
 
In order to study the effects of ablation of the P2RX7 receptor on telomerase activity, 
which was described to be altered in mdx and DMD muscles (Decary et al., 2000; 
Sacco et al., 2010) the expression levels of telomerase and telomerase regulators 
were analysed in RNA-Seq datasets. The telomerase levels were not altered in any of 
the samples. Interestingly, the expression levels of the negative telomerase 
regulators, Pml  (Oh et al., 2009) and 5'-To-3' DNA helicase  (Pif1) (Snow et al., 
2007), were up-regulated in mdx compared to C57/BL10, while their expression 
levels were significantly down-regulated in mdx/P2rx7
-/- 
compared to mdx. 
Moreover, the expression levels of the telomerase positive regulator Krüppel-like 
Factor 4 (kfl4) (Wong et al., 2010) were down-regulated in mdx compared to 
C57/BL10. In contrast, in mdx/P2rx7
-/-
 kfl4 expression was significantly up-
regulated compared to mdx (Figure 4.25.A). Importantly, this result indicated that 
not only was the expression of telomerase regulator abnormal in mdx, but it was also 
normalised in mdx/P2rx7
-/-
. 
To further confirm the RNA-Seq data on the telomerase regulators, the expression 
levels of pml (negative regulator) were also measured by qPCR in two- and four-
week-old TA muscles derived from C57/BL10, mdx and mdx/P2rx7
-/-
. In two-week-
old muscles, the expression levels of Pml in C57/BL10, mdx and mdx/P2rx7
-/-
 
samples did not differ significantly (P= 0.148). in contrast, the expression level of 
Pml was very significantly different in in four-week-old TA muscles, with 2.5-fold 
up-regulation in mdx compared with C57/BL10. The qPCR also confirmed 
significantly lower expression level of Pml gene in mdx/P2rx7
-/-
 compared to mdx 
(Figure 4.25.B).  
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Figure 4.25: 
The expression levels of telomerase regulators in RNA-Seq datasets and the qPCR 
analysis validating the Pml expression level. (A) Two negative regulator genes (Pml 
and Pif1) were up-regulated in mdx compared to C57/BL10, while both of them were 
down-regulated in mdx/P2rx7
-/-
 compared to mdx. The expression level of the positive 
telomerase regulator Klf4 was down-regulated in mdx compared to C57/BL10 and up-
regulated in mdx/P2rx7
-/-
 compared to mdx. (B) The mRNA expression levels of the 
telomerase negative regulator Pml in two- and four-week-old TA muscles from 
C57/BL10, mdx and mdx/P2rx7
-/-
. (Left) The expression level of Pml displayed no 
statistically significant differences (P=0.148) in two-week-old TA muscles samples. 
(Right) Four-week-old TA muscles showed up-regulation of Pml expression in mdx 
and significant down-regulation in mdx/P2rx7
-/-
(one way ANOVA, N=4, *P ≤ 0.05 and 
**P≤ 0.01). 
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To examine the behaviour of satellite cells in mdx and mdx/P2rx7
-/-
, the cell cycle 
regulator genes were analysed by cross-referencing RNA-Seq datasets against 
Qiagen PCR “Cell Cycle” gene array list. A novel and unexpected alteration in cell 
cycle regulators was identified in mdx compared with C57/BL10 samples. Eleven 
out of 32 checkpoint genes were altered significantly in mdx, with most of them 
being up-regulated. During the progression of the cell cycle, there are several 
checkpoints to ensure the proper condition before entering the next phase such as 
ensuring that all DNA is replicated and the chromosome structures are adequate 
(Lodish et al., 2000). Among the 36 genes belonging to cyclin regulators, there were 
18 genes that were up-regulated significantly in mdx. Cdk1 and Slfn1 were the only 
genes that normalised in mdx/P2rx7
-/- 
(Figure 4.26). Thus, RNA-Seq identified a 
significant alteration of cell cycle pathways in mdx and that either represents the 
division of satellite cells or of the infiltrating immune cells. 
To assess whether the elevation of the expression of cell cycle gene regulators in 
mdx related to the satellite cells or to the infiltrating immune cells in the muscle 
tissue, qPCR (SYBR-Green detection method) was used in myoblasts and myotubes 
to test the expression level of several genes involved in regulating the cell cycle. The 
analysis demonstrated the increase in expression levels of Ccnb2, Aurka, cdk4 and 
Cdk6 in dystrophic myoblasts compared with wild-type. The expression levels of 
Ccnd3, Ccne1 and E2f2 transcripts were down-regulated significantly in dystrophic 
myoblast. In addition, the expression levels of Ccnd2 and Akura transcripts were up-
regulated and those of Ccnb1, Ccnb2, Ccnd3, Ccne1, E2f2 and Cdk1 were down-
regulated in dystrophic myotubes compared with wild-type. The remaining genes 
showed no statistically significant difference between the dystrophic and wild-type 
samples (Figure 4.27). Myoblasts and myotubes were cultured ex vivo therefore no 
immune cells could infiltrate these and alterations in a particular gene should 
represent the change in muscle rather than in its environment. Therefore, these 
findings indicate that the absence of dystrophin triggers the cell cycle alteration in 
myogenic as well as in, differentiated myotubes. 
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Figure 4.26: 
The cell cycle gene expression level changes in RNA-Seq datasets represented in a 
schematic format. The colour codes represent the following: red: up-regulation, green: 
down-regulation, white: not statistically significantly different and grey: not shown in 
our datasets. The outline colour of each shape represents mdx while the inside of the 
shape represents mdx/P2rx7
-/-
. The results indicate alteration of multiple transcripts in 
mdx compared to C57/BL10. In contrast, comparison of mdx/P2rx7
-/-
 with mdx showed 
only two altered genes: Cdk1 and Slfn1. 
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Figure 4.27: 
The relative expression levels normalised to the Gapdh showing the analysis of cell 
cycle regulator genes in myoblasts and myotubes derived from C57/BL10 and mdx. 
(Top) The expression levels of Ccnb1, Ccnb2, Ccnd2, Ccnd3, Ccne1, E2f2, Aurka, 
Cdk1, Cdk4 and Cdk6 in myoblast. The (bottom) graph represents the expression level 
of the same genes in myotube. The statistical analysis was performed using t-test, N=3, 
**P≤ 0.01 and ***P≤ 0.001. 
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4.3.9 The effect of ablation of the P2RX7 receptor on early fibrotic signature  
Fibrosis is the one of important features of DMD. However, it is reported that mdx 
show little fibrosis in their muscles compared to DMD (Coulton et al., 1988; 
Willmann et al., 2009; Desguerre et al., 2009; Contreras et al., 2016). In an attempt 
to characterise the profiles of fibrosis in the early stage of the disease in mdx, and to 
compare the findings with mdx/P2rx7
-/-
 to assess the role of P2RX7 receptor ablation 
in reducing this phenotype, the genes involved in fibrosis were studied in the 
respective RNA-Seq datasets. Figure 4.28 shows the 84 genes from RNA-Seq 
datasets, which were represented in the qPCR fibrosis array from Qiagen. 
Interestingly, and contrary to expectations, the analysis demonstrated the up-
regulation of the expression levels of the pro-fibrotic and down-regulation of anti-
fibrotic genes in the mdx. Another important finding was that ablation of P2RX7 
reduced the pro-fibrotic gene expression, while, at the same time, the anti-fibrotic 
genes were up-regulated compared with mdx. To the best of our knowledge, this is 
the first study to demonstrate that mdx mice share the same fibrotic phenotype with 
DMD and also that this fibrosis is present at an early stage of the disease. This 
analysis also confirmed the lessening of the fibrotic signature in mdx/P2rx7
-/-
 due to 
ablation of P2RX7. 
The IPA analysis interestingly detected that the hepatic fibrosis / hepatic stellate cell 
pathway was one of the top altered pathways in TA muscle from mdx/P2rx7
-/-
. 
Twenty-eight out of 146 genes were altered significantly (Table 4.2). Il1rl1, 
Tnfrsf1a, Ctgf, Il1r2, Acta2, CCR5, Il1r1, Stat1, Cd14, Myl6b, Igf2, Tnfsrsf11b, Ccl2, 
Csf1, Il4r, Myh8, Timp1 and Serpine1 were elevated in mdx compared with 
C57/BL10 and were down-regulated in mdx/P2rx7
-/- 
compared with mdx. In 
contrast, Cyp2e1, Kdr and Col11a2 were down-regulated in mdx compared with 
C57/BL10 and were up-regulated in mdx/P2rx7
-/-
 compared to mdx.  The mdx 
showed no statistically significant difference in the expression levels of Fgfr2, 
Mmp9, Smad3, Igfbp3, Il1b, Col22a1 and Ccl28a1, while the expression levels of 
Smad3, Igfbp3 and Il1b were decreased and those of Col22a1 and Ccl28a1 increased 
in mdx/P2rx7
-/-
 compared with mdx. 
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Figure 4.28: 
Fibrosis-related genes in four-week-old muscles from C57/BL10, mdx and mdx/P2rx7
-
/-
 represented in RNA-Seq and the mouse fibrosis array. The analysis revealed the up-
regulation of pro-fibrotic and down-regulation of anti-fibrotic genes in mdx. In 
contrast, in mdx/P2rx7
-/-
 the expression levels of pro-fibrotic genes were down-
regulated, whereas the anti-fibrotic genes showed up-regulation in their expression 
pattern. The colour codes represent the following: red: up-regulation, green: down-
regulation, white: not statistically significantly different in mdx/P2rx7
-/-
, while the 
pointed top and down arrows represent the up-regulation and down-regulation in mdx 
samples.  
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4.3.10 DMD muscles display altered nonsense-mediated decay (NMD) and 
highly aberrant mRNA splicing patterns 
In order to explore the potential functions of the NMD mechanism in degrading the 
mutant Dmd gene in dystrophic muscle, the expression of the full-length dystrophin 
was tested in the four-week-old TA muscles from mdx and mdx
βgeo
. Two TaqMan 
primers located in 5' end (exons 6-7) and (exon 13-14) were used in the qPCR 
method to detect this expression. The results in Figure 4.29 indicate that full-length 
dystrophin expression (both exons) was statistically significant, and more highly 
expressed in mdx than in mdx
βgeo
. Similar levels of expression were found between 
mdx and C57/BL10 while the expression was down-regulated significantly in 
mdx
βgeo 
compared with C57/BL10. Another set of primers located in the 3' end 
(exons 65-66), which is present in all dystrophin isoforms (Dp260, Dp140, Dp116 
and Dp71), was assessed. Significantly lower expression levels of exon 65-66 
dystrophin were found in both mdx and mdx
βgeo
 compared with C57/BL10 (Figure 
4.29). Moreover, the expression levels of exon 65-66 in mdx displayed statistically 
significant up-regulation compared with mdx
βgeo
. Altogether, these results indicated 
that mutant dystrophin was not degraded by NMD efficiently in mdx, while in 
mdx
βgeo 
the transcript was degraded completely.  
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Figure 4.29: 
Relative expression levels normalised to the Gapdh showing the expression of Dmd in 
four-week-old TA muscles in C57/BL10, mdx and mdx
βgeo
. The expression levels of 
full-length dystrophin represented by exon 6-7 and 13-14 were statistically significantly 
higher in mdx compared with mdx
βgeo
. Moreover, in a comparison with C57/BL10, the 
expression of full-length dystrophin in mdx was observed not to be significantly 
different. Unlike mdx, mdx
βgeo
 displayed significant down-regulation in the expression 
of full-length dystrophin compared with C57/BL10. Second, the expression levels of 
transcripts form the 3'end of dystrophin gene (exon 65-66) displayed statistically 
significant down-regulation in both mdx and mdx
βgeo 
compared with C57/BL10. The 
statistical analysis was performed using one-way ANOVA, N=3–5, *P ≤ 0.05, **P≤ 
0.01 and ***P≤ 0.001. 
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Semi-quantitative PCR was performed to study the expression of full-length 
dystrophin in C57/BL10 and mdx muscles. The reason for using this particular 
technique was to compare the actual difference in dystrophin expression between the 
wild-type and mdx muscle before the PCR reaches the plateau phase. The advantages 
of this technique included the ability to control the time course of reaction manually 
and calculate the relative expression levels of a target gene quantitatively by using 
the housekeeping gene. As a part of the optimisation step, several dystrophin primer 
sets were tested in order to find one set that works efficiently. In order to obtain the 
equal intensity between both samples at the end of amplifications, the expression of 
Gapdh between the samples was tested. Figure 4.30.A shows the best two optimal 
primer sets: the dystrophin primer set (mnd-5B), which amplified the region of exon 
2-9, and Gapdh primer. Figure 4.30.B summarises the semi-quantitative PCR results; 
the cDNA samples used in this experiment were derived from four-week-old TA 
muscles of C57/BL10 and mdx. The numbers of PCR cycles were 26, 28, 30, 32 and 
35 for dystrophin and 20, 23, 26, 29 and 32 for Gapdh. mdx showed a significant 
down-regulation in the expression of dystrophin compared with C57/BL10. The 
differences in dystrophin expression in mdx were approximately one-third of its 
expression in wild-type, while the expression of the housekeeping gene Gapdh was 
nearly stable in all samples over each reaction cycle. These findings suggested the 
existence of dystrophin mRNA in leg muscle and the difference of this expression 
between mdx and C57/BL10 was approximately one-third. Hence, the mdx mouse 
model of DMD has a nonsense stop-gain mutation in exon 23 affecting the 
expression of the full-length dystrophin isoform, and theoretically expression of full-
length dystrophin should be inhibited completely (Bulfield et al., 1984). Therefore, 
the presence of this transcript in mdx muscle predicts the possibility of abnormality 
of NMD function in the degradation of full-length dystrophins.  
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Figure 4.30: 
Expression of dystrophin transcript in cDNA derived from four-week-old TA muscles 
of C57/BL10 and mdx. (A) RT-PCR showed equal levels of dystrophin exon 2-9 and 
Gapdh expression after 35 cycles (saturation) in both C57/BL10 and mdx as a part of 
the optimisation step. (B) Semi-quantitative PCR showed the difference in the 
expression of dystrophin between mdx and C57/BL10 in each of the following cycles: 
26, 28, 30, 32 and 35. The result indicated that mdx expresses about one-third of the 
expression of dystrophin in C57/BL10 compared to Gapdh expression. (C)  
Densitometric analysis represented the difference in the expression of dystrophin 
between mdx and C57/BL10 and also showed the stability of Gapdh expression 
between the samples in all reaction cycles. 
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Because the previous investigation showed the high levels of expression of full 
length dystrophin in mdx, it was decided to test the expression of full-length 
dystrophin and 3' end  dystrophin (exon 65-66) in mdx muscle cells. Therefore, the 
second qPCR experiment was performed using the RNA samples that were extracted 
from myoblasts and myotubes. Starting with myoblasts, the expression levels of full-
length dystrophin were down-regulated significantly in dystrophic cells compared to 
wild-type. Also, the expression level of exon 65-66 was down-regulated in 
dystrophic cells compared with wild-type. The finding of dystrophin expression in 
myotubes suggested a statistically significant down-regulation of the region that is 
present in all isoforms (exon 65-66) in dystrophic cells compared with wild-type 
(Figure 4.31). However, the full-length dystrophin (exon 6-7) showed a statistically 
significant down-regulation in dystrophic cells compared with wild-type cells, while 
the expression of exon 13-14 showed no statistically significant difference. The 
results indicated that both dystrophic myoblast and myotubes have five times less 
dystophin transcript than the wild-type. And this low expression suggested the 
effective function of NMD in degrading the dystrophin transcript in cells. 
The expression of full-length dystrophin and 3' end  dystrophin between wild-type 
myoblast and myotube as well as between dystrophic myoblast and myotube was 
also compared. Figure 4.32 shows agreement with previous results, which indicated 
the gradual increase of full-length dystrophin starting from a very low level in 
myoblasts to a detectable level in myotubes in wild-type (Dalkilic, 2003). However, 
the expression of full length dystrophin in dystrophic cells was not in line with the 
previous study, which indicated the undetectable level of dystrophin transcript in 
both myoblasts and myotubes in mdx. Nevertheless, the expression of Dp71 was not 
in line with the literature, which indicated a high expression level of Dp71 in 
myoblast and low expression level in myotube of both wild type and dystrophic cells 
(Tennyson et al., 1996; de León et al., 2005). 
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Figure 4.31: 
Relative expression levels of dystrophin gene normalised to the Gapdh in myoblast and 
myotube. The expression levels of full-length dystrophin represented by exon 6-7 and 
13-14 were statistically significantly reduced in dystrophic cells compared with wild-
type. The expression of exon 65-66 was also significantly down-regulated in dystrophic 
myoblasts compared with wild-type. Notably, myotubes showed the expression levels 
of both full-length and 3' end  dystrophin. The statistical analysis was performed using 
a t-test, N=3–5, *P ≤ 0.05, **P≤ 0.01 and ***P≤ 0.001. 
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Figure 4.32: 
Relative expression levels of dystrophin gene normalised to the Gapdh in wild-type and 
dystrophic cells. The expression levels of full-length dystrophin represented by exon 6-
7 and 13-14 as well as the Dp71 represented by exon 65-66 were statistically 
significantly reduced in myoblast compared to myotube in wild-type cell samples. 
Notably, the dystrophic cells also showed low expression levels of both full-length and 
isoforms dystrophin in myoblast compared with myotubes. The statistical analysis was 
performed using a t-test, N=3–5, **P≤ 0.01 and ***P<0.005. 
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In order to test whether the inhibition of the NMD mechanism would affect the 
expression of Dmd gene, the NMD activity was suppressed by treating the dystrophic 
and normal myoblasts with nonsense mediated decay inhibitor 14 (NMDI-14). 
Additionally, the same numbers of biological cell replicates were treated with 
DMSO as a control; both treatments were carried out in parallel for 6, 16 and 24 
hours. The relative expression level of the Dmd gene was assessed using a qPCR 
experiment, and we initially used 3'end (exon 65-66) primer. The analysis, which is 
summarised in Figure 4.33.A, showed that after 6 hours of treatment the expression 
of dystrophin was statistically significantly reduced in the wild-type treated with 
NMDI-14 compared with the wild-type treated with DMSO as a control. It also 
showed statistically significant down-regulation in dystrophic cells treated with 
NMDI-14 compared with DMSO-treated cells, but there was no difference between 
wild-type and dystrophic cells in the two treatments. In 16 hours of treatment, the 
expression of 3'end of dystrophin in both DMSO- and NMDI-14-treated dystrophic 
cells was only down-regulated significantly compared with wild-type treated with 
DMSO and NMDI-14. The same results were obtained when the cells were treated 
longer, for 24 hours (Figure 4.33.A). Notably, the treatment for 16 and 24 hours 
indicated unchanged levels of dystrophin in dystrophic cells, which should be up-
regulated due to inhibition of the NMD mechanism, and the expression pattern 
shows similar expression levels of dystrophin in Figure 3.2. This result suggests that 
the activity of NMD was not inhibited after 16 and 24 hours of treatment, probably 
because the long-time treatment has a negative effect on the experimental conditions 
overall. 
Next, we used full-length dystrophin primer (exon 6-7) to test the activity of NMD 
on the dystrophin transcript decay. After 6 hours of treatment, the expression of 
dystrophin in dystrophic cells (treated with DMSO and NMDI-14) was down-
regulated significantly compared with wild-type treated with DMSO and NMDI-14 
cells. The expression of dystrophin in dystrophic cells treated with NMDI-14 was not 
shown to be statistically significantly different compared with dystrophic cells 
treated with DMSO. The dystrophic cells showed even more reduction in the 
expression of dystrophin compared with wild-type in 16 hours of treatment and no 
difference between the two dystrophic groups. Similarly, the expression of full-
length dystrophin using a different primer (exon 13-14) was found down-regulated in 
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dystrophic cells treated with DMSO and NMDI-14 compared with wild-type cells 
treated with DMSO and NMDI-14 in both 6- and 16-hour treatments. All together it 
was determined that cell treatement with NMDI-14 does not affect the function of 
NMD in degrading the full-length dystrophin (Figure 4.33.B). 
    
Figure 4.33: 
Effect of NMDI-14 treatment on expression of dystrophin in dystrophic (SC5) and 
wild-type (IMO) myoblasts. (A) The expression of dystrophin exon 65-66 was 
determined by qPCR using a myoblast cell line treated with NMDI-14 for 6, 16 and 24 
hours respectively. The analysis indicated that after 6 hours of treatment, the expression 
of 3ˈend dystrophin showed significant down-regulation in dystrophic cells treated with 
the inhibitor rather than the dystrophic cells treated with DMSO. Also there was more 
significant down-regulation in the expression of dystrophin in wild-type treated with 
the inhibitor than the one treated with DMSO. Treatment for 16 and 24 hours showed 
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the same pattern of dystrophin expression, which was down-regulated in both 
dystrophic cells treated with (DMSO and NMDI-14) compared with wild-type cells. 
(B) The relative expression levels of exon 6-7 and exon 13-14 in myoblasts treated for 
6 and 16 hours respectively. In the 6-hour treatment, the expression of both regions was 
reduced in dystrophic cells compared with wild-type cells. Further reductions in the 
expression of both regions were seen in dystrophic cells compared with wild-type when 
the treatments with NMDI-14 were continued for 16 hours. 
 
 
To determine whether the NMDI-14 inhibitor attenuates the activity of the NMD 
mechanism in myotubes, the expression of dystrophin was evaluated by qPCR. As in 
the previous experiment, different primer sets (detecting the full-length and 3' end 
dystrophins) were tested. The expression of 3' end dystrophin (exon 65-66) was 
reduced significantly in dystrophic cells treated with NMDI-14 compared with 
dystrophic cells treated with DMSO. This reduction in the expression of dystrophin 
was seen in both 6- and 16-hour treatments. This indicates that short-term treatment 
is unable to inhibit the NMD mechanism in myotubes. A treatment for 24 hours 
showed a significant increase in the level of dystrophin in dystrophic myotubes 
treated with NMDI-14 compared with dystrophic controls. The last figure showes no 
significant difference between wild-type myotubes treated with DMSO and these 
myotubes treated with NMDI-14 (Figure 4.34). 
 
Figure 4.34: 
Relative expression levels of the dystrophin gene in myotubes treated with NMDI-14 
for 6, 16 and 24 hours, respectively. The expression of exon 65-66 of the dystrophin 
gene was reduced in NMDI-treated dystrophic cells compared with DMSO control in 
both 6- and 16-hour treatments. In the 24-hour treatment, the expression of dystrophin 
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in dystrophic cells (NMDI-14) was statistically significantly up-regulated compared 
with DMSO. Finally, the expression levels of dystrophin exon 65-66 were found to be 
not significantly different between wild-type myotube treated with NMDI-14 and 
treated with DMSO as a control. A t-test was used to calculate the relative expression 
level of dystrophin, N=4–5 and *P ≤ 0.05 and **P≤ 0.01. 
 
 
 
Next, the full-length dystrophin primer set (exon 6-7) was investigated. The results 
shown in Figure 4.35 indicate no significant difference in the expression of 
dystrophin between dystrophic myotubes treated with DMSO and treated with 
NMDI-14 in both 6 and 16 hours treatments. Importantly, the 24-hour treatment 
significantly enhanced the expression of dystrophin in NMDI-treated dystrophic cells 
compared with DMSO-treated cells. Finally, the qPCR results using another full-
length dystrophin primer flanking exon 13-14 (Figure 4.36) matched the qPCR 
results using exon 6-7 primer. These findings implied that NMDI-14 was efficient in 
inhibiting the NMD machinery in myotubes after 24 hours of treatment. 
 
          Figure 4.35: 
Expression levels of full-length dystrophin gene using exon 6-7 primer set in dystrophic 
myotubes treated with NMDI-14 or DMSO for 6, 16 and 24 hours, respectively. In both 
6- and 16-hour treatments, the analysis showed no significant difference between the 
dystrophic cells treated with NMDI-14 and DMSO. The expression of full-length 
dystrophin matched the expression of exon 65-66 when the myotube cells were treated 
with NMDI for a longer time (24h treatment). The results showed high expression 
levels of full-length dystrophin in dystrophic cells treated with NMDI-14 compared 
with controls. A t-test was used to calculate the relative expression of dystrophin, N=4–
5 and *P ≤ 0.05. 
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Figure 4.36: 
Expression levels of full-length dystrophin gene using exon 13-14 primers in 
dystrophic myotubes treated with NMDI-14 or DMSO for 6, 16 and 24 hours, 
respectively. In both 6- and 16-hour treatments, the analysis showed no significant 
difference between the dystrophic cells treated or control. The expression matched the 
results with exon 65-66 and exon 6-7 primer sets when the myotubes were treated with 
NMDI for a longer time (24h) as there was a higher expression in NMDI-14 treated 
compared with control cells. A t-test was used to calculate the relative expression of 
dystrophin, N=4–5 and **P≤ 0.01. 
 
 
 
Trying to understand these results analysis of RNA-Seq data comparing wild-type 
and mdx muscles in the degeneration-regeneration phase revealed significant 
differences (both up- and down-regulation) in the expression of a number of genes 
involved in regulated unproductive splicing and translation (RUST) and alternative 
splicing (AS). Table 4.5 shows the down-regulation of both Upf3a and Upf3b in mdx 
muscles compared with C57/BL10. These genes are RNA-binding proteins that 
recognise the mRNA with premature stop codons to form NMD-component EJC 
(Kurosaki and Maquat, 2013). Moreover, the mdx samples have a higher expression 
of Hnrnpa0, Hnrnpa1 and Hnrnpf as well as Srsf3 and Srsf9. Belonging to the 
subfamily of hnRNPs, Ptbp3 was also found to be up-regulated. There was a 
significant up-regulation of Myc and Mycl1 and down-regulation of Myct1 (Myc 
target) in mdx samples. It is generally known that the environmental condition 
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present in mdx may be mediated by increased Myc, which inhibits the NMD 
mechanism (Wang et al., 2011). The master regulators of alternative splicing Nova 1 
and Nova 2 in some cells (Villate et al., 2014) were significantly decreased in mdx. 
Both Mbln1 and Mbln2, but not 3, were also down-regulated in mdx. These proteins 
function as target-specific regulators of pre-mRNA splicing and are involved in 
myotonic dystrophy (Konieczny et al., 2014). 
 
Table 4.5: RNA-Seq dataset representing genes involved in NMD regulation. The 
expression of NMD regulatory factors shows up- and down-regulation between mdx 
and C57/BL10. The colour codes represent the following: red: up-regulation and green: 
down-regulation. 
Nearest_ref_ID gene Sample Sample value_1 value_2 p_value Significant 
NM_001163131 Elf3 C57/BL10 mdx 0.114444 0.037745 1 no 
NM_019680 Elf4 C57/BL10 mdx 2.00779 3.81824 5.00E-05 yes 
NM_010155 Erf C57/BL10 mdx 3.99503 4.89977 0.08105 no 
NM_029872 Hnrnpa0 C57/BL10 mdx 15.6646 21.1209 0.002 yes 
NM_010447 Hnrnpa1 C57/BL10 mdx 49.4641 66.6733 0.0033 yes 
NM_001001792 Hnrnpf C57/BL10 mdx 64.528 84.4757 0.00395 yes 
NM_008506 Mycl1 C57/BL10 mdx 0.58951 1.82129 0.00005 yes 
NM_026793 Myct1 C57/BL10 mdx 7.21917 4.7631 0.00035 yes 
NM_026793 Myct1 C57/BL10 mdx 7.21917 4.7631 0.00035 yes 
NM_025968 Ptbp3 C57/BL10 mdx 9.58615 14.1278 0.00005 yes 
NM_001031814 Smg1 C57/BL10 mdx 7.70367 8.35385 0.38405 no 
NM_178246 Smg5 C57/BL10 mdx 19.3253 17.0728 0.18555 no 
NM_001002764 Smg6 C57/BL10 mdx 5.74571 5.58562 0.7775 no 
NM_001160256 Smg7 C57/BL10 mdx 13.1965 11.4639 0.1391 no 
NM_013663 Srsf3 C57/BL10 mdx 19.5815 25.6868 0.005 yes 
NM_026398 Srsf9 C57/BL10 mdx 10.6894 14.8006 0.0062 yes 
NM_001122829 Upf1 C57/BL10 mdx 14.4216 12.2202 0.1384 no 
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To confirm the RNA-Seq results, qPCR experiments were carried out using cDNA 
extracted from four-week-old TA muscles from C57/BL10 and mdx. These 
confirmed the RNA-Seq analysis, which showed a statistically significant up-
regulation of Hnrnpa1, Srsf9 and Upf3b genes expression but not of Upf3a in mdx 
compared with C57/BL10 (Figure 4.37.A). Also, the cDNAs were extracted from 
dystrophic and wild-type myoblasts and were used to test the expression of NMD 
regulators. Interestingly, Figure 4.37.B shows the significant up-regulation of the 
expression level of the Hnrnpa1 splice repressor gene in undifferentiated dystrophic 
myoblasts compared with normal cells. The expression of Upf3b transcript was 
significantly down-regulated in dystrophic myoblasts compared with wild-type cells. 
Next, we used cDNA prepared from myotubes differentiated in vitro to test further 
whether this difference in the expression of genes regulating NMD in dystrophic 
muscles is a cell-autonomous abnormality or a result of the dystrophic environment. 
The qPCR results matched the RNA-Seq data that were obtained from the muscle 
tissue, thereby indicating the cell-autonomous effects of Dmd gene mutation (Figure 
4.37.C). Taken together, these results indicated that mdx muscle cells may have less 
efficient NMD and also repression of splicing and thus an aberrant mRNA splicing 
pattern. 
NM_001081132 Upf2 C57/BL10 mdx 5.67093 4.41567 0.01505 no 
NM_025924 Upf3a C57/BL10 mdx 13.1902 8.92925 0.0006 yes 
NM_026573 Upf3b C57/BL10 mdx 7.0173 4.40568 0.0002 yes 
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Figure 4.37: 
Relative expression levels of NMD regulator factors in C57/BL10 and mdx muscles. 
(A) Shows the statistically significant up-regulation in the expression of Hnrnpa1, Srsf9 
and Upf3b genes but not the Upf3a gene. (B) Shows the significant up-regulation of 
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Hnrnpa1 and down-regulation of Upf3b expression in dystrophic myoblast compared 
with wild-type whereas there is no significant difference in Srsf9, Upf3a and Mbln1. 
(C) Represents the significant up-regulation of Hnrnpa1 and Srsf9 expression and 
significant down-regulation of Upf3a, Upf3b and Mbln1 in dystrophic myotubes 
compared with wild-type. The statistical analysis was performed using a t-test, N=3–5, 
*P ≤ 0.05, **P≤ 0.01 and ***P≤ 0.001. 
 
 
 
To assess the effect of DMD-induced alterations in the expression of AS regulator 
genes, the differences in isoform ratio profiles of transcripts assayed by RNA-Seq 
were quantified by Dr Mikhail Shugay. Isoform ratio profiles characterise the 
relative expression of alternative transcripts for a given gene. The entropy of isoform 
profile highlights the uniformness of alternative transcript usage and can be used to 
quantify global splicing disorders (Ritchie et al., 2008). For example, a switch 
between dominant isoforms for a given gene will not cause a change in isoform 
profile entropy, while the emergence of multiple alternative transcripts will increase 
the entropy. A clear increase in isoform profile entropy was observed in mdx 
samples for genes that are alternatively spliced between mdx and C57/BL10 samples 
(Figure 4.38.A), highlighting the alteration of the AS pathway function. The entropy 
gain suggests attenuation of tight AS regulation mechanisms (Wang et al., 2008). 
Notably, the increase of entropy was also observed on a larger scale when studying 
the entropy distribution of entire gene sets (Figure 4.38.B) and was not limited to 
genes that have few dominant isoforms. The NMD pathway efficiency can be 
quantified by measuring the relative abundance of transcripts that are likely to 
undergo NMD. Several such methods exist, for example measurement of transcripts 
with a premature stop codon (Hurt et al., 2013). A simpler measure (the abundance 
of out-of-frame splice junctions) that can be directly inferred from RNA-Seq data 
was performed. The NMD quantification using a gold standard dataset in 
Weischenfeldt et al. (2012) was used and a concordant increase of out-of-frame 
junctions was found in mdx compared to C57/BL10 (Figure 4.38.C). These findings 
suggest that NMD pathway efficiency is attenuated in DMD mutants compared to 
control. 
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Figure 4.38: 
Changes in alternative splicing and nonsense mediated decay pathway function as 
revealed by RNA-Seq. (A) Differentially spliced genes tend to have more uniform 
isoform expression profiles in mdx samples than in control. These genes show an 
increase of isoform expression profile entropy compared to non-differentially-spliced 
genes (P<10
-10
, Mann-Whitney test). (B) Isoform profiles across all genes were more 
uniform in mdx samples than in control ones (P<10
-10
, Kolmogorov-Smirnov test). 
Note that the shift to higher entropy values is still observed when filtering out genes 
that have a single dominant isoform in control (selected by the threshold H<0.1) as 
shown in the insert (P<10
-10
, Kolmogorov-Smirnov test). (C) Extent of nonsense-
mediated decay as measured by out-of-frame splice junction frequency. The number of 
out-of-frame junctions was estimated using TopHat RNA-Seq aligner and the custom 
analysis pipeline generated by M Shugay in the present study (mdx mouse muscle 
tissue), as well as bone marrow (BM) and liver (Liver) from the Upf2 knockout mouse 
model (Weischenfeldt et al., 2012) used as the gold standard for this pipeline. Error 
bars show standard deviation computed according to binomial distribution. The 
difference between control and mdx muscle tissue is significant (t=4.2, df=5.4, p-
value=0.007, paired t-test). The difference between the out-of-frame junction frequency 
in both of the Weischenfeldt et al. datasets is highly significant (P<10
-10
, binomial ratio 
test). 
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Together, these results indicate the abnormalities of NMD functions and AS 
regulator genes in mdx. The abnormality of these mechanisms is linked with the 
increased number of alternatively altered spliced genes; interestingly, P2rx7 has 
appeared as one of the highly altered alternative splice transcripts (Appendix 10.11).  
The absence of dystrophin protein alters the expression and function of the P2RX7 
receptor. In the previous and the present study the up-regulation of P2rx7 in mdx 
muscles, myoblasts and myotubes compared with equivalent wild-types was found 
(Figure 4.39.A) (Yeung et al., 2006; Young et al., 2012; Young et al., 2015; 
Sinadinos et al., 2015). In addition, these findings confirmed that different mutations 
in the Dmd gene (i.e. insertional mutation in the 3' end) cause the same (or perhaps 
even stronger) up-regulation of the P2rx7 expression (Figure 4.39.B). The up-
regulation of this receptor is linked to the stimulation of the immune response and 
autophagic cell death (Sinadinos et al., 2015; Young et al., 2015). In this section, we 
focused on the P2rx7 knockdown models that were mentioned in the animal model 
chapter, Pfizer-P2rx7, Glaxo-P2rx7 and mdx/P2rx7
-/-
, to study the rule of 
degradation of aberrant P2rx7 transcript by the NMD mechanism. The mutant 
transcript degradation via NMD prevents the dominant negative function of 
truncated proteins. Since Pfizer-P2rx7 was generated by inserting a neomycin 
cassette into the last exon, the decaying via NMD machinery was avoided in 
accordance with the “55-nt rule” (Nagy and Maquat, 1998). Interestingly, using the 
primer set located in the 5' end (exon 3-4) showed the high expression levels of 
P2rx7 in Pfizer-P2rx7, and Pfizer mdx/P2rx7
-/-
 (Figure 4.39.B.), myoblasts and 
myotubes (Figure 4.39.A), while using primer complementarily to exon 13 showed 
low levels, but still detection of P2rx7 expression in Pfizer-mdx/P2rx7
-/-
 (Figure 
4.39.A). By contrast, Glaxo-P2rx7 was generated by the insertion of LacZ into the 
exon 1, so this transcript is considered a target for decaying by NMD. The result of 
P2rx7 expression in Glaxo-P2rx7 is shown in Figure 4.39.B, which indicates the 
significantly low levels of expression compared with C57/BL10 and Pfizer models. 
Moreover, this experiment also confirmed that another mutation in the Dmd gene 
(i.e. insertional mutation in the 3ˈend) causes the same (or perhaps even stronger) up-
regulation of the P2rx7 expression. 
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Figure 4.39: 
Real-time PCR analysis showing: (A) the relative expression levels of P2rx7 transcript 
in four-week-old TA muscles, myoblasts and myotubes, respectively. The analysis 
shows high levels of P2rx7 (exon 13) expression in mdx compared with C57/BL10 and 
also a low expression level in Pfizer-mdx/P2rx7
-/-
compared with mdx. Using primer 
sets located in exon 3-4, the expression levels of P2rx7 were up-regulated in both 
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dystrophic myoblasts and  myotubes, respectively. (B) The relative expression levels of 
Dmd exon 65-66 and P2rx7 exon 3-4 in C57/BL10, mdx, mdx
βgeo
, mdx/P2rx7
-/-
, Pfizer-
P2rx7 and Glaxo-P2rx7. The analysis demonstrated that knockout P2rx7 transcript in 
Pfizer is not degraded by NMD, presumably because the stop codon is not separated by 
an intron while Glaxo transcript is degraded efficiently. The statistical analysis was 
performed using either a t-test or one-way ANOVA, N=3–5, ***P<0.005. 
 
The absence of dystrophin in mdx leads to abnormal expression of another transcript 
(Bmp7). The abnormality in the expression of this transcript was represented by a 
significant down-regulation of BMP7 transcript in mdx muscles, muscle fibres and 
myoblasts. This indicates the cell-autonomous mechanism of this abnormality. The 
next chapter will discuss Bmp7 as an example of an aberrant splice variant. 
 
163 
 
 Discussion 4.4
4.4.1 Validation of RNA-Seq experiments 
The complexity of DMD pathogenesis and the existence of many factors that 
interrupt the symptoms of disease, as well as there being no known treatment 
available to cure the symptoms, led our group to test the genome-wide expression in 
mdx and mdx/P2rx7
-/-
 using RNA-Seq. Thus aimed at better understanding of the 
molecular basis of this disease and identifying novel transcripts and transcript 
alterations that were the result of the absence of dystrophin. Second, we identified 
the genes that were corrected in mdx as a result of deletion of the P2RX7 receptor 
and using them as bio-markers in pharmacological inhibitor studies. The reasons for 
choosing this technique were associated with its unique features. RNA-Seq is based 
on high-throughput sequencing to digitally investigate thousands of transcripts that 
are present in a specific tissue. This method provides unbiased measurements and 
does not require any prior knowledge about the transcriptome. It allows, in a single 
experiment and with high specificity and sensitivity, to detect the cellular 
transcriptional profile including common and rare transcripts, and to discover the 
expression of novel transcripts and splice variants, both coding and non-coding (e.g. 
lncRNAs). Finally, RNA-Seq has a very low background signal, high levels of 
technical and biological reproducibility, high accuracy to quantify expression levels 
and requires only small amounts of RNA samples (Cloonan et al., 2008; 
Nagalakshmi et al., 2008; Wang et al., 2009; Oshlack et al., 2010; Costa et al., 
2013). 
The cost of the RNA-Seq method is still high compared with other techniques used 
for detecting gene expression. Sample preparation is also a complicated process; 
therefore, monitoring the quality of samples is important for successful sequencing. 
Again, the RNeasy Plus Universal mini kit (Qiagen) was used to extract RNA from 
TA muscle samples. The quality of RNA samples was measured using the NanoDrop 
and Bioanalyzer 2100; good quality samples were selected with a 260/280 close to 2 
and with an RIN over 7. In addition to checking the quality of the starting RNA, two 
more checkpoints were performed using Bioanalyzer 2100: adapter-ligated and 
cDNA-pooled library checkpoints. The adapter-ligated results displayed a single 
peak between 225 and 275 bp and the cDNA-pooled libraries showed a peak with an 
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average size between 250 and 350 bp. It has been documented that an average size of 
250 and 280 bp indicates successful ligation and library amplification. The 
intermediate QC helps to detect any artefact that arises during library preparation and 
affects the quality of raw data for downstream analysis (Schmieder and Edwards, 
2011; Gargis et al., 2012; Zhou et al., 2013). Most sequencing protocols recommend 
using either a Bioanalyzer or fluorometer based quality control (Endrullat et al., 
2016; Yuan et al., 2016). Robin et al. (2016) suggested quantifying the RNA/DNA 
samples using quantitative PCR (qPCR) or digital droplet PCR (ddPCR). The 
advantage of using new digital PCR over standard PCR is associated with avoiding 
the number of cycles used to generate a sufficient amount of DNA libraries for QC 
assessment. The increasing number of standard PCR cycles distorts the library’s 
heterogeneity and reduces the ability to discover a rare variant.  
The RNA-Seq was performed by Source BioScience using the Illumina HiSeq 2000 
platform. The sequencing produced millions of reads that were normalised to the 
mouse genome using TopHat software (mm10 genome assembly, UCSC Genome 
Browser). TopHat is a fast splice junction computational mapper; it maps 2.2 million 
reads to the mammalian reference gene per hour. In addition, this program captures 
about 80% of splice junctions even for very low level transcribed genes. Since the 
non-coding and 3' untranslated regions (UTRs) are distinguished, TopHat provides 
an approximate quantity for exon expression (Trapnell et al., 2009; Kim et al., 
2013). Mapping the reads to the reference gene is a very challenging step, because 
they need to be in a real and accurate location. Before analysis, sequencing and 
reaching a biological conclusion, filtering the abnormal reads to increase the high 
throughput data is required (Patel and Jain, 2012; Edgar and Flyvbjerg, 2015). 
Mapping reads of complex organisms such as humans and mice need to take into 
account the repetitive regions that form about 50% of the genome, covering the 
annotated transcripts from the 5' to the 3' end and the non-coding region (Lander et 
al., 2001; Chinwalla et al., 2002). Following mapping, the reads were converted to 
quantitative measurements of gene expression by fragments per kilobase of transcript 
per million mapped (FPKM) metric (Mortazavi et al., 2008). The reason for applying 
this approach is to normalise the reads in order to avoid the differences in expression 
resulting from variability of the transcript length. The long transcripts cover more 
reads than the short ones; therefore, the FPKM normalises the reads considering the 
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length of transcript and the number of reads (Mortazavi et al., 2008; Oshlack et al., 
2009).  
Cufflink is an assembler software used in this study to assemble the reads into 
transcripts. This software contains a package called Cuffdiff, which is responsible for 
generating differential gene expression between samples, discover new genes and 
new splice variants (Trapnell et al., 2012). One advantage of this software is 
associated with its function as a de novo transcriptome assembler, which allows 
novel transcripts to be discovered. A further advantage of using Cufflink is 
associated with its ability to assemble transcripts from very short reads, typically 25–
400 bp. The transcriptome assembly is more complex than the genome assembly 
because of the presence of splice variants and the unavailability of a reliable genome 
datasets e.g. in the case of human cancer (Grabherr et al., 2011; Chang et al., 2015). 
In order to detect rare transcripts, deep sequencing with high coverage depth was 
performed. In spite of the increasing costs of experiments due to the increased 
coverage, the expression of huge numbers of genes (23,000) was surveyed in this 
experiment. Not only the level of gene expression, but also different types of analysis 
were performed.  
Analysis performed at the gene level indicated that the most altered genes in mdx 
compared with C57/BL10 were inflammation-related and lysosomal genes. Also, the 
inflammation and chemotaxic cytokine genes were indicated as the most altered 
genes in mdx compared with mdx/P2rx7
-/-
. Prior studies have demonstrated the role 
of the inflammatory response in the pathogenesis of DMD (Carnwath and Shotto, 
1987; McDouall at al., 1990; Tews and Goebel, 1996; Nahirney et al., 1997; Fang et 
al., 2000; Villalta et al., 2015). To the best of our knowledge, most reports were of 
targeted NGS for the genetic diagnosis of DMD; however, this may be the first study 
to investigate the biological role of altered genes in mdx using NGS approach (Wei 
et al., 2014; Gonorazky et al., 2016; Lim et al., 2011; Okubo et al., 2016). In 
contrast, the differential expression of genes has been revealed in many studies using 
microarrays (Tkatchenko  et al., 2000; Boer et al., 2002; Tseng et al., 2002; Roberts 
et al., 2015). For example, Porter et al. (2002) performed DNA microarrays using 
leg tissue samples; they found that most of the globally altered genes in mdx 
participate in inflammatory pathways, such as cytokines, chemokines, leukocyte 
adhesion and diapedesis or were invasion cell markers. Marotta also showed the up-
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regulation of inflammatory genes as well as 75% of the genes being related to cell 
adhesion and regeneration (Marotta et al., 2009). Importantly, these findings showed 
the down-regulation of genes related to fibrosis and inflammation in mdx/P2rx7
-/- 
compared with mdx. This new important finding further confirmed that the ablation 
of P2RX7 may be a potential therapeutic target for DMD. 
4.4.2 IPA analysis of genes expressions 
Computational software (IPA and GSEA) was used to group the differential gene 
expression results into common pathways and to interpret their biological functions 
in DMD. Notably, the importance of using this type of analysis may be related to 
reduction of false positive results when the sets of genes display similar regulation. It 
shows the relation between genes under different pathways that give clear insights 
into their biological roles in disease progression. It narrows the dimension of datasets 
and therefore the statistical analysis that needs to be performed. Finally, it may 
strengthen the alterations in expression levels of single genes (Emmert-Streib and 
Glazko, 2011). 
The IPA analysis demonstrated that granulocyte/agranulocyte adhesion and 
diapedesis, hepatic fibrosis/hepatic stellate cell activation, which is representative of 
general fibrosis (See below), atherosclerosis signalling and LXR/RXR activation 
were over-represented as the top five canonical pathways in mdx/P2rx7
-/- 
compared 
with mdx. The granulocyte and agranulocyte adhesion and diapedesis pathways 
represent the first defence line of hosts against the inflammation generated due to 
muscle injury in the case of DMD. Many genes involved in these pathways were up-
regulated in mdx compared with C57/BL10; this result showed agreement with 
Porter et al. (2002), who detected the up-regulation of leukocyte adhesion and 
diapedesis pathways in mdx. In DMD, muscle injury triggers the immune response. 
Part of this response is where inflammatory signals such as TNF, interleukins and 
granulocyte colony stimulation factor (GCSF) are elevated. The up-regulation of 
these molecules attracts leukocytes (granulocyte or agranulocyte) from the blood-
stream to the injury site. Leukocytes migrate through a mechanism called 
extravasation, which enables them to roll on the surface of the endothelium via P-, E-
, and L-selectins (expressed on both leukocytes and endothelium) (McEver and 
Cummings, 1997; Rosen, 2004). Later, cells adhere tightly to the surface of the 
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endothelium by binding Integrin β2 (ligand on leukocytes) via immunoglobulin 
superfamily intercellular adhesion molecule-1 and -2 (ICAM1 and ICAM2) and 
vascular cell adhesion molecule-1 (VCAM1), both of which are expressed on the 
surface of endothelial cells (Dustin and Springer, 1988; Meerschaert and Furie, 1995; 
Ley et al., 2007). Finally, the transmigration of leukocytes into tissue passes 
endothelial cells by the diapedesis mechanism (Muller, 2003). There are different 
inflammatory cytokine and chemokine molecules regulating the extravasation 
mechanism according to the leukocyte cell type and tissue. Additionally, the 
endothelial cells also stimulate the adhesion of leukocytes via releasing chemokines 
such as stromal cell-derived factor-1 (SDF1) and N-formyl-met-leu-phe (fMLP). The 
generation of reactive oxygen species (ROS) and matrix metalloproteinases (MMPs) 
is involved in regulating transmigration events (Middleton et al., 2002; Muller, 
2013). Interestingly, the RNA-Seq analysis of the mdx/P2rx7
-/- 
detected the down-
regulation of the expression level of several genes (Table 4.2) involved in these 
pathways, suggesting that the ablation of the P2RX7 receptor in mdx reduces both 
the immune and inflammatory responses.  
The atherosclerosis signalling pathway was predicted by IPA as the fourth top 
altered canonical pathway. In total, 17 out of 81 genes regulated by this pathway 
were altered in mdx/P2rx7
-/-
 compared with mdx, with Apod, Il1rn, Clu, Ccl2, 
Selplg, Csf1, Ccr3, Il33 and Alox15 being down-regulated and Cd36, Lpl and 
Col11a2 up-regulated. Atherosclerosis is a chronic inflammatory disease (Ridker et 
al., 2005) which is triggered by pro-inflammatory cytokines (Rajamäki et al. 2013). 
It has been demonstrated that the production of pro-inflammatory cytokines is 
associated with the stimulation of P2RX7 receptors by ATP released from damaged 
muscles (Di Virgilio, 2007; Ferrari et al., 2006). Activation of the P2RX7 receptor 
leads to activation of the NLRP3 inflammasome, and the release of caspase-1, which 
is required for cleavage of the inactive form of pro-inflammatory cytokines (IL1β 
IL1α, IL6, IL18 and TNF-α) to the active form (Tschopp and Schroder, 2010; Latz et 
al., 2013). The role of Toll-like receptor in the formation of inflammasomes and 
producing the inactive form of pro-inflammatory cytokines has been reported 
(Giordano et al., 2015; Zimmer et al., 2011). In addition to pro-inflammatory cells, 
numerous danger signals have been detected in atherosclerotic lesions, such as the 
debris of dead cells, cholesterol deposits, and components of the degraded 
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extracellular matrix (ECM) (Zimmer et al, 2015). The lipids are separated from 
proteoglycans of the degraded ECM and then taken up by intimal macrophages, 
which accumulate in atherosclerotic lesions; this is one of the important mechanisms 
responsible for developing atherosclerosis (Chait and Wight, 2000; Skålén et al., 
2002; Galkina and Ley, 2007).  Recently, Rauch et al. (2012) indicated that the 
expression of dystrophin in vascular smooth muscle cells is required for nNOS-
stimulated vasodilation in arteries; this process is attenuated in mdx mice (Ito et al., 
2006). An absence of dystrophin leads to vascular injury; in response to this injury, 
smooth muscle cells migrate to the site of the injury and proliferate to generate vast 
amounts of ECM (Rzucidlo et al., 2007). This process stimulates neointima 
formation (artery injury-induced intimal thickening) (Rauch et al., 2012). Based on 
that, the role of dystrophin in inducing atherosclerosis has been suggested (Shami et 
al., 2015).  
The top fifth canonical pathway in mdx/P2rx7
-/-
 compared with mdx was the 
LXR/RXR activation pathway. Again, 17 out of 81 genes were altered (Table 4.2). 
Liver X receptors (LXRα and LXRβ) are nuclear receptors that regulate the 
transcription of several genes involved in cholesterol and bile acid metabolism 
(Willy et al., 1995). These receptors form heterodimers with retinoid X receptor 
(RXR) and act in absorbing and metabolising cholesterol when activated by 
oxysterols (Willy and Mangelsdorf, 1997). Additionally, these receptors can make 
complexes with peroxisome proliferator-activated receptor (PPAR), and together 
involved in the storage and degradation of fatty acids (Willson et al., 2000; Ide et al., 
2003; Yue et al., 2005). It has been found that the PPARγ-LXR-complex plays an 
important role in regulation of the macrophage-lipid-uptake (Mangelsdorf et al., 
1995; Chawla et al., 2001). The best investigated lipid is the low-density lipoprotein 
(LDL), which is oxidised to form oxLDL by either enzymatic activity 
(myeloperoxidase) or non-enzymatic activity (superoxide, hydrogen peroxide, and 
nitric oxide) (Miller et al., 2011). Macrophages recognise the oxidised epitope of 
oxLDL via scavenger receptors (SR-A1, SR-A2, SR-B1, PSOX, MARCO, LOX1 
and CD36) and degrade the oxLDL (Miller et al., 2011). However, expression of the 
macrophage-CD36 receptor leads to the accumulation of cholesterol in macrophages 
and the conversion to crystals, which in turn, activates the pro-inflammatory 
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response and the development of atherosclerotic lesions (Stewart et al., 2010; Sheedy 
et al. 2013). 
IPA analysis of RNA-Seq datasets detected the top ten down-regulated genes in 
mdx/P2rx7
-/-
 compared with mdx (Table 4.3): Cxcl6, Krt14, Elvol4, Dsp, Dsc3, 
Krt17, Krt79, S100a8, S100a9 and Slfn12l. Chemokine (C-X-C motif) ligand 6 
(Cxcl6) regulates the migration of leukocytes (neutrophils) (Ruth et al., 2006; Mittal 
et al., 2008) and it has been observed in regeneration areas of injured skeletal 
muscle (Iwasaki et al., 2013). Keratin 4 (Krt14) is produced from keratinocyte cells 
and together with KRT5 creates keratin intermediate filaments, which form 
cytoskeletal networks associated with adhesion, migration, and metabolism 
(Windoffer et al., 2011). Recently, this gene has been linked to bladder cancer 
(Papafotiou et al., 2016). Keratin 79 (Krt79), an intermediate filament protein, 
encodes epithelial keratin located in skeletal muscle, skin and scalp (Veniaminova et 
al., 2013), keratin17 (Krt17) is expressed by hair follicles, nails and palm skin and 
regulates the growth and survival of keratinocytes (Tong and Coulombe, 2006; Kim 
et al., 2006; Depianto et al., 2010); additionally, it has been detected that keratin 17 
is involved in wound healing (Than et al., 2012). While keratins are the most 
common contaminant in these studies, these were mouse keratins, so it was not 
considered contamination with human skin samples. However, it cannot be excluded 
that this difference was caused by a variable contamination of muscle samples with 
mouse skin, especially that the expression of keratins in striated muscles has not 
been described. On the othe hand, the expression of keratin genes in a wide range of 
non-epithelial cells such as lymph nodes, smooth muscle, bone marrow cells, blood 
mononuclear cells and different types of cancers has been demonstrated (Traweek et 
al., 1993). Elongation of very long chain fatty acids protein 4 (Elvol4) is localised in 
the endoplasmic reticulum, where it participates in the biosynthesis and 
transportation of the long chain of fatty acid (Agbaga et al., 2014). It has been found 
that mutations in this gene lead to Stargardt-like macular dystrophy (STGD3) 
(Strom et al., 2012; Logan and Anderson, 2014). The desmoplakin  (Dsp) gene 
encodes the desmoplakin protein, which is found in cells rich in desmosomes that 
are responsible for holding onto neighbouring cells. Weiske et al. (2001) found that 
the desmoplakin protein is cleaved during apoptosis by caspases, leading to the 
disarrangement of the desmosome and fragmentation of connections between cells. 
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Desmocollin (Dsc3) encodes the desmocollin protein, which is also one of the 
desmosome structural components and is required for its formation (Petrof et al., 
2012). S100 calcium binding protein A8 and 9 (S100a8) and (S100a9) are expressed 
in the cytoplasm and nucleus of a wide variety of cells. They are found as natural 
ligands of CD69 to support Treg function (Lin et al., 2015). In addition, these genes 
trigger the immune response in atherosclerosis and therefore emerge as a biomarker 
for human atherosclerosis (Oesterle and Bowman, 2015). Finally, schlafen family 
member 12 like  (Slfn12l) has been found to be stimulated in response to elevated 
IFN-α, which is activated by monocytes, T-cells and dendritic cells (Puck et al., 
2015).  
The analysis of RNA-Seq using IPA also indicated the top ten most up-regulated 
genes in mdx/P2rx7
-/-
 compared to mdx (Table 4.3): Pttg1, Gpnmb, Tesc, Spp1, 
Col28a1, Atp6v0d2, Dbp, Mybphl, Sec14l2, and Znf676. PTTG1 pituitary tumor-
transforming 1 (Pttg1) has emerged as a hepatic pro-fibrosis mediator in the injured 
liver of animal models (Buko et al., 2015). Its upregulation is therefore contrary to 
the anti-fibrotic effect of P2RX7 ablation. Moreover, it is in an anaphase-promoting 
complex, during cell division and interacts with dlk1 (pref-1), which has a role in 
wound healing and inhibits adipogenesis. Interestingly, Dlk1 is significantly 
downregulated in mdx/P2X7
-/-
 compared to mdx.  On the other hand, transmembrane 
glycoprotein NMB (Gpnmb) is expressed by phagocytic macrophages infiltrating 
injured livers to stimulate liver repair via MMP13 signalling activation (Kumagai et 
al., 2015). It is also shown that the overexpression of Gpnmb protects muscle against 
damage and fibrosis (Furochi et al., 2007). Tescalcin (Tesc) is a Ca
2+
-binding 
protein, which acts as a negative regulator of cardiomyocyte hypertrophy (Kobayashi 
et al., 2015). Secreted phosphoprotein 1 (Spp1) encodes for osteopontin (Opn) 
intracellular protein which behaves as a Th1 cytokine that regulates the expression of 
Ifnγ and Il12. The major source of this protein is the myoblasts of dystrophic muscle, 
suggesting the role of Opn in the regulation of inflammation and the early stages of 
regeneration (Wang and Denhardt, 2008; Uaesoontrachoon et al., 2008). It has been 
considered a biomarker of cardiovascular disease and is also found at high levels in 
mice with dilated cardiomyopathy (Wang and Denhardt, 2008; Renault et al., 2010).  
Collagen type XXVIII alpha 1 chain (Col28a1) encodes a novel protein belonging to 
the von Willebrand factor A (VWA) domain-containing protein, which is associated 
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with the formation of collagen filaments (Veit et al., 2006). ATPase H+ transporting 
V0 subunit D2 (Atp6v0d2) is an osteoclast-specific proton pump component. It is 
involved in regulation of the osteoblast cell fusion during differentiation (Wu et al., 
2009). Its upregulation is interesting given the improved bone phenotype in 
mdx/P2RX7
-/-
 mice. D-Box binding PAR BZIP transcription factor (Dbp) encodes a 
protein that is able to bind with DNA and regulates the expression of Cyp2a4 and 
Cyp2a5 in the mouse liver (Lavery et al., 1999). Mutations in the myosin binding 
protein H like (Mybphl) gene have been linked with hypertrophic cardiomyopathy 
(Harris et al., 2011). Multiple functions for SEC14 like lipid binding 2 (Sec14l2) 
have been reported, such as those involved in cholesterol biosynthesis, vitamin E 
degradation and regulation of the PI3K/Akt pathway (Mokashi and Porter, 2005; Ni, 
et al., 2005). Zinc finger protein 676 (Znf676) gene encodes zinc finger proteins. It 
interferes with the expression of telomere gene regulator and also stabilises the G-
quadruplex structure, which sequesters the 3ˈend of telomeric DNA to prevent 
elongation (Mangino et al., 2012). Its increased expression is interesting considering 
the abnormalities in telomerase regulation described above. 
4.4.3  Ablation of P2RX7 receptor reduces the immune response and 
inflammation in mdx mice: RNA-Seq data analysis  
The analysis of RNA-Seq using the GSEA program showed that the inflammation-
regulated genes, fibrosis and chemotaxis of immune cells were the most altered in 
mdx/P2rx7
-/-
 compared with mdx (Figure 4.4). There are a number of possible 
reasons for not detecting the same top altered genes in the RNA-Seq analysis using 
both IPA and GSEA. The differences in the applied threshold to reduce the false 
positive differential expression of genes may reduce the inclusion of common genes. 
In addition, different statistical methods are used in these programs to detect the 
differentially expressed genes; for example, IPA uses the Fisher’s exact test (FET) P-
value while GSEA uses the Kolmogorov-Smirnov test (Clark and Ma’ayan, 2011; 
Krämer et al., 2014).  
GSEA showed the down-regulation of 12 out of 32 genes involved in the regulation 
of cytokine functions. The role of chemokines in trafficking immune cells in normal 
and inflammatory conditions is well established (Kim, 2004; McGovern and Wilson, 
2013). Their function goes further than attracting immune cells, however, as they are 
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important actors in muscle regeneration. For example, treating myoblasts with 
monocyte chemoattraction protein-1(MCP-1) and macrophage inflammatory protein-
1 (MIP-1) induces their proliferation via the ERK1/2 signalling pathway (Yahiaoui et 
al., 2008). Interestingly, Ccl2 (up-regulation in mdx and down-regulation in 
mdx/P2rx7
-/-
 was observed here) has a dual function, driving immune cells to the site 
of the injured muscle and recruiting the proliferation of satellite cells (Warren et al., 
2005; Yahiaoui et al., 2008). Several chemokines have been demonstrated to be up-
regulated in DMD and mdx Ccl3, Ccl5, Ccl7, Ccl8, Ccl9, Ccl11, Ccl17, Cxcl1, 
Cxcl2, Cxcl3, Cxcl8, Cxcl10, Cxcl11 and Cxcl12 (most of these were up-regulated in 
mdx and down-regulated in mdx/P2rx7
-/- 
here). However, in the normal muscle, the 
expression of the chemokines is only slightly detectable (Porter et al., 2003; 
Demoule et al., 2005; Pescatori et al., 2007; Abdel-Salam et al., 2010; De Paepe et 
al., 2012).  
The majority of innate immune response-regulated genes that are down-regulated in 
mdx/P2rx7
-/-
 were associated with the stimulation of macrophage and neutrophil 
infiltration into muscle tissue. These genes were ranked from top to bottom as 
follows: Mx2, Lcn2, Rab27a, Mx1, Tlr9, Cd86, Gbp6, Ccl2, Il12b, Lag3, Masp1, 
Ccr1, Tlr3, Unc13d, Ereg, Gbp5, Irf7, Stx11, Rsad2, Cfb, Tnip1, Ddx58, Ripk2, Ifih1,  
VNN1, Klrk1, Tmem173, Myd88, Pik3ap1, Ifitm3, Lsm14a, Adam8, Clec5a, Gbp2, 
Pdpk1, Tlr7, Cited1, Peli1 and Stat11. For example, the Lcn2 is encoded by immune 
cells and found to be involved in muscle differentiation (Zerega et al., 2000). Klrk1 
is expressed by all natural killer (NK) cells and T-cells and promotes autoimmune 
disease (Guerra et al., 2013). 
The major advantage of using these computational programs is capturing the 
biological interaction between genes and providing a direct link for each molecule, 
representing the name, location, function and the references (Jiménez-Marín et al., 
2009; Jin et al., 2014). However, some limitations have been observed due to the use 
of these programs in the analysis of the large datasets like these of RNA-Seq (St 
John and Johnson, 2000). Firstly, the cut-offs are selected by the user, which can 
introduce bias. For example, some molecules do not pass the cut-off even when they 
are statistically significantly different, which means that the final pathway figure 
contains only a few activated molecules. Secondly, the direction of function is 
determined by threshold setting. Further limitations have been noticed about IPA that 
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there are a huge number of regulatory molecules in some pathways, which makes the 
molecules in the exported figures very small and hard to distinguish. Furthermore, 
the capacity of uploaded raw genes is limited to no more than 8000 genes, and 
reducing some of these genes may result in misinterpretation of important pathways 
that directly correlate to the disease. Therefore, the decision was taken to draw the 
pathways manually based on a qPCR layout array from Qiagen. The first choice was 
the inflammatory response and autoimmunity qPCR array.  
The absence of dystrophin is the primary causative agent of DMD. However, the 
exacerbation of the disease is determined according to the secondary mechanism 
(inflammatory response to the myofibre damage). Spencer and Tidball (2001) 
reviewed the important role of cytotoxic T-lymphocytes, helper T lymphocytes and 
myeloid cells (macrophages, neutrophils, eosinophils and mast cells) in progression 
of DMD. Not only the immune cell, but also the cytokine (TNF, IFNγ and TGFβ) 
and complement system (C8 and C9) contribute to the dystrophinopathy. The 
histological observations support the hypothesis of the damage-associated with 
invading immune cells. It has been noticed that the early infiltrating immune cells in 
DMD display similarities with those that invade in the inflammatory muscle disease. 
The depletion of myeloid cells, lymphocytes or inflammatory mediators (IFNγ) 
causes a great reduction in muscle pathology (Spencer et al., 2001; Wehling et al., 
2001; Wehling-Henricks et al., 2008; Villalta et al., 2011). Furthermore, treating 
patients with immunosuppressive drugs reduces the expression of cellular adhesion 
molecules that contributes to trafficking of the immune cells to the site of 
inflammation (Wehling-Henricks et al., 2004; Hussein et al., 2006). However, some 
of these molecules have dual functions in DMD. For example, IL6 is produced from 
infiltrating macrophages (M1) in the early stage of disease and is involved in the 
degeneration process, while in later stages of DMD, this molecule promotes muscle 
growth and myogenesis via activation of satellite cells proliferation (Serrano et al., 
2008; Guerci et al., 2012). Therefore, non-selective attenuation to the immune cells 
may affect the regeneration process. 
 Dystrophin-deficient muscle releases high levels of ATP, which are sufficient to 
stimulate large pore formation of the P2RX7 receptor. In response to ATP, the 
P2RX7 receptor expressed on most immune cells stimulates inflammation by 
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releasing pro-inflammatory cytokines. Therefore, deletion of the P2RX7 receptor 
may have a significant impact on reducing the disease progression. Interestingly, in 
mdx/P2rx7
-/-
, a significant decrease in inflammatory chemokines that regulate 
inflammation has been found. In addition to the chemokines, Tlr9, Csf1, Il1r1, Cd14 
and myd88 were also down-regulated in mdx/P2rx7
-/-
. The, GM-CSF and M-CSF 
(Csf1) cytokines enhance macrophage numbers and regulate their survival, 
proliferation and differentiation in inflammatory conditions. Fleetwood et al. (2007) 
demonstrated that impaired M-CSF signalling reduces M2, resulting in a significant 
disruption of regeneration and muscle growth. Tlr9 encodes for a protein that is 
released from dystrophic muscle as a danger signal and binds with its receptor 
located on muscles and immune cells to stimulate the innate immune response 
(Henriques-Pons et al., 2014). These authors found that targeting Tlr7/9 reduces 
dystrophic muscle inflammation, degeneration and regeneration in mdx mouse. It has 
been shown that CD14 acts as a co-receptor of TLR4 to detect pathogen-associated 
molecules; it is expressed on macrophages and neutrophils to mediate the release of 
IL6 and IL10 (Estruch et al., 2013).  
To confirm the major changes in inflammatory genes obtained from RNA-Seq 
analysis and as a result of ablation of the P2RX7 receptor, the inflammatory 
pathways qPCR panel array was used. Importantly, P2rx7, Cx3cr1, P2rx4, Rela, 
Rorc, Bmp7 and Foxp3 were normalised toward the wild-type phenotype in 
mdx/P2x7
-/-
 compared to mdx. These genes were re-analysed by qPCR using 
TaqMan probes. The analysis of these experiments indicated that the blockage of 
P2RX7 receptor ameliorates the mdx dystrophic inflammation.  
These findings also showed the down-regulation of Tnf in mdx/P2rx7
-/-
 in 4 week-
old and 18 month-old mice, indicating a decrease in the number of stimulated 
macrophages and thereby muscle damage. TNF is a pro-inflammatory cytokine that 
is able to stimulate macrophages and neutrophils to produce other Th1 cytokines as 
well as high levels of TNF. The high level of TNF in early stages of inflammation 
indicates their role in lysis and damage to muscle fibres (Grounds and Torrisi, 2004). 
However, Tnf expressed in muscle fibres in the late stage of injury modulates muscle 
regeneration as it influences satellite cell proliferation via three pathways: NF-κB, 
p38 MAPK and JNK (Yuan et al., 2001).  
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The results from this study detected the down-regulation of Ccl2 in mdx/P2rx7
-/-
 
compared with mdx, suggesting a decrease in macrophage accumulation. The role of 
the CCL2 chemokine and its receptor in regeneration has been implicated. Ccr2 is 
expressed on both satellite cells and macrophages and signalling through this 
receptor mediates the regeneration events (Warren et al., 2005). A deficiency of 
Ccr2 reduces the macrophage population in normal injured muscle and impedes 
successful regeneration. In addition, muscle of Ccr
-/-
 is characterised by impaired 
regeneration and infiltration of fat tissue. However, this situation is different in 
DMD, in where levels of inflammatory macrophages are chronically elevated. 
Mojumdar et al. (2014) demonstrated that CCL2 is associated with the progression 
of muscle degeneration and interfering with CCR2 functions reduces inflammatory 
macrophages and recruits muscle regeneration.   
The up-regulation of Foxp3 and Il12a transcript levels at both 4 weeks and 18 
months has been demonstrated in this study, suggesting a shift in the Treg cells. 
Foxp3 is a transcription factor that regulates the development and function of Treg 
cells (Josefowicz et al., 2012). Il12a is required for Treg maximal activity and it is 
highly expressed by mouse Foxp3
+
 Tregs (Collison et al., 2007). Treg cells are 
immunosuppressive lymphocytes, which modulate DMD progression by regulating 
the balance between Th1 and Th2 immune response (Villalta et al., 2014). High 
levels of IL10 are secreted, which eliminates the M1 and resolves the IFNγ-
dependent T-cells (Koch et al., 2009). In addition to chronic inflammation, Tregs 
have the capacity to maintain tolerance to self-antigens during the course of injury 
(Bennett et al., 2001 Kim et al., 2007). The lower tolerance to self-antigens in the 
DMD and mdx has been demonstrated (Villalta et al., 2014). Finally, their function 
extends beyond supressing immunity as it is regulating muscle regeneration by 
expressing amphiregulin, which is known to promote satellite cell differentiation 
(Burzyn et al., 2013). 
Despite the decrease of inflammation found here and in our previous study 
(Sinadinos et al., 2015), 4 week-old mdx/P2rx7
-/- 
mice displayed the up-regulation of 
Ifnγ transcript levels. This finding may suggest the essential role of Ifnγ in 
regeneration and also as an anti-fibrosis agent. Ifnγ is a pro-inflammatory cytokine 
which is considered a strong inducer of type 1 macrophages (Villalta et al., 2011). It 
is expressed from macrophages, natural killer cells, T-cells and myoblasts shortly 
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after muscle injury. However, a sufficient level of Ifnγ transcript is also required for 
the early stages of regeneration and Ifnγ declines when the regenerative muscle 
transitions from proliferation to differentiation (Cheng et al., 2008). The same study 
demonstrated that blocking the IFNγ receptor decreases the proliferation and 
regenerates fibres dependent on IFNγ. Furthermore, it has been demonstrated that 
injecting IFNγ for 1-2 weeks reduced fibrosis and improved the healing of injured 
skeletal muscle, suggesting an anti-fibrotic function for this cytokine (Foster et al., 
2003). 
 The analysis of qPCR results in TA muscles from 18 month-old mice (Figure 4.13) 
showed similar alterations in key inflammatory factors (Tnf, P2rx4, Foxp3 and Il12a) 
identified in 4 week-old muscles. Therefore, these results suggest that ablation of the 
P2RX7 receptor has long term anti-inflammatory effects in mdx mice. 
It has been reported previously that P2rx4 is a macrophage marker (Yeung et al., 
2004). Here, the quantitative observations using both mRNA transcript (4 week- and 
18 month-old) and protein levels (4weeks) indicated the reduction in the macrophage 
population in mdx/P2rx7
-/-
 mice. Since P2RX4 activation during the acute stage of 
disease is linked to inflammatory responses (Yeung et al., 2006) this receptor may 
represent the activation of M1. Regarding the mechanism by which activated P2RX7 
contributes to the release of pro-inflammatory cytokines from M1, and because the 
receptor is knocked-out in mdx/P2rx7
-/-
, the reduction in macrophage load indicates 
the inflammatory decline which correlated with decreased pro-inflammatory 
cytokines. Macrophages (M1) are the first population to invade an injured muscle 
due to the fact that they are elicited by pro-inflammatory cytokines (IFNγ and TNFα) 
and are involved in muscle degeneration through the production of NO and other 
pro-inflammatory cytokines such as IL6, IL1β, IFNγ and MCP-1 (Villalta et al., 
2009). The reduction in total macrophages (F4/80) was also found. Wehling et al. 
(2001) treated mdx mice with anti-F4/80 to reduce muscle degeneration. 
Nevertheless, the long-term depletion of all macrophages has a negative impact on 
regeneration. In the later stage of disease another population of macrophage M2 
(F4/80
+
/CD68
low
/CD206
+
) that promotes muscle regeneration shifts to become the 
predominant one (Tidball et al., 2014). The M2 macrophages participate in the Th2 
immune response and can be classified into three types: M2a is induced by IL4 and 
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IL13, M2b is enhanced by toll-like receptors and M2c is activated by IL10. Both 
M2a and c have significant roles in repairing the damaged muscle and removing 
debris via releasing IL10, IL1α, IL4 and arginase (Villalta et al., 2009). Sinadinos et 
al. (2015) improved the potential shift towards M2 in mdx/P2rx7
-/-
 animals when 
they tested the ratio of total macrophages to M2 (F4/80 to CD163). 
It has been recently shown by our group that activation of the P2RX7 receptor leads 
to the autophagy–mediated cell death, contributing to a loss of muscle fibres and 
satellite cells required for regeneration, while the inhibition of P2RX7 blocks this 
process (Young et al., 2015). 
 The results of this study demonstrated a decrease in the LC3BII protein level (the 
autophagy hallmark) in mdx/P2rx7
-/-
 mice measured by western blotting and 
immunofluorescence in GC from 4 week-old mice. 
Autophagy is the process of engulfing cytoplasmic constituents by double-membrane 
vesicles and then degradation of the components via the lysosome. Autophagy plays 
an essential role in physiological mechanisms (Mizushima et al., 2002). It hydrolyses 
misfolded proteins and degrades damaged organelles (Glick et al., 2010). As a result 
of inflammation in dystrophic muscles, the organelles are damaged due to apoptosis 
or necrosis and therefore produce debris. Under acute damage conditions, initiation 
of the regeneration process requires the removal of all damage by autophagy (Smith 
et al., 2008). However, in spite of the housekeeping role in debris clearance, 
excessive autophagy causes muscle wasting (Sandri, 2010). Therefore, inhibiting 
autophagy in the early stages of disease could prevent muscle wasting (Masiero et 
al., 2009).   
4.4.4 Ablation of P2RX7 receptor ameliorates the NF-кB signalling in mdx  
While the qPCR analysis (Table 4.4) indicated the up-regulation of Rela transcripts, 
one of NF-kB components (Acharyya et al., 2007), in mdx/P2rx7
-/-
 compared with 
mdx animals, the RNA-Seq analysis indicated that the NF-кB pathway was down-
regulated in mdx/P2rx7
-/- 
and the
 
majority of genes controlled by NF-κB and which 
were also down-regulated in mdx/P2rx7
-/-
 included those for inflammatory 
mediators, cytokines and chemokines, stress response, type I interferon responsive 
genes and anti-apoptosis genes. These results indicate that targeting the P2RX7 
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receptor improves muscle pathology and reduces the inflammation via this 
mechanism. 
NF-кB, a transcription factor, is located in the cytoplasm as inactive form. Kumar 
and Boriek (2003) found that the absence the dystrophin, influx of Ca
2+
 and 
production of free radicals in DMD stretched muscle, leading to the activation of 
NF-кB. Consequently, TNF or IFNγ bind to the NF-кB receptor, followed by the 
activation of IKKγ to stimulate the formation of an active form of NF-кB; the later 
translocates to the nucleus and becomes involved in the transcription of several 
genes (Baldwin, 2001). The high expression level of NF-кB has been detected in TA, 
GC and diaphragm muscles of mdx (Porter et al., 2002; Grounds and Torrisi, 2004; 
Ghosh et al., 2007). It regulates the expression of numerous components of the 
chronic inflammatory such as cytokines and chemokines (Karin and Delhase, 2000). 
For example, in DMD, different cytokine and chemokine molecules that have 
important roles in muscle damage, such as IL8, CCl2, MMP9, iNOS and COX2, 
contribute to the activation of NF-кB (Lundberg et al., 1995; Kherif et al., 1999; 
Watanabe, 2001; Acharyya et al., 2007; Messina et al., 2011). It has been shown that 
inhibition of the NF-кB assembly improves the pathology of mdx by reducing the 
infiltration of macrophages and stimulating the formation of new fibres (Acharyya et 
al., 2007). Therefore, its downregulation by P2RX7 inhibition might be a good 
therapeutic target.  
4.4.5 Mitochondrial dysfunction and the apoptosis are not normalised upon 
ablation of P2RX7 
Previous studies, also from our laboratory (Onopiuk et al., 2009; Kelly-Worden and 
Thomas, 2014; Timpani et al., 2015), showed that DMD gene mutations affect 
mitochondrial structure and function in myoblasts and muscles. The investigation of 
differential gene expression in mdx muscle determined that, in general, most of the 
genes involved in the regulation of mitochondrial functions including apoptosis, the 
transport system, mitochondrial fusion and fission and membrane polarisation in 
mdx were altered, indicating mitochondrial dysfunction It is notable that in addition 
to the impairment of mitochondrial function in mdx, results of this study also showed 
that ablation of the P2RX7 receptor did not improve this mitochondrial abnormality. 
Among all of the altered genes in mdx, only two genes were statistically significantly 
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decreased in mdx/P2rx7
-/-
: Bcl2l1 and Slc25a25. Bcl2l1 belongs to the Bcl2 family 
and acts as apoptosis regulator (Ealovega et al., 1996), while Slc25a25 gene encodes 
a protein located in the inner mitochondrial membrane and acts as a metabolite, 
nucleotide, and cofactor transporter (Anunciado-Koza et al., 2011).  
The mitochondrial pathway also showed the down-regulation of Mitofusin2 (Mfn2) 
expression in mdx and there was no significant difference in mdx/P2rx7
-/-
. Because 
the importance of this gene lies in regulating many aspects of mitochondrial 
function, including mediating the mitochondrial outer membrane fusion, regulating 
the concentration of cellular calcium, cell proliferation and the initiation and 
formation of autophagosomes (autophagic process) (Chen et al., 2003; Zhao et al., 
2012; Ding et al., 2015), therefore the analysis of this gene using qPCR was 
conducted. The result confirmed up-regulation of this transcript in mdx and no 
significant difference in mdx/P2rx7
-/-
.  
Since the mitochondrial function showed the elevation of apoptosis in mdx, and 
because apoptosis is one of the most important downstream signals that is altered as 
a result of the absence the dystrophin, we decided to study the apoptosis pathway 
based on RNA-Seq datasets. Analysis of the apoptosis pathway parallels 
mitochondrial dysfunction; the absence of dystrophin induces apoptosis in mdx mice 
and the ablation of P2RX7 does not reduce this pathological pathway as a whole. 
The expression levels of a few genes that regulate apoptosis were altered in 
mdx/P2rx7
-/-
. However, both the pro-apoptosis regulators Tnfsf10 and Diablo and the 
anti-apoptosis regulator genes Bcl2l1 and Bag3, and the Death domain receptors: 
Tnfrsf11b and Tnfrsf1a, all showed down-regulation in mdx/P2rx7
-/-
.  
The mitochondrion is a cytoplasmic organelle, which also functions in providing 
living cells with the required biological energy (McBride et al., 2006). Mitochondria 
maintain Ca
2+ 
ion concentrations in the cell. Increasing Ca
2+
 concentrations inside 
the cell enables the mitochondria to produce more ATP through respiration. 
However, the overloading of cytoplasm with Ca
2+
 ions promotes the mitochondrial 
permeability pore formation and mitochondrial swelling, inducing cytochrome C-
induced apoptosis and the apoptotic factors that cause morphological and 
biochemical changes such as DNA fragmentation and membrane blebbing leading to 
cell death via apoptosis (Millay et al., 2008; Santo-Domingo and Demaurex, 2010; 
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Bhosale et al., 2015). It seems that caspase 3 is the main effector in DMD muscle 
(Sandri et al., 2001), which is also showed to be up-regulated in mdx in our dataset.  
In dystrophic muscle, deficiency of the dystrophin is responsible for overloading the 
sarcoplasm with Ca
2+ 
ions. It has been noticed that mitochondrial dysfunction in 
dystrophic muscle and myoblasts results in an overload of Ca
2+ 
ions, and reduces 
oxygen consumption, decreases ATP production, and increases the mitochondrial 
membrane potential and the ROS production (Onopiuk et al., 2009; Schuh et al., 
2012; Rybalka et al., 2014). Kuznetsov et al. (1998) reported that the oxidation and 
phosphorelation processes in mitochondria are decreased in dystrophic muscle 
overloaded with Ca
2+
. Altogether, these induce apoptotic and necrotic pathways, 
which are considered a major cause of cell death. Recently, the impaired 
mitochondrial function in mdx has been linked to the reduction of neuronal nitric 
oxide synthase (nNOS) that is stabilised by DAPC. The nNOS converts the L-
arginine to NO, which is involved in different muscular functions including the 
mitochondrial function and biogenesis via activation of the MAPK (Hafner et al., 
2016).   
4.4.6 Ablation of P2RX7 does not correct with the adherens junctions 
abnormality 
The RNA-Seq analysis showed that several genes associated with regulation of the 
adherens junction (AJs) were up-regulated in mdx compared to C57/BL10, while this 
pathway was not normalised in mdx as a result of ablation of the P2RX7 receptor. 
The IPA analysis was in agreement with the results of the study by Tian et al. 
(2014), who found that epithelial AJs signalling is a top altered pathway in DMD, 
resulting from analysis of the human microarray data by IPA. Adherens junctions are 
protein complexes in a highly regulatable structure, which link cells together and 
regulate their contact by strong mechanical attachments. The AJs connect different 
cell types, in epithelial and endothelial tissue. Additionally, the cluster of AJs merges 
to form a belt surrounding the cardiac muscle tightly to support the expansion and 
contraction of the heart (Harris and Tepass, 2010). Besides linking adjacent cells, 
other interesting functions of this complex have been discovered, such as 
involvement in transducing cellular signals in proliferation and differentiation (Meng 
et al., 2009). The AJs complex consists of two protein superfamilies E-cadherin and 
181 
 
catenin; the latter contains three members: p120-catenin, β-catenin and α-catenin 
(Hartsock et al., 2008 Niessen et al., 2008). A cluster of the transmembrane protein 
(E-cadherin) binds with cytoplasmic catenins to form bridges that link bundles of 
actin filaments of neighbouring epithelial cells to the cytoskeleton (Yonemura et al., 
1995; Etienne-Manneville, 2011). 
4.4.7  Absence of DMD result in global changes of telomerase and cell cycle 
regulators  
It is well established that the satellite cell exhaustion in DMD is responsible for the 
impaired regeneration (Luz et al., 2002). The exhaustion of satellite cells may be 
linked to telomerase activity being different in humans and mice (Sacco et al., 2010). 
In stem cells, maintaining the length of telomeres is controlled by the enzyme 
telomerase, which adds the uncopied nucleotides of the telomere to the chromosome 
ends in each cell division. Because the unidirectional activity of the DNA 
polymerase enzyme, telomeres cannot be replicated during cell replication, which 
causes telomere shortening each time a cell divides (Greider and Blackburn, 1985). It 
has been shown that the telomere length maintains stem cell proliferation and 
prolongs regeneration capacity. Humans have short telomeres, 5-15 kb, while mdx 
mice have longer telomeres of about 40 kb (Meyne et al., 1989). The longer telomere 
in mdx mice has been used to explain why these mice exhibit a milder muscle 
phenotype and prolonged successful regeneration cycles (Kipling and Cooke, 1990).  
Interestingly, the demonstration that the negative telomerase regulators Pml and Pif1 
were significantly up-regulated in mdx and down-regulated in mdx/P2rx7
-/-
mice, as 
well as the expression of positive kfl4 to be down-regulated in mdx and up-regulated 
in mdx/P2rx7
-/- 
mice, suggest both the abnormality of telomerase regulators in mdx 
and restoration in mdx/P2rx7
-/-
. This novel finding was identified by RNA-Seq and 
the expression level of Pml was further confirmed using qPCR in 2 and 4 week-old 
TA muscles. Furthermore, there was no statistically significant difference in 2 week-
old TA muscles, whereas the analysis of 4 week-old mice was concurrent with RNA-
Seq results. This result suggests that the shortening of satellite cells telomere in mdx 
and this shortening may start when the satellite cells proliferate in degenerating 
muscle. This agreed with the study by Turk et al. (2005), which mentioned that 
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regeneration events are initiated in mdx mice at the age of 6 weeks and continue to 
undergo repeated cycles of degeneration-regeneration until 12 weeks. 
The abnormality in expression of telomerase regulator genes led to examining the 
expression of genes regulating the cell cycle and to check whether the cell cycle is 
activated in satellite cells and whether this activation leads to the exhaustion of 
satellite cells in mdx. Importantly, RNA-Seq data demonstrated the activation of the 
cell cycle pathway in mdx compared with C57/BL10 and that also led to testing 
whether this alteration in regulatory genes of the cell cycle is related to muscle cells 
or infiltrating immune cells. Interestingly, the qPCR analysis showed the up-
regulation of cell cycle genes in myoblasts and myotubes, suggesting that the altered 
cell cycle in muscle is related to the myogenic cells and not to the environment of 
dystrophic muscle, such as infiltrating immune cells. Additionally, this finding 
indicating the over activation of satellite cells in the acute stage of disease, may 
explain the mild phenotype in mdx compared with DMD. Combined with the 
abnormality of telomerase regulator genes, the continuous over activation of satellite 
cells may lead to their exhaustion and impairment of regeneration. Importantly, the 
over-activation of cell cycle regulatory genes in myoblasts may also lead to their 
exhaustion and loss, and the early defect in satellite cells during the embryogenesis 
could affect muscle development. All these indicate that the pathology of DMD 
starts as early as in stem cells and that the primary dystrophin mutation itself appears 
sufficient for the disease progression without any subsequent membrane instability. 
The RNA-Seq results of the cell cycle analysis showed alteration of only two genes: 
Cdk1 (negative regulator of the cell cycle) (Enserink and Kolodner, 2010) and Slfn1 
(inhibiting cyclin D1, leading to keeping the cell cycle arrested in G1) (Brady et al., 
2005)  in mdx/P2rx7
-/-
 compared with mdx, suggesting that the cell cycle is not 
affected by P2RX7 ablation, unlike many other processes described earlier. 
The cell cycle is a sequence of events where a mature cell divides into two daughter 
cells. In eukaryotes, the cell cycle consists of four major phases; G1, S, G2, and M. 
DNA is synthesised during the S phase, while the M phase corresponds to mitosis, in 
which the chromosomes are separated between two nuclei, followed by cytoplasm 
separation in a process called cytokinesis. The two gap phases, G1 and G2, separate 
the S and M phases and prepare the cell for upcoming events (Lodish et al., 2000). 
The cell cycle progression depends on the activity of Cyclin-Dependent Kinases 
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(CDKs), which are controlled by positive regulators (cyclins) and negative regulators 
(CKI). A genetic mutation in one or more of these regulators results in uncontrolled 
cell growth and division, leading to carcinogenesis (Lim and Kaldis, 2013).  
Skeletal muscle consists of large multinucleated fibres, which are unable to divide. 
However, muscle has stem cells (satellite cells) located underneath the basal lamina, 
which are responsible for maintaining and repairing the injured muscle fibres 
(Mauro, 1961). In adult muscle, the satellite cells are under mitotic arrest 
characterised as Pax7
+
/MyoD
- 
phenotype
 
(Schultz et al., 1978; Cornelison and Wold, 
1997). However, when muscle fibres are injured and infiltrated by immune cells, 
both muscle and immune cells recruit satellite cells to divide and proliferate 
(McGeachie and Grounds, 1987; Tatsumi et al., 1998; Wozniak et al., 2007; Lu et 
al., 2011). Activation of satellite cells can go further than the site of injury, for 
example, satellite cells can be activated and migrate between myofibres and even the 
muscle barriers (Watt et al., 1987). The proliferating myogenic precursor cells or 
myoblasts, characterised as Pax7
+
/MyoD
+
, enter the differentiation stage to form 
myotubes under the control of Myf5 before fusing to form myofibres (Dhawan and 
Rando, 2005; Gayraud-Morel et al., 2007). During the differentiation stage, some of 
the myogenic precursor cells marked by Pax7
+
/MyoD
–
 expression return to the rest 
phase to maintain the satellite cell population. The division occurs in two patterns: 
asymmetric cell division, in which one of the stem cells is divided into one stem cell 
and one active cell ready for differentiation (Zammit et al., 2004; Shinin et al., 
2006), and symmetric division, where the parental stem cell is divided into two 
mitotically quiescent stem cells (Dumont et al., 2015).  
In DMD, even though regeneration is activated, newly generated fibres also lack 
dystrophin, leading to constant cycles of degeneration-regeneration. After many 
cycles of regeneration, the satellite cells lose their capacity for regeneration and 
become exhausted. The exhustion and loss of the capacity of satellite cells to repair 
the damage could be explained by (i) that telomere lengthening in mdx and DMD is 
altered as a result of abnormalities in telomerease control genes. (ii) That cell cycle is 
altered in dystrophic muscle cells and (iii) That both of these are inherent, 
autonomous abnormalities in muscle cells caused by Dmd mutations and not the 
result of external factors, for example inflammation.   
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4.4.8 The early fibrotic signature is reduced by P2RX7 ablation 
One of the interesting findings of RNA-Seq analysis was the alteration of genes 
related to the fibrosis in mdx/P2rx7
-/-
 compared with mdx, when the dataset was 
analysed by GSEA and IPA. In IPA, the result was presented as the hepatic 
fibrosis/hepatic stellate cell pathway (Table 4.3). This pathway is liver-specific, but 
the significant enrichment of this pathway in TA may relate to the absence of 
separately annotated muscle fibrotic pathways in IPA. Furthermore, most of the 
regulator genes of fibrosis are similar in different tissues. Therefore, the hepatic 
fibrosis/hepatic stellate cell pathway is considered here as a general fibrosis pathway. 
This was in agreement with the study of Chaillou et al. in 2013, who found the 
hepatic fibrosis pathway to be one of the top pathways in hypertrophic skeletal 
muscle. Fibrosis is a pathophysiological event leading to the replacement of tissue 
with extracellular components such as collagen. This process developes as a result of 
chronic tissue injury or stress and is regulated by inflammatory cells (Tidball, 2005). 
It impairs the function of a diverse range of vital organs causing chronic disease 
(Muir and Chamberlain, 2009; Mann et al., 2011). Fibrosis shows differences 
between distinct tissues; however, the cellular mechanisms that lead to the 
development of fibrosis are common and involve leukocytes, immune cells, 
proteolytic enzymes and fibrogenic cytokines that all have been detected in the 
environment of fibrotic tissues (Lehto et al., 1985; Tidball, 1995; Tidball, 2005; 
Darby et al., 2016; Laumonier and Menetrey, 2016). 
In DMD, the continuation of proliferation and differentiation exhausts satellite cells 
and attenuates their capacity to repair tissue (Webster and Blau, 1990; Watkins et al., 
1988; Renault et al., 2000; Chang et al., 2016). Therefore, after a vicious cycle of 
degeneration-regeneration the connective, adipose and fibrous tissues accumulate 
and replace muscle (Mauro, 1961; Huard et al., 2002). It was suggested in previous 
studies that the mdx mouse is not an appropriate model for studying DMD (Collins 
and Morgan, 2003; Pessina et al., 2014), because it shows less severe phenotypes 
than DMD and only a slightly shorter life span than the wild-type, even though it 
shares most but not all of the disease features with DMD patients (Pastoret and 
Sebille, 1995; Lynch et al, 2001). For example, the fibrosis becomes apparent 
extensively and early only in the diaphragm, while the limb muscle develops fibrosis 
at 20 months of age (Ardite et al., 2012). The levels of TGFβ found in the fibrotic 
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diaphragm of mdx suggest that TGFβ may directly contribute to fibrosis (Zhou et al., 
2006; Ishizaki et al., 2008; Kharraz et al., 2014). Meyers and Townsend (2015) 
indicated that the ventricular fibrosis in mdx occurs and it is an early indicator of 
dystrophic cardiomyopathy. Au et al. (2011) found that cardiac fibrosis appears in 
mdx mice at 29 weeks of age with high expression levels of Tgfβ, Ctgf, Mmp2 and 
Mmp9. Also, fibrosis has been identified in other tissues including the skin, kidney, 
bone, cartilage and liver (Hidestrand et al., 2008).  
Here, using RNA-Seq and qPCR analyses, it was found that the fibrotic phenotype 
already exists in four week-old TA mdx muscles. This novel finding suggests that 
mdx shares the same fibrotic features with DMD in the early stages of disease. The 
expression pattern of genes involved in regulating the fibrosis has shown that the 
pro-fibrotic and anti-fibrotic genes were up- and down-regulated in mdx and 
C57/BL10, respectively. Importantly, the ablation of P2RX7 ameliorates the fibrotic 
signature, the important abnormality of DMD pathology, thus making this receptor a 
good therapeutic target.  
4.4.9  The nonsense-mediated decay (NMD) and mRNA splicing machinery 
alterations in mdx  
NMD is a mechanism responsible for the regulation of gene splicing and elimination 
of the transcripts harbouring premature stop (termination) codons (PTC) (Kalyna et 
al., 2012). PTC either terminates mRNA translation or reduces the steady-state 
mRNA, both leading to the production of a non-functional protein. PTCs that elicit 
NMD were classified into four classes according to their location on transcripts: (i) 
transcripts with a PTC upstream of the open reading frame (uORF), (ii) transcripts 
with a PTC located further than 50-55 nucleotides upstream of the last exon-exon 
junction (exon junction complex) (EJC), (iii) an alternative splice transcripts with 
PTC upstream of the EJC, and (iv) transcript with a PTC in the middle of the long 3'-
UTR (Zhang et al., 2009; Huang and Wilkinson, 2012; Schweingruber et al., 2013). 
The qPCR analysis using 5'end primers sets showed higher dystrophin levels in mdx 
compared with mdx
βgeo
 while no statistically significant difference was identified 
between mdx and C57/BL10. In contrast, using primer sets complementary to exons 
65-66 (3'end), the analysis detected significantly decreased expression levels of 
transcripts containing exons 65-66 in mdx and mdx
βgeo
 compared with C57/BL10 
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and also between mdx and mdx
βgeo
. The possible explanation for the differences in 
expression of the 5' end dystrophin between both genotypes is the more efficient 
degradation of dystrophin in mdx
βgeo
 by NMD mechanisms than mdx, which may be 
related to (i) the location and type of the mutation, as mdx mice have point mutation 
located in exon 23 of the Dmd gene leading to a premature stop codon (Sicinski et 
al., 1989) while the mdx
βgeo
 mouse contains a promoter-less rosa-geo construct 
inserted into exon 63 of dystrophin which affects all dystrophin isoforms (Wertz and 
Füchtbauer, 1998), (ii) the dystrophin retention in mdx is perhaps related to the 16 
hours being required for dystrophin to be transcribed; the 5'end of nascent dystrophin 
is expressed about 2.9 ± 0.9 more than mature dystrophin (3'end) in wild-type muscle 
(Tennyson et al., 1996). On the other hand, the expression of dystrophin in the 3ˈend 
in mdx could represent the Dp71 variant, as Lederfein et al. (1993) showed that 
expression of this short dystrophin variant is not affected in mdx. In contrast, the 
mdx
βgeo 
does not express any dystrophin transcripts as the large rosa-bgeo construct 
inserted into exon 63 leads to disruption of the expression of all variants (Wertz and 
Füchtbauer, 1998).  
Our findings (Figure 4.30) of dystrophin expression in mdx mice indicated the 
abnormality of the NMD mechanism in these mice. 
It has been known that mutations in the dystrophin gene are the cause of DMD 
(Hoffman et al., 1987). Since the DMD protein is detected in fully differentiated 
muscle only, most of research has focussed on the effects of the full-length 
dystrophin absence in myofibres, where it anchors a set of dystrophin-associated 
proteins (DAPC) in the sarcolemma. This complex is believed to provide structural 
stability to the sarcolemma and its loss triggers muscle degeneration (Ehmsen, 2002). 
However, there is increasing evidence that, while important, this is not the only 
pathological mechanism. For instance, muscle degeneration did not initiate as a 
result of knocking-out the full-length dystrophin in adult mouse (Ghahramani Seno 
et al., 2008). In contrast, the absence of dystrophin in early embryogenesis in the 
mdx mouse disrupts muscle development due to stem cell loss and disrupted muscle 
patterning (Merrick et al., 2009). Myoblasts contain low, undetectable levels of 
dystrophin; given the variety of phenotypic alterations including the nucleus, 
cytoplasm and sarcolemma, proliferation and differentiation (Yablonka-Reuveni, 
2011), abnormalities of energy metabolism (Onopiuk, 2009), in store-operated 
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calcium entry (Onopiuk, 2015) and in P2RX7 receptor expression and function 
(Yeung, 2006; Young, 2012, Young, 2015, Sinadinos 2015), it seems unlikely that 
such diverse functions could be executed by so little protein that it could escape 
detection (Yeung et al 2006; Onopiuk et al., 2009; Young et al., 2012). Furthermore, 
the mutations of dystrophin also lead to abnormalities in non-contractile organs such 
as the brain, which is also developmental (Anderson et al., 2002). All these 
alterations could therefore be the direct effect of Dmd mutations. 
The mutant transcripts are degraded by NMD; this process is regulated by cellular 
stress (Gardner, 2010), sterile inflammation and hypoxia (Gardner, 2008; Karam et 
al., 2013), which are the hallmarks of DMD. Thus, dystrophic cells are under severe 
stress and stabilisation of the mutant RNA in such a microenvironment could result 
in the generation of non-functional or dominant-negative truncated proteins, thereby 
evoking cellular abnormalities. Furthermore, various alternatively spliced transcripts 
are directly stabilised by NMD inhibition or indirectly by the NMD-dependent 
regulation of splicing factors (Wang et al., 2011). NMD abnormalities in DMD 
muscles could lead to the up-regulation of such alternatively spliced transcripts with 
altered reading frames and to the production of nonsense and/or misfolded proteins 
that could also alter cell functions. 
The qPCR analysis (Figure 4.31) showed (i) the down-regulation of dystrophin in 
both dystrophic myoblasts and myotubes compared with wild- type, and (ii) the 
expression level of dystrophin in dystrophic cells was 5 times less than in wild-type.  
Figure 4.32 shows that (i) full length dystrophin was gradually increased from 
myoblast to myotubes in wild-type type animals, and (ii) the expression level of full 
length dystrophin in the dystrophic myoblasts was lower than its expression in 
myotubes. These findings indicate that the NMD mechanism works efficiently in 
eliminating mutant dystrophin transcripts in dystrophic cells in vitro. That may be 
related to the absence of the inflammatory environment found in muscle tissue. 
Moreover, the same rate of expression of the 5' end (nascent) and mature dystrophin 
(3'end) was observed in both myoblasts and myotubes, indicating that the long time 
(16 hours) of transcription does not affect the speed of degradation of mutant 
dystrophin via NMD mechanism. The results of dystrophin expression analysis in 
mdx muscle and cells suggest the full length dystrophin to be the major factor in 
DMD disease while Dp71 has a minor effect.  
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These investigations showed that expressions of Dp71 and full length dystrophin 
were still down-regulated in myoblasts even after treatment with NMDI for 6, 16 and 
24 hours. Unlike the full length dystrophin, the expression of Dp71 in dystrophic 
myoblasts was demonstrated (Tennyson et al., 1996; de León et al., 2005). Our 
findings only showed the up-regulation of Dp71 in wild-type cells treated for 16 
hours with NMDI compared with wild type-cells treated with dimethyl sulfoxide 
(DMSO), while the remaining experiments of both Dp71 and full length dystrophin 
showed either down-regulation or no statistically significant difference. The up-
regulation of  Dp71 after 16 hours of treatment in wild-type cells could be related to 
the other function of NMD in the regulation of splicing and maintaining the 
expression levels of broad classes of transcripts; inhibition of NMD affects control of 
the level of dystrophin post-transcription (Mendell et al., 2004; Isken and Maquat, 
2008).  
Treating myotubes with NMDI for 24 hours significantly increased the expression of 
Dp71 and full length dystrophin in dystrophic cells, suggesting that the long 
treatment effectively reduces the NMD mechanism in myotubes. It has been shown 
that expression of the Dp71 variant is reduced in normal and dystrophic myogenic 
cells, while the expression of full length dystrophin is observed in wild–type 
myotubes only (Dickson et al., 1988; Tennyson et al., 1996; de León et al., 2005); 
therefore, their elevation as a result of the inhibition of NMD demonstrates a 
reduction of the decay of the Dp71 variant and full length dystrophin transcripts in 
myotubes. 
NMD not only eliminates the mutant transcript associated with pathological 
conditions, but also degrades the alternatively spliced forms of transcripts that 
contain premature termination codons in a mechanism called regulated unproductive 
splicing and translation (RUST); this is also known as alternative splicing coupled to 
NMD (AS-NMD). Alternative splicing is regulated by the relative ratio of splicing 
activators (SRSF proteins) and splicing repressors (HnRNPs). Interestingly, genes 
encoding proteins involved in splicing use RUST to auto-regulate. Therefore, altered 
NMD could have a widespread impact on alternative splicing via changes in the 
concentration of SRSF and hnRNPs (Weischenfeldt et al., 2012).   
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Analysis of the expression of NMD factors by NGS (Table 4.5) suggested that some 
splice activators like SRSF and splice repressors like HnRNP are up-regulated in 
mdx. Both regulate the degradation of alternatively spliced forms that contain 
premature stop codons via the RUST mechanism. UPF3a and UPF3b are involved in 
the NMD of mRNAs containing premature stop codons by associating them with the 
nuclear exon junction complex and serving as a link between the EJC core and 
NMD. The expression of Upf3a and Upf3b was down-regulated in mdx muscles in 
RNA-Seq datasets. These results together indicate that mdx may have less efficient 
NMD and also repressed splicing and thus an aberrant mRNA splicing pattern. The 
results of some splice regulators were confirmed by qPCR in mdx muscle, and 
dystrophic myoblasts and myotubes, also indicating the aberrant splicing machinery 
in mdx muscle and cells. This suggests that the defect in the splicing machinery is a 
cell-autonomous abnormality and not a result of the dystrophic environment. This 
might be important because there are now precedents where the accumulation of 
mutated proteins in the cytoplasm can affect transport across the nuclear membrane 
(Da Cruz and Cleveland, 2016). It is possible that the altered regulation of alternative 
splicing and NMD is a consequence of impaired nuclear transport. Impaired nuclear 
transport has been implicated in a number of neurodegenerative diseases such as 
Parkinson's disease (PD), Alzheimer's disease (AD) (Ward and Cooper, 2010; Patel 
and Chu, 2011). 
The demonstration of elevated isoform ratio entropy in mdx compared with 
C57/BL10 highlights alterations of the AS pathway and its regulatory genes (Wang 
et al., 2008). Furthermore, the increase in out-of-frame junctions in mdx compared 
with C57/BL10 seems to confirm aberrant NMD functions. The out-of-frame splice 
junctions have a high chance of resulting in a transcript with a premature stop codon 
(Brogna and Wen, 2009) and can be used to reveal differences in NMD pathway 
functions (Mahowald et al., 2011). Therefore, increased out-of-frame spliced 
transcripts confirm the attenuation of NMD functions. Our results conclude that 
abnormalities of NMD in DMD muscles could lead to the up-regulation of 
alternatively spliced transcripts with altered reading frames. This usually leads to the 
accumulation of truncated proteins that may have dominant negative effects and/or 
misfolded proteins that are able to trigger unexpected cellular responses (Kawashima 
et al., 2009; Weischenfeldt et al., 2012).  
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Taking P2rx7 as an example of highly altered transcripts in mdx, the high expression 
level of P2rx7 in Pfizer-P2rx7 and Pfizer-mdx/P2rx7
-/-
 highlights that the aberrant 
P2rx7 transcript is avoided by NMD. This is related to the molecular basis of 
generating Pfizer-P2rx7, where the neomycin cassette was inserted into exon 13 
(Solle et al., 2001), resulting in the production of a PTC within the last exon without 
intron separation; this failed to elicit the NMD mechanism. On other hand, the 
Glaxo-P2rx7 showed very low expression level, presumably because it is 
efficiently degraded by NMD, which is related to the insertion of Lac-Z in exon 1 
(Chessell et al., 2005), meaning that the PTC is upstream of the exon-exon junction 
by more than 50 nt. Interestingly, mutations in 3' Dmd in mdx
βgeo
 (Wertz and 
Füchtbauer, 1998) also result in the increased expression levels of P2rx7. The 
mdx
βgeo
 should be evaluated carefully as it may have more severe dystrophy 
compared to mdx as this genotype differs from mdx by lacking all dystrophin 
isoforms. 
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5  
Analysis of alternative splicing of the Bmp7 transcrip in mdx mouse 
 
 Introduction 5.1
In the course of RNA-Seq and qPCR analyses, the bone morphogenic 7 (BMP7) 
expression downregulation and splicing alteration were identified. While the role of 
BMPs in muscle function and also in DMD has been documented, this specific 
BMP7 has not been identified in this context. Therefore, it was investigated further 
as a potential new therapeutic target.  
The study of BMPs was started in the 1960s by Marshall, with the search for the 
factor responsible for bone regeneration (Reddi, 2003). There are over 20 BMPs; 
based on peptide sequencing; these proteins were found to belong to the TGFβ 
superfamily (Wozney et al., 1988). BMPs are classified according to the similarity of 
their amino acid and nucleotide sequences into subgroups: BMP2/4, BMP5/6/7, 
BMP9/10 and BMP12/13/14 (Miyazono et al., 2010). BMP7 is a 34-38 kDa 
homodimeric secreted protein with an important role in the development of embryos. 
BMPs are needed for mesoderm formation and organ development in the 
embryogenic stage; BMP7 is a key player in kidney and eye development (Wang et 
al., 2014). Unlike other BMPs, a homozygous deletion of the Bmp7 gene causes 
embryonic lethality due to renal dysplasia, characterised by small kidneys with 
apparently absent glomeruli (Dudley et al., 1995; Luo et al., 1995; Li et al., 2004a).   
All members of the TGFβ family are synthesised as precursor cytokines, which are 
enzymatically cleaved into mature C-terminal and N-terminal fragments (Sampath et 
al., 1992; Jones et al., 1994). Monomeric BMP7 produces a 431 amino precursor; 
the proteolytic enzyme breaks it down into a 263 residue pro-protein, a 29 amino 
acid signal peptide and a 139 residue mature protein domain. Once it is ready to be 
secreted, a secondary enzymatic cleavage separates the mature BMP7 from the pro-
domain (Jones et al., 1994). The crystal structure of BMP7 (OP-1) displays limited 
sequence homology (38%) with TGFβ, but shares a common polypeptide fold. In 
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addition, BMP7 shows 60 and 85% similarity to BMP2 and BMP5, respectively 
(Griffith et al., 1996; Granjeiro et al., 2005). BMP7 possesses the structural cysteine-
knot, which forms the core of BMP7 monomers and consists of three disulphide 
bonds. Four strands of antiparallel β-sheets form two finger-like projections 
emanating from this cysteine-knot (Figure 5.1) (Griffith et al., 1996).  
 
Figure 5.1: 
Schematic diagram representing the three dimensional structure of BMP7. The core of 
the monomer consists of a cysteine-knot that contains three disulphide bonds. Two of 
these bonds form a ring, allowing to third bond to pass through. Furthermore, two 
finger-like projections made of four antiparallel β-sheets emanate from the cysteine-
knot (Griffith et al., 1996). 
 
 
BMP7 and other BMPs have been found in a wide variety of tissues; they were 
originally identified for their ability in the formation of bone and cartilage (Wozney 
et al., 1988). Although the name of the bone morphogenic protein represents their 
function in skeletal tissue, extensive studies have demonstrated the wide range of 
functions for these proteins outside this tissue. For instance, they regulate the 
development of teeth, kidneys, hearts, eyes, skin, hair and neurons and maintain iron 
homeostasis (Dudley et al., 1995; Ducy and Karsenty, 2000; Zhao, 2003; Chen et al., 
2004a; Chen et al., 2004b; Miyazono et al., 2005; Corradini et al., 2009; Meynard et 
al., 2009; Jain et al., 2013). The disruption of the BMP signalling pathway has been 
linked to several diseases such as DMD, cancer, vascular abnormalities, obesity, 
congenital anomalies of the kidney and the urinary tract (CAKUT), chronic kidney 
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disease (CKD), fibrodysplasia ossificans progressive (FOP), osteogenesis imperfecta 
(OI), osteoarthritis (OA), Myhre syndrome, pulmonary arterial hypertension (PAH), 
hereditary haemorrhagic telangiectasia (HHT), juvenile polyposis syndrome (JPS) 
and colorectal cancer (Wang et al., 2014). 
The role of BMPs in the regeneration of damaged muscle is well known (Ruschke et 
al., 2012). The nucleus of the activated satellite cells in damaged muscles expresses 
Smad1/5/8, the indicator of stimulation of the BMP pathway (Ono et al., 2011). 
However, the activity of BMP is switched off when the satellite cells differentiate 
and express the BMP inhibitors (Noggin or Chordin) (Clever et al., 2010; Friedrichs 
et al., 2011; Ono et al., 2011). Ongoing research has focused on the role of BMP2 
and BMP4 in the pathology of DMD (Pescatori et al., 2007). Sterrenburg et al. 
(2006) used microarray to compare the gene expression between dystrophic and 
healthy myoblasts. The analysis of the microarray dataset detected high expression 
levels of Bmp4 in DMD compared with wild-type. Interestingly, RNA-Seq described 
here found no difference in BMP2 gene expression and statistically significant 
downregulation of BMP4 transcript in 4 week old mdx muscles. The expression of 
Bmp4 maintains satellite cells in the proliferation state, preventing myogenic 
differentiation (Ono et al., 2011, Shi et al., 2011). The up-regulation of BMP4 in the 
satellite cell may explain the inability of these cells to differentiate (Kottlors and 
Kirschner, 2010). Another study has shown the elevation of several members of the 
Bmp family, such as Bmp15, Bmpr1a, Inhbc, Inhbe, and Idb2, in the mdx muscle, 
suggesting the role of these genes in regulating the regeneration process (Turk et al., 
2005).  
Regulation of BMP7 signalling is achieved by binding type I and II receptors 
(Yamashita et al., 1996; Miyazono et al., 2010). Binding the receptors initiates 
subsequent phosphorylation of the R-Smad (1, 5, 8) signal. Activation the BMP7 
pathway inhibits the TGFβ pathway, which binds with receptor; however, in this 
case, binding phosphorylates Smad 2 and Smad 3. Activation of these pathways 
promotes the assembly of R-Smad or Smad 2 and Smad 3 with the co-activator Smad 
(co-Smad 4) to form heterodimers that translocate to the nucleus, where they act as a 
transcription factor to regulate the expression of Bmp7 or Tgfβ, respectively 
(Miyazono et al., 2005). In addition to Smad signalling, BMPs are stimulated by 
signals via the non-Smad pathway, including ERK, P38, MAP kinase, small 
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GTPases, LIMK, TAK1 and P13K-Akt-PKBP (Moriguchi et al., 1996; Gallea et al., 
2001). Both the Akt and P38-ERK MAPK pathway are needed for BMP-induced 
differentiation. The activation of P13K is essential for generating the PIP3, which is 
involved in cell survival and migration (Ghosh-Choudhury et al., 2002; Cain and 
Ridley, 2009). GTPases are involved in the formation of filamentous actin (Hall, 
1998). Another key player in rearrangement the cytoskeleton actin is Lim domain 
kinase (LIMK), which is also induced by BMP7 signalling (Foletta et al., 2003). The 
activity of BMPs can be inhibited by secreted proteins (antagonists) binding directly 
with BMPs and preventing their binding to their receptor. Three subfamilies of BMP 
antagonists have been identified: the DAN subfamily (Sclerostin and USAG1), 
twisted gastrulation (tsg) and Chordin and Noggin (Vitt at al., 2001; Yanagita, 
2005). Both Chordin and Sclerostin interact with BMP7 (Kusu et al., 2003; Lowery 
and Caestecker, 2010).  
 Aim and objectives 5.2
Investigate the role of Bmp7 in muscle function and in DMD pathology. 
 Analyse the expression profile of Bmp7 at different ages and tissues of 
C57/BL10, mdx and mdx/P2rx7
-/- 
as well as in the myogenic cells. 
 Study the role of this transcript in muscle fibrosis and whether ablation of  
PRX7 receptor had a positive impact in reducing this pathological feature. 
 Study the possible existence of an alternative Bmp7 splice variant via 
bioinformatics tools and RT-PCR analysis of the the expression of individual 
exons and the alignment of of Bmp7 reads obtained  from RNA-Seq datasets.   
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 Results 5.3
5.3.1 Altered splicing and expression of Bmp7 in dystrophic muscles 
One of the transcripts showing altered expression patterns between wild-type, mdx 
and mdx/P2rx7
-/- 
samples was Bmp7. Bmp7 expression was found altered in 4 week-
old mdx muscles compared to C57/BL10 in the initial qPCR analyses with the 
qPCR-SYBR Green detection method (Table 4.4). Subsequently, the expression 
level of Bmp7 transcript in the four week-old TA muscles was showed significantly 
down-regulation in mdx compared with C57/BL10, and restored to normal levels in 
mdx/P2x7
-/-
. Furthermore, Bmp7 transcript analysis using TaqMan hybridisation 
probe located between exon three and four confirmed the altered regulation of Bmp7 
expression in muscles (Figure 5.2). Again, this analysis showed that the relative 
expression level of Bmp7 in mdx was down-regulation while it was increased 
significantly in mdx/P2rx7
-/-
 compared to mdx. Interestingly, the same expression 
patterns were obtained when the 18 month old TA muscles were tested. The 
expression levels of Bmp7 in two week-old TA muscles of C57/BL10, mdx and 
mdx/P2rx7
-/-
 were also measured, but there was no significant difference in 
expression between samples at this age. Next, Bmp7 expression levels were 
measured in heart muscles, myoblasts and myofibres to establish whether the 
differential expression is due to changes in muscle or non-muscle cells. The results 
showed the down-regulation of Bmp7 in mdx heart muscles, which was however not 
restored by P2RX7 ablation. Importantly, it also showed the near absence of Bmp7 in 
dystrophic myoblasts (SC5) compared with wild-type cells (IMO) and also 
demonstrated that Bmp7 levels were significantly reduced in isolated primary mdx 
myofibres (Figure 5.2).   
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Figure 5.2: 
BMP7 expression measured by qPCR. Relative expression levels normalised to Gapdh, 
showing significantly reduced Bmp7 transcript in mdx of the four-week- and 18 month-
old TA leg muscle, heart and myofibre compared with C57/BL10. The results also 
indicate Bmp7 transcript levels corrected towards the normal levels in the mdx/P2rx7
-/-
 
in four-week- and 18-month old TA muscles. There was no Bmp7 expression in 
dystrophic myoblasts (SC5) in contrast to wild-type cells (IMO). The statistical analysis 
was performed using one way ANOVA and t-test, N=3-5, *P ≤ 0.05 and .0 **P≤ 0.01. 
 
 
The Figure 5.3 shows the BMP/TGF signalling pathway with the expression levels of 
the relevant genes found in the RNA-Seq datasets. In contrast to Bmp7 down-
regulation in mdx and increase in mdx/P2rx7
-/-
, the Tgfβ was up regulated in mdx 
compared with C57/BL10 and down-regulated in mdx/P2rx7
-/-
 compared with mdx. 
Except for the down-regulation of Smad3 in mdx/P2rx7
-/-
, no others Smads were 
detected in RNA-Seq datasets. These results may suggest differential activation of 
Tgfβ and Bmp7 in mdx and mdx/P2rx7-/-. 
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Figure 5.3: 
The signalling pathway chart showing the down-regulation of Bmp7 in mdx (green) and up-regulation in mdx/P2rx7-/- (red). Also, 
the expression levels of Tgfβ being up-regulated in mdx compared to C57/BL10 and down-regulated in mdx/P2rx7-/- are shown. 
Other genes involved in this pathway are highlighted according to their regulation, red: up-regulation, green: down-regulation, 
white: no significant difference or a gene present in the pathway but not shown in our datasets. The genes that show differences in 
RNA-Seq datasets but not pass the automatic threshold were added manually to the pathway. 
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The activation of BMP7 may be also achieved by a non-Smad pathway. To confirm 
whether the BMP7 activation was regulated by SMAD, the BMP7 and SMAD (1, 5, 8) 
proteins were analysed by Western blotting. BMP7 antibody from Sigma showed 
multiple unspecific bands in C57/BL10, mdx and mdx/P2rx7
-/-
 (Figure 5.4) while 
with, BMP7 antibody from Abcam, there was, unexpectedly, a band of the size similar 
to the expected one (48 kDa), which was stronger in mdx and not found in mdx/P2x7
-/
. 
It is not clear whether this band was specific for BMP7. Next, the SMAD (1, 5, 8) 
protein levels in wild-type and dystrophic myoblasts were determined. No statistically 
significant difference was detected between these cells.  Besides SMAD (1, 5, 8), 
SMAD3 was also tested to identify whether the TGFβ was activated in myoblasts. The 
SMAD3 protein level was low in dystrophic myoblast compared with wild-type.  
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Figure 5.4: 
Representative immunoblots showing (A) BMP7 analysis in C57/BL10, mdx and 
mdx/P2rx7
-/- 
using antibody from Sigma, resulting in multiple unspecific bands (B) 
BMP7 detection in C57/BL10, mdx and mdx/P2rx7
-/- 
using antibody from Abcam, 
resulting in a near-expected size band strongly expressed in mdx compared with 
C57/BL10 and not detectable in mdx/P2rx7
-/-
. (C-Top) shows the protein levels of 
SMAD 1, 5, 8 and SMAD 3 (both Cell Signalling Technology)in dystrophic and wild-
type myoblasts. The densitometric analysis in (C-Bottom) indicated no significant 
difference in SMAD 1, 5, 8 levels between samples whereas SMAD3 protein level was 
lower in dystrophic compared with wild-type cells. The statistical analysis was 
performed using t-test, N=3, P=0.796 and P=0.037 for SMAD 1, 5, 8 and SMAD3 
respectively. 
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The interesting finding from qPCR analysis was the reduction of Bmp7 expression 
levels in different mdx tissues and cells with a primer set across exon 3-4. Therefore, 
the expression of each exon of Bmp7 identified in RNA-Seq datasets was studied 
using bioinformatics tools and the results are given in Figure 5.5. In mdx samples, 
the region between exon 3 and 4 shows significant dysregulation compared with 
C57/BL10 and mdx/P2rx7
-/-
. Using the Integrative Genomics Viewer (IGV), the 
comparison of mapped reads in exonic and intronic regions across the samples 
demonstrated the lower proportion of reads aligned to region of exon 3-4 in mdx 
compared with C57/BL10 and mdx/P2rx7
-/-
. In the IGV software, the RNA-Seq 
reads of C57/BL10, mdx and mdx/P2rx7
-/-
 were mapped to the mouse genome 
mm10. Figure 5.6 shows large reduction in the numbers of reads coverage between 
the region of the exon 3 and 4 in mdx compared to C57/BL10. The reads coverage 
aligned again just a few base pairs distal to the exon 4 junction. This result indicates 
the possibility of skipped exons in mdx and also the existance of an alternative, 
presumably wild-type transcript (aligned reads) in the region between exons 3 and 4 
in mdx/P2rx7
-/-
. 
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Figure 5.5: 
Location and structure of Bmp7 transcript: (A) the location of Bmp7 transcript within 
the chromosome 2 (Marker et al., 1995), highlighted in red. (B) The expression levels 
of seven exons of Bmp7 in the C57/BL10 (green), mdx (red) and mdx/P2rx7-/- (blue). 
(C) Bmp7 transcripts were categorised to exonic and intronic regions  (D) The snapshot 
of Bmp7 transcript in IGV software showing the alignment of sequenced reads (grey 
bricks) to exonic and intronic region and at the base pair levels. It shows the lower 
proportion of reads in the region between exon 3 and 4 in mdx compared with 
C57/BL10 and mdx/P2rx7
-/-
. 
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Figure 5.6: 
Visualisation of RNA-Seq data of four-week-old TA muscles of C57/BL10 and  mdx in 
IGV software. Each panel tracks reads coverage aligned to different regions of Bmp7 
transcript, (A) Region between exons 3 and exon 4, (B) Exon junction 3 and (C) exon 
junction 4. The aligned reads are presented as segments splitting across the exons and 
connected with thin blue lines. 
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Consisting of seven exons, 3670 bp of the full length Bmp7 transcript encodes a 430 
amino acid protein. So far, only one short alternatively splice transcript of Bmp7 has 
been identified. It is a non-coding variant which has two exons (Figure 5.7.A) and it 
is not consisten with the sequence identified here.  
The possibility of having a novel splice variant of Bmp7 expressed in mdx was 
investigated using different sets of primers located in different places across the full 
length of the Bmp7 transcript. The locations of these primers are given in Figure 
5.7.A. Using RT-PCR, the regions between exon 2-5 and 1-7 were amplified in 
skeletal muscle and in myoblast samples. The four- week-old TA muscles from 
C57/BL10, mdx and mdx/P2rx7
-/-
 showed the same pattern of expression for both 
regions. Interestingly, this analysis found that the 485bp band expected for the exon 
2-5 region was present in wild-type myoblasts, whereas this band was absent in 
dystrophic cells. Moreover, the wild-type showed 884 bp band in RT-PCR with 
primer pair for exons 1-7, which was absent in dystrophic cells (Figure 5.7.B). These 
results confirmed that an alternative Bmp7 transcript missing or with alternative 5ˈ 
exons is expressed in dystrophic myoblasts.  
In order to analyse this possibility further, additional sets of primers spanning the 
regions upstream and downstream of exons 2-5, such as exon 1-2 and exon 5-7, were 
used. The reason for choosing these locations was to identify whether the mis-
amplification started upstream of the exon 2-5 and/or continued downstream. In 
skeletal muscles, there was no difference between C57/B10, mdx and mdx/P2rx7
-/-
 in 
expression of both regions spanning exons 1-2 and 5-7.  In contrast, the exon 1-2 
region was amplified only in the wild-type myoblasts while the exon 5-7 region was 
amplified in both wild-type and dystrophic cells. This indicated that either there is a 
skipped exon located in the 5ˈend or that the primer mismatches as a result of the 
existing alternative nucleotides sequence there (Figure 5.7.B). 
To further confirm these expression patterns, myofiber samples were extracted from 
two-week-old TA muscles of C57/BL10, mdx and mdx/P2rx7
-/-
 and were amplified 
with primers sets for exon 1-2 and 5-7. The typical levels of expression were seen in 
C57/BL10 and mdx/P2rx7
-/-
 samples for exons 1-2 and 5-7. In contrast, in mdx 
myofibres, the expression of exon 1-2 was undetected while a 287 bp exon 5-7 
amplicon was faint (Figure 5.7.B).    
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From these results it was concluded that dystrophic myoblasts and myofibers express 
Bmp7 transcript containing exons 5-7 that are located in the 3ˈend but not the 5ˈ exon 
1-2 region. The results could be explained by an 5' alternatively initiated or spliced 
transcript variant. 
 
 
 
Figure 5.7: 
Bmp7 exons structures and their expression in RT-PCR analysis. (A) Schematics 
representing the structure of Bmp7 transcripts and the location of primer pairs that flank 
regions between exon 2-5, 1-7, 1-2 and 5-7. (B) Images of RT-PCR products visualised 
in 2% agarose gels showing the amplification of different regions of the Bmp7 
transcript in four week-old TA muscles from C57/BL10, mdx and mdx/P2rx7
-/-
, in 
myoblasts and myofibres. Similar expression levels of exon 1-7, 2-5, 1-2 and 5-7 
amplicons were found in all samples of skeletal muscles. Unlike muscles, the wild-type 
and dystrophic myoblasts show a clear difference in the expression levels of exon 2-5 
and 1-7. The wild-type expresses specific 485 and 884 bp bands, which denote the 2-5 
and 1-7 exon amplicons, respectively, whereas no such bands were detected in 
dystrophic cells. Furthermore, the specific primer pairs used to amplify exon 1-2 and 
exon 5-7 in myoblast and myofibers show the expected 169bp band for the exon 1-2 
present in samples of C57/BL10 and mdx/P2rx7
-/-
 but no bands were detected in mdx. 
 
myofibre 
         2 1 2 
                           
A 2 3 4 5 6 7 1 
B 
      -  
      -  
     -  
      -  
       
       
       
       Exon 5-7 
Exon 1-2 
205 
 
The exon 5-7 region was expressed in all samples, including mdx. Negative controls 
contained water instead of the cDNA sample. 
 
To test for the possible alternative splicing protecting the reading frame, a primer 
spanning the ATG start codon was used. The RT-PCR experiment performed using 
such a forward primer and a reverse primer located in exon 5 showed the faint band of  
expected size (1075 bp) in muscle samples from all genotypes and in control (Imo) 
myoblasts but not in dystrophic (Sc5) cells. A smaller product size was seen in 
dystrophic cells (Figure 5.8.A), which could indicate the existence of a Bmp7 
alternative splice variant. The same result was observed in normal and dystrophic 
myoblasts when the experiment was repeated (Figure 5.8.B). To maximise the 
amplification efficiency for the exon 1-5 amplicon in myoblasts higher cDNA 
concentration (150ng) and two different DNA polymerase enzymes were used in RT-
PCR. The same myoblast samples were used in parallel RT-PCR experiments to avoid 
confounding effects related to biological and technical variations during samples 
preparation. Using GoTaq DNA polymerase, two different size bands were detected in 
wild-type cells, one of these bands being the expected molecular size 1075bp, while 
the other showed slightly lower size at than ~1000 bp. In dystrophic cells there was no 
clear band detected. In addition, smaller bands were observed in both wild-type and 
dystrophic cells when iProof DNA polymerase was used (Figure 5.8.C). 
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Figure 5.8: 
RT-PCR products visualised in 2% agarose gels showing amplification of exon 1-5 of 
the Bmp7 transcript in muscle and myoblasts. (A) The amplification of 1075 bp bands 
representing the exon 1-5 region found C57/BL10, mdx, mdxβgeo, mdx/P2rx7-/-, 
Pfizer-P2rx7, Glaxo-P2rx7, and wild-type myoblasts, respectively. A smaller band was 
detected in dystrophic myoblasts (arrow). (B) The similar expression pattern was found 
in wild-type and dystrophic myoblasts when the experiment was repeated. (C) Modified 
RT-PCR protocols resulted in the detection of the specific 1075 bp and a smaller one in 
wild-type myoblasts and no band in dystrophic myoblasts when GoTaq enzyme was 
used. Using iProof enzyme, bands smaller than 1000bp were detected in both wild-type 
and dystrophic cells. The negative control contained water instead of the cDNA sample. 
 
 
Two approaches were undertaken in an attempt to identify the sequence of the short 
band that appeared in the previous experiment. First, the PCR product in wild-type 
myoblasts obtained using GoTaq was digested by a single cut restriction enzyme 
(Msp1). The expected restriction fragments were 871bp and 204bp (Figure 5.9.A).The 
digested product was visualised in 2% of agarose gel Figure 5.9.B, and the result 
revealed the presence of three bands. None of these bands represented the expected 
restriction fragment. The second approach involved gel purification of the PCR 
product using NucleoSpin® Gel and PCR Clean-up kit (Macherey-Nagel) and its 
sequencing. The sequence analysis revealed that the amplicon was not a Bmp7  but a 
product with 68% identity with Mus musculus amyloid beta (A4) precursor-like 
protein 2 (Figure 5.9.C). 
 
1075bp 
          GoTaq                                iproof 
100bp   Imo     Sc5     NC    100bp   Imo    Sc5    NC 
B 
1075bp 1075bp 
A 
C 
207 
 
 
 
 
 
 
A 
Query  61   CTTCCTCCCCTTCCACCTCGACCTCTTC-GCCACCTCTGCTGCTGCTTCTGTG-AGCCTG  118 
            |||||||||||||| ||||  |||||||  || | |||||||||||||||||| || ||  
Sbjct  859  CTTCCTCCCCTTCCTCCTCATCCTCTTCTTCCTCATCTGCTGCTGCTTCTGTGAAGTCTT  800 
Query  119  ACCCATCTGCTTCAAGA-GCTGTTTTGTTTTATCGA-ATAAGTTCTTTCCTCTGCCTCGT  176 
             |  ||||||||||  | |   ||   ||||||| | || |     ||||||| | || | 
Sbjct  799  CCAAATCTGCTTCAGTAGGAAATTCACTTTTATCAAGATCATAGTCTTCCTCTTCGTCCT  740 
Query  177  CTTCTTCCTCTACCTCTTCATCCTCTTCGTTGTGGATACTCAAGTCCCAGTCATATTGCT  236 
            |||| |||||| ||||||| |||||||| |||   ||| || ||||| |||||     || 
Sbjct  739  CTTCATCCTCTTCCTCTTCCTCCTCTTCTTTGGACATAGTCGAGTCCGAGTCAACAGTCT  680 
Query  237  TTGTGTGACCGAAG-GGACATACGCAGTGCCATAGTCCTGTTGTTCCCCATTCGGTGTC-  294 
            |||| |||  | ||   |||||| | ||||||| |  ||| | | ||||    ||   |  
Sbjct  679  TTGTCTGAGGGCAGCACACATACTCGGTGCCATGGAACTGGTCTACCCCGCAGGGCAGCA  620 
Query  295  -TTGGCCATGAATTTGTAATGATGTCCCCTCAGTTCCACATGCCTGCTTGATTTTCCACC  353 
                |||||   | | ||| |    |||||||||   |||||||| ||||| |  |     
Sbjct  619  GCATGCCATAGCTATATAAGGTCAGCCCCTCAGTCAGACATGCCTCCTTGACTAACGTGT  560 
Query  354  GCCAGCGGATGGGCTTCTGTGAGA-CTCC-CCCGCTCTTGGTGG-TTAACTGGGAGGCTT  410 
            |||||||   | ||||||   | | ||||  |||||||||||||   |||||| ||  || 
Sbjct  559  GCCAGCGCTGGTGCTTCTCACACACCTCCATCCGCTCTTGGTGGAAAAACTGGCAG--TT  502 
Query  411  GTCTG--ACT-GAAGGACTTACCTTACATATTCATCCACTGCAGCTGTCCTGGGGATAAC  467 
             ||||  ||| | ||||| |  |||||| ||||| ||||   |    |    || ||||| 
Sbjct  501  ATCTGGAACTAGCAGGACATCACTTACAAATTCACCCACAAGACACTTGAATGGTATAAC  442 
Query  468  ACTGTGTCTCTGGCACTGACTATTGGCGCTTCCCTCACACCTATACTGATTGACTCGGAC  527 
            | |||| |||| |||||| || ||| | ||||     || ||||    ||||||| ||   
Sbjct  441  AATGTGACTCTTGCACTGCCTTTTGTCCCTTCGGCACCAACTATCAATATTGACT-GGCT  383 
Query  528  TCTTCGATGCCCTCACATTAGTAATCTGAGGATCAGGATGAATCTCACGACAATACTGAC  587 
              || | | || ||||||| || |||||  | || ||||  |||||  | || ||||||  
Sbjct  382  GGTTTGCTTCCATCACATTTGTGATCTGCAGCTCTGGATATATCTCCTGGCAGTACTGAA  323 
Query  588  TATGCTCTTGATTTGTGCGAATTTCCTTCTGGGTGCCAGTTGGATCACTTCTCCCATTTG  647 
             |  ||| |  ||||| | ||      ||| |||||| ||||| |||   |||||||||| 
Sbjct  322  GAACCTCCTCCTTTGTTCCAAGGCAGCTCTTGGTGCCTGTTGGGTCA-GGCTCCCATTTG  264 
Query  648  CCAGTCTGATGTGTTAACATG  668 
            |||||||||  |||| ||||| 
Sbjct  263  CCAGTCTGA-ATGTTCACATG  244  
E1                              E2                E3               E4 s    E5    E6                                E7 
204bp 871 bp ATG TAG 
100bp Imo   n.c B 
C 
Figure 5.9: 
Representation of the Bmp7 sequence (short band) identification approaches  (A) 
Schematics showing the position of the single cutter enzyme (MspI) as well as the 
exons, start and stop codons of the Bmp7 transcript. (B) Image of the digestion 
product visualised in 2% agarose gel and showing three, presumably non-specific 
bands (C) DNA sequence alignment of the purified and sequenced amplicon 
against the Bmp7 transcript. The result identified a non-specific product with 68% 
homology to Mus musculus amyloid beta (A4) precursor-like protein 2. 
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In a further attempt to identify the sequence of the 5ˈend of Bmp7 in dystrophic cells, 
the Rapid Amplification of cDNA Ends (5'-RACE) was used. Initially, the 
functionality of reagents and enzymes of the RACE kit was checked, especially the 
tailing enzyme, 5'-RACE was performed with the control RNA isolated from HeLa 
cells and with the control primers provided with the kit. The analysis of this 
amplification is given in Figure 5.10. The expected PCR products of 711bp and 
500bp were detected in the first and the second round of RACE-PCR in cDNA, 
purified cDNA, tailed cDNA and DNA control, respectively. This result confirmed 
the proper functioning of the RACE kit reagents and enzymes. No bands were 
observed in cDNA prepared from dystrophic cells, purified cDNA and tailed cDNA, 
when these samples were tested in parallel with the control.  This result confirmed 
the control primers to be specific for the control gene (chloramphenicol 
acetyltransferase (CAT). 
 
Figure 5.10: 
RACE-PCR products visualised in 2% of agarose gel showing specific products of 
711bp and 500bp representing the first and second round PCR respectively for the 
control anchor primer and GSP2 (1PCR) and GSP2 and GSP3 (2PCR) with (1) HeLa 
cells cDNA, (2) S.N.A.P. column-purified cDNA used to verify the cDNA recovery (3) 
TdT-tailed cDNA to verify dC tailing (4) Tailed cDNA by another brand (Affymetrix) 
TdT enzyme (5) DNA control to check the activity of PCR reagent and the thermal 
cycle conditions. In contrast, no bands were found in (6) cDNA synthesised from the 
dystrophic cell RNA or (7) purified dystrophic cDNA or (8 and 9) cDNAs tailed with 
the different TdT enzymes.  
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In order to test the experimental sample, Gene Specific primer 1 (GSP1) located in 
exon 4 was used to synthesise the first strand cDNA. Figure 5.11.A shows the 
validation of the synthesised cDNA by using primers sets for 5ˈ exon 1-2 region. The 
result indicated the presence of intact cDNA in wild-type cells. The expected size 
band of 169bp was detected in wild-type, but it was undetectable in dystrophic cells. 
Next, a homopolymeric tail consisting of dCTP was added by Terminal 
deoxynucleotidyl transferase (TdT) to the 3' end of the cDNA. The tailed cDNAs 
were amplified using Gene specific primer 2 (GSP2) located in exon 3-4 boundary 
and the dCTP anchor primer. The latter is complementary to the dC tail and also has 
an adapter region at its 5'end. Finally, nested PCR was carried out using the gene 
specific primer 3 (GSP3) located in exon three and the AUAP primer complementary 
to the adapter region (Figure 5.11.B). This approach provides more specificity and 
efficiency in amplification. The gel electrophoresis of the PCR product showed many 
bands. Therefore, the RACE experiment was repeated using a new set of wild-type 
and dystrophic RNA samples and also a new primer set: GSP1 located in exon 5, 
GSP2 located in exon 4-5 boundary and GSP3 located in exon 4. The design of these 
primers was informed by the analysis of the RNA-Seq in IGV software and aimed to 
position GSP3 downstream of exon 3-4 boundary, which is known to be present in 
the mdx samples. No bands were detected in wild-type and dystrophic cells after the 
first and the second round of PCR (Figure not shown).  Therefore, an attempt to 
amplify a smaller region and to check the tailing quality was made using the forward 
primer Abridged Anchor Primer (AAP) and a reverse primer in exon 1(Figure 
5.11.C). This amplification gave no bands detectable in the agarose gel.  
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Figure 5.11: 
5'-RACE analysis. Agarose gel electrophoresis visualisation of: (A) the quality of 
synthetised cDNA in wild-type and dystrophic cells using the GSP1 located in exon 4. 
The 169 bp band is visible in the wild-type but not in dystrophic cells. (B) Nested PCR 
was carried out at two different annealing temperatures: 55°C and 65°C using the GSP2 
(exon 3-4 boundary) in combination with the Anchor primer in the first step PCR and 
the GSP3 (exon 3) with AUAP primers in the second PCR step (Nested PCR). Non-
specific bands were found in wild-type and dystrophic cells. (C)  No PCR product was 
seen in wild-type and dystrophic cells when Abridged Anchor Primer (AAP)-exon1 
region was amplified. Negative controls contained water instead of the cDNA sample. 
SYBR Green was used to visualise the PCR product in 2% agarose gel. 
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 Discussion 5.4
Bmp7 is one of the altered (down-regulated) transcripts in mdx and which is 
normalised in mdx/P2rx7
-/-
. This alteration was demonstrated in 4 week and 18 
month-old TA muscles, but not in 2 week-old TA muscle; this may be related to the 
onset of expression of this transcript with the onset of the mdx pathology. Heart 
muscle, while also displaying decreased levels in mdx, showed that expression was 
not restored by P2RX7 ablation. The reduction of Bmp7 in mdx in these datasets may 
be the reason for the depletion of satellite cells and the decline of the regeneration 
process in mdx. The role of Bmp7 in maintaining the pool of activated satellite cells 
after muscle injury has been demonstrated (Friedrichs et al., 2011; Ono et al., 2011). 
BMPs stimulate satellite cells to proliferate, and prevent Noggin and Chordin to 
initiate satellite cells differentiation. The impairment of regeneration and repair of 
the damaged muscle leads to the accumulation of adipocytes and fibrosis (Avraham 
et al., 2009; Hecker and Thannick et al., 2011). The anti-fibrotic effect of Bmp7 was 
previously reported in renal and cardiac tissues (Morrissey et al., 2002: Zeisberg et 
al., 2007). Therefore, the elevation of Bmp7 in mdx/P2rx7
-/-
 indicates the reduction 
of fibrosis and may also protect satellite cells against depletion.  
Bmp7 and Tgfβ regulate each other to balance their activity; for example, the up-
regulation of Tgfβ activates the SMAD3 pathway and reduces the SMAD1/5/8-
dependent Bmp7. This happens due to both BMP7 and TGFβ sharing the same 
SMAD signalling pathway (Meng et al., 2013). It is well known the Tgfβ acts as an 
essential mediator of fibrosis and inhibiting this transcript prevents fibrosis 
development (Taniguti et al., 2011). Therefore, the elevation of Bmp7 in mdx/P2rx7
-
/-
 reduces Tgfβ and fibrosis. Indeed, the down-regulation of Tgfβ and Smad3 was 
detected in mdx/P2rx7
-/-
 in the RNA-Seq dataset. Moreover, detection of the down-
regulation of SMAD3 protein levels as well as the non-statistically significant 
difference of SMAD 1/5/8 in dystrophic myoblasts agree with the TGFβ pathway 
reduction in dystrophic cells. It has been shown that BMP7 prevents the development 
of fibrosis due the inhibition of the production of fibroblasts from stimulated 
endothelial-mesenchymal transition (EndMT) via TGFβ (Zeisberg et al., 2007). We 
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failed to detect BMP7 protein levels in GC muscle because of the low specificity of 
antibodies available for western blotting experiments.  
The down-regulation of the Bmp7 transcript (exon 3-4) in myoblasts, mdx TA and 
cardiac muscle compared with C57/BL10 indicated the possibility of an alternative 5' 
exons. This result was confirmed by (i) R package in R software, which was shown 
by the reduction of expression levels of only the region between exons 3-4 in mdx 
compared with both C57/BL10 and mdx/P2rx7
-/-
, (ii) The IGV software showing low 
numbers of reads aligned to region between exons 3-4 in mdx compared with 
C57/BL10 and mdx/P2rx7
-/-
. Altogether, this suggested either the skipped 5' exon(s) 
or an alternative 5' exon(s) in mdx.  IGV is a high performance genomic viewer 
software package that can handle large heterogeneous data types, such as NGS and 
arrays and it visualises the position where exons and introns of the transcript align to 
the genome at the base pair levels, allowing discovery of  novel transcripts and 
alternative splice variants (Thorvaldsdóttir et al., 2013). 
The alternative 5' exons in mdx were demonstrated via PCR experiments. 
Interestingly, there was no expression in dystrophic myoblasts and myofibres for 
exons 1-2 and a clear amplification of Bmp7 exons 5-7 agreed with the IGV analysis 
of RNA-Seq, which showed the re-alignment of reads just a few bp after the exon 4 
junction. Furthermore, dystrophic myoblasts showed smaller products in regions 
flanking ATG and exon 5 compared with wild-type cells suggesting that Bmp7 in 
dystrophic cells has skipped regions and also that the region between exons 1 and 5 
may contain different nucleotide sequences (alternative splice variants). 
Unfortunately, the very faint bands were insufficient for further studies but the same 
experiment repeated using two different amplification enzymes (GoTaq and iProof)  
gave confusing results, as both wild-type and dystrophin myoblasts amplify the same 
band sizes. It may represent contamination rather than biological alterations; 
especially since the same cDNA samples were used in both experiments. The 
presumed spliced band in the GoTaq experiment was digested by Msp1 to confirm 
the specificity of the band in preparation for cloning and sequencing. The band 
amplified in wild-type cells was used because the dystrophic cells showed 
insufficient quantity of amplified product that could not be used for downstream 
experiments. In addition, this band had the same size as the one found in dystrophic 
samples and  therefore, these bands should  represent the same transcript. 
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Unfortunately, the result of digestion showed three fragments, none of the expected 
molecular size. Finally, the sequencing revealed this to be the non-specific amplicon 
thus confirming the existence of a contamination in PCR products obtained using 
GoTaq and iProof. 
The 5'-RACE was used to identify the 5' end of Bmp7. This technique is used to 
amplify and characterise the unknown region where only a part of the sequence is 
known. This can be achieved by amplifying the region between a defined sequence 
and an adaptor that is added at the 3' end of the cDNA that is complementary to the 
5'-end of the mRNA (Scotto-Lavino et al., 2006). Initially, the proper functioning of 
reagents was established using the control samples and primers and good quality 
cDNA sample was confirmed upon the validation step.  
The initial 5'-RACE using GSP3 (exon 3) gave multiple non-specific bands, which 
was explained by bioinformatics showing the absence of exon 3 in the spliced 
transcript. However, using correct sets of primers: GSP1 (exon 5), GSP2 (exon 4-5 
junction) and GSP3 (exon 4) the results showed no amplification products. There are 
several possible explanations: Suboptimal primers and/or optimisation steps, the 
poor tailing of cDNA or, most likely the amplification failed because a too long 
stretch of the 5'sequence was to be amplified. Indeed, this region in the wild-type 
BMP7 transcript is in excess of 1 kb (providing that the alternative 5'end is of similar 
size to the canonical one). Our result agrees with Schaefer (1995), who mentioned 
that even though many RACE protocols have been developed, getting correct results 
from these methods is very complicated. There are many factors controlling this 
method, including primers, the tailing step, PCR conditions and the non-specific 
truncated products that result from PCR amplification (Edwards et al., 1991; Apte 
and Siebert, 1993; Maruyama and sugano, 1994; Schaefer, 1995). The major 
problem with RACE experiments is unsuccessful tailing, which result from the free 
excess nucleotides and cDNA primer. The remaining primer used in the synthesis of 
cDNA can either bind cDNA or is tailed by TdT in the tailing strategy (Templeton et 
al., 1993). Moreover, the tailed short fragments can act as templates in PCR 
reactions and would amplify preferentially to the full length transcript due to their 
small size, leading to the generation of truncated products (Frohman et al., 1993). 
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Nevertheless, the combination of bioinformatics, qPCR and standard RT-PCR 
methods indicate the presence of an alternatively spliced BMP7 transcript in mdx 
mucle and muscle cells. This transcript has an alternative sequence upstream of exon 
4 and shares the rest with the canonical one, Further studies are needed to estblish the 
full sequence of this transcript and its corresponding peptide to understand the 
functional significance of this BMP7 alteration in dystrophic muscles. 
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6  
Pharmacological inhibition of P2RX7 reduces the dystrophic 
phenotype in mdx mouse 
 
 Introduction 6.1
DMD is a lethal disease. Researchers have developed several therapeutic methods, 
some of which are currently undergoing clinical trials. However, to date, none of 
these methods have produced an effective treatment to cure this disease. At present, 
corticosteroids (deflazacort and prednisolone) are the only known treatment for 
DMD that delays the loss of ambulation (Ashwal et al, 2005; Kuntzer et al, 2008). 
While reduction in the time of climbing four stairs, walking 9 metres and 
improvement of the lung function has been shown (Armaroli et al, 2012; Ashwal et 
al, 2005; Kuntzer et al, 2008; Manzur et al., 2008), little is know about the 
mechanism responsible for the beneficial effect of corticosteroids in slowing the 
disease progression. Doses of 0.75 mg/kg/day and 0.9 mg/Kg of prednisone and 
deflazacort, respectively, appear to increase muscle strength in the short-term 
(Ashwal et al, 2005). Overweight and low growth rate are common but no clinically 
severe side effects due to the use of these drugs have been described (Alman et al, 
2012; Armaroli et al, 2012). However, further trials are required to detect the 
effective dose and suitable age to start the treatment as the effects of long-terms 
treatment is unknown.  
Molecular-based therapies are the second approach, in which the DMD transcript is 
modified by (i) exon skipping, (ii) dystrophin protein expressed by stop codon read-
through or (iii) dystrophin is replaced with utrophin. The first two methods were 
developed by exploiting the natural phenomenon of the formation of revertant fibres 
in DMD. The expression of revertant fibres in DMD either results from an alternative 
splicing event or a second mutation that represses the premature stop codon (Burrow 
et al., 1991; McClorey et al., 2005; Winnard et al., 1995). The stop codon read-
through induces the production of full-length dystrophin by using genetamycin or 
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Ataluren (Translarna) (Barton-Davis et al., 1999; Barth, 2011; Lee et al., 2012). The 
daily injection of these drugs shows some improvement in the production of the full-
length dystrophin and reduces the creatine kinase level. However, Ataluren, which 
has recently been approved in the UK, is only relevant to a small proportion of 
patients (13-15%) affected by non-sense mutations and incurs a very high cost 
(~£220,000/year). Its efficacy long-term is unclear as re-expressed dystrophin can be 
immunogenic (Malik et al., 2012). Antisense oligonucleotides (AOs) approach uses 
20–30 nucleotides to target the pre-mRNA transcript and induce skipping of targeted 
exon producing a shorter but functional dystrophin protein (Aartsma-Rus et al., 
2007). Synthetic equivalents of oligonucleotides such as Drisapersen (2OME-PS), 
Etepliresen (PMO), and peptide nucleic acid (PNA) are currently used in DMD 
animal models, while 2OME-PS, PMO and GSK2402968 (PRO 051) targeting the 
exon 51 have been tested in human clinical trials (van Deutekom  et al., 2007; 
Hoffman et al, 2009; Brolin  and Shiraishi , 2011; GlaxoSmithKline, 2011; Malik et 
al., 2012). Interestingly, most of the AO-receiving patients showed partial restoration 
of dystrophin in muscle fibres with moderate improvement in the six-minute walking 
test (Cirak et al., 2012; Aartsma-Rus et al., 2011). Two separate clinical trials using 
PMO in the UK and 2OME-PS in the Netherlands showed promising dystrophin 
expression outcomes initially. However, although all the treated patients tolerated 
these drugs (Brolin and Shiraishi, 2011; Malik et al., 2012) a Phase III trial with 
Drisapersen failed to reach a single clinical outcome measure and was terminated by 
GSK. The limitations of this strategy are associated with low efficacy due to the 
variation of dystrophin restoration in different muscles, with the lowest efficiency 
being observed in the heart (Lu et al., 2005). Arginine-rich or muscle-specific 
peptides were conjugates with AOs to increase the uptake efficacy (Wang et al., 
2010; Yin et al., 2010). The second limitation is the fact that these AOs are 
developed to target exon51, skipping of which would help only 13% of DMD 
patients (Aartsma-Rus et al., 2003). Targeting more or double exons could overcome 
this limitation.   
A third treatment approach is gene therapy. A smaller version of the dystrophin gene 
(minidystrophin) packed into an adeno-associated viral vector was delivered to the 
biceps of DMD patients (Bourque et al, 2002; Bowles et al, 2010; Bowles et al., 
2012; Duan and Zhang, 2012). Even though the vector was detected in all parts of 
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the body, future studies need to address the immune response, the function of 
dystrophin and the region of delivery problems (Mingozzi  and High, 2013). 
Recently, Sharma et al. (2016) provide a proof-of-principle study, demonstrating the 
co-injection of non-self-antigens with an immunosuppressive factor  triggers the 
prolong expression of the transgene with increase in the expression of Treg marker in 
pre-existing inflammation tissue, such as dystrophic muscles.  
Two strategies were used in treating the DMD via the muscle stem cell based therapy 
(autologous and allogenic). The first method including isolation of the satellite cells 
from DMD patient and after genetically induced to produce dystrophin, these cells 
are transferred back to the patient (Mendell and Clarke, 2006). In contrast, the 
allogenic method is preformed via isolation the functional satellite cells from a 
normal individual and transfection them into the DMD patient (Partridge, 2004). Not 
only the muscle stem cells, but Bone marrow cells such as mesenchymal stem cells 
(MSCs) are also used in treating the DMD due to the ability of these cells to 
differentiate into the several connective tissues including the myoblast (Bongs and 
Lee, 2005). Several clinical trials were carried out with encouraging results (Miller et 
al., 1997; Skuk et al., 2006; Farini et al., 2012; Hogrel et al., 2013; Sharma et 
al., 2013), but the stimulation of immune response and the early death of 90% of 
donor cells make this method need a careful and more in-depth observation 
(Maffioletti et al., 2014). 
The discovery of the up-regulation of the P2RX7 receptor in myoblasts and tissues 
derived from mdx, as well as the positive impact of ablation of the P2RX7 receptor 
in reducing the disease pathology, suggests this receptor could be an attractive target 
for treating DMD using pharmacological inhibitors (Ferrari et al., 1994; Yeung et al., 
2006; Rawat et al., 2010; Young et al., 2012; Valladares et al., 2013; Young et al., 
2013; Sinadinos et al., 2015). Two efficient and safe P2RX7 receptor antagonists 
(CE-224,535 and AZD9056) have been reported in clinical trials of rheumatoid 
arthritis (Keystone et al., 2012; Stock et al., 2012). In none of these trials serious 
infections or death occurred but both of these compounds failed to offer therapeutic 
advantages in rheumatoid arthritis. This was taken as a proof that P2RX7 compounds 
are not useful in the treatment of this disease (Coddou et al., 2011; Keystone et al., 
2012; Stock et al., 2012). Besides rheumatoid arthritis, these compounds have also 
been used in trials in Crohn’s disease associated with colorectal adenocarcinoma, 
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uterine cancer, hip fracture, osteoporosis and cardiac allograft vasculopathy (De 
Marchi et al., 2016) and the list of potential applications is growing.  
Periodate-oxidised ATP (oATP) was originally introduced as a specific label for 
nucleotide-binding-proteins and later as a selective antagonist for P2RX7 (Lowe & 
Beechey, 1982; Colman, 1983). Soon after, Sikora et al. (1999) demonstrated the 
role of oATP in the inhibition of Tnf-stimulating NO production in macrophages 
derived from P2RX7 knockout mice. This observation indicated its function in the 
blockage of other P2X receptors. However, it is still widely used as a valuable 
inhibitor for P2RX7 receptor inhibition (Ferrari et al., 1997a, Ferrari et al., 1997b; 
Gu et al., 1998; Hu et al., 1998; Mehta et al., 2001). Consideration of the conditions 
required for this reagent to be an antagonist of P2RX7 is important; for example, the 
acute exposure to oATP (100–300 mM) has the ability to repress 60% of P2RX1 and 
2 functions (Evans et al., 1995). oATP blocks the P2RX7 receptor via covalent 
reaction between the dialdehyde and lysine residues of the ATP-binding site on 
P2X7R (Lowe & Beechey, 1982; Colman,1983). This blocking causes the 
irreversible inhibition of Ca
2+
 influx. It can significantly attenuate the inflammatory 
response mediated by P2RX7, such as TNF and IL1β production (Solle et al., 2001; 
Labasi et al., 2002). The administration of oATP for 24 hours reduced the 
inflammatory pain in rats with arthritis mediated by up-regulation of the P2RX7 
receptor (Dell’Antonio et al., 2002).  
Unlike oATP, a new specific antagonist belonging to the tetrazole group (drug-like 
compound) has been developed (A-438079) (Nelson et al., 2006). The ability of this 
compound to block P2RX7-mediated calcium influx, pore formation and IL1β 
release has been demonstrated (Donnelly-Roberts and Jarvis, 2007). This antagonist 
can block P2RX7 receptors at low concentrations in humans and rats and at a slightly 
higher concentration in mice (Donnelly-Roberts et al, 2009). Treating rats with 3µg 
of A-438079 reduced the release of pro-inflammatory cytokines after global cerebral 
injury (Chu et al., 2012). The administration of A-438079 also attenuated the 
neuropathic pain in a rat model (McGaraughty et al., 2007). Importantly, there are no 
studies to date indicating the toxicity of this compound in vivo; therefore, it has been 
used in preclinical trials of hyperalgesia, epilepsy and Parkinson's disease 
(Marcellino et al., 2010; Teixeira et al., 2010; Jimenez-Pacheco et al., 2013; Mesuret 
et al., 2014). 
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AFC-5128 is a highly potent P2RX7 antagonist, which has been developed to treat 
patients suffering from neuropathic pain and multiple sclerosis. This drug can cross 
the blood-brain barrier to target the P2RX7 receptor expressed on CNS cells. Fischer 
et al. (2016) used this drug to target P2RX7 receptor in selected seizure models. It 
has been demonstrated that administration AFC-5128 alone has a limited effect on 
anticonvulsant tests, while the combination of this compound with JNJ-47965567 
was found to significantly delay the development of seizures and reduce the 
inflammatory response. There is no evidence about using this compound in other 
research; however, Dortmund (2015) announced their collaboration with Affectis 
Pharmaceuticals (AG). The collaboration aims to use AFC-5128 in treating Charcot-
Marie-Tooth disease type 1A (CMT1A), which has been linked to the over-activity 
of the P2RX7 receptor (Nobbio et al., 2009). 
Zidovudine (AZT) is a nucleoside analogue that was introduced in 1986 as an anti-
viral medication for the treatment of patients with HIV/AIDS. The mechanism by 
which AZT inhibits the virus depends on the phosphorylation of AZT (3′-Azido-3′-
deoxythymidine) by the host enzyme to produce AZT-5′-triphosphate (AZT-TP). 
The latter competes with thymidine-5′-triphosphate to be incorporated into the DNA 
of HIV and terminates the viral replication (Mitsuya et al., 1990). Recently, it has 
been found that this drug can act as a P2RX7 receptor antagonist. AZT (146 ng/µL) 
successfully reduced VEGF-A, the downstream signal of the P2RX7 receptor in 
Laser-Induced Choroidal Neovascularisation in mice (Mizutani et al., 2015). Another 
study showed that the twice daily administration of AZT prevents the release of 
P2RX7-dependent-mature-Il1b and inhibits the P2RX7 receptor-induced NLRP3 
inflammasome-dependent cell death in a mouse model of geographic atrophy, a type 
of age-related macular degeneration (AMD) (Fowler et al., 2014). Importantly, while 
bone marrow reductions, nausea, reduction of circulating neutrophils and 
mitochondrial myopathy have been reported as side effects of AZT, these are well 
known and manageable and this drug has been in use for over a decade, including in 
the pediatric population. Therefore, re-purposing it for the treatment of DMD could 
be accomplished quickly and the well-known side effects monitored and managed. 
Moreover, these side effects are related to the incorporation of AZT-TP by 
mammalian DNA polymerases β and γ (Mitsuya et al., 1990; Izuta et al., 1991; 
220 
 
Moore et al., 1995) and modifications of AZT molecule led to the retention of anti-
P2RX7 activity but decreased side effects (Fowler et al., 2014).  
 Aim and objectives 6.2
Study the effects of pharmacological inhibition of P2RX7 in dystrophic mice at 
the acute disease stage and compare these to the effects of genetic ablation of 
P2RX7. 
 Study and compare the effects of administration of various P2RX7 blockers: oATP, 
A-438079, AZT and AFC-5128  in mdx mice. 
  Select and compare different parameters based on the biomarkers identified from 
RNA-Seq analysis, immune cell infiltrations, pro- and anti-inflammatory cytokines 
as well as biochemical tests.  
 Use morphological analysis to compare the variation in fibre size, central 
nucleation, revertant fibre numbers, the integrity of sarcolemma and the number of 
infiltrating immune cells between treated and control mdx. 
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 Result 6.3
6.3.1 Effect of the oxidized ATP treatment 
In order to determine whether inhibiting the P2RX7 receptor with a pharmacological 
inhibitor can ameliorate the dystrophic phenotype, two week-old mdx mice (7 
animals) were injected intraperitoneally with 8.4 mg/kg body weight oxidized ATP 
(oATP) (Tocris Bioscience) every two days for four weeks. The age-matched control 
mice (5 animals) were injected with the same volume of sterile PBS. The animals 
were killed and the TA, GC, heart, diaphragm muscles brain and blood were 
collected. To gain some insight into the effect of oATP on the general health of 
animals, the body weights were measured for both mdx-oATP and mdx-saline every 
two days. At the end of the treatment, a similar body weight was observed in both 
groups, suggesting that administration of oATP does not affect the growth of mdx 
(Figure 6.1).  
 
Figure 6.1: 
Trend lines showing the relation between the age and weight of animals treated with 
P2RX7antagonist (oATP) or saline control for four weeks. No difference in body 
weight between mdx-oATP compared with mdx-saline was found. The gap represents a 
missed day in recording the body weight of tested animals. 
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6.3.1.1 The sarcolemmal integrity in mdx mouse treatment with oATP 
To study potential changes in the damage in the skeletal muscle of mdx injected with 
oATP compared with that injected with saline, several approaches were used. The 
creatine kinase level in the serum is an important marker of the sarcolemma 
permeability in damaged muscle fibres. The CK levels assessed in serum samples 
collected from mdx mouse injected with oATP (mdx-oATP) for four weeks indicated 
no statistically significant difference between mdx-oATP and control mdx injected 
with saline (mdx-saline) and both of these sets of samples had a high levels of CK 
typical for mdx (Figure 6.2.A). Next, to detect the sarcolemmal injury in individual 
fibres, the fibre permeability to antibody was assessed by immunodetection and 
confocal microscopy. The cross-sections through the entire GC muscle from three 
biological replicates for mdx-oATP and mdx-saline each were immunostained with 
fluorophore-labeled anti-mouse IgG antibody. The number of IgG positive fibres was 
not significantly different in mdx-oATP compared with mdx-saline (Figure 6.2.B). 
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Figure 6.2: 
Sarcolemmal integrity in mdx mice treated with P2RX7 antagonist oATP. Serum CK 
levels (A-left) in mdx mouse injected intraperitoneally with oATP compared to mdx 
injected with saline showed a high level of CK in both samples and no significant 
difference between mdx-oATP and mdx-saline. (A-right) The analysis of IgG positive 
fibre numbers indicated no significant difference between mdx-oATP and mdx-saline. 
(B) Representative immunofluorescence of IgG in positive fibres (purple signal) in 
mdx-oATP and mdx-saline. Entire GC sections of three biological replicates were 
scanned using the confocal microscope and a semi-automated method was used to 
analyse these images to avoid bias.  
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6.3.1.2 Analysis of revertant fibre numbers and muscle structure in mdx mice 
injected with oATP 
Muscle sections of six week-old GC were immunostained with anti-dystrophin 
antibody and analysed by confocal microscope. Manual counts of revertant fibres 
were achieved using Image J software. The analysis indicated that the percentage of 
revertant fibres relative to all fibres was decreased in mdx-oATP compared with 
mdx-saline, but it failed to reach the significant values (Figure 6.3). Furthermore, GC 
sections were processed for standard H and E staining to investigate the histology of 
dystrophic muscles, such as immune cells infiltration area, necrotic area, variability 
in fibre size and central nucleation. To account for the variable distribution of 
pathological features within a single specimen, the entire sections from three 
biological replicates were used in this test (Kobayashi et al., 2012). The result 
presented in Figure 6.3 indicated the reduction in dystrophic feature in mdx-oATP 
compared with mdx-saline. Furthermore, the diameter of muscle fibres was measured 
to study the impact of oATP on skeletal muscle pathology. The dystrophic muscles 
undergo the regeneration and degeneration cycle, which alters the morphological 
features (irregular shape and size) of muscle fibres. To obtain the measurement of 
these alterations, the GC muscle sections were immunostained with collagen type-IV 
and imaged under the confocal microscope. The confocal images were then analysed 
according to semi-automated measurement of the coefficient of variation of 
minimum Feret diameter developed in our lab. For this method, specific macros were 
written and applied in Image J software to measure the diameter of muscle fibre and 
calculate the number of fibres with centralized nuclei. The entire sections were used 
in the analysis to avoid the heterogeneity of the random filed studies. Three 
biological replicates of 6 week-old GC of mdx-oATP and mdx-saline muscles were 
measured and compared. Comparing average fibre size, the coefficient of variation 
of minimum Feret diameter was significantly reduced in mdx-oATP compared to 
mdx-saline.  
The healthy muscle rarely contains centrally nucleated fibres (C/N), which is an 
indicator of a fibre undergone regeneration. Therefore, sub-level of morphometric 
analysis was done to distinguish between normal and central nucleated fibre. The 
percentage of myofibres with central nuclei was compared between mdx-oATP and 
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mdx-saline. The calculation indicated no statistically significant difference in central 
nucleated fibres between both samples (Figure 6.3). 
 
Figure 6.3: 
Example immunofluorescent images of 6 week-old GC muscles from the mdx-oATP 
and mdx-saline stained with anti-dystrophin (Sigma) (red signal) highlighting numbers 
of revertant fibres (arrows). The H and E staining shows the reduction in inflammatory 
and degeneration regions, which were characterised by the immune cell-infiltrated 
muscle fibres and fragmentation of muscle fibres. The confocal images represent the 
GC muscles immunostained with Collagen type-IV (Abcam) and Hoechst/DAPI 
nuclear stain, which was used to calculate the coefficient of variation of minimum Feret 
diameter and centrally-nucleated fibres. The analysis indicated that mdx-oATP had 
significantly lower diameter compared with mdx-saline, no significant difference in 
central nucleation and no significant difference in number of revertant fibre between 
both samples. Entire GC sections of three biological replicates were scanned using the 
confocal microscope and a semi-automated method was used to analyse these images to 
avoid bias. All images have the same scal bar (100µm). 
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6.3.1.3 Administration of oATP decreases the immune cell infiltration 
The major pathological feature in mdx muscle is inflammation, which is associated 
with progression of the DMD disease (Porter et al., 2002; Tidball, 2005). There is 
much evidence to suggest that P2RX7 receptors play an important role in stimulating 
the immune response because they exist on the surface of a wide variety of immune 
cells and are involved in releasing the pro-inflammatory cytokines (Ferrari et al., 
1996; Ferrari et al., 2006; Lister et al., 2007). The most predominant infiltrating 
immune cell is the macrophage, which was found at a high number already in the 
early stage of the disease (Arahata and Engel, 1984; McDouall et al., 1990; Spencer 
et al., 2001). Therefore, the study aimed to establish whether the inhibition of the 
P2RX7 receptor by oATP reduces the accumulation of macrophages. The protein 
lysates were extracted from GC muscles of mdx-oATP and mdx-saline and used in 
Western blotting to detect the levels of P2RX4 protein. This receptor was found 
previously to be a good macrophage marker (Yeung et al, 2004). Immunoblot 
analysis using anti-P2RX4 revealed that there was a significant reduction in P2RX4 
levels in mdx-oATP compared with mdx-saline (Figure 6.4.A). To further confirm 
this result, the mRNA samples were extracted from TA and diaphragm muscles to 
identify the expression level of P2rx4 transcript in mdx-oATP and mdx-saline by 
qPCR. TA and diaphragm muscles were compared because diaphragm of mdx 
mouse shows similarity with human muscles in the severity of dystrophic features, 
such as degeneration, fibrosis, reduced muscle strength and elasticity (Stedman et al., 
1991). However, the analysis depicted in Figure 6.4.B found no statistically 
significant difference between these samples.  
TNF plays crucial role in triggering the macrophage M1 subpopulation to produce 
iNOS (Villalta et al., 2009). To explore the effect of oATP administration on this 
pro-inflammatory cytokine, the expression level of Tnf transcript in TA and 
diaphragms was tested by qPCR. The expression level of Tnf was not found 
statistically different between mdx-oATP and mdx-saline (Figure 6.4.B). 
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Figure 6.4: 
The effect of the oATP on the macrophage infiltration and inflammatory cytokines (A) 
Representative immunoblot showing levels of P2RX4 (Alomone) in mdx-oATP 
compared with mdx-saline. Densitometric analysis showed the reduction in P2RX4 
levels in mdx-oATP. The statistical analysis was performed using t-test, N=3, P=0.019. 
(B) mRNA expression level of P2rx4 (Top) and Tnf (Bottom) in 6 week-old TA and 
diaphragm muscles of mdx-oATP and mdx-saline. The analysis indicated no 
statistically significant difference in expression of P2rx4 and Tnf between the groups. t-
test, N=4-5, P=0.303, P=0.367, P=0.098, P=0.149 for P2rx4 (TA and diaphragm) Tnf 
(TA and diaphragm) respectively. 
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Finally, the cryosectioned GC muscle from mdx-oATP and mdx-saline mice were 
stained with macrophage M1 specific antibodies (CD68 and P2RX4), and observed 
under the confocal microscope. Interestingly, the number of CD68 positive cells was 
significantly reduced in mdx-oATP compared with mdx-saline. Also, fewer P2RX4 
positive cells were found in mdx-oATP compared with controls (Figure 6.5). 
Additionally, the GC sections were immunostained with macrophage M2 specific 
antibody (CD206), and the analysis showed that there was no significant difference 
between mdx-oATP and mdx-saline (Figure 6.5). 
Neutrophils have also been indicated as cells important in the initiation and 
progression of the DMD disease (Hodgetts et al., 2006). Therefore, the 
immunodetection with the neutrophil marker was used to study the effect of oATP 
administration on the neutrophil population. The GC sections were stained with the 
anti-LY6G antibody and the result indicated no significant difference between the 
mdx-oATP and the control samples (Figure 6.5). However, even when not reaching 
statistical significance, all parameters showed decreased values in the oATP treated 
group. 
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Figure 6.5: 
Immunofluorescence images showing fewer CD68 positive cells (AbD Serotec) (purple 
signal) in mdx-oATP compared with mdx-saline. The morphometric analysis of CD68 
positive cells indicated the fewer CD68 cells in mdx-oATP compared with mdx-saline. 
The analysis was performed by t-test, N=3, P<0.005. P2RX4 staining showed, 
significantly lower P2RX4  (Alomone)(green signal) levels in mdx-oATP. P2RX4 
positive cells were statistically significantly reduced when the morphometric analysis 
was applied (t-test, N=3, P=0.034). The confocal images and the morphometric analysis 
together indicated no significant difference in CD206 (AbD Serotec) (macrophage M2 
     
   -          -     
      
mdx-oATPmdx-saline
600
500
400
300
200
100
0
L
Y
6
G
P=0.512
      
     
mdx-oATPmdx-saline
600
500
400
300
200
100
0
C
D
2
0
6
P=0.417
mdx-oATPmdx-saline
400
300
200
100
0
C
D
6
8
**
mdx-oATPmdx-saline
1200
1000
800
600
400
200
0
P
2
R
X
4
*
230 
 
marker) positive cells between mdx-oATP and mdx-saline, t-test, N=3, P=0.417. GC 
sections stained with neutrophil marker LY6G (eBioscience) (red signal) and the 
morphometric analysis showed no statistically significant difference between samples t-
test, N=3, P=0.512. Entire GC sections of three biological replicates were scanned 
using the confocal microscope and a semi-automated method was used to analyse these 
images to avoid bias. All images have the same scal bar (50µm). 
 
 
It is well established that CD11B is expressed on a variety of leukocytes such as 
monocytes, neutrophils, natural killer cells, granulocytes and macrophages. 
Additionally, it contributes to the regulation of leukocyte adhesion and migration 
towards the inflammatory region (Ward et al., 2006). Therefore, the CD11B was 
studied as a hallmark for infiltrating leukocytes in the oATP-treated muscles. 
Importantly, the CD11B level was reduced significantly in mdx-oATP compared 
with mdx-saline, when the protein lysates was tested by Western blotting (Figure 
6.6.A). The immunodetection was used next to study the population of infiltrated 
leukocytes in situ. In mdx-oATP, the CD11B was reduced significantly when 
compared with mdx-saline (Figure 6.6.B). These findings are consistent with a 
scenario in which P2RX7 receptor blockade preferentially ameliorates the 
intramuscular infiltration of leukocyte.  
Taken together, these results indicate that the pharmacological blockade of P2RX7 
receptor at an early stage of the disease resulted in a significant decrease in 
coefficient of variation of minimum Feret diameter and decrease the accumulation of 
macrophages and leukocytes. However, it is well known that oATP is not a selective 
P2RX7 drug (Beigi et al., 2003; Di Virgilio, 2003). Therefore, a more specific 
P2RX7 antagonist would be needed for human trials.  
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Figure 6.6: 
Injection of oATP decreases leukocyte infiltrations. (A) An example immunoblot 
showing the reduction of CD11B protein (Sigma) in mdx-oATP compared with mdx-
saline. The densitometric analysis showed the significantly lower level of CD11B 
relative to GAPDH and ACTIN, respectively (P=0.041 and P=0.047). (B) The confocal 
images show higher numbers of infiltrating CD11B positive cells (red signal) in mdx-
saline compared to mdx-oATP. The morphometric analysis confirmed that mdx-oATP 
samples had fewer CD11B positive cells compared with mdx-saline. t-test, N=3, P< 
0.008. Entire GC sections of three biological replicates were scanned using the confocal 
microscope and a semi-automated method was used to analyse these images to avoid 
bias. 
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6.3.2 Effects of the A438079 selective P2RX7 inhibitor 
The tetrazole compound, 3-[[5-(2,3-Dichlorophenyl)-1H-tetrazol-1-yl]methyl] 
pyridine hydrochloride (A438079) is a reversible and competitive P2RX7 antagonist. 
It was demonstrated that this antagonist is more selective in blocking P2RX7 pore 
formation than oATP (Nelson et al., 2006; Honore et al., 2006). In order to 
determine whether inhibiting the P2RX7 receptor with A438079 can ameliorate the 
dystrophic phenotype in a manner similar to the genetic ablation of the P2RX7 
receptor in mdx/P2rx7
-/-
 model, two week-old mdx mice (8 animals) were injected 
intraperitoneally with 150 μmol/kg of body weight every day over two weeks. The 
age-matched control mice (7 animals) were injected with same volume of sterile 
PBS. The animals were killed and the TA, GC, heart, diaphragm tissues brain, blood, 
and tails were collected. The relation between the weight and age of mdx-A438079 
and mdx-saline were measured to determine whether the A438079 causes any side 
effects that may be affecting the animal growth. At the end of the treatment, similar 
body weight was observed between both groups (Figure 6.7). The trend line drop at 
the end of the treatment was caused by the deterioration of the health condition of 
two mice and was not related to the treatment regimen. 
 
Figure 6.7: 
Trend line representing the relationship between the age and weight of mdx animals 
treated with A438079 or saline. The result indicated that mdx-A438079 treated mice do 
not suffer from growth retardation. 
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6.3.2.1 The A438079 antagonist administration reduced skeletal muscle 
damage  
The CK levels were assessed in serum samples of four week-old mdx injected with 
A438079 or with saline. The findings indicated statistically significant reduction of 
CK levels in mdx-A438079 compared with mdx-saline, (Figure  6.8.A). 
Additionally, the percentage of fibres permeable to IgG, as an indicator of 
sarcolemmal injury, was quantified using immunodetection and confocal 
microscopy. The GC sections from three animals (treated as individual biological 
replicates) showed the percentage of IgG positive fibers in mdx-A438079 to be not 
significantly different from mdx-saline (Figure 6.8.B).  
 
Figure 6.8: 
The A438079 antagonist treatment reduced the skeletal muscle injury. Serum CK 
analysis (A-left) in mdx mouse injected with antagonist showed significantly lower 
levels of CK compared with mdx-saline. (t-test, N=6, P=0.050). No significant 
difference was found in the proportion of IgG-permeable fibres (A-right) when 
analysed by image J (B) Example immunofluorescence images show infiltrated muscle 
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fibres (IgG -purple signal) in mdx-A438079 and with mdx-saline.  Entire GC sections 
of three biological replicates were scanned using the confocal microscope and a semi-
automated method was used to analyse these images to avoid bias.  
 
6.3.2.2 Analysis of revertant fibre numbers and muscle structure in mdx 
injected with A438079  
The GC sections were immunostained with anti-dystrophin antibody and analysed by 
confocal microscope. The revertant fibres were counted manually in Image J software. 
The analysis demonstrated that the percentage of revertant fibres relative to total fibres 
was decreased in mdx-A438079 compared with mdx-saline (Figure 6.9). Standard H 
and E staining carried out in these GC sections showed less dystrophic features in 
mdx-A438079 compared with mdx-saline, which is characterised by reduction in the 
immune cell-infiltrated muscle fibres and the fragmentation of muscle fibres (Figure 
6.9). As has previously been discussed, the coefficient of variation of minimum Feret 
diameter of muscle fibres were measured to study the impact of A438079 on skeletal 
muscle pathology and showed that average diameter of mdx-A438079 muscle fibres 
was not significantly different when compared to mdx-saline. Moreover, the 
percentage of centrally nucleated myofibres was observed not to be statistically 
significantly different (Figure 6.9). 
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Figure 6.9: 
Representative immunofluorescence images of dystrophin (Sigma)(red signal) 
highlighting numbers of revertant fibres (arrow) in four week-old GC muscle sections 
from the mdx-A438079 and mdx-saline. The H and E result shows reduction of 
inflammatory cell infiltrations and degeneration regions in treated muscles. The 
Collagen type-IV (Abcam) (green signal) and Hoechst/DAPI nuclear stain 
immunostaining in cryosectioned GC muscles was used to calculate the minimum Feret 
diameter and centrally nucleated fibre numbers. Entire GC sections of three biological 
replicates were analysed and the morphometric analysis of coefficient of variation of 
minimum Feret diameter and central nucleation analysed by t-test indicated no 
significant difference between mdx-A438079 and mdx-saline. The revertant fibre count 
indicates significantly lower revertant fibre numbers in mdx-A438079 compared with 
saline controls. All images have the same scale bar (100µm). 
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6.3.2.3 The impact of A438079 antagonist on the immune cell infiltrations 
The relative levels of P2RX4 protein in both samples were not statistically 
significantly different (Figure 6.10.A). qPCR was used to compare the mRNA 
expression levels of P2rx4 between both treated groups. mRNA expression levels of 
P2rx4 also showed no significant difference in TA muscles but the expression levels 
in diaphragms were significantly reduced in mdx-A438079 compared with mdx-
saline (Figure 6.10.B). Furthermore, qPCR analysis of mRNA samples extracted 
from TA muscles revealed significant up-regulation of Tnf expression levels in mdx-
A438079 compared with control while the Tnf expression was found not to be altered 
significantly in the diaphragm samples (P=0.278) (Figure 6.10.B). 
 
Figure 6.10: 
The effect of A438079 on the macrophage infiltration and Tnf expression. (A) A 
representative immunoblot showing P2RX4 protein levels (Alomone) in mdx-A438079 
compared with mdx-saline. Densitometric analysis showed no difference in P2RX4 
protein levels. The statistical analysis was performed using t-test, N=3, P=0.86. (B) 
mRNA expression levels of P2rx4 (Top) and Tnf (Bottom) in TA and diaphragm 
muscles of mdx- A438079 and mdx-saline. The analysis indicated no statistically 
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significant difference in expression of P2rx4 in TA, however the P2rx4 transcript 
showed significant down-regulation in mdx-A438079 compared with control in 
diaphragm muscles. In contrast, the expression levels of Tnf transcript in TA muscle 
showed significant up-regulation while in diaphragm there was no significant 
difference. t-test, N=4-5, P=0.668, P=0.025, P=0.028, P=0.278 for P2rx4 (TA and 
diaphragm) Tnf (TA and diaphragm) respectively. 
 
 
In further investigations to characterise whether the A438079 antagonist reduces the 
immune cells infiltration, four week-old GC sections of mdx-A438079 and mdx-
saline were immunostained with macrophage-specific antibodies (F4/80, CD68 and 
P2RX4). F4/80 was identified as one of the murine macrophage surface components 
(Austyn and Gordon, 1981). The analysis of whole sections identified significantly 
lower F4/80 expression (P=0.016) in mdx-A438079 compared with mdx-saline. 
Also, it was obvious (Figure 6.11) that the F4/80 positive cells locate in the 
degeneration regions. There was no significant difference in the CD68 positive cells 
between both samples, whereas significantly fewer P2RX4 positive cells (P<0.005) 
were identified in mdx-A438079 compared with control (Figure 5.22). However, 
reduction in macrophage M2 marker (CD206) (P<0.005) was also found in GC 
sections of mdx-A438079 compared with mdx-saline (Figure 6.11). 
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Figure 6.11: 
Immunofluorescence images showing the effect of A438079 antagonist on the immune 
cell infiltrations in GC sections: lower number of F4/80 (Abcam) positive cells (red 
signal) was found in mdx-A438079 compared with mdx-saline. The morphometric 
analysis of F4/80 positive cells indicated fewer cells in mdx-A438079. The analysis 
was performed by t-test, N=3, P<0.016. The CD68 (AbD Serotec)  positive cells 
showed no significant difference between both groups of samples. Using anti-P2RX4 
antibody (Alomone), the significantly lower number of P2XR positive cells was found 
in mdx-A438079 compared with mdx-saline. P2RX4 signal was statistically 
significantly reduced in the morphometric analysis (t-test, N=3, P<0.005). The confocal 
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images and the morphometric analysis together indicated significantly lower numbers 
of anti-CD206 9AbD Serotec) (macrophage M2 marker) positive cells in mdx-A438079  
compared with mdx-saline, t-test, N=3, P<0.005. Entire GC sections of three biological 
replicates were scanned using the confocal microscope and a semi-automated method 
was used to analyse these images to avoid bias. All images have the same scale bar 
(50µm). 
 
  
 
 
The CD11B was used as a marker for infiltrating leukocytes. Western blot analysis 
of four week-old GC muscles showed no significant difference in CD11B protein 
levels between mdx-A438079 and mdx-saline (Figure 6.12.A). Immunolocalisation 
performed to identify the population of infiltrating leukocytes revealed that GC 
sections of mdx-A438079 had significantly fewer CD11B-positive cells compared 
with mdx-saline (Figure 6.12.B). These findings suggest that A438079 antagonist is 
same effect as oATP in ameliorating the intramuscular infiltration of leukocytes.  
To determine the effect of A438079 on infiltrating neutrophils, the immunodetection 
method with anti-LY6G (neutrophil marker) antibody was used and revealed 
significantly fewer LY6G in the mdx-A438079 compared with the dystrophic control 
samples (Figure 6.12.B). 
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Figure 6.12: 
The impact A438079 antagonist treatment on the infiltrating-leukocytes. (A) 
Immunoblot images and their respective densitometric analyses showing no significant 
difference (P=0.864) in CD11B protein levels (Abcam) in mdx-A438079 compared 
with mdx-saline. (B) The confocal images showed fewer infiltrating CD11B positive 
cells (red signal) in mdx-A438079 compared with controls and the morphometric 
analysis confirmed that mdx-A438079 has fewer CD11B cells. t-test, N=3, P= 0.013. 
Final figures represent the GC sections stained with neutrophil marker LY6G 
(eBioscience) (red signal) and their morphometric analysis indicating statistically 
significant reduction of LY6G in mdx- A438079 compared with control; t-test, N=3, 
P<0.005. Entire GC sections of three biological replicates were scanned using the 
confocal microscope and a semi-automated method was used to analyse these images to 
avoid bias. 
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6.3.2.4 Treatment with A438079 antagonist reduces autophagy in mdx 
Autophagy plays an essential role in recirculation of damaged organelles and is 
involved in muscle repair through the regeneration process (Grumati and Bonaldo, 
2012). Recent work from our laboratory demonstrated that activation of the P2RX7 
receptor by high concentration of ATP on dystrophic muscle cells resulted in large 
pore formation, autophagic flux and cell death (Young et al., 2015). Therefore, the 
next step aimed to study whether the autophagic cell death of dystrophic muscles 
mediated by ATP is prevented when the P2RX7 receptor is blocked. We investigated 
whether A438079 produced the same effect as did the genetic ablation (Sinadinos et 
al., 2015). Protein samples were extracted from GC muscle of mdx-A438079 and 
mdx-saline and were used to test the level of LC3BII protein (autophagy marker) by 
Western blot (Mizushima and Yoshimori, 2007). The result indicated a significant 
decrease in the LC3BII levels in mdx-A438079 compared with mdx-saline (Figure 
6.13).  
 
Figure 6.13: 
Adminstration of A438079 reduces the autophagic flow. (A) An example Western blot 
of protein samples extracted from GC muscles of mdx-A438079 and mdx-saline tested 
for an autophagy marker. (B) A significantly lower level of LC3BII  (Sigma) relative to 
GAPDH was found in mdx-A438079 compared with the saline control. t-test, N=3, P= 
0.009.  
 
 
In summary, these results indicate that the pharmacological blockade of P2RX7 
receptor at an early stage of the disease altered the dystrophic phenotype in a number 
of parameters such as: (i) reduced muscle injury, (ii) reduced revertant fibre 
numbers, (iii) reduced immune cell infiltrations including pan-leukocyte, 
macrophage M1 and M2, and neutrophil populations, (iv) autophagy and (v) down-
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regulated expression of P2rx4. Finally, the result also indicated that A438079 
treatment did not impede the growth of the animals.  
6.3.3 Effects of AFC-5128 P2RX7 inhibitor in mdx mice 
AFC-5128 is a novel drug developed by Affectis Pharmaceuticals to target the 
P2RX7-receptor mediated neuro-inflammation. It has been shown that the orally 
administered drug can pass the blood brain barrier and reduce the inflammation and 
neuropathic pain in an animal model. The most commonly used method for oral drug 
delivery into rodents is by gavage. This method may however cause oesophagus 
injury or death of animals as a result of inserting the gavage needle into the trachea. 
Therefore, it was decided to use a palatable mixture feeding instead of gavage as a 
means of refinement in animal experimentation. In this approach the animals are fed 
with the drug suspended in carboxymethyl cellulose (CMC) with honey (Küster et 
al., 2012), which animals consume voluntarily. 
The four week-old mdx mice (12 animals) were fed with 200mg/kg (2.5µl /g) of 
AFC-5128 twice a day over four weeks. The age-matched control mice  (12 animals) 
were fed with the same volume of CMC and honey mixture. The animals were killed 
and the TA, GC, heart, diaphragm brain and blood were collected within 90 minutes 
from the last administration. Initially, the serum samples were sent to Affecties to 
measure the drug concentration. The analysis showed a large fluctuation of AFC-
5128 serum levels (0.2-2.7µM) in mdx-AFC-5128 samples. This variability might be 
related to the drug delivery method because it was difficult to ensure that animals 
received the same volume (dose) of drug during each treatment. 
As before, the impact of the drug on general health and growth of treated animals 
was assessed and the daily body weight analysis showed that administration of AFC-
5128 did not affect the growth (Figure 6.14). 
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Figure 6.14: 
Trend line representing the relation between the age and the weight of mdx animals 
treated with AFC-5128 for four weeks. Results indicated that mdx-AFC-5128 group 
grows similarly to the mdx-control group. 
 
6.3.3.1 The AFC-5128 treatment reduced the skeletal muscle injury  
The CK levels measured in serum samples indicated statistically significant 
reduction in CK level in mdx-AFC-5128 compared with mdx-control (Figure 
6.15.A). To investigate the possible effect of drug level fluctuations on the 
experimental result, the correlation analysis between the serum drug concentration 
and the CK results was performed. The result (Figure 6.15.B) indicated no 
correlation between these variables (VIF=1). Next, the GC sections from 
independent animals were immunostained for IgG antibody and this analysis showed 
no significant difference in the IgG positive fibres in mdx-AFC-5128 compared with 
control (Figure 6.15.C). 
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Figure 6.15: 
The effects of AFC-5128 treatment on skeletal muscle injury (A-left) Serum CK levels 
in mdx mouse were significantly lower in mdx-AFC-5128  compared with controls (t-
test, N=6, P=0.045). (A-right) The densitometric analysis showed no significant 
difference in the number of IgG-infiltrated myofibres. (B) Scatter plot showing a lack 
of correlation between the serum concentration of AFC-5128 and the CK levels VIF=1 
(C) Immunofluorescence images showing the typical distribution of IgG infiltrated 
(purple signal) fibres. Entire GC sections of three biological replicates were scanned 
using the confocal microscope and a semi-automated method was used to analyse these 
images to avoid bias. 
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6.3.3.2 Analysis of revertant fibres and the muscle structure following AFC-
5128 administration  
GC sections of mdx-AFC-5128 and mdx-control were used in this part of the study 
to characterise the histological phenotype of mdx muscle after the treatment with 
AFC-5128. Initially, these sections were stained with anti-dystrophin antibody to 
count the revertant fibres. The analysis identified no significant difference between 
mdx-AFC-5128 and mdx-control (Figure 6.16). Secondly, GC sections were stained 
with H and E and scanned using the automated Ariol microscope system. This 
analysis revealed an increase the infiltrations of immune cell in mdx-AFC-5128 
compared with mdx-control (Figure 6.16). Finally, analyses of the coefficient of 
variation of minimum Feret diameter and the percentage of centralised nuclei 
myonuclei showed no statistically significant differences between samples (Figure 
6.16).  
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Figure 6.16: 
 Representative immunofluorescence images of eight week GC muscle sections from 
mdx-AFC-5128 and mdx-controls for: revertant fibres (red signal; highlighted by the 
arrow); The H and E showing an increase in inflammatory cell infiltrations in mdx-
AFC-5128. The Collagen type-IV (Abcam) (green signal) and Hoechst/DAPI nuclear 
stain immunostaining was used to calculate the coefficient of variation of minimum 
Feret diameter and centrally nucleated fibre numbers. The morphometric analysis of the 
minimum Feret diameter and central nucleation was calculated by t-test and indicated 
no significant difference between mdx-AFC-5128 and mdx-control. No significant 
difference in revertant fibre numbers between mdx-AFC-5128 and mdx-control was 
found. Entire GC sections of three biological replicates were scanned using the 
confocal microscope and a semi-automated method was used to analyse these images to 
avoid bias. All images have the same scale bar (100µm). 
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6.3.3.3 The impact of AFC-5128 treatment on the immune cell infiltration 
RNAs from the mdx-AFC-5128 and mdx-control TA muscles were used to analyse 
the expression levels of Tnf, P2rx4, Foxp3, Il12a and Il10 transcripts by qPCR. The 
expression level of Tnf was not significantly affected by AFC-5128 treatment. P2rx4 
expression was up-regulated significantly in mdx-AFC-5128 compared with mdx-
control (Figure 6.17). This enhancement was in agreement with the H and E staining 
results. The relative expression of Treg marker (Foxp3) showed no significant 
difference between samples, whereas Il12a expression was significantly up-regulated 
in mdx-AFC-5128 compared with mdx-control, indicative of the effect promoting 
the Treg cells. Moreover, there was an elevation of Il10 expression in mdx-AFC-
5128. This cytokine has a role in switching from M1 to M2 macrophages and this 
transition is essential for muscle growth and regeneration (Deng et al., 2012). 
 
Figure 6.17: 
The relative expression of Tnf, P2rx4, Foxp3, Il12a and Il10 in TA muscles from mdx-
AFC-5128 and mdx-control. P2rx4, Il12a and Il10 showed significant up-regulation in 
mdx-AFC-5128 compared with mdx-control. The Tnf and Foxp3 were not significantly 
affected. The level of genes expression was calculated using 2
−ΔΔCT
 method and the 
statistical analysis was performed by t-test, N=5, P< 0.074, P<0.005, P=0.438, P=0.028 
and P=0.043 for Tnf, P2rx4, Foxp3, Il12a and Il10 respectively. 
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Further investigations involved immunostaining of GC cryosections for macrophage 
specific marker (F4/80, CD68 and P2RX4). There was, however, no statistically 
significant difference in any of these markers in mdx-AFC-5128 compared to 
controls (Figure 6.18). The CD206 (M2 marker) was also not significantly changed 
between these samples (P=0.795) (Figure 6.1). 
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Figure 6.18: 
Typical immunofluorescence images of immune cell infiltrations in GC sections from 
mdx-AFC-5128 and mdx-controls: There was no significant difference in numbers of 
F4/80 (Abcam), CD68 (AbDSerotec), P2RX7 (Synaptic System) and CD206 (AbD 
serotec) positive cells between both groups of samples. (t-test, N=3 and P=0.576, 
P=0.88, P=0.773 and P=0.795, respectively). Entire GC sections of three biological 
replicates were scanned using the confocal microscope and a semi-automated method 
was used to analyse these images to avoid bias. All images have the same scale bar 
(50µm). 
 
 
 
Furthermore, the CD11B analysis by immunoblot demonstrated the lower level of 
CD11B protein in GC muscles from mdx-AFC-5128  versus mdx-control (Figure 
6.19.A) while the immunolocalisation of CD11B cells in the same muscle showed no 
significant difference in numbers between the two groups (Figure 6.19.B).  
 
 
Figure 6.19: 
The impact of AFC-5128 administration on the leukocyte population. (A) Immunoblot 
images showing significantly lower levels of CD11B protein (Abcam) in mdx-AFC-
5128 compared with mdx-control (P=0.034). (B) Example of confocal images showing 
no significant difference in numbers of CD11B positive cells (red signal) in mdx-AFC-
5128 compared with dystrophic controls. (N=3, t-test, P= 0.132). Entire GC sections of 
three biological replicates were scanned using the confocal microscope and a semi-
automated method was used to analyse these images to avoid bias. 
 
  
      
   -           -   -     
  
      
      
        
       
   -   -        -        
mdx-AFC-5128mdx-control
1.2
1.0
0.8
0.6
0.4
0.2
0.0
C
D
1
1
B
/G
A
P
D
H
*
mdx-AFC-5128mdx-control
500
400
300
200
100
0
C
D
1
1
B
P=0.132
250 
 
6.3.3.4 Administration of AFC-5128 reduced autophagy in mdx muscles 
To investigate whether AFC-5128 treatment can reduce the autophagic flux and cell 
death, protein samples from GC muscles were used to test the levels of LC3BII 
protein (autophagy marker) by Western blotting (Mizushima and Yoshimori, 2007). 
The results showed significantly lower levels of the LC3B11 in mdx-AFC-5128 
compared with mdx-control (Figure 6.20). 
 
 
  
Figure 6.20: 
Adminstration of AFC-5128 reduced the autophagy in mdx muscles. Western blotting 
showing the levels of autophagy marker LC3BII protein (Sigma) loading control. 
Densitometric analysis of these blots showed a significantly reduced LC3BII protein 
levels in mdx-AFC-5128 compared with controls (N=7, t-test, P= 0.010).  
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In conclusion, treating mdx with AFC produced reduction in releasing the creatine 
kinase (myofibre injury marker), in CD11B protein levels (leukocytes cells 
infiltrations marker), the LC3BII protein levels (autophagy marker), elevation of Il12 
and Il10 transcript levels (with a role in shifting M1 toward M2). Finally, the result 
also indicated that AFC treatment does not impede the growth of animals. 
6.3.4 Effects of Azidothymidine (AZT) 
Azidothymidine (AZT) also known as Zidovudine is a nucleoside reverse 
transcriptase inhibitor widely used in treating the HIV/AIDS (Senanayake et al., 
2015) but found recently to be a P2RX7 receptor antagonist (Fowler et al., 2014; 
Mizutani et al., 2015). To evaluate the impact of AZT-evoked inhibition of P2RX7 
in mdx muscular dystrophy, four week-old mdx mice (10 animals) were injected 
intraperitoneally with 50mg/kg body weight twice a day for two weeks and the 
treatment outcome was analysed at six weeks. The age-matched control mice (10 
animals) were injected with the same volume of sterile PBS. The animals were killed 
and the TA, GC, heart, diaphragm, brain, and blood were collected. Moreover, the 
effect of AZT on the body weight have been analysed by measuring the weight of 
animals daily and then calculating the relation between the weight and age. The body 
weight increased in both groups at the same rate, suggesting no significant side 
effects of the drug/dose (Figure 6.21). 
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Figure 6.21: 
Trend line representing the relation between the age and weight of mdx animals treated 
with AZT for two weeks. Result indicated that mdx-AZT grows similarly to mdx-saline 
group.  
 
6.3.4.1 The analysis of serum CK level and IgG muscle fibre permeability in 
mdx mouse treated with AZT  
The analysis of CK levels in serum samples indicated that there was no statistically 
significant change in CK level in mdx-AZT compared with mdx-saline, (Figure 
6.22.A). Subsequently, the percentage of fibre permeability to IgG antibody was 
measured as an indicator of sarcolemmal injury revealed that the IgG positive fibers 
decreased significantly in mdx-AZT compared with mdx-saline (Figure 6.22.B).  
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Figure 6.22: 
The effect of AZT on skeletal muscle injury (A-left) Serum CK levels in mdx mouse 
injected with AZT or saline showed no significant difference in CK level between the 
samples (t-test, N=6, P=0.053). (A-right) The densitometric analysis of IgG positive 
fibres showed lower IgG infiltration in GC muscles of mdx-AZT compared with mdx-
saline. (B) Immunofluorescence images illustrating the lower number of IgG infiltrated 
(purple signal) fibres in mdx-AZT compared with mdx-saline. Entire GC sections of 
three biological replicates were scanned using the confocal microscope and a semi-
automated method was used to analyse these images to avoid bias. 
 
 
 
 
 
 
 
   -          -    
    
  
  
mdx-AZTmdx-saline
18
16
14
12
10
8
6
4
2
0
Ig
G
 (
%
)
*
mdx-AZTmdx-saline
600
500
400
300
200
100
0
C
K
 U
/L
P=0.053
254 
 
 
 
 
 
Interestingly, while the serum creatine kinase is considered to be a diagnostic marker 
for DMD, some new studies suggest that CK does not reflect the severity of the 
disease. Several studies indicated the role for miRNAs (dystromirs) (miR-1, miR-
133a, miR-133b, miR-31 and miR-206) as good markers for detecting the severity of 
DMD disease (Cacchiarelli et al., 2011; Wang et al., 2012; Zaharieva et al., 2013). 
These muscle miRNAs become released into the bloodstream in both DMD patients 
and mdx mice due to sarcolemmal damage and the circulating miRNAs in serum 
parallel the disease severity (Roberts et al, 2012). Here, one of these miRNAs was 
analysed. Total RNA samples including miRNAs extracted from sera of C57/BL10, 
mdx and mdx/P2rx7
-/-
 were used to detect the expression of miR-206. Moreover, to 
compare the expression levels of miR-206 between serum and muscle samples, RNA 
samples from muscles of C57/BL10, mdx, mdx
βgeo
, mdx/P2rx7
-/-
, Pfizer-P2rx7 and 
Glaxo-P2rx7 knockout were analysed by qPCR. The level of miR-206 was found 
elevated in serum samples of mdx compared with C57/BL10. There was no 
significant difference between mdx/P2rx7
-/-
 compared with mdx in the expression of 
miR-206. In muscle samples, the expression of miR-206 was significantly up-
regulated in mdx and mdx/P2rx7
-/-
 compared with C57/BL10, mdx
βgeo
, Pfizer-P2rx7 
and Glaxo-P2rx7 knockouts. Interestingly, this analysis showed that mdx had a 
higher level of miR-206 than mdx
βgeo
. This result shows agreement with Zahariev et 
al., 2013 study, who found high levels of circulating miRNAs in the acute stage of 
DMD compared with the late stage of disease. In addition, this analysis showed the 
same pattern of miR-206 expression in serum and TA muscle samples. This result is 
in agreement with a previous study by Roberts et al., 2012, which showed that the 
expression of miR-206 is moderately high in dystrophic TA muscle. The expression 
of miR-206 was analysed in serum samples collected from mdx-AZT and mdx-
saline. Interestingly, the expression of this miRNA was significantly down-
regulation in mdx-AZT compared with control samples (Figure 6.23).  
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Figure 6.23: 
The relative expression of miR-206 in (A) TA muscle of C57/BL10, mdx, mdx
βgeo
, 
mdx/P2rx7
-/-
, Pfizer-P2rx7 and Glaxo-P2rx7 knockout, indicated up regulation of miR-
206 in mdx and mdx/P2rx7
-/-
 compared with C57/BL10, mdx
βgeo
, Pfizer-P2rx7 and 
Glaxo-P2rx7 (one way ANOVA, N=5, P<0.005). (B) Analysis of serum samples from 
C57/BL10, mdx and mdx/P2rx7
-/-
, demonstrated the up-regulation of miR-206 in mdx 
compared with C57/BL10 and no significant difference between mdx and mdx/P2rx7
-/-
 
(one way ANOVA, N=5, P<0.005). (C) The expression of miR-206 was down-
regulated in mdx-AZT compared with mdx-saline (t-test, N= 4, P=0.021). 
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6.3.4.2 Analysis of revertant fibres and muscle structure in mdx injected with 
AZT 
To characterise the histological phenotype of mdx muscle after the treatment with 
AZT, sections were stained with anti-dystrophin antibody to compare the revertant 
fibre numbers. This analysis indicated that there was no significant difference in the 
percentage of revertant fibres between these samples (Figure 6.24). Secondly, the GC 
sections were stained with H and E and analysed using an automated microscopy 
system (Ariol). Interestingly, this showed a clear reduction in histological feature of 
DMD such as reduction in the immune cell-infiltrated muscle fibres and the 
fragmentation of muscle fibres. The regeneration region (small myotubes with 
central nuclei) was reduced too (Figure 6.24). However, the coefficient of variation 
of minimum Feret diameter and the percentage of myofibres with central nuclei were 
not statistically significantly different between samples (Figure 6.24).  
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Figure 6.24: 
Representative immunofluorescence images of GC muscle sections from mdx-AZT and 
mdx-saline showing: Revertant fibres (red signal an arrow). The H and E staining, 
shows very obvious reduction in the inflammatory infiltrations in mdx-AZT. The anti-
collagen type-IV (Abcam) (green signal) and Hoechst/DAPI nuclear stain 
immunostaining was used to calculate the coefficient of variation of minimum Feret 
diameter and centrally nucleated fibres. Entire GC sections of three biological 
replicates were scanned using the confocal microscope and a semi-automated method 
was used to analyse these images to avoid bias. There was no significant difference 
between mdx-AZT and mdx-saline in the coefficient of variation minimum Feret 
diameter, the central nucleation and the revertant fibre count (t-test). All images have 
the same scale bar (100µm). 
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6.3.4.3 The impact of AZT on the immune cell infiltration 
Given the very significant and reproducible reduction of immune cell infiltration 
areas in mdx-AZT muscles (see above), the expression levels of Tnf, P2rx4, Il12a, 
Foxp3, Bmp7 and Ccl2 transcripts were analysed in the mdx-AZT and mdx-saline 
TA muscle RNAs by the qPCR method. The expression level of Tnf was 
significantly down-regulated in mdx-AZT compared with mdx-saline (Figure 5.36). 
Importantly, this decrease suggested that Tnf production, being dependant on 
P2RX7, decreased as a result of this receptor blockade as the genetic ablation of theis 
receptor also resulted in lower Tnf levels (Sinadinos et al., 2015). Clearly, AZT 
reduced the expression of one of the important inflammatory cytokines linked to 
DMD pathogenesis (Grounds and Torrisi, 2004; Chessell et al., 2005). Additionally, 
the P2rx4 was down-regulated significantly, and this receptor is expressed on 
macrophages. Therefore its reduction confirmed the decline in the macrophage load 
(Yeung et al., 2004). Interestingly, there was a significant down-regulation of 
relative expression levels of Foxp3 and Il12a in mdx-AZT compared with mdx-
saline. This could indicate the suppression of Treg cells and this result was in 
contrast to the increased Treg levels in mdx/P2rx7
-/-
 muscles. Treg cells are essential 
in regulating the immune response and in maintaining tolerance to the self-antigens 
thus suppressing the autoimmune disease. Finally, the mRNA expression levels of 
Bmp7 and Ccl2 showed no significant difference between the samples (Figure 6.25). 
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Figure 6.25: 
The relative expression levels of Tnf, P2rx4, Foxp3, Il12a, Bmp7 and Ccl2 transcripts 
in TA muscles from mdx-AZT and mdx-saline. Tnf, P2rx4, Foxp3 and Il12a showed 
significant down-regulation in mdx-AZT. Bmp7 and Ccl2 were not significantly 
different. The level of gene expression was calculated using 2
−ΔΔCT
 method and the 
statistical analysis was performed by t-test, N=4, P<0.005, P=0.029, P<0.005, P<0.005, 
P=0.133 and P=0.748 for Tnf, P2rx4, Foxp3, Il12a, Bmp7 and Ccl2, respectively. 
 
 
In further investigations to characterise whether the AZT reduces the immune cells 
infiltration, six week-old GC cryosections were immuno-stained with macrophage 
specific antibodies (F4/80, CD68 and P2RX4). The analysis of whole sections 
indicated statistically significant decrease of F4/80 and P2RX4 positive cells and the 
fluorescence intensity of CD68 (P=0.016, P=0.036 and P=0.044 respectively) in 
mdx-AZT compared with mdx-saline (Figure 6.26). The fluorescence intensity of 
macrophage M2 marker (CD206) showed no significant difference between both 
samples (P=0.599) (Figure 6.26). 
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Figure 6.26: 
The effect of AZT on immune cell infiltrations. Immunofluorescence images of GC 
sections from mdx-AZT and mdx-saline and respective graphs summarizing the 
numerical analyses: fewer F4/80 positive cells (Abcam) (red signal) were detected in 
mdx-AZT compared with mdx-saline. N=3, t-test, P=0.016. The CD68 (AbD Serotec) 
fluorescence intensity were significantly lower in mdx-AZT compared with control 
(P=0.044). P2RX4 positive cells (Alomone) were also significantly reduced in mdx-
AZT (N=3, t-test, P<0.036. There was no significant difference in the fluorescence 
intensity of CD206 (AbD Serotec) (macrophage M2 marker) cells in mdx-AZT 
      
      
     
      
   -          -    
mdx-AZTmdx-saline
500
400
300
200
100
0
P
2
R
X
4
 
*
mdx-AZTmdx-saline
8
7
6
5
4
3
2
1
0
C
D
6
8
 a
re
a
 %
*
mdx-AZTmdx-saline
7
6
5
4
3
2
1
0
C
D
2
0
6
 A
re
a
% P=0.599
mdx-AZTmdx-saline
600
500
400
300
200
100
0
F
4
/8
0
*
261 
 
compared with mdx-saline (N=3, t-test, P <0.599). Entire GC sections of three 
biological replicates were scanned using the confocal microscope and a semi-automated 
method was used to analyse these images to avoid bias. All images have the same scale 
bar (50 µm). 
 
 
 
 
Furthermore, the levels of the CD11B leukocyte marker were analysed by, 
immunoblot in GC muscles of mdx-AZT and mdx-saline. The analysis demonstrated 
a significant difference in CD11B protein levels, which was reduced in mdx-AZT 
compared with the control (Figure 6.27.A). However, the immunodetection although 
indicated the lower number, did not identify a statistically significant difference in 
CD11B population in md-AZT compared with mdx-saline (Figure 6.27.B). In 
contrast, staining for LY6G (neutrophil marker) showed significantly fewer LY6G 
positive cells (P=0.030) in the mdx-AZT compared with the control mdx samples 
(Figure 6.27.B). 
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Figure 6.27: 
The impact of AZT on the leukocyte population. (A) Immunoblot showing significantly 
lower levels of CD11B protein (Abcam) in mdx-AZT compared with mdx-saline. The 
densitometric analysis confirmed this result (P<0.005). (B) The confocal analysis 
showed no significant difference in numbers of infiltrating CD11B positive cells (red 
signal) in mdx-AZT compared with controls. (N=3, t-test P=0.125). The neutrophil 
marker LY6G (eBioscience) (red signal) and the morphometric analysis data graph 
showing a statistically significant reduction of LY6G cells in mdx-AZT compared with 
controls (N=3, t-test, P=0.030). Entire GC sections of three biological replicates were 
scanned using the confocal microscope and a semi-automated method was used to 
analyse these images to avoid bias. 
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6.3.4.4 Analysis of Mitofusin 2 in muscles of mdx mice treated with AZT 
In order to establish the effect of AZT treatment on mitochondrial function, the 
relative expression level of Mfn2 gene was analysed. This gene was chosen because 
it has essential role in mediating the mitochondrial functions (Zhao et al., 2012; Ding 
et al., 2015).  Interestingly, the result indicated up-regulation of this transcript in 
mdx-AZT compared with saline-injected samples, indicating that AZT does not 
negatively affect the mitochondrial functions (Figure 6.28). 
To confirm the effect of long term treatment of AZT on the mdx mouse, the 4 weeks 
old mdx were injected the same dose 50mg/kg body weight twice a day for 4 weeks 
and the treatment outcome was analysed at 8 weeks. The age-matched control mice 
were injected with the same volume of sterile PBS. The qPCR analysis showed 
(Figure 6.29) the statistically significant reduction in neutrophil (Ly6g), macrophage 
(Cd68, P2rx4) and pro-inflammatory cytokines markers (Tnf) and elevation of Treg 
marker (Il12a). These results matched the short treatment (2 weeks) analysis and also 
improved Treg marker expression. Taken together, these data indicated that short and 
long term treatment improve the pathological feature of DMD that coincide with 
activation of P2RX7, suggesting that AZT is a sufficiently effective P2RX7 
antagonist and targeting this receptor using AZT may attenuate the DMD disease.   
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Figure 6.28: 
The relative expression levels of Mfn2 in TA mdx-AZT and mdx-saline revealed the 
up-regulation of Mfn2 transcript in mdx-AZT compared with the saline group (t-test, 
N=7, P<0.005). 
 
Figure 6.29: 
The relative expression levels of Tnf, P2rx4, Cd68, Ly6g, Foxp3, Il12a and Bmp7 
transcripts in TA muscles from mdx-AZT and mdx-saline treated for 4 weeks (long 
term treatment). Tnf, P2rx4, Cd68, Ly6g, Foxp3 and Bmp7 showed significant down-
regulation in mdx-AZT. Il12a was significantly up-regulated. The level of gene 
expression was calculated using 2
−ΔΔCT
 method and the statistical analysis was 
performed by t-test, N=5-6, P<0.005 for all of the transcripts except Bmp7, P=0.030. 
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The short and long term P2RX7 blockade by AZT altered a number of dystrophic 
parameters and did not cause any detectable side effect. In short term treatment the 
permeability of IgG and miR206 were reduced and both are markers for muscle 
injury. There were significantly reduced expression levels of Tnf and P2rx4. In 
addition, the expression level of Mfn2 was elavated. The immune cell infiltrations 
(pan-leukocyte, macrophage M1, leukocytes cells and neutrophil populations) were 
also reduced. The treatment did not have negative effects on the animal’s growth. 
The qPCR analysis of several selected parameters of long term treatment showed the 
same expression pattern as in 2 week treatment with increased expression of the 
Treg-marker (Il12a). This result suggests that AZT is an effective P2RX7 inhibitor 
even in a short term therapy with an extensive impact on the disease pathology. The 
major advantage of this drug is its long history of use in patients, including in 
children, for other diseases and therefore it can be re-purposed for DMD relatively 
easily. 
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 Discussion 6.4
It is well known that prolonged agonist (ATP) exposure leads P2RX7 to form the 
large pore, to activate and release pro-inflammatory cytokines, apoptosis and in some 
cells/circumstances autophagic cell death. Interrupting the overactivation of P2RX7 
by genetic knockout or by pharmacological inhibitor produces a significant 
improvement in the key features of DMD disease as shown in this thesis and also as 
published (Sinadinos et al., 2015; Young et al., 2015). With regards to the 
mechanism through which the ablation of P2RX7 receptor recovers muscle we 
compared the effects of P2RX7 pharmacological inhibitors (oATP, A-438079, AZT 
and AFC-5128) in mdx. In spite of the extensive research to find a treatment for 
DMD, there is a noticeable lack of generally agreed parameters such as age of 
animals, length of treatment and end points for testing efficacy. Clearly, such 
treatments demand that standardised procedures should be established (Harcourt et 
al., 2005; Payne et al., 2006; Radley and Grounds, 2006). Spurney et al. (2009) 
suggested that studying the muscle strength, cardiac function, minimum Feret 
diameter and CK is enough to monitor the outcome of an applicable drug but this 
appears to be an over simplification.  
Based on the biological markers identified by RNA-Seq as well as the tests 
recommended by the DC Wellstone Center and the TREAT-NMD Network 
(http://www.treat-nmd.edu/activities/treatment/html), it was decided to use several 
parameters to identify the effects of these pharmacological inhibitors in this study. (i) 
creatine kinase is a muscle protein and its existence in the serum used is an indicator 
of muscle damage. However, the CK test is used in routine diagnostic tests for DMD 
disease, and the CK level can be influenced by exercise, age and gender as well as 
the method used for collecting blood from animals (Grounds et al., 2004; De Luca et 
al., 2005; Spurney et al.,2009). In mdx, correlating CK to the severity of the disease 
is difficult due to the manifestation of a mild dystrophic phenotype. For example, in 
one preclinical study the improvement in some parameters has been shown but not 
including the CK (Anderson et al., 1996). (ii) The miRNAs, non-protein-coding 
RNAs, regulate post-transcriptional gene expression. They suppress the expression 
of target genes either by stimulating the degradation or inhibiting the translation 
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(Obernosterer et al., 2006). miR-1, miR-133a, miR-133b, miR-31 and miR-206 are 
abundant in muscle and maintain muscle function and regeneration and therefore 
they are called “dystromirs”. miR-206 and miR-133b are encoded only in muscle. It 
has been noticed that miR-206 is expressed on satellite cells and triggers their 
differentiation (Liu et al., 2012). Dystromirs are released into blood upon 
degeneration (Cacchiarelli et al., 2011). The same authors described these miRNAs 
as valuable non-invasive biomarkers for detecting DMD disease and identifying the 
effect of new therapeutic drugs. It has been indicated that the amount of released 
miRNAs is relevant to the severity of DMD disease; for example, the expression of 
miRNAs is found to be elevated in mdx and DMD but not in wild-type and 
dystrophin-restored animals (Denti et al., 2006). Interestingly, higher levels of 
circulated dystromirs have been seen in the serum of DMD patients under a daily 
steroid regimen, contradicting the efficacy of corticosteroids in treating this disease 
(Mendell et al., 1989; Ricotti et al., 2012). (iii) It has been seen that normal muscle 
contains serum globulin (IgG and IgM) in endo- and perimysium, while in mdx, 
these immunoglobulins pass into the cytoplasm (Straub et al., 1997) The 
accumulation of immunoglobulin inside the muscle fibres indicates the disruption of 
the sarcolemma. Many studies have used this technique to investigate the effects of 
therapeutic drugs in reducing the muscle damage (von Maltzahn et al., 2012; Hindi 
et al., 2014; Janssen et al., 2014). (iv) A histological method was proposed to 
estimate the effects of treatment on the degeneration-regeneration cycles, which is 
based on counting the number of revertant fibres. Secondly, this can be achieved by 
measuring the coefficient of variation of the minimum Feret diameter of muscle fibre 
and calculating the number of fibres with centralised nuclei. It has been observed in 
some DMD, mdx and in Golden Retriever muscles that single or small clusters of 
dystrophin positive fibres (revertant fibres) can occur (Hoffman et al., 1990; Fanin et 
al., 1995; Schatzberg et al., 1998). A study by Lu et al. (2000) indicated that 
revertant fibres were produced by alternative transcript splicing that skipped a 
number of adjacent exons and produced a novel transcript that translated into an in-
frame-truncated dystrophin protein, or arose from another somatic mutation that 
reversed the dystrophin mutation and restored the dystrophin open reading frame 
(Hoffman et al., 1990). These revertant fibres were suggested to be an indicator of a 
number of degeneration-regeneration cycles because they only occurred when the 
satellite cells proliferated due to the degeneration event (Yokota et al., 2006; Yokota 
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et al., 2009; Sacco et al., 2010; Young et al., 2012; Pigozzo et al., 2013). The 
minimum Feret diameter is a geometrical parameter that enables the size of a cross 
section of muscle fibres to be measured (Briguet et al., 2004; Pertl et al., 2013). This 
method is very robust for compensating for the technical error that occurs due to the 
orientation of the sectioning. Dystrophic muscle is characterised by the consequence 
of degeneration-regeneration cycles. The regeneration is identified by small-size 
centrally nucleated fibres (Karpati et al., 1988; Turk et al., 2005). Accordingly, the 
increase of muscle fibre size is an indicator of amelioration of the muscle damage 
(Gehrig et al., 2010). Moreover, the heterogeneity of muscle fibre size is observed in 
the same section of the adult mdx muscle representing intact, necrotic and 
regenerated myofibres (Grounds et al., 2008). The variability of muscle fibre can be 
quantified by using the coefficient of variation (CoV) of the minimum Feret diameter 
and relying on the minimum Feret diameter value (Briguet et al., 2004). The 
regenerated fibres are recognised by centrally located nuclei obtained and act as an 
indicator of muscle pathology. Louboutin et al., in 1993, identified about 40, 70 and 
65% of internal nuclei myofibres in the diaphragm, TA and soleus, respectively. 
Therefore counting the number of fibres with these centrally located nuclei is a 
reliable measurement of the regenerated muscle tissue (Grounds et al., 2008). 
However, the centrally nucleated fibre alone was indicated as not being an accurate 
marker for muscle pathology because some of the myofibres display resistance to 
damage (Narita et al., 1999). A higher variability of muscle fibre size and high 
percentage of centrally nucleated fibre have been detected in mdx muscle (Torres 
and Duchen, 1987; Coulton et al., 1988). (v) The haematoxylin and eosin (H and E) 
method is a very common histological method in investigating the morphological 
features of mdx muscles (Ballmann et al., 2015). In young mdx mice, it is used to 
quantify the necrotic area (recognised by the presence of infiltrating immune cells 
and degeneration of myofibres) (Jearawiriyapaisarn et al., 2008) and the regeneration 
region (identified by the appearance of small myofibres with central nuclei) (Morgan 
et al., 1990). In older mdx mice, the H and E method is used to observe fibres 
resistant to degeneration (characterised by normal-size fibres with peripheral nuclei) 
(McGeachie et al., 1993) and fibrosis. However, it has been found that the use of 
Masson’s trichrome staining (MT) clearly differentiates the collagen deposition and 
therefore the fibrosis in mdx muscle sections (Suvik and Effendy, 2012). For 
histological study, van Putten et al., (2010) recommended collecting sections from 
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one constant muscle location as long as the researcher mentioned the region. In this 
study, all sections were collected from the middle third of the gastrocnemius (GC) 
muscle. The large-size GC muscle section may result in difficulties in cutting cross 
all myofibres horizontally and also may easily get folded. In this study, the 
morphometric results were based on analysis of whole sections of three biological 
replicates because the histopathological phenotypes of mdx are not homogenous 
within a single muscle section. (vi) As explained earlier, dystrophin-deficient 
muscles serve as a source of a high level of danger signal (ATP) together with other 
DAMPs (Matzinger, 2002). These released danger signals attract immune cell-
mediated inflammation (Andrei et al., 2004; Mehta et al., 2001). The inflammatory 
response is the important feature of DMD disease (Porter et al., 2002). A mixed 
population of innate and adaptive immune cells such as macrophages, neutrophils, 
eosinophils, mast cells and CD4+ and CD8+ T-cells infiltrate the damaged myofibre 
and are candidates for exacerbating the disease (Gorospe et al., 1994b; Gussoni et 
al., 1994; Spencer and Tidball, 2001; Spencer et al., 2001; Karmakar et al., 2016). 
Immunosuppression therapy was shown in one study to ameliorate the disease and 
prolong the life span of patients (Kissel et al., 1993). The high concentration of ATP 
stimulates the P2RX7 receptor, which is known to be expressed on a wide variety of 
immune cells and dystrophic muscle fibres. The activated receptor induces the 
production of pro-inflammatory cytokines including IL1β, IL6, IL18 and TNF and 
also the autophagic death of dystrophic muscle cells (Ferrari et al., 1996; Ferrari et 
al., 1997b; Di Virgilio, 2007; Lister et al., 2007; Young et al., 2015).   
Treating mdx with oATP has shown some impact in reducing the infiltration of 
leukocyte and macrophage M1 cells and the coefficient of variation of the minimum 
Feret diameter and does not have a negative effect on animal growth. Recently, it has 
been shown that in vivo blockading of P2RX7 by oATP improves the inflammatory 
feature of mdx (i.e. reduces the infiltration of leukocytes and macrophages, decreases 
the production of pro-inflammatory cytokine and increases the Treg cells in mdx 
(Gazzerro et al., 2015). Treatment with A438079 significantly attenuated the levels 
of creatine kinase, the number of revertant fibres, the leukocyte (CD11B) 
macrophage M1 (P2rx4, F4/80) and M2 (CD206), and neutrophil (LY6G) load in TA 
and diaphragm muscles. Moreover, A438079 reduced autophagy (LC3BII), which, in 
dystrophic muscle cells, is triggered by P2RX7 large-pore formation (Young et al., 
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2015). It has been shown that blocking P2RX7 using A438079 prevents 
inflammation-mediated neurovascular damage during septic encephalopathy (Wang 
et al., 2015), and protects kidneys against glomerulonephritis. It reduces the release 
of CCL2 from both macrophages and tissue and that reduces further recruitment of 
macrophages to the site of the injury (Taylor et al., 2009). Furthermore, A438079 
has been shown to prevent the large pore formation in pancreatic ductal 
adenocarcinoma and demonstrated the contribution of P2RX7 in regulating cell 
cancer proliferation, migration and invasion (Giannuzzo et al., 2015). In comparison, 
four weeks of oral administration of AFC-5128 reduced the sarcolemmal leakage 
represented by the serum CK level, normalised the mRNA expression levels of Il10 
and Il12a markers and the protein levels of leukocyte (CD11B) and autophagy 
(LC3BII) markers. It is worth noting that the efficacy of this drug might be heavily 
underestimated as the tissue drug level analyses demonstrated low and highly 
variable values. This was caused by the mode of administration used in this study as 
a subsequent analysis of drug levels administered by gavage showed excellent 
bioavailability profile (data not shown). 
Unlike oATP, A438079 and AFC-5128, nucleoside reverse transcriptase inhibitors, 
for example AZT, are already used clinically (Senanayake et al., 2015). Interestingly, 
treatment with AZT reduced several important dystrophic features in mdx without 
any detectable side effect. After short-term treatment, there was a reduction of 
sarcolemmal permeability to immunoglobulin G, a dystromir marker (miR-206), pro-
inflammatory cytokine (Tnf), an mRNA macrophage M1 marker (P2rx4), the number 
of M1 positive cells (F4/80, CD68 and P2RX4), neutrophils (LY6G) load and the 
protein level of the leukocyte marker (CD11B). Long-term treatment also showed 
reduction in the mRNA expression levels of Tnf, P2rx4, Cd68 and Ly6g and an 
increase in Il12a and therefore pointed to the persistent effect of treatment. 
In spite of the selective activity of AZT in inhibiting the P2RX7 receptor-induced 
NLRP3 inflammasome-dependent cell death (Fowler et al. in 2014), the long 
exposure to this drug has been found to cause some side effects. These include 
muscle fatigue, and weakness similar to symptoms observed in patients with 
mitochondrial myopathy (Sinnwell et al., 1995). In addition, it has been found that 
long-term exposure (four months) to this drug significantly decreased the 
mitochondrial level and function in the liver and muscle but not in neurons (Zhang et 
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al., 2014). AZT also causes cardiac mitochondrial dysfunction after prolonged 
exposure, which led to cardiomyocyte and cardiovascular dysfunction (Gao et al., 
2011; Varga et al., 2015). These side effects have been observed not only in patients 
but also in individuals with occupational exposure to AZT in order to protect them 
against HIV transmission (Cai et al., 2014). In this study, there was up-regulation of 
the mRNA level of Mitofusin2, used as a marker because mutations of this gene has 
been linked to mitochondrial dysfunction-mediated muscle atrophy (Baloh et al., 
2007; Chen et al., 2010; Sebastián et al., 2012). This analysis indicated that AZT 
treatment used in this study might not cause these common side-effects of AZT. 
However, further studies are needed to clarify the effect of AZT on mitochondrial 
functions in dystrophic subjects especially following a long term treatment. 
However, despite the mentioned side effects, AZT drug is still used extensively in 
the clinic to treat incurable diseases such as HIV and cancer (McGowan and Shah, 
2000; Humer et al., 2008).  
Interestingly, the oATP treatment used here did not reduce the CK levels, the number 
of IgG-positive fibres, the number of revertant fibres, Tnf levels and the neutrophil 
(LY6G) accumulation. The centrally nucleated fibres were also not decreased in 
treated mdx. Collectively, these results indicate that the dose or length of treatment 
may need to be adjusted for greater efficiency. Despite it being known that oATP is a 
non-selective antagonist for P2RX7 (Sikora et al., 1999) that may also act on P2X1 
and P2X2 receptors, ( Evans et al. 1995) , many researchers used this antagonist for 
blocking P2RX7 due to its availability, low cost and irreversible receptor binding 
(Murgia et al., 1993). Fulgenzi et al. (2008) used oATP to improve the essential role 
of P2RX7 rather than other P2X receptors in pain transmission. The overloading of 
intracellular Ca
2+
, uptake of ethidium bromide and releasing of IL8 and CCL20 were 
also counteracted following inhibition of presumably P2RX7 function by oATP 
(Trubiani et al., 2014). In contrast, it is known that the A438079 has high potency 
and selectivity on rodent and human P2X7 with the same efficiency and it is not 
toxic when used in vivo (Nelson et al., 2006). Administration of AFC-5128 decreases 
the leukocyte and autophagy and the elevation of Treg and anti-inflammatory 
markers. These encouraging findings indicate that AFC-5128 has a potential to slow 
down the disease progression.  
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In conclusion, our data confirms that P2RX7 has a role in DMD pathology and that 
targeting this receptor may be a promising treatment for this lethal disease (Yeung et 
al., 2006; Rawat et al., 2010; Young et al., 2015). Selective and potent inhibitors, 
A438079 and AZT appear to be most effective in ameliorating the dystrophic 
features in mdx and did so without any noticeable side effects. Importantly, AZT is 
already being used in humans and could easily be re-purposed for the treatment of 
DMD. 
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7  
                                       General Discussion 
 
The absence of the dystrophin protein is the primary cause of DMD and loss of its 
function leads to alteration of a wide variety of transcriptome expression and 
signalling pathways providing a complicated secondary pathology process. 
Numerous proteins and pathways have been explored by different molecular and 
pharmacological methods to identify therapeutic strategies with the potential to cure 
DMD patients. So far, data from DMD clinical trials indicate limited progress in 
reducing the dystrophic features upon using any of these therapeutic strategies. The 
data presented here demonstrate that genetic or pharmacological targeting the 
P2RX7 receptor play a significant role in ameliorating the pathology of this lethal 
disease in the most widely used pre-clinical model of DMD, the mdx mouse. The 
decreasing of inflammation and fibrosis, the hallmark of DMD, were clearly detected 
in mdx/P2rx7
-/-
 (Dmd and P2rx7-double mutant mouse models). Beside the new 
discoveries regarding the ablation of P2RX7 receptor, this study provides a new 
insight into the surprisingly large number of genes mediating the regulation of the 
novel altered pathways, such as NMD and cell cycle mechanisms.   
Dystrophin-deficient muscles release high concentrations of ATP and DAMPs. The 
former is also released from normal muscle in small amounts and in response to 
muscle physiological function. The extracellular ATP induce the binding of 
acetylcholine with ACh nicotinic receptors to transmit the excitation signal from the 
pre-synaptic (motor neuron) to the post-synaptic (muscle fibre) region of 
neuromuscular synapses leading to intracellular Ca
2+
 mobility and muscle plasticity 
(Henning, 1997; Choi et al., 2001; Buvinic et al., 2009). The low level of eATP 
regulates the expression and function of P2X and P2Y purinoceptors and both have a 
major role in the regeneration and differentiation of the muscle stem cells 
(Banachewicz et al., 2005; Tarricone et al., 2011).The concentration of eATP is 
controlled by ecto-ATPases, and α-sarcoglycan has been discovered as one of the 
members of the ATPases family (Sandona et al., 2004). The absence of dystrophin 
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and (DAPC) leads to a decrease in ATPase activity and therefore the high amount of 
released and undegraded ATP stimulates the P2RX7 overexpression (Bodin and 
Burnstock, 1996). The mechanism causing upregulation of P2RX7 in dystrophic 
muscle cells (both myogenic and myotubes) is unclear. It might be that due to the 
absence of dystrophin, the P2RX7 lacks proper anchoring for its function and this 
triggers compensatory upregulation. However, while this is possible in myotubes, it 
is less likely in myoblasts, which do not produce detectable levels of dystrophin 
protein; still, very small amounts of dystrophin concentrated in specific 
microdomains in functional complexes with P2RX7 cannot be completely excluded. 
The P2RX7 upregulation in response to high levels of eATP would be a good 
explanation for the muscle in situ. However, since this receptor upregulation exists in 
dystrophic muscle cells (both primary and established cell lines) in vitro, without any 
exposure to eATP, this is not a convincing explanation. The most likely explanation, 
therefore, is that Dmd gene mutations cause a secondary abnormality in the 
expression pattern of P2rx7. Interestingly, in this study significant abnormalities in 
gene splicing and NMD were found to be affecting a range of mRNAs and one of the 
alternatively spliced transcript in mdx muscles and cells was the P2RX7. It is 
therefore possible that this purinergic abnormality is the transcriptomic abnormality 
of the mutant Dmd gene. Importantly, Ferrari et al. found identical purinergic 
phenotype in human DMD lymphoblasts and these cells also have dystrophin 
transcript but no detectable protein (Ferrari et al., 1994). Therefore, it suggests that 
P2RX7 abnormality not only affects humans but also that the mechanism of this 
alteration is at the level of gene expression. As a result of increased expression on the 
dystrophic muscle tissue, the activation of this receptor increases the intracellular 
Ca
2+
 leading or at least contributing to damage of the myofibre (Carnwath and 
Shotton, 1987). 
In addition, this receptor is expressed on a wide range of immune cells, and its 
activation leads to the release of pro-inflammatory cytokines and then attraction of 
the immune cells to the injury site (Tang et al., 2012). Macrophages and neutrophils 
are the predominant infiltrating immune cells, which contribute to the progression of 
disease by producing pro-inflammatory cytokines and NO (Mojumdar et al., 2014; 
Villalta et al., 2015). Altogether, it generates the chronic inflammation, which is 
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responsible for reducing the satellite cells capacity for repairing the damage, 
resulting in significant decrease in the regeneration process.  
Therefore, this work focussed on extensive analysis of the effects of ablation of 
P2RX7 receptor on the DMD pathology using an advanced sequencing method. In 
addition, it demonstrates that targeting this receptor may be a promising treatment for 
this lethal disease. 
RNA-Seq data obtained in this work provide evidence that most of the altered genes 
in mdx compared with C57/BL10 are inflammation-related and lysosomal genes 
while in mdx/P2rx7
-/-
 most of the altered genes are related to inflammation and 
chemotactic cytokines. Interestingly, the analysis of results showed the down-
regulation of fibrosis- and inflammation-related genes compared with mdx and 
C57/BL10 respectively upon ablation of the P2RX7 receptor. Inflammation is the 
hallmark of DMD disease and inflammation-regulated genes were detected as the 
most altered in mdx in several previous studies (Porter et al., 2002; Marotta et al., 
2009; Villalta et al., 2015).  
Several transcriptome analysis studies have been performed in the mdx mouse 
model,  In 2000, Tkatchenko et al. found 93 altered genes in the leg and diaphragm 
of mdx, and analysis of the differential gene expression implicated that the majority 
of altered genes were associated with growth and differentiation, calcium 
homeostasis and protein degradation, activation of macrophages and inflammation, 
and fibrosis. In addition, Marotta et al. (2009) also found that inflammation-related 
genes, cell adhesion-associated genes, muscle regeneration and extracellular matrix 
remodelling are the most up-regulated genes in mdx. More recently, Almeida et al., 
in 2016, performed a whole genome expression profiling using microarray 
comparing the mdx with two mouse models of other MDs. They found that the 
common dominant enriched genes are the inflammatory genes followed by 
regeneration-controlling genes and extracellular matrix genes. Interestingly, these 
authors noticed expression stability of some genes during all stages of disease in all 
genotypes, while the expression of the other genes was altered within the progression 
of disease. For example, at 21 days, most of the elevated genes were related to the 
cell cycle (Ccna2, Ccnb1/Gm5593 and Cdkn1A) and regeneration (Myh8, Spp1 and 
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Osteopontin), at the age of three months, most fibrosis-related genes (Col3a1, 
Col6a3 and Col8a1) were elevated. 
In the data presented here, a total of 780 genes were altered significantly in 
mdx/P2rx7
-/-
 compared to mdx. These genes were analysed further using the IPA 
software to identify significantly altered canonical pathways. The IPA analysis 
demonstrated that granulocyte/agranulocyte adhesion and diapedesis, fibrosis, 
atherosclerosis signalling and LXR/RXR activation were the top five canonical 
pathways showing differences between mdx/P2rx7
-/- 
and mdx. 
Granulocyte/agranulocyte adhesion and diapedesis-regulated genes were found to be 
up-regulated in mdx and down-regulated significantly in mdx/P2rx7
-/-
. Interestingly, 
this pathway is associated with the host defence mechanism against inflammation 
that developed as a result of muscle injury (Tidball, 1995). It is well known that 
muscle injury in DMD leads to an increase in the number of pro-inflammatory 
cytokines, which regulate the transmigration of the granulocyte and agranulocyte 
leukocyte cells from blood to the site of the injury via the diapedesis mechanism 
(Muller, 2003). These results are in line with those of Porter et al. in 2002, who 
found that the leukocyte adhesion and diapedesis pathway is one of the top up-
regulated pathways in mdx using microarray. IPA also detected changes in genes 
involved in the atherosclerosis signalling pathway, which is stimulated by pro-
inflammatory cytokines and numerous danger signals (DAMPs) (Ridker et al., 2005; 
Rajamäki et al., 2013; Zimmer et al., 2015). Notably, the expression of dystrophin in 
vascular smooth muscle cells has been demonstrated (Rauch et al., 2012). The 
absence of dystrophin in DMD leads to vascular injury and therefore the smooth 
muscle cells migrate to the injury site to repair the damage. The constant 
degeneration–regeneration cycles lead to neointima formation and then 
atherosclerosis (Rauch et al., 2012).  
Multiple LXR/RXR activation pathway genes were upregulated in mdx and down-
regulated in mdx/P2rx7
-/-
. This pathway is generally responsible for regulating 
cholesterol and bile acid metabolism (Willy et al., 1995) but the function of these 
receptors depends on their binding with either the retinoid X receptor (RXR) or 
peroxisome proliferator-activated receptor (PPAR) (Willy and Mangelsdorf, 1997; 
Willson et al., 2000; Ide et al., 2003; Yue et al., 2005). The PPARγ-LXR complex 
regulates the macrophage-lipid uptake (Mangelsdorf et al., 1995; Chawla et al., 
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2001), which mediates the atherosclerotic lesion due to accumulation and conversion 
of cholesterol into the crystals inside the macrophages (Stewart et al., 2010; Sheedy 
et al., 2013). However, the pharmacological activation of the peroxisome 
proliferator-activated receptor (PPAR) β/δ increases the utrophin level and the 
number of slow oxidative muscle fibres (Miura et al., 2009). Therefore, changes in 
these three pathways indicate that Dmd mutation results in dysregulated leukocyte 
adhesion, migration and, more generally, in inflammation and that P2RX7 plays a 
role in all these processes. 
The novel finding was the change in pathological pathways commonly associated 
with atherosclerosis, which appear to have commonalities with DMD. Furthermore, 
this data agree with recent studies that P2RX7 is involved in atherosclerosis 
progression via NLRP3 inflamamsome activation (Peng et al., 2015). Given the 
normalisation of several genes in this pathway, including the NLRP3 expression (up-
regulation in mdx and down-regulation in mdx/P2rx7
-/-
), inhibition of P2RX7 could 
have therapeutic impact in this common blood vessel disease. 
The GSEA analysis of RNA-Seq found multiple genes belonging to the cytokine/ 
chemokine family to be down-regulated significantly in mdx/P2rx7
-/-
. Cytokines are 
the main key activators and recruiters of inflammatory cells in DMD also involved in 
regeneration and fibrosis. It has been identified that CXCL8 (IL8), CCL2 and CCL5 
are the most predominant chemokines associated with the acute stage of disease 
(Porter et al., 2003; Yahiaoui et al., 2008). In addition to chemokines, the roles of 
TNF, IFNγ, IL and TGFβ have been demonstrated in both DMD and mdx (De Paepe 
and De Bleecker, 2013). The GSEA analysis also showed in mdx/P2rx7
-/- 
the down-
regulation of innate immune response-regulated genes associated with stimulation of 
macrophages, neutrophils, mast cells and eosinophils (Madaro and Bouché, 2014).  
Comparative analysis of RNA-Seq data against qPCR arrays gave consistent results 
with GSEA. Importantly, our results showed that most differential genes seen in the 
inflammatory response and autoimmunity qPCR array were down regulated in 
mdx/P2rx7
-/-
 compared with mdx. Altogether, these results confirm that 
inflammatory markers are overexpressed in mdx, as was reported in many previous 
studies (Porter et al., 2003; Haslett et al., 2002; Haslett et al., 2005; Turk et al., 
2005). Interestingly, most of the inflammatory genes were restored to the normal or 
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almost normal level in mdx upon ablation of P2RX7. Additionally, the reduction in 
inflammatory markers in 18-month-old animals suggested that blockade of this 
receptor has a long-term advantage in reducing inflammatory signatures such as pro-
inflammatory cytokines and the infiltration of leukocytes. Therefore, reducing these 
features through blockade of the P2RX7 receptor is a promising therapeutic approach 
toward the treatment of this disease. 
Unsurprisingly, P2RX7 blockade cannot treat all abnormalities associated with Dmd 
mutations. For example, the adherens junction pathway is the top altered one in mdx 
compared with C57/BL10 in RNA-Seq data. Likewise, the mitochondrial 
dysfunction is a well-known abnormality in DMD and mdx (Onopiuk et al., 2009; 
Kelly-Worden and Thomas, 2014; Tian et al., 2014; Timpani et al., 2015) and 
changes in genes encoding proteins involved in mitochondrial functions were found 
in this study. However, P2RX7 ablation made no significant improvement in 
expressions of genes associated with these pathways. 
The impairment of regeneration is another hallmark of DMD disease. The absence of 
dystrophin results in infiltration of immune cells that cause chronic inflammation and 
then severe muscle degeneration. The muscle stem cell (satellite cell) has the ability 
to renew the damaged muscle (McGeachie and Grounds, 1987; Tatsumi et al., 1998; 
Wozniak et al., 2007; Lu et al., 2011). Unfortunately, the persistent degeneration-
regeneration cycles in DMD make the pool of satellite cells exhausted (Zacharias and 
Anderson, 1991). Interestingly, RNA-Seq data indicated an abnormality in the 
expression of the telomerase gene regulators in mdx pointing towards reduced 
telomerase activity in these muscles. These genes were restored to their normal 
levels in mdx/P2rx7
-/-
. The shortening of telomeres due to abnormal telomerase 
activity has been linked to the exhaustion of satellite cells in DMD and therefore 
impairment of regeneration (Sacco et al., 2010). This can also be linked to the 
severity of the disease and short lifespan of DMD patients (Kipling and Cooke, 
1990). It will be important to compare the expressions of telomerase regulators in 
human samples. 
Because of the abnormality of telomerase enzyme in mdx, the cell cycle-regulated 
genes were examined to test the behaviours of the satellite cells in mdx and 
mdx/P2rx7
-/-
. The cell cycle pathway was found altered in mdx and while it was not 
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corrected in mdx/P2rx7
-/-
,
 
it is
 
a significant novel finding. Further analysis using 
qPCR showed that alteration of cell cycle-regulated genes exists in myoblasts and 
therefore its abnormality in muscle samples might be reflecting the activation and 
proliferation status of satellite cells and not the infiltrating immune cells. The over-
activation of satellite cells may explain the mild phenotype of mdx compared with 
DMD patients (Almeida et al., 2016). However, the continuous proliferation of these 
cells may lead to their exhaustion and slow the regeneration process (Zacharias and 
Anderson, 1991; Sacco et al., 2010). This result matched the shortening of telomere 
hypothesis stating that continued proliferation of satellite cells leads to the shortening 
of the telomere and because the satellite cells in mdx mice have longer telomere than 
humans, the capacity of regeneration lasts longer (Kipling and Cooke, 1990). Our 
results are in line with the Almeida et al. (2016) study, which showed the up-
regulation of cell cycle genes (Ccna2, Ccnb1/Gm5593 and Cdkn1A) in microarray 
analysis of 21-day-old mdx mice, suggesting the activation of satellite cells and 
regeneration. However, the over-activation of cell cycle gene regulators in myoblasts 
suggests an early defect of this pathway in embryogenesis as a result of the absence 
of the dystrophin expression. This early alteration could lead to the exhaustion and 
loss of satellite cells and then affect muscle development. Dumont et al. (2015) 
detected another possible way of decreasing the satellite cell numbers in dystrophic 
stem cells. They showed that the absence of dystrophin expression in satellite cells 
caused a loss of linkage with the cell polarity regulator, Ser/Thr kinase Mark2. This 
defect decreases the asymmetric division of satellite cells and also their number 
required for successful regeneration. 
The failure of the regeneration process in DMD promotes the initiation of fibrosis. 
Fibrosis is one of the pathophysiological events that result from the accumulation of 
extracellular matrix inside the muscle tissue (Mauro, 1961; Huard et al., 2002). 
Several studies suggested that mdx is not an appropriate model for DMD due to the 
mild dystrophic phenotype, long life span and lack of fibrosis (Collins and Morgan, 
2003; Pessina et al., 2014). It has been demonstrated that the mdx shows late fibrosis 
in TA muscle (at nearly 20 months of age). However, in this study, elevation of the 
fibrosis pathway was found already in four-week-old TA muscle. This important 
finding suggested that mdx share DMD the same early fibrotic feature. Furthermore, 
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not only is fibrosis increased in mdx, but it was also down-regulated significantly in 
mdx/P2rx7
-/-
.  
The non-sense-mediated decay (NMD) is an important pathway that regulates the 
splicing mechanism and degrades the aberrant transcript containing premature stop 
codons (Kalyna et al., 2012). The qPCR analysis using different sets of primers 
located in the 5'end and 3'end indicated inefficient NMD in mdx while this 
mechanism efficiently degraded mutant dystrophin transcripts in mdx
βgeo
. This might 
have been caused by the nature of mutations in these two mutants, one being a 
nonsense mutation and the other a large insertion (Sicinski et al., 1989; Wertz and 
Füchtbauer, 1998). It has been reported that several genes and splice variants are 
stabilized by NMD inhibition or indirectly by the NMD-dependent regulation of 
splicing factors (Wang et al., 2011). Cellular stress (Gardner, 2010) and sterile 
inflammation and hypoxia (Gardner, 2008; Karam et al., 2013) conditions affect the 
efficiency of NMD function. It is well-known that dystrophic cells are under 
conditions of inflammation and stress. These conditions would negatively affect 
NMD and therefore stabilisation of the mutant RNA in dystrophic cells could lead to 
accumulation of the negative truncated proteins or aberrant splice variants that evoke 
a cell abnormality. The RNA-Seq data indicated the alteration of genes (up and down 
regulation) belonging to the mechanism that recognises the premature stop codon in 
alternative splice variants (regulated unproductive splicing and translation (RUST) 
(Weischenfeldt et al., 2012). This mechanism utilises the NMD to decay the 
alternative splice variants with premature stop codons (Kurosaki and Maquat 2013). 
The RUST mechanism is used by two groups of splicing regulator genes, splicing 
activators (SRSF proteins) and splicing repressors (HnRNPs). Interestingly, mdx 
showed a higher expression level of splicing activators (SRSF proteins: Srsf3 and 
Srsf9) and splicing repressors (Hnrnpa0, Hnrnpa1 and Hnrnpf). Again the 
environment present in the dystrophic muscle may be mediated by increased Myc, 
which inhibits NMD (Wang et al., 2011). There was a significant up-regulation of 
Myc and Mycl1 and down-regulation of Myct1 (Myc target) in mdx samples. The 
mRNA expression level of some of these regulator genes was confirmed by qPCR. 
The defect in splicing machinery may cause accumulation of the aberrant splice 
variant ameliorating the transport system through the nuclear membrane (Ward and 
Cooper, 2010; Patel and Chu, 2011). The result obtained in dystrophic cells in vitro 
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proved that the deficiency in the splicing machinery is a cell-autonomous 
abnormality and not related to inflammatory environment of the dystrophic muscle. 
The detection of an out-of-frame junction is considered the best indicator of a 
transcript with a premature stop codon (Brogna and Wen, 2009). Comparisons of the 
out-of-frame junctions between mdx and C57/BL10 showed a significant increase of 
aberrant splice variants in mdx. This finding suggests the abnormality of the splicing 
mechanism and NMD functions. As mentioned earlier, P2rx7 was found to be one of 
the highly altered transcripts in mdx muscles, which could explain the altered 
expression profile of this receptor.  
Another interesting highly altered transcript in mdx was Bmp7. This gene has been 
reduced in mdx significantly and restored to the near-normal levels in mdx/P2rx7
-/-
. 
The reduction of this transcript has been detected in four-week-old and 18-month-old 
TA muscles, heart, myoblast and myofibre indicating the disease-specific alteration. 
BMP7 stimulates satellite cells to proliferate (Friedrichs et al., 2011; Ono et al., 
2011), therefore reduction in Bmp7 expression may result in the depletion of satellite 
cells and reduction of the regeneration process. It has been shown that BMP7 is an 
anti-fibrotic factor (Morrissey et al., 2002; Zeisberg et al., 2007) and therefore 
elevation of this transcript in mdx/P2rx7
-/-
 is considered very encouraging. This 
thesis provides further evidence of the anti-fibrotic role of Bmp7 in RNA-Seq 
analysis. BMP7 and TGFβ share the same co-SMAD, so the activation of BMP7 
reduces the TGFβ signal. TGFβ has a major role in mediating the fibrosis event 
(Taniguti et al., 2011). Interestingly, down-regulation of Tgfβ and Smad3 in 
mdx/P2rx7
-/-
 was identified in our RNA-Seq analysis. The analysis at protein level of 
SMAD3 and SMAD 1/5/8 was performed in myoblasts in an attempt to find out 
whether the TGFβ signal starts early in dystrophic cells. Down-regulation of 
SMAD3 and no significant difference in SMAD 1/5/8 were detected, possibly 
indicating the non-active TGFβ pathway in these cells. The non-activation of the 
TGFβ pathway in myoblasts was in line with previous studies, which highlighted the 
induction of this cytokine during the regeneration event (Gosselin et al., 2004; Li et 
al., 2004a). The qPCR combined with bioinformatics analysis identified an alteration 
of 5'exons of Bmp7, upstream of exon 4. Most likely the alteration in the 5'end either 
represents the skipped 5' exons or the existence of alternative 5' exons, which has an 
alternative ATG codon. However, the precise identification of this alteration was not 
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successful presumably due to the lengths of this alternative 5'-end being unstable for 
the 5'-RACE analysis. Research to date has provided evidence about the role of 
BMP7 in renal disease but there is no data suggesting the involvement of BMP7 in 
the DMD pathology (Dudley et al., 1995; Luo et al., 1995; Li et al., 2004b). 
However, Friedrichs et al. (2011) showed that the up-regulation of Bmp7 in the 
myogenic cell line C2C12 in an acute injury model balances the proliferation and 
differentiation of these cells. In addition, to regulate the regeneration, multiple 
studies identified the expression of Bmp7 in adult tissues and indicated its role as an 
anti-fibrotic factor (Morrissey et al., 2002; Zeisberg et al., 2007). Interestingly, it has 
also been found to be a positive regulator of skeletal muscle mass (Winbanks et al., 
2013; Zhong et al., 2013; Liang et al., 2016). Winbanks et al. (2013) demonstrated 
that Bmp7-Smad1/5/8 signalling increased in denervated muscle to protect muscles 
against atrophy and induces remodelling of the nerve terminal and neuromuscular 
junctions. This indicates the novel role of BMP7 in promoting muscle growth and 
inhibiting muscle wasting. Therefore, further work is needed to identify this 
alternative transcript in mdx as it may constitute an important novel abnormality. 
Furthermore, it would be interesting to establish whether the same BMP7 alteration 
exists in human dystrophic muscles.  .  
Recently, the role of BMP7 in the polarisation of monocytes to M2 macrophages via 
activation of the P13K-AKt-mTOR pathway has been suggested (Rocher and Singla, 
2013). Moreover, the expression of Bmp7 has been linked to reducing macrophage 
and neutrophil infiltration and inflammation. This effect is mediated by decreasing 
the expression of pro-inflammatory cytokines such as Il6 and Il1b and chemokines 
such as Mcp1 (Amthor et al., 2002; Gould et al., 2002; Lee et al., 2003). However, 
these aspects of BMP7 function were not investigated here. 
Several studies demonstrated reduced symptoms of diseases associated with 
activation of P2RX7 by using P2RX7 antagonists and several supported these 
findings further in P2RX7 knockouts. For example, in neurological disease, Kim et 
al. (2011) found a decrease of TNF-α in response to inhibition of P2RX7 by oATP, 
A-438079 and A-740003 and that treatment ameliorated the status epilepticus. It has 
been demonstrated that inhibition of P2RX7 in animal models of pain and 
inflammation using a variety of P2RX7 antagonists and blockers reduced the IL1β 
and IL6 release and the increase in body temperature Broom et al., 2008; Csölle and 
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Sperlágh, 2010; Barberà et al., 2012). In addition, the role of P2RX7 in 
musculoskeletal disorders has been identified in numerous studies (for reviews, see 
Bartlett et al., 2014; Young et al., 2013). In the model of chronic inflammatory 
rheumatic disorders 3 mM oATP administered for 10 days successfully attenuated 
the adaptive immune response and increased the Treg cell levels (Ardissone et al., 
2011). In mdx mouse treatment with Coomassie Brilliant Blue reduced the number 
of degeneration-regeneration cycles (Young et al., 2012) and restored the migratory 
capacity of T-cells (Cascabulho et al., 2012). Treating mdx with suramin for three 
months reduced the inflammation, fibrosis and myonecrosis and improved the 
electrocardiographic readings (De Oliveira et al., 2013).  Recently, our group 
demonstrated significant improvements of muscle and non-muscle symptoms by 
genetic ablation of P2RX7 in mdx mouse (Sinadinos et al., 2015). Therefore, 
therapeutic effects of pharmacological inhibition of this receptor using several 
different P2RX7 inhibitors were analysed.  
The efficiency of the applied pharmacological inhibitors was identified and 
compared based on several parameters as end points: serum creatine kinase levels, 
sarcolemma permeability to the serum immunoglobulin , the coefficient of variation 
of minimum Feret diameter and centrally nucleated fibres, the number of revertant 
fibres, general histology in haematoxylin and eosin staining, several cytokines and 
infiltrating immune cell markers were also used as standard measures to investigate 
the efficacy of pharmacological inhibitors. The present data provide evidence that 
targeting the P2RX7 receptor using oATP reduces the infiltration leukocyte and 
macrophage M1 cells and the coefficient of variation of the minimum Feret diameter 
and does not have a negative effect on animal growth. Long-term treatment or higher 
dose of oATP may be essential to improve the other disease parameters. A438079, in 
contrast, seems to be the most potent P2RX7 antagonist. It evokes significant 
attenuation of creatine kinase, the number of revertant fibres, infiltration by 
leukocytes and specifically by macrophages, neutrophils and the reduction of 
autophagic flux related to cell death. This analysis also indicates that the newer 
P2RX7 inhibitor, AFC-5128, which showed significant effect despite inadequate 
administration can be effective in treating DMD. Moreover, given that this drug 
penetrates blood-brain barrier and that mdx/P2RX7
-/-
 mice showed significant 
improvements in cognitive and behavioral functions (Sinadinos et al., 2015) 
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treatment with AFC-5128 may produce reduction of both muscle symptoms and of 
the DMD-associated cognitive dysfunction. A therapeutic strategy that can improve 
both muscle and non-muscle abnormalities would be a significant development as 
cognitive and behavioral impairments associated with DMD add to the very severe 
burden of this disease, affecting the quality of life of patients and their families. 
Furthermore, none of the new therapeutic modalities currently in clinical trials 
targets the non-muscle symptoms of this disease. 
Importantly, AZT was demonstrated to be a very effective P2RX7 inhibitor and it 
did not cause any noticeable side effects.  
It should be taken into account that not all P2RX7 blockers work the same in pre-
clinical tests. Therefore, the clinical trials should not be based on just one drug as 
this one may just happen to be less effective in blocking the P2RX7 effects that are 
crucial in DMD pathology. If another drug was tested, its slightly different properties 
could produce much better therapeutic responses.  
In summary, this study has used the RNA-Seq approach to obtain an in-depth insight 
into the complexity of gene expression patterns altered in response to the disease and 
modified as a result of P2RX7 ablation. It showed that the Dmd mutation causes 
abnormalities in myogenic cells, including several previously unrecognised such as 
the nonsense mediated decay and alternative splicing mechanisms, the expression of 
Bmp7 and in cell cycle regulatory genes that are likely to cause abnormalities of 
regeneration processes. These results suggest a need to re-evaluate the established 
belief about sarcolemma fragility as the sole trigger for DMD. Alteration of the wide 
range of functions in myogenic cells may suggest that targeting these cells instead of 
myofibres may be required for therapeutically effective re-expression of dystrophin.  
In addition, data presented here suggest that the P2RX7 plays an essential role in 
DMD and targeting this receptor can be a candidate for therapeutic intervention. 
Such a treatment protects muscle cells from damage, reduces the inflammation and 
fibrosis and improves the muscle regeneration, all of which are considered 
substantial hallmarks of DMD pathology. Finally, results presented in this thesis 
show that blockade of the P2RX7 receptor with different pharmacological inhibitors 
attenuates the dystrophic features without noticeable side effects. Importantly, one 
285 
 
such drug, AZT is already in human clinical use and could be re-purposed for trials 
in DMD. 
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8  
Future work 
 
Based on the current study findings and the demonstration of the involvement of the 
P2RX7 receptor in DMD pathology, it would be interesting to perform the following 
work in order to have the complete picture of DMD pathology and the possible 
therapeutic impact of P2RX7blockade.  
Investigate the mitochondrial function in mdx/P2rx7
-/-
 compared with mdx 
We previously have shown that dystrophic cells exhibit a severe impairment in 
mitochondrial functions compared with wild-type cells. The abnormalities extend 
from the morphology to the reduction in respiratory rate (Onopiuk et al., 2009). The 
defect of cellular energy metabolism cannot be explained by mutation of dystrophin 
alone; in particular, wild-type and myoblasts do not produce detectable amounts of 
dystrophin protein. However, the susceptibility of dystrophic cells to purinergic 
stimulation has been detected. Furthermore, exposure of dystrophic cells to a high 
concentration of eATP induces the influx of a vast amount of Ca
2+
 and the P2RX7 is 
the main contributor in controlling this process (Yeung et al., 2006; Young et al., 
2012). Therefore, the correction of mitochondrial dysfunction by ablation of P2RX7 
would be expected. While data presented in this thesis (Figure 4.19) showed a few 
regulated genes of the mitochondrial function were normalised in mdx/P2rx7
-/-
 
compared with mdx. Further study including validation of RNA-Seq analysis may be 
necessary to fully understand the effect of ablation of P2RX7 on mitochondrial 
dysfunction. In addition, the negative effect of prolonged treatment with AZT on 
mitochondrial function has been reported (Gao et al., 2011; Varga et al., 2015). It 
was demonstrated here that there are no detectable side effects on mitochondrial 
functions after two weeks of treatment with AZT. Despite this analysis based on 
Mitofusin2 that regulates key mitochondrial functions such as fusion, more studies, 
perhaps with an increase in the treatment duration, would be interesting to clarify the 
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effect of AZT on the mitochondria. Analysis of copy numbers of mitochondrial DNA 
is one such a study. 
Detection of the Bmp7 alternative splice variant and its role in DMD disease 
It has been shown that BMP7 has a synergistic role as an anti-fibrotic factor 
(Morrissey et al., 2002; Zeisberg et al., 2007). The current study has already shown 
the restored level of this transcript in mdx/P2rx7
-/-
. An interesting finding was that 5' 
exons of Bmp7 showed down-regulation in dystrophic muscle, myoblasts and 
myofibres but attempts at identifying the novel sequence of this region were not 
successful. Therefore, a further study would be worthwhile to find out whether the 
difference in regulation of 5' exons represents the existence of novel splice variants 
or a novel promoter. In addition, the function of BMP7 and its relation with DMD 
disease needs further investigation. Next-generation sequencing (targeting the 
transcript of interest) and BMP7 inhibitor may be the methods to achieve these aims. 
Detection of the role of non-coding RNAs (ncRNA) in mdx and mdx/P2rx7
-/-
  
Divided into two classes, microRNAs (miRNAs) and long non-coding RNAs 
(LncRNAs), non-coding RNAs (ncRNA) have emerged as gene expression 
regulators in muscle development and pathophysiology (Bartel, 2004; Rinn and 
Chang, 2012). miRNAs regulate the post-transcriptional gene level by binding to the 
UTR region of the mRNA target, which then represses the translation and/or 
degrades the mRNAs (Chendrimada et al., 2005; Filipowicz et al., 2008). It is well 
known today that miRNAs play an integral role in every step of myogenic 
modulation; they govern the expression of several myogenic transcription factors 
such as PAX, MRFs, MEF2 and SRF (Braun and Gautel, 2011; Bentzinger et al., 
2012; Lagha et al., 2008). The miRNAs not only have a role in myogenesis, but also 
have a redundant function in regulating myosin isoforms and muscle mass (van 
Rooij et al., 2009; Aoi  et al., 2010). In DMD, many of these miRNAs are found to 
be elevated in the serum and tissues of DMD patients and mdx mice, affecting the 
cell cycle and myogenesis process (Mizuno et al., 2011; Alexander et al., 2014). On 
the other hand, lncRNAs are the most functional versatile class. They regulate all 
steps of gene expression due to their ability to form a secondary structure complex 
with DNA, RNA and protein (Guttman and Rinn, 2012). Functionally, lncRNAs 
regulate the transcription of muscle skeletal genes. They also decay certain 
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molecules in order to regulate the expression level of their target; the 
transcription/splicing factor in the nucleus and miRNAs and mRNA in cytoplasm are 
such molecules. Furthermore, many lncRNAs can act as a scaffold to support the 
expression of genes in different biological contexts (Nie et al., 2015). Besides 
regulating the biological functions, they are also found to be involved in DMD 
disease; for example, Bovolenta in 2012 found that the DMD locus encodes specific 
lncRNAs and mutations can deregulate the expression of such lncRNAs, which, in 
turn, can trigger abnormalities in muscle stem cells. Moreover, the KUCG1 gene has 
been identified (lncRNAs generated from intra-chromosomal inversion) in the brain 
of some DMD patients and it is believed that this gene is associated with mental 
retardation (Tran et al., 2013). Overall, it would be of great interest to examine the 
role of these ncRNAs in the molecular mechanism of DMD disease and to define 
whether they udergo an evolution in response to P2RX7 treatment. The present 
RNA-Seq analysis was not aimed at miRNAs but identified several alterations in 
expression of lncRNAs. 
Exploring the new DMD rat model 
Recently, two dystrophic rats were successfully generated. The first line was 
generated by inserting a short palindromic repeat by CRISPR/Cas system in exons 3 
and 6 (Nakamura et al., 2014). The second line was created using TALEN 
technology, which introduced a premature stop codon due to 11 bp deletion in exon 
23 (Larcher et al., 2014). These models have several phenotypes, which may make 
them useful alternative species to mdx mouse and dog models. Besides their small 
body size and their ability to learn complex social traits, both models exhibit muscle 
degeneration starting at ~13 weeks of age. Muscle strength is significantly reduced. 
The number of infiltrating immune cells is increased in leg and diaphragm muscles. 
The myofibre with central nuclei and myosin heavy chain positive fibres were also 
detected in these models, confirming that regeneration events occur. Furthermore, 
the cardiac muscle showed severe pathological features such as dilated 
cardiomyopathy, necrosis and fibrosis. However, the replacement of myofibres with 
adipose tissue was not detected in the first model and this might be an age-associated 
phenotype (Nakamura et al., 2014) as at seven months, severe fibrosis with 
infiltrating adipose tissue was found in muscles from the second rat model (Larcher 
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et al., 2014). Rats could represent a new and promising small animal model of DMD 
and it should be analysed for P2RX7 abnormalities. 
How about analysis of human dystrophic myoblasts and myotubes? 
Whilst DMD lymphoblasts showed the same purinergic, P2RX7 dependent 
phenotype (Ferrari et al., 1994) and DMD muscle have eleveated P2RX7 levels 
(Gazzerro et al., 2015), the human dystrophic myogenic cells and myofibres have not 
been analysed for this purinergic abnormality. Such analysis is difficult as muscle 
cells isolated form biopsy materials are always contaminated to a varying extent with 
other cell types. Moreover, the individual genetic variability between patients both in 
relation to DMD mutation and underlying genetics makes identification of 
commonalities rather difficult. Nevertheless, such a study should be attempted and 
inducible pluripotent stem cells offer a mean of obtaining large numbers of identical 
cells from a number of patients. 
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Appendix 10.1  
PCR products visualized in 2% agarose gel showing the genotyping amplicons used for 
selecting the mdx/P2rx7
-/- 
mice. The lanes1-7 represent male, while 8-15 represent 
female mouse samples. In lane 1, 2 and 7, samples represent mutant dystrophin and 
mutant P2rx7, therefore these males were identified as mdx/P2rx7
-/-
 and were used for 
generating a colony. The amplification profiles in lane 9 and 10 showed mutant 
dystrophin and mutant P2rx7, therefore these female were identified as mdx/P2rx7
-/-
 
and used for breeding. (B) The amplifications of dystrophin wild type and mutant were 
repeated for sample 9 and 10 to confirm the genotype of these samples. The result 
indicated the accurate genotyping for both samples. Positive control was mdx/P2rx7
-/-
 
sample, while NC contained water instead of DNA samples. 
 
Dmd wt 105bp 
105bp 
Male Femal
Dmd mut 
P2rx7 mut 
P2rx7 wt 363bp 
280bp 
100bp  1    2     3     4    5     6    7    8     9   10   11   12  13  14  15  NC 
A 
105bp 
100bp  9    10   PC NC    100bp 9   10  PC  NC 
Dmd wt Dmd mut 
B 
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Rename ("1"); 
run ("Split Channels"); 
select Window("C1-1"); 
close (); 
select Window("C2-2"); 
close (); 
select Window("C3-3"); 
run ("Threshold..."); 
wait For User("Please adjust threshold to distinguish positive signal"); 
run ("Create Selection"); 
set BackgroundColor(0, 0, 0); 
set ForegroundColor(255, 255, 255); 
run ("Clear Outside"); 
run ("Select None"); 
set Option("BlackBackground", true); 
run ("Make Binary", "thresholded remaining"); 
run ("Options...", "iterations=1 count=5 black edm=Overwrite do=Erode"); 
run ("Options...", "iterations=1 count=3 black edm=Overwrite do=Dilate"); 
run ("Watershed"); 
set Threshold(1, 255); 
run ("Analyze Particles...", "  show=Outlines display clear summarize") 
 
Appendix 10.2: 
Macro used for Fiji semi-automatic morphometry to calculate the number of CD11B, 
F4/80, P2RX4, CD68, CD206 and LY6G positive cells. 
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rename("Original"); 
run("Duplicate...", "title=[IgG Area]"); 
selectWindow("IgG Area"); 
setThreshold(20, 255);//  
CHANGE THE FIRST VALUE TO ADJUST         THRESHOLD 
run("Colors...", "foreground=white background=black selection=yellow"); 
run("Make Binary", "thresholded remaining"); 
run("Options...", "iterations=1 count=5 black pad do=Close"); 
run("Set Measurements...", "area mean standard min redirect=None decimal=3"); 
run("Analyze Particles...", "  show=Nothing include summarize"); 
//break 
selectWindow("Summary"); 
lines = split(getInfo(), "\n");  
values = split(lines[lengthOf(lines)-1], "\t"); 
a = parseFloat(values[2]); 
//break 
selectWindow("Original"); 
run("Duplicate...", "title=[Total Area]"); 
selectWindow("Total Area"); 
setThreshold(5, 255); 
run("Make Binary", "thresholded remaining"); 
run("Options...", "iterations=1 count=1 black pad do=Close"); 
run("Remove Outliers...", "radius=2 threshold=50 which=Bright"); 
run("Options...", "iterations=1 count=2 black pad do=Dilate"); 
run("Options...", "iterations=5 count=3 black pad do=Close"); 
run("Analyze Particles...", "include summarize"); 
//break 
selectWindow("Summary"); 
lines = split(getInfo(), "\n");  
values = split(lines[lengthOf(lines)-1], "\t"); 
b = parseFloat(values[2]); 
//break 
c = (a/b)*100; 
///showMessage("a = " + a); 
///showMessage("b = " + b); 
showMessage("IgG = " + c + "% of total area");  
 
Appendix 10.3: 
Macro used for Fiji semi-automatic morphometry to calculate the fibre permeability to 
IgG. 
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Run ("Set Measurements...", "area mean min perimeter feret's area_fraction   
redirect=None decimal=3"); 
run ("Options...", "iterations=1 count=1 black edm=Overwrite do=Nothing"); 
wait (1000); 
set ForegroundColor(255, 255, 255); 
set BackgroundColor(0, 0, 0); 
wait (1000); 
run ("Channels Tool..."); 
run ("Make Composite"); 
Stack.set Display Mode ("color"); 
Stack.set Channel (2); 
run("Blue"); 
Stack.set Channel (1); 
Run ("Green"); 
Stack.set Display Mode("composite"); 
Run ("Stack to RGB"); 
set ForegroundColor(0, 0, 0); 
run ("Line Width...", "line=15"); 
make Rectangle(0, 0, 1024, 1024); 
run ("Draw"); 
run ("Select None"); 
wait (1000); 
set ForegroundColor(255, 255, 255); 
set Background Color(0, 0, 0); 
rename ("Original"); 
run ("Subtract Background...", "rolling=40"); 
run ("Split Channels"); 
wait (1000); 
select Window("Original (blue)"); 
set Threshold(22, 255); 
run ("Make Binary", "thresholded remaining"); 
run ("Watershed"); 
select Window("Original (green)"); 
run ("Threshold..."); 
wait (1000); 
wait For User("Please adjust the Threshold until the border is well defined."); 
run ("Make Binary", "thresholded remaining"); 
wait (1000); 
run ("Remove Outliers...", "radius=2 threshold=50 which=Bright"); 
wait (1000); 
run ("Remove Outliers...", "radius=2 threshold=50 which=Dark"); 
wait (1000); 
run ("Options...", "iterations=1 count=4 black edm=Overwrite do=Close"); 
wait (1000); 
run ("Options...", "iterations=3 count=1 black edm=Overwrite do=Dilate"); 
wait (1000); 
run ("Options...", "iterations=1 count=4 black edm=Overwrite do=Close"); 
wait (1000); 
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wait ForUser("Close obvious gaps in borders and fill large areas of interstitial  
space"); 
run ("Skeletonize"); 
wait (1000); 
run ("Convolve...", "text1=[0 0 0 0 0\n0 0 0 0 0\n0 0 2 2 0\n0 0 0 0 0\n0 0 0 0 0\n]"); 
wait (1000); 
run ("Convolve...", "text1=[0 0 0 0 0\n0 0 0 0 0\n0 0 2 2 0\n0 0 0 0 0\n0 0 0 0 0\n]"); 
wait (1000); 
set Threshold (0, 254); 
set BackgroundColor(255,255,255); 
wait For User("Create border around cross-section"); 
run ("Select None"); 
wait (1000); 
run ("Analyze Particles...", "size=0-Infinity circularity=0.00-1.00 show=Masks   
exclude include"); 
wait (1000); 
select Window ("Original (green)"); 
close(); 
select Window("Original (blue)"); 
run ("Copy"); 
wait(1000); 
set Paste Mode("Transparent-Zero"); 
wait (1000); 
select Window("Mask of Original (green)"); 
wait (1000); 
run ("Invert"); 
wait (1000); 
run ("Paste"); 
wait (1000); 
run ("Select None"); 
wait (1000); 
run ("Options...", "iterations=1 count=2 edm=Overwrite do=Close"); 
wait (1000); 
set ForegroundColor(0, 0, 0); 
wait (1000); 
run ("Options...", "iterations=1 count=2 edm=Overwrite do=Dilate"); 
wait (1000); 
set Threshold(0, 150); 
run ("Analyze Particles...", "size=50-Infinity circularity=0.00-1.00 show=Outlines       
display exclude clear include summarize") 
 
Appendix 10.4: 
Macro used for Fiji semi-automatic morphometry to calculate the muscle morphologies 
(coefficient of variation of minimum Feret diameter and centrally nucleated fibres). 
 
 
345 
 
Appendix 10.5: Lis of software used for bioinformatics analysis of the Next Generation Sequencing 
data(Sønderkær, 2012; Kulski, 2016). 
Program Website 
1. Aligner, assembly, and postassembly tools 
MUMmer aligner http://mummer.sourceforge.net 
Bowtie aligner http://bowtie-bio.sourceforge.net/index.shtml 
TopHat RNA-Seq aligner https://ccb.jhu.edu/software/tophat/index.shtml 
Anytag aligner http://sourceforge.net/projects/anytag/files/anytag2.0/ 
Soap de novoassembler http://soap.genomics.org.cn/soapdenovo.html 
Allpaths-LG assembler http://www.broadinstitute.org/software/allpaths-lg/blog/ 
Celera assembler http://wgsassembler.sourceforge.net/wiki/index.php?title=Main_Page 
Velvet assembler https://www.ebi.ac.uk/~zerbino/velvet/ 
SPAdes assembler http://bioinf.spbau.ru/spades 
Galaxy tools https://usegalaxy.org 
Genomic tools http://molbiol-tools.ca/Genomics.htm 
BaseSpace Illumina https://basespace.illumina.com/home/sequence 
Torrent Suite Software http://www.lifetechnologies.com/torrentsuite 
RATT: rapid annotation 
transfer tool 
http://ratt.sourceforge.net 
2. Eukaryote annotation web servers 
NCBI pipeline http://www.ncbi.nlm.nih.gov/genome/annotation_euk/process/ 
RepeatMasker http://www.repeatmasker.org/ 
Censor http://www.girinst.org/censor/ 
WindowMasker http://nebc.nerc.ac.uk/bioinformatics/docs/windowmasker.html 
CEGMA tool http://korflab.ucdavis.edu/datasets/cegma/ 
BUSCO http://busco.ezlab.org 
PASA http://pasapipeline.github.io 
MAKER http://www.yandell-lab.org/software/maker.html 
Babelomics http://www.babelomics.org 
3. Archives and databases 
DDBJ http://www.ddbj.nig.ac.jp 
EMBL http://www.embl.org 
GenBank http://www.ncbi.nlm.nih.gov/genbank/ 
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REPBASE http://www.girinst.org 
dbSNP http://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi 
dbGAP http://www.ncbi.nlm.nih.gov/gap 
Complete Genomics 
data 
http://www.completegenomics.com/public-data/ 
SRA http://www.ncbi.nlm.nih.gov/sra 
OMIM http://www.ncbi.nlm.nih.gov/omim 
COSMIC http://cancer.sanger.ac.uk/cosmic 
ENCODE https://www.encodeproject.org 
GTEx http://www.gtexportal.org 
FANTOM http://fantom.gsc.riken.jp 
Roadmap epigenomics http://www.roadmapepigenomics.org 
Blueprint epigenomics http://www.blueprint-epigenome.eu 
Regulome DB http://regulomedb.org 
ExPASy proteomics http://www.expasy.org/proteomics/protein-protein_interaction 
PRIDE proteomics http://www.ebi.ac.uk/pride/archive/ 
FAME metabolomics http://f-a-m-e.fame-vu.cloudlet.sara.nl 
Metabolomexpress https://www.metabolome-express.org 
MetaboAnalyst http://www.metaboanalyst.ca 
AromaDeg http://aromadeg.siona.helmholtz-hzi.de 
EGA phenome https://www.ebi.ac.uk/ega/home 
GOLD https://gold.jgi-psf.org 
MG-RAST https://metagenomics.anl.gov 
ViralZone http://viralzone.expasy.org 
UCNEbase UCelements http://ccg.vital-it.ch/UCNEbase/ 
UCbase 2.0 UC 
elements 
http://ucbase.unimore.it/ 
DEG database http://www.essentialgene.org 
PhylomeDB http://phylomedb.org/ 
Compara GeneTrees http://asia.ensembl.org 
TreeFam http://treefam.genomics.org.cn 
PANTHER http://pantherdb.org 
FATCAT http://phylogenomics.berkeley.edu 
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HOGENOM database http://doua.prabi.fr 
4. Gene ontology databases and tools 
Gene Ontology 
Consortium 
http://geneontology.org 
OBBO http://www.obofoundry.org, http://obofoundry.github.io 
Reactome http://www.reactome.org/ 
DAVID 6.7 https://david.ncifcrf.gov/ 
KEGG Pathway 
database 
http://www.genome.jp/kegg/pathway.html 
5. Genome browsers, projects, and fourth task providers 
Kbase http://kbase.us/glossary/systems-biology/ 
Earth Microbiome 
Project 
http://www.earthmicrobiome.org 
Terragenome Project http://www.terragenome.org 
Tara Oceans Project http://ocean-microbiome.embl.de/companion.html 
MetaHit project http://www.metahit.eu 
Vertebrate Genome 
10K 
http://genome10k.org 
Human Microbiome http://hmpdacc.org 
Personal Genome 
Project 
http://www.personalgenomes.org 
1000 Genomes Project http://www.1000genomes.org 
HapMap http://hapmap.ncbi.nlm.nih.gov/ 
UCSC browser https://genome.ucsc.edu 
Ensembl browser http://www.ensembl.org 
Jbrowse browser http://jbrowse.org 
Web Apollo browser http://genomearchitect.org 
NCBI mapview http://www.ncbi.nlm.nih.gov/projects/mapview/ 
NCBI resources http://www.ncbi.nlm.nih.gov/guide/all/ - tab-all_ 
KEGG http://www.genome.jp/kegg/ 
6. Optical mappers 
BioNano mapper http://www.bionanogenomics.com 
Whole-Genome 
Mapping 
http://opgen.com/genomic-services/what-is-whole-genome-mapping 
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7. NGS and bioinformatics software providers and biological databases 
Omicsmap for NGS http://omicsmaps.com/ 
The NGS WikiBook http://en.wikibooks.org/wiki/Next_Generation_Sequencing_(NGS) 
The Sequencing 
Marketplace 
http://allseq.com 
Genomeweb https://www.genomeweb.com 
Bioinformatic software http://seqanswers.com/wiki/Software/list 
 https://en.wikipedia.org/wiki/List_of_open-
source_bioinformatics_software 
 https://en.wikipedia.org/wiki/List_of_RNA-Seq_bioinformatics_tools 
 http://bioinformaticssoftwareandtools.co.in 
Bioinformatics Web http://www.bioinformaticsweb.net 
Biological databases https://en.wikipedia.org/wiki/List_of_biological_databases 
Applied Bioinformatics http://www.appliedbioinformatics.com.au 
8.Transcriptome Reconstruction 
G-Mo.R-se http://www.genoscope.cns.fr/externe/gmorse/ 
Cufflinks http://cole-trapnell-lab.github.io/cufflinks/manual/ 
Scripture http://www.RNA-Seqblog.com/tag/scripture/ 
TransAbySS http://www.bcgsc.ca/platform/bioinfo/software/trans-abyss 
9. Estimation of isoform-level expression 
ALEXA-seq http://www.alexaplatform.org/alexa_seq/ 
MISO http://genes.mit.edu/burgelab/miso/ 
Cufflinks http://cole-trapnell-lab.github.io/cufflinks/manual/ 
10. Determination of Differential Gene Expression 
DEGseq http://www.bioconductor.org/packages/2.6/bioc/html/DEGseq.html 
EdgeR http://www.bioconductor.org/packages/release/bioc/html/edgeR.html 
DESeq http://bioconductor.org/packages/release/bioc/html/DESeq.html 
BaySeq http://bioconductor.org/packages/release/bioc/html/baySeq.html 
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Appendix 10.6: 
List of top Ingenuity Canonical Pathways and the most relevant pathways to DMD 
pathology shows the genes that were involved in these canonical pathways. These 
results were detected by IPA as being altered in mdx
 
vs. C57/BL10. The colour code 
represents the regulation of gene expression (red: up-regulated gene. Green: down-
regulated gene). 
Ingenuity Canonical 
Pathways 
Molecules 
Mitochondrial 
Dysfunction 
Ndufa10,Vdac3,Cox7b,Atp5f1,Trak1,Cox5a,Ndufa1,Ndufb7,Ndufaf1,Ndufa5,Cyc
s,Sdhb,Ndfa8,Snca,Cox17,Gsr,Cat,Ndufa9,Sdhd,Atp5a1,At5c1,Atpaf1,Bace1,Atp
5b,Atp5e,Uqcrc1,COx4I1,Ndufb3,Park7,Mapk12,Cox4I2,Aco2,Ndufb8,Cpt1b,Nd
ufa2,Ndufs4,Cyc1,Atp5g1,Sod2,Uqcrc2,Vdac2,Casp3,NdufsS6,Aifm1,Maob,Nduf
b2,Ndufb9,Vdac1,Cox7A1,Ndufa12,Ogdh,Cpt1a,Ndufv3,Atp5j,Cox6a2,Ndufa13,
Cox7a2,Atp5o,Cox6b1,Uqcr11,Ndufa6,Uqcrfs1,Ndufv2,Ndufs8,Ucp2,Pink1,Rhot
2,Sdha,Casp9,Ndufv1,Pdha1,Cox6c,Ndufb10,Ndufs1,Ndufs2,Ndufb6,Uqcrq,Cyb5
a,Ndufs3,Ndufa3,Atp5h,Atp5j2,Cox8a,Ndufb5,Ndufb4,Furin,Casp8,Gpd2 
Oxidative 
Phosphorylation 
Ndufa10,Cox7b,Atp5f1,Cox5a,Ndufa1,Ndufb7,Ndufa5,Cycs,Sdhb,Ndufa8,Cox17,
Ndufa9,Sdhd,Atp5a1,Atp5c1,Atpaf1,Atp5b,Atp5e,Uqcrc1,Cox4I1,Ndufb3,Cox4I2,
Ndufb8,Ndufa2,Ndufs4,Cyc1,Atp5g1,Uqcrc2,Ndufs6,Ndufb2,Ndufb9,Cox7a1,Nd
ufa12,Ndufv3,Atp5j,Cox6a2,Ndufa13,Cox7a2,Atp5o,Cox6b1,Uqcr11,Ndufa6,Uqc
rfs1,Ndufv2,Ndufs8,Sdha,Ndufv1,Cox6c,Ndufb10,Ndufs1,Ndufs2,Ndufb6,Uqcrq,
Cyb5a,Ndufs3,Ndufa3,Atp5h,Atp5j2,Cox8a,Ndufb5,Ndufb4 
TCA Cycle II 
(Eukaryotic) 
Dld,Fh,Idh3b,Ogdh,Sdha,Dlst,Idh3g,Aco2,Suclg1,Idh3a,Sdhb,Cs,Sdhd,Mdh2,Suc
la2,Mdh1 
Hepatic Fibrosis / 
Hepatic Stellate Cell 
Activation 
Igfbp4,Il1rl1,Tgfb1,Mmp2,Tnfrsf1a,Ctgf,Il1r2,Acta2,Cyp2e1,TLr4,Myh14,Myh11
,Flt1,Tgfbr1,Vegfc,Myl4,Ccl5,Kdr,Vegfa,Cd14,Pdgfra,Tnfrsf1b,Myl6b,Timp2,Pdg
fc,Tnfrsf11b,Tgfbr2,Col16a1,Il18rap,Col4a2,Il4r,Serpine1,Hgf,Fgf1,Ifnar2,Col6
a1,Klf12,Il6r,Col27a1,Ednrb,Cd40,Vcam1,Ccr5,Col12a1,Ly96,Fn1,Il1r1,Tnf,Stat
1,Col20a1,Ece1,Vegfb,Tgfb3,Pdgfrb,Col6a3,Flt4,Col18a1,Igf2,Col23a1,Ccl2,Csf1
,Col2a1,Lep,Myh8,Timp1,Col11a2,Icam1 
phagosome 
formation 
Plcd4,Fcgr1a,Tlr1,Prcq,Rhoc,Tlr9,Fcer1g,Tlr4,Tlr8,Syk,Mrc1,Fn1,Inpp5d,Pik3c
d,Pik3ca,Prkcb,Tlr6,Tlr2,Fnbp1,Rhot2,Tlr7,Pik3r3,Plcb4,Msr1,Fcgr2a,Pik3cg,R
hog,Prkcd,Vtn,Fcgr2b,Tlr3,Prkca,Rhob,Pdia3,Plcl2,Rhou,Itga5,Clec7a,Prkcg 
Epithelial Adherens 
Junction Signaling 
 
Cdh2,Iqgap1,Tubb3,Tubg1,Acta2,Arpc1b,Zyx,Arpc5,Myh14,Tuba1a,Actb,Myh11,
Actn2,Tgfbr1,Myl4,Ptprm,Src,Jup,Myl6b,Acvr1b,Arpc2,Bmpr2,Tgfbr2,Nras,Sorb
s1,Tuba1b,Rap1b,Tuba4a,Actn3,Yes1,Hgf,Notch3,Actr2,Epn2,Fgf1,Mllt4,Tuba8,
Tubb6,Arpc5l,Notch2,Snai1,Tubb2a,Clip1,Arpc4,TCF7l2,Rras2,Tubb,Notch4,Ep
n1,Actr3,Baiap2,Tubb2b,Myh8,Keap1 
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          Appendix 10.7: 
GSEA heat map illustrating the genes involved in (A) aminoglycan metabolic process, 
(B) blastocyst formation, (C) cell-cell adherens junction, (D) CGMP metabolic process, 
(E) enhancer binding, (F) endoplasmic reticulum lumen, (G) membrane lipid 
biosynthetic process (H) mating, (I) mitochondrial membrane organization. Red and 
blue colours indicate the up and down-regulated transcripts respectively. Colour 
intensity indicates the strength of regulation. N=4. 
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Appendix 10.8: 
GSEA heat map illustrating the genes involved in (A) anchoring junction, (B) cellular 
lipid catabolic process, (C) cilium morphogenesis, (D) cofactor metabolic process, (E) 
negative regulation of hormone secretion, (F) negative regulation of peptide secretion. 
Red and blue colours indicate the up and down-regulated transcripts in mdx/P2rx7
-/- 
compared with mdx respectively. Colour intensity indicates the strength of regulation. 
N=4. 
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Appendix 10.9: 
GSEA heat map illustrating the genes involved in (A) cyclic nucleotide metabolic 
process, (B) multi-organism reproductive process, (C) peptidyl serine modification, (D) 
regulation of insulin secretion, (E) sphingolipid biosynthetic process, (F) positive 
regulation of leukocyte chemotaxis, (G) regulation of B cell proliferation. Red and blue 
colours indicate the up and down-regulated transcripts in mdx/P2rx7
-/- 
compared with 
mdx respectively. Colour intensity indicates the strength of regulation. N=4. 
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Appendix 10.10: 
GSEA heat map illustrating the genes involved in (A) macromolecular complex 
disassembly, (B) methyltransferase activity, (C) monocarboxylic acid catabolic 
process,(D) monosaccharide biosynthetic process, (E) monovalent inorganic cation 
homeostasis, (F) photoreceptor connecting cilium, (G) positive regulation of JUN 
kinase activity (H) regulation of peptide transport, (I) RNA polymerase II core 
promoter proximal region sequence specific DNA binding transcription factor activity 
involved in positive regulation of transcription. Red and blue colours indicate the up 
and down-regulated transcripts in mdx/P2rx7
-/- 
compared with mdx respectively. 
Colour intensity indicates the strength of regulation. N=4.
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Appendix 10.11: 
Analysis of alternatively spliced transcripts in RNA-Seq dataset comparing wild-type, mdx and mdx/P2rx7
-/- 
muscles at the degeneration-regeneration 
phase revealed significant differences (both gains and losses) in the expressions of a number of such transcripts.  
 
gene_short_name SampleB1 SampleB2 SampleB3 SampleB4 SampleM1 SampleM2 SampleM3 SampleM4 SampleP1 SampleP2 Samplep3 Samplep4 
        Adam15 1.06321 3.19574 3.51894 3.49593 9.05075 9.05899 8.52098 8.74229 10.0461 11.2899 4.02651 5.47014 
Adam15 17.4843 13.6236 14.9112 14.6717 13.5866 15.0408 13.7662 8.64208 11.6145 10.2311 15.9871 16.5824 
Adcy3 0.493331 0.179858 0.004881 0.840233 0.007022 1.70E-09 1.39072 0.000393 0.966848 1.31502 0.747935 1.60272 
Adcy3 2.83E-14 0.184795 1.03E-13 1.87E-09 0.340437 1.36324 8.63E-12 0.000117 1.76E-13 0.177409 0.167627 0.451316 
Adcy3 0.631223 0.001177 0.415456 0.000279 0.687505 1.19398 0.000266 0.654212 0.002725 0.258546 0.000288 0.025098 
Adcy3 0.028219 1.08686 1.15375 0.279194 1.39109 0.103564 0.922518 2.12618 2.54536 1.43611 1.63971 0.933508 
Cbfa2t2 1.14403 0.495732 0.930442 9.18E-05 0.190521 0.509435 0.449518 0.288607 1.68241 1.43222 0.86489 0.880922 
Cbfa2t2 3.00414 4.19726 2.57108 4.07327 3.89105 3.2286 3.87191 3.05061 2.56292 2.49304 2.81154 3.01166 
Cd82 1.26E-05 4.85E-06 5.49E-06 3.45E-06 2.01E-06 1.82E-06 1.10E-05 2.15E-06 3.19E-09 1.03E-05 1.10E-05 1.31E-05 
Cd82 6.13E-05 5.46E-05 5.26E-05 2.00E-05 0.005752 0.007256 0.007564 0.005473 3.81362 0.001673 0.007655 0.005704 
Cd82 1.72E-07 1.45E-11 7.92E-11 2.94E-08 2.56E-34 0.42672 1.34384 1.46E-37 1.40341 2.77E-24 2.28E-31 3.96E-29 
Cd82 3.62E-16 3.66E-22 4.81E-21 6.76E-18 9.91E-56 1.07E-61 3.05E-49 1.20E-58 1.76E-65 2.34E-39 2.82E-49 4.36E-46 
Cd82 0.703946 1.99897 2.51489 0.772909 3.38793 4.69394 5.37889 3.54199 2.25124 2.35948 2.25149 6.21181 
Cd82 0.000264 0.00051 0.000424 0.000101 8.9612 15.3081 3.16281 7.63787 0.035984 9.88458 3.21729 1.5574 
Cd82 8.56551 8.65397 7.7746 10.3486 15.863 9.32423 14.3307 19.811 15.5375 15.4037 14.146 13.5243 
Cldn25 6.59E-11 7.23E-17 3.79E-44 3.40E-53 2.42E-06 4.28E-07 1.01E-05 3.44E-07 2.69E-56 1.40E-05 2.32E-17 0.002819 
Cldn25 1.08993 1.48671 1.46862 1.96676 6.87E-05 0.386613 0.751648 9.77E-05 2.33309 1.72792 2.25E-05 1.19187 
Cldn25 1.36E-09 6.15E-12 2.26E-42 4.09E-51 5.83E-06 0.007784 0.081037 9.70E-07 3.32E-54 0.048748 3.83E-17 0.299155 
Cldn25 0.064993 0.00013 0.032033 0.022501 3.03E-05 4.58E-05 0.000178 3.72E-05 0.026188 0.000896 1.41E-05 0.01526 
Cldn25 5.32951 5.61502 5.38844 7.30455 4.28074 7.18386 5.81106 7.69924 2.84592 4.66442 5.35545 4.85803 
Cldn25 5.80E-09 1.67E-11 1.14E-42 9.62E-52 0.906916 0.233103 0.757811 0.202847 2.44E-55 0.141013 1.91E-10 1.08353 
Crlf2 0.000358 0.000743 0.000803 0.00057 0.67504 2.23826 0.000418 2.83007 0.000158 7.07E-05 1.4075 0.801776 
355 
 
Crlf2 4.19223 3.21506 3.26501 3.02792 7.87702 6.22795 7.99741 6.15109 6.73642 8.92407 5.93393 5.55911 
Cyb561d1 1.07479 1.02736 1.10322 1.33242 9.67E-05 0.47643 0.000127 9.15E-05 1.06691 1.86058 1.29576 1.01089 
Cyb561d1 0.572646 0.902448 0.799876 0.002657 1.68633 1.25776 1.98766 1.95751 0.642826 0.003177 0.128836 0.878956 
Dzip3 0.672904 0.361638 0.242947 0.774746 1.00532 1.26841 0.663748 1.36454 0.501715 0.998382 0.654287 0.204633 
Dzip3 0.648225 0.603556 0.515167 0.283061 0.197793 0.234701 0.325545 0.191853 0.61684 0.466998 0.566956 0.866431 
Entpd5 4.52342 1.701 5.7319 4.36733 3.70805 3.69253 1.2921 4.15906 2.11278 2.03288 2.3896 4.23232 
Entpd5 0.011751 2.61337 0.000704 0.004037 0.84295 0.287078 2.9248 0.000114 2.7192 1.87437 2.00758 0.00048 
Inpp5d 0.00011 1.63E-16 2.59E-09 2.30E-21 0.185453 0.622501 0.762537 1.26943 0.337592 0.440453 2.52E-05 0.087592 
Inpp5d 0.000194 3.76E-13 3.40E-08 0.001085 2.56548 1.83543 2.99333 2.80151 4.83138 1.29289 0.000186 0.747758 
Inpp5d 1.32204 0.005097 0.421253 1.53E-17 0.637598 2.8268 1.02958 2.31088 0.308488 2.8259 1.28995 0.805948 
Inpp5d 1.60076 2.66885 2.40673 3.13442 8.11795 7.71189 3.96741 4.95676 4.42904 7.61337 5.89355 6.11757 
Irak1bp1 6.92E-06 1.06E-05 0.000294 1.82E-05 0.741396 0.733053 0.134595 0.347116 0.001701 0.295118 0.000141 9.33E-06 
Irak1bp1 1.33697 1.14771 1.14787 1.22313 0.483137 0.000212 1.04809 0.632406 1.36801 1.22141 0.811051 1.29465 
Jak3 2.7331 2.8804 2.63236 2.5269 2.39889 3.1879 2.88409 1.43644 2.80295 2.10394 1.95335 2.49211 
Jak3 0.000945 0.000268 0.000488 0.000114 0.433128 0.508307 5.10E-05 1.2965 0.350592 0.587445 0.988371 0.581719 
Kcnn4 4.11E-07 4.58E-07 2.69E-05 5.20E-06 0.547114 0.504233 0.198505 0.704515 1.10569 1.04845 0.721268 0.549483 
Kcnn4 0.242533 0.421157 0.575922 0.354967 2.53083 2.32689 2.65672 1.60002 1.96848 4.13654 4.11742 1.37872 
Lin9 0.000101 5.32E-05 5.26E-05 3.13E-06 0.482697 0.669467 1.58E-05 0.915986 0.701423 0.460502 2.64E-05 0.725625 
Lin9 4.18623 3.44829 2.65465 3.79634 3.16947 1.91641 1.91381 2.02751 2.09544 2.74616 2.46718 1.97566 
Mcf2l 5.22E-14 7.31E-06 1.84E-23 2.32E-07 0.000111 5.20E-06 1.48E-07 1.96E-07 6.01E-09 3.82E-06 8.43E-08 7.68E-06 
Mcf2l 5.83E-13 8.66E-05 7.96E-20 9.80E-06 0.92799 7.66E-05 6.66E-07 1.09E-06 3.11E-08 2.43E-05 2.32E-07 3.76E-05 
Mcf2l 13.3362 15.123 6.47097 23.1934 9.92281 10.235 11.335 7.75792 7.42157 7.48133 5.50977 7.96978 
Mcf2l 2.14318 1.67045 0.004329 0.774026 0.001149 0.917779 3.45764 1.88977 2.12557 1.56279 2.82226 2.1285 
P2rx7 4.39E-15 0.154209 1.67E-13 0.00222 1.08779 1.10257 1.0364 3.91E-08 0.73329 0.399556 1.71285 0.94143 
P2rx7 6.36E-09 0.113801 3.42E-14 4.45E-27 1.65E-17 3.42E-22 6.61E-09 7.07E-14 1.36E-06 2.67E-06 7.34E-06 5.33E-06 
P2rx7 1.37813 1.18832 1.64916 1.42775 2.67172 2.89531 3.20273 3.44966 1.07653 1.21093 1.31772 1.00483 
P2rx7 0.095228 0.299345 1.67E-05 0.294724 0.000129 0.042747 0.205282 6.57E-05 1.58043 3.83563 1.51589 1.46294 
356 
 
Postn 30.3496 18.77 23.1127 33.1091 44.9215 53.9552 37.5207 91.0379 37.692 42.763 63.3765 56.4692 
Postn 12.2454 17.3941 14.2787 11.2999 236.093 264.159 157.757 379.817 196.393 153.688 172.624 163.436 
Postn 23.3354 19.1324 17.0963 28.8839 68.2512 64.0178 54.7876 107.753 63.3804 65.487 88.0863 70.8355 
Prkd3 0.046468 0.005639 0.09591 0.000309 0.010042 1.72E-07 1.04E-06 6.68E-08 0.13483 0.002665 0.000213 0.049186 
Prkd3 1.59341 0.5813 0.713464 0.005432 1.61325 0.433492 0.698118 0.487114 2.1349 0.051047 0.003295 1.06452 
Prkd3 6.21101 6.45016 5.92938 7.26451 6.82888 6.39527 6.85354 7.12493 5.78075 7.4984 7.03942 5.68936 
Prkd3 0.339842 0.151757 1.15714 0.704292 0.103231 2.74E-05 7.94E-05 1.21E-05 0.590631 0.704783 0.804493 0.458088 
Psap 84.4158 104.772 96.8073 112.413 296.104 295.184 296.7 318.436 372.945 540.805 332.742 249.821 
Psap 18.1931 24.1404 26.0258 26.8659 18.8517 18.3532 21.4271 16.8177 25.2487 18.5444 14.9146 14.6668 
Psap 12.8441 14.0972 14.2036 19.9779 31.6473 32.0647 24.0944 32.1291 31.3923 43.7977 33.283 23.8964 
Psap 1.57E-61 1.30851 0.787591 0.44796 1.26979 0.33838 0.466144 1.31E-76 1.75E-34 0.785986 1.23219 4.56E-51 
Psap 94.2846 111.071 98.9629 111.845 90.2631 87.3638 95.0654 76.4123 93.8914 83.7714 82.1267 80.6132 
Psap 1.26E-68 0.034355 0.02438 0.007493 0.077105 0.022262 0.043963 5.77E-81 2.28E-37 0.012176 0.02778 9.04E-55 
Psap 0.008603 3.82905 4.19821 2.81266 24.9078 29.1823 31.3835 22.8209 20.1298 13.6793 10.9309 9.21591 
Rps24 214.2 201.959 216.854 226.354 337.329 261.681 284.988 399.688 304.852 351.366 349.867 328.108 
Rps24 92.2194 83.0386 78.9399 92.7317 201.174 207.434 182.859 251.017 224.119 296.557 230.237 173.974 
Rps24 395.18 411.309 411.899 404.674 278.201 258.589 303.075 298.598 266.582 265.403 329.831 289.666 
Sept6 0.152254 0.346203 3.66E-06 0.000132 9.43E-06 0.002009 3.91E-05 9.77E-07 2.29E-06 2.29E-06 2.25E-06 1.07E-05 
Sept6 0.148693 0.000354 0.218722 0.458014 0.368226 0.874928 0.456969 0.185002 0.376046 0.643987 0.375397 0.324616 
Sept6 0.207192 0.496594 0.000214 0.000374 0.000536 0.018836 0.00127 0.000204 0.000136 0.000187 0.000189 0.000642 
Sept6 3.88128 3.79033 4.44257 4.82105 3.21166 1.48642 3.13592 4.26792 3.45026 3.13232 3.74315 3.00189 
Sept6 0.203559 0.002917 0.691865 0.163117 1.32925 1.64916 1.33432 1.55257 0.938652 1.92858 1.33808 1.32422 
Slu7 13.1827 12.2964 10.0645 12.9255 11.1901 10.0314 11.2021 11.5302 2.57399 7.38907 3.29972 3.26493 
Slu7 8.75E-05 0.752362 8.78E-05 4.01E-05 0.275202 6.57E-05 3.21E-05 0.767014 11.8919 5.39717 12.6145 8.64493 
Smg7 8.21833 2.23116 3.64964 2.42514 2.81875 3.27756 2.14674 1.94998 3.23029 3.29164 3.53634 1.95551 
Smg7 0.009089 0.001304 0.188397 2.05E-05 0.43269 0.923716 0.001143 1.34458 1.18805 0.995574 2.11205 0.563576 
Smg7 5.53348 2.45364 5.33985 3.11296 3.40997 2.01216 2.28947 0.37132 1.09189 1.84185 1.74063 1.24954 
357 
 
Smg7 2.83E-06 0.002016 0.07644 2.72E-05 0.303481 0.797747 0.001996 2.79177 0.93667 0.471967 0.93605 1.02723 
Smg7 0.00322 3.34241 1.51271 3.10806 1.99363 2.83872 3.61646 3.97225 2.56145 1.59533 1.60585 3.48971 
Smg7 0.002197 3.671 2.21892 3.98553 2.41245 1.74331 3.85308 0.759514 0.866395 0.890737 0.787304 2.23356 
Smtn 4.19217 7.7118 2.44759 7.58362 7.16407 3.44485 4.45647 0.000261 0.000143 0.000115 9.44E-05 2.12306 
Smtn 29.269 25.0192 30.1424 20.6992 18.7304 27.8795 27.7957 24.9904 28.3396 25.3363 23.5103 35.9358 
Spn 6.67E-05 0.026788 3.31E-06 5.47E-06 0.951219 1.64953 1.53758 1.04785 1.432 1.17947 1.23525 0.395604 
Spn 0.122245 0.337107 0.642408 0.521063 1.99256 1.20088 1.20054 1.36609 1.4207 1.75246 1.02482 1.16608 
Tmem255b 4.2765 4.35585 2.14743 1.86505 0.348456 0.474486 0.000143 1.58E-05 1.92895 0.877875 1.70828 1.18252 
Tmem255b 0.050352 0.002499 2.03217 3.07157 2.69187 3.96287 3.75691 3.69344 2.41281 3.1485 2.13085 3.10264 
Tmem41a 0.9586 0.911478 0.975123 2.76782 2.03467 2.5465 2.7086 2.66266 1.96078 2.63112 1.90349 2.23412 
Tmem41a 2.06336 1.69394 3.08387 3.33178 2.02832 1.99653 0.00033 1.72267 0.354763 0.510337 1.21142 0.936051 
Tmem70 0.000129 0.861385 1.50904 0.905595 1.71122 2.39369 1.26334 1.03706 0.382841 3.61E-05 4.73E-05 2.84E-05 
Tmem70 23.6876 22.2357 24.8066 28.414 16.598 13.88 14.546 14.8195 16.583 16.399 16.9997 17.2233 
Tnnt2 4.00E-43 1.82E-25 1.01E-36 1.33E-43 8.71E-25 3.80E-25 4.54E-47 2.59E-25 2.26E-25 3.06E-53 8.96E-39 1.17E-45 
Tnnt2 0.001807 0.000316 0.000951 0.000185 2.42688 1.24877 5.70526 8.05E-05 0.000144 1.67E-05 0.000258 1.69E-07 
Tnnt2 3.05E-07 3.02E-05 4.53E-06 0.000939 0.000119 0.000221 7.30E-05 2.38E-05 1.39E-06 0.569509 3.42E-05 0.001084 
Tnnt2 0.000393 9.75E-05 0.000184 2.46E-05 21.5035 10.1059 0.000812 15.9742 8.982 16.3748 7.18435 13.7908 
Tnnt2 0.549348 1.23E-23 3.66E-34 1.87E-40 3.08343 2.95209 4.04749 3.18417 4.01887 1.18177 2.52123 4.4423 
Tnnt2 7.20E-46 0.328132 3.81E-37 9.54E-40 0.151493 0.671591 1.03157 6.41E-18 9.14E-34 1.38938 2.56E-20 0.543242 
Tnnt2 3.97E-39 2.02E-20 1.97E-32 2.52E-38 6.13E-25 8.78E-25 2.76E-42 2.89E-25 4.97E-25 2.39E-54 6.38E-39 3.61E-46 
Tnnt2 3.01E-44 1.06E-23 2.09E-35 1.31E-37 0.144191 1.13859 0.626505 1.15241 1.13128 1.04452 0.693496 0.498747 
Tnnt2 4.17562 5.35139 3.90386 5.21293 68.1131 82.6957 44.3347 72.8173 63.7046 51.2061 46.822 75.0149 
Tnnt2 4.74E-32 2.30E-14 2.53E-22 1.55E-21 1.83E-20 3.08E-17 1.36E-31 5.22E-20 1.47E-24 8.99E-43 2.36E-33 4.58E-39 
Tpm3 8.2045 2.8117 4.39655 5.9617 6.50598 2.79393 5.7815 6.16296 6.44206 2.38111 2.76644 2.32224 
Tpm3 15.6817 14.9405 13.5905 12.6509 13.1724 11.2784 11.4699 18.0618 16.2985 12.3428 7.59098 10.8767 
Tpm3 2.74567 3.40931 7.11931 3.47831 17.1503 34.5131 17.2161 22.6723 10.0537 37.2114 24.6135 26.5869 
358 
 
Tpm3 22.8015 24.364 26.6987 23.5602 28.0429 25.7357 31.7933 30.1504 40.512 35.1879 26.9423 24.5942 
Tpm3 1.50481 0.64638 2.35184 1.70301 8.59306 8.91552 8.84117 7.88668 4.08924 7.55538 9.13116 5.9243 
Trim33 0.642183 0.814729 0.655351 1.47745 0.235619 0.205685 0.509285 0.000115 0.886878 0.820613 1.02585 1.60216 
Trim33 2.77287 2.16904 1.85072 1.06373 2.05762 2.39073 2.06287 2.81156 1.68958 1.62839 1.33279 1.14999 
Trmt1 3.88661 5.70536 4.55074 6.44555 8.26376 15.3486 10.2609 6.23659 11.8206 11.4104 8.08358 9.64493 
Trmt1 11.1925 10.4236 10.0418 12.2691 7.17169 1.70252 4.30442 9.01991 5.0208 6.2359 5.21148 5.22399 
Trmt1 0.000212 0.000133 8.50E-05 0.533285 0.000103 8.64E-14 6.09E-05 4.67E-05 7.00E-05 0.434478 0.688081 0.409222 
Zdhhc24 0.643016 1.70006 1.43481 1.44637 0.085388 6.38E-06 1.13941 0.000131 0.739462 2.28828 1.50307 0.985204 
Zdhhc24 1.00658 0.710315 4.63E-20 0.365299 2.11805 1.59541 1.21431 1.71408 1.05325 0.423183 0.611669 0.933111 
Zdhhc24 0.001415 0.000656 0.000719 0.000505 0.000112 0.265318 0.000571 1.73E-06 0.000594 0.000392 0.00058 0.000437 
359 
 
 
Appendix 10.12: 
An example of an original uncropped Western blotting showing: (A) The level of 
P2RX4 protein to be up-regulated in mdx muscles compared with C57/BL10 and 
down-regulated in mdx/P2rx7
-/-
 compared with mdx. (B) High levels of P2RX7 
receptor in 4 week-old GC muscles from mdx compared to C57/BL10 and no 
detectable protein in mdx/P2rx7
-/-
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         Appendix 10.13: 
Example of microscope fields of view at low power magnification (10x) in 6 week GC 
muscle from mdx injected with oATP compared with mdx injected with saline. The 
confocal images show higher numbers of infiltrating CD11B positive cells (red signal) 
in three images represent three different locations of one section from mdx-saline (A) 
compared to other three images from mdx-oATP (B). Entire GC sections of three 
biological replicates were scanned using the confocal microscope and a semi-automated 
method was used to analyse these images to avoid bias. All images have the same scale 
bar 100µm. 
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Appendix 10.14: 
Example of microscope fields of view at low power magnification (10x) in 4 week GC 
muscle from mdx injected with A438079 compared with mdx injected with saline. 
Immunofluorescence images show infiltrated muscle fibres (IgG -purple signal) in three 
images represent three different locations of one section from mdx-saline (A) and  also 
three images represent three different locations of one section from mdx-A438079 (B). 
No significant difference was found in the proportion of IgG-permeable fibres when 
analysed by image J. Entire GC sections of three biological replicates were scanned 
using the confocal microscope and a semi-automated method was used to analyse these 
images to avoid bias. All images have same scale bar 100µm. 
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